quinazolines has been researched along with Carcinoma, Non-Small Cell Lung in 3235 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.12) | 18.7374 |
| 1990's | 3 (0.09) | 18.2507 |
| 2000's | 1122 (34.68) | 29.6817 |
| 2010's | 1982 (61.27) | 24.3611 |
| 2020's | 124 (3.83) | 2.80 |
| Authors | Studies |
|---|---|
| Altan, M; Blumenschein, G; Carter, BW; Elamin, YY; Feng, L; Fossella, FV; Gibbons, DL; Heymach, JV; Lam, VK; Le, X; Mott, FE; Negrao, MV; Patel, AB; Robichaux, JP; Tsao, AS; Zhang, J | 1 |
| Dahal, A; El-Sadek, M; Emam, AM; Enriz, RD; Ibrahim, SM; Jois, SD; Kothayer, H; Singh, SS; Tosso, RD | 1 |
| Chen, H; Ding, L; He, X; Ma, Y; Shen, Z; Wang, Y; Yang, M; Yuan, X | 1 |
| Gao, X; Li, H; Lian, S; Lin, J; Song, C | 1 |
| Asano, K; Hayama, N; Ito, Y; Niimi, K; Obayashi, S; Oguma, T; Tanaka, J; Tomomatsu, K; Urata, M | 1 |
| Deng, Q; Ma, S; Mao, Y; Yin, W; Yu, Q; Zhang, K; Zhao, R | 1 |
| Chen, K; Chen, P; Dai, CH; Li, J; Shi, ZH; Su, JY; Wang, Y; Wu, JN | 1 |
| Bhat, G; Clarke, JM; Cornelissen, R; Garassino, M; Goldman, JW; Heymach, JV; Le, X; Lebel, F; Leu, SY; Socinski, MA; Tchekmedyian, N | 1 |
| Cui, J; Jiang, P; Li, Y; Wang, X; Zhang, Y | 1 |
| Lee, JY; Lin, CF; Liu, SY; Lo, TK; Su, PL | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Dezfouli, AA; Dezfuli, MM; Heshmatnia, J; Lotfabadi, AS; Mirtavoos-Mahyari, H; Rismani, E; Sheikhy, K | 1 |
| Chen, S; Deng, Q; Fang, Q; Huang, X; Li, X; Lin, Z; Liu, X; Miao, Y; Wang, J; Yang, L; Yu, XY | 1 |
| Feng, X; Jiang, H; Meng, J; Meng, W; Wang, K; Zhang, F; Zhao, F | 1 |
| Ahn, D; Bekaii-Saab, T; Walden, D | 1 |
| Das, S; Haider, K; Joseph, A; Yar, MS | 1 |
| Alonso Horcajo, N; Castañón López, C; Delgado Sillero, I; Díez Tascón, C; Diz Tain, P; García Palomo, A; Garrido Onecha, ML; Lopetegui Lia, N; López González, A; Martín, V; Medina Valdivieso, S; Pedraza Lorenzo, M; Rojas Piedra, M; Sánchez Cousido, LF; Távara Silva, B | 1 |
| Cai, Y; Dong, Z; Sheng, Z; Wang, J | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Guo, H; Hui, H; Shi, B; Wang, M; Wang, Y | 1 |
| Koshlan, TV; Kulikov, KG | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Ali, SM; Chen, G; Chen, J; Chen, S; Chen, Y; Cui, J; Dong, X; Duan, J; Fang, J; Feng, J; Guo, R; Hu, C; Hu, J; Hu, Y; Ji, Y; Jian, H; Jiang, L; Jie, W; Jie, Z; Li, B; Li, C; Li, J; Li, W; Lin, Z; Liu, C; Lu, J; Lu, S; Lu, Y; Lv, D; Ma, L; Ma, R; Miller, VA; Shi, J; Sun, C; Sun, M; Sun, Y; Tong, W; Wang, Q; Wang, Z; Wei, H; Wu, Q; Wu, X; Xiong, J; Xu, X; Xu, Z; Yang, H; Yang, N; Yao, Y; Ye, X; Yu, X; Yu, Z; Zhang, G; Zhang, H; Zhang, L; Zhang, Z; Zhou, J; Zhou, X | 1 |
| Abbasi, AM; Ayaz, Z; Darwish, NM; Gatasheh, MK; Rashid, U; Zainab, B | 1 |
| Cao, L; Chen, G; Cheng, Y; Cui, J; Feng, J; Gu, C; Hao, Y; Jiang, Y; Li, Y; Liu, C; Liu, F; Liu, J; Liu, Y; Shi, Y; Wang, X; Wu, L; Yang, N; Zang, A; Zhang, S; Zhang, X; Zhao, H; Zhu, S | 2 |
| Cai, Y; Cao, HQ; Fang, L; He, ML; Jiang, YY; Li, YP; Qian, XD; Wang, DG; Wang, GR; Wang, J; Zhao, ZT | 1 |
| Guo, J; Li, M; Xie, Y | 1 |
| Biswal, BK; Panda, M | 1 |
| Fan, D; Gan, W; Guo, Y; Li, Y; Pan, Q; Peng, Y; Rao, Z; Wang, C; Xu, S; Zheng, P; Zhu, W | 1 |
| Altan, M; Blumenschein, G; Byers, LA; Carter, BW; Cascone, T; Cross, JB; Elamin, YY; Feng, L; Fossella, FV; Gibbons, DL; Heeke, S; Heymach, JV; Lam, VK; Le, X; Lu, C; Luthra, R; Mantha, G; Negrao, MV; Nilsson, MB; Patel, A; Robichaux, JP; Routbort, M; San Lucas, FA; Tran, H; Tsao, AS; Vijayan, RSK; Zhang, J | 1 |
| Dai, X; Feng, C; Guo, D; Huang, L; Jiang, S; Liu, Y; Ma, S; Qahar, M; Wang, L | 1 |
| Chairoungdua, A; Janpipatkul, K; Panvongsa, W; Reungwetwattana, T; Worakitchanon, W | 1 |
| Cha, HJ; Choi, SK; Jang, SJ; Kim, M; Kwon, Y; Lee, H; Lee, YS; Na, Y | 1 |
| Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Li, B; Liao, H; Wang, Y; Zhou, B | 1 |
| Espinoza, JL; Fujii, A; Fujimoto, K; Fujiwara, R; Hanamoto, H; Iwata, Y; Kumode, T; Matsumura, I; Morita, Y; Rai, S; Serizawa, K; Tanaka, H; Taniguchi, Y | 1 |
| Dong, W; Gong, Y; Hu, S; Li, M; Wang, C; Xie, C; Zhao, K | 1 |
| Fujii, R; Hayashi, K; Honda, T; Ishida, T; Kawamura, M; Matsutani, N; Ochiai, R; Saichi, N; Seki, N; Shimizu, T; Shinchi, H; Ueda, K; Yamamoto, H | 1 |
| Hong, J; Kang, S; Kim, JH; Ko, SG; Kwon, YY; Moon, JH | 1 |
| Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M | 1 |
| Cai, Y; Chen, T; Chen, W; Cui, D; Guo, H; Wang, L; Wang, X; Xie, D; Xie, S; Zhang, X | 1 |
| Gao, J; Li, X; Liu, Z; Teng, Y; Yin, P; Yu, P | 1 |
| Fan, XX; Feng, SL; He, F; Leung, EL; Xie, Y; Yan, PY; Yao, XJ; Zhou, H | 1 |
| Chen, Z; Chu, L; Diao, Y; Dou, D; Gong, M; He, H; Jiang, W; Li, H; Li, S; Li, W; Ma, X; Mei, W; Qiao, Y; Sha, W; Su, R; Sun, B; Wang, C; Wang, J; Wumaier, G; Xie, L; Xu, Y; Yang, T; Zhang, C; Zhao, Z; Zhu, L | 1 |
| Cheng, Y; Song, R; Zheng, T | 1 |
| Aggarwal, G; Ahsan, A; Ahsan, W; Javed, S; Kumar, P; Mangla, B; Musyuni, P | 1 |
| Brueckl, WM; Ficker, JH; Griesinger, F; Kokowski, K; Krüger, S; Laack, E; Möller, M; Neben, K; Rawluk, J; Reck, M; Schäfer, H; Schueler, A | 1 |
| Amrhein, JA; Beyett, TS; Eck, MJ; Feng, WW; Hanke, T; Jänne, PA; Knapp, S; Krämer, A; Rana, JK; Schaeffner, IK; Weckesser, J | 1 |
| Ballet, S; De Grève, J; Elsocht, M; Giron, P | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Hatakeyama, N; Ichihara, S; Kadota, N; Kunishige, M; Machida, H; Naruse, K; Okano, Y; Shinohara, T; Takeuchi, E | 1 |
| Amelia, T; Kartasasmita, RE; Ohwada, T; Setiawan, AN; Tjahjono, DH | 1 |
| Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
| Jia, YY; Lv, WH; Nie, F; Wu, H; Zhu, YY | 1 |
| Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C | 1 |
| Chen, CH; Hour, MJ; Hsieh, HH; Kuo, YH; Wu, TY | 1 |
| Mohammadnejadi, E; Razzaghi-Asl, N | 1 |
| Lai, XY; Shi, YM; Zhou, MM | 1 |
| Huang, Z; Jiang, H; Li, J; Shao, Z; Tang, Y; Wang, Y; Zhang, G; Zhou, Z; Zhu, Y | 1 |
| Cui, Y; Dai, J; Guo, R; Qu, T; Yin, D; Zhang, C; Zhang, E | 1 |
| Gu, S; Song, P; Wang, W; Wu, K; Zhou, J | 1 |
| Chen, Y; Dai, J; Guo, R; Jin, S; Li, J; Zhang, C; Zhang, Z | 1 |
| Borm, FJ; Smit, EF | 1 |
| Chen, H; Cui, J; Fan, L; Fu, Y; Han, K; Hu, H; Yin, S; Zhao, C; Zhao, S | 1 |
| Chang, X; Chen, Y; Ding, L; He, Y; Lei, C; Ma, C; Tang, Q; Xiao, Z; Yu, Y; Zhang, H; Zhu, Y | 1 |
| Rai, GP; Shanker, A | 1 |
| Chen, MC; Li, YH; Liao, WL; Lin, H; Yang, TY | 1 |
| Cui, Y; Kang, X; Liang, J; Liu, M; Zhang, H; Zhang, Q | 1 |
| Ahn, MJ; Arslan, C; Bondarenko, I; Cho, BC; Cicin, I; Danchaivijitr, P; Fong, CH; Kang, JH; Kilickap, S; Kim, JH; Lee, H; Lee, KH; Lee, SS; Lee, YG; Lim, CS; Lim, YN; Orlov, S; Pang, YK; Park, SN; Soo, RA; Yang, JC; Zimina, A | 1 |
| Fan, D; Gan, W; Lv, Q; Pan, Q; Zhang, H; Zheng, P; Zhu, W | 1 |
| Chang, L; Dai, Q; Du, L; He, P; Li, G; Yu, B | 1 |
| Adelson, DL; Aung, TN; Chen, Z; Cui, J; Lin, L; Liu, X; Qu, Z; Sun, L; Wang, J; Zhang, J | 1 |
| Asquith, CRM; Crona, DJ; Laitinen, T; Maffuid, KA; Tizzard, GJ; Torrice, CD; Zuercher, WJ | 1 |
| Ban, S; Chen, X; Li, X; Qian, J; Yang, J | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Choowongkomon, K; Kuaprasert, B; Srisook, P; Tabtimmai, L; Thumanu, K | 1 |
| Fang, MY; Fang, Y; Lei, L; Li, JL; Lv, TF; Song, Y; Wang, H; Wang, LP; Wang, WX; Wang, XJ; Xu, CW; Zhang, YB; Zhu, YC; Zhuang, W | 2 |
| Chae, JI; Cho, SS; Choi, JS; Kim, E; Kwak, AW; Lee, MH; Lee, SM; Oh, HN; Seo, JH; Seo, KS; Shim, JH; Yoon, G | 1 |
| Hu, ZY; Wang, GH | 1 |
| Chen, BY; Clark, PM; Damoiseaux, R; Ghezzi, C; Ribalet, B; Wong, A | 1 |
| He, X; Jia, Y; Jiang, Y; Li, Z; Qiu, Y | 1 |
| Arulananda, S; John, T; Loh, Z; Mitchell, P | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Chen, P; Cheng, J; Guan, S; Sun, J; Zhao, Q | 1 |
| Bai, L; Bai, R; Chen, N; Cui, J; Han, F; Li, J; Li, W; Qian, L; Yu, Y; Zhao, Y | 1 |
| Chu, CY; Lin, MH; Sheen, YS; Tzeng, WC | 1 |
| Huang, Y; Lu, L; Qi, X; Su, T; Wang, Y; Yang, X; Zhang, Y | 1 |
| An, G; Cheng, G; Ding, C; Ding, L; He, X; Hu, X; Jiang, D; Li, X; Li, Y; Liang, L; Liu, J; Mao, L; Su, W; Wang, H; Wang, Y; Wu, J; Zang, A; Zhang, C; Zhang, L; Zhang, S; Zhang, Y; Zhao, M; Zhong, D | 1 |
| Ahn, JS; Ahn, MJ; Ku, BM; La Choi, Y; Lee, J; Lee, SH; Park, K; Shim, JH; Sun, JM | 1 |
| Han, C; Hu, X; Li, M; Ren, J; Su, F; Wang, Z; Wu, L | 1 |
| Jha, RK; Jia, M; Li, K; Liu, Y; Zhan, W; Zhao, Y; Zhou, L | 1 |
| Chen, Y; Haase, D; Li, Y; Lu, G; Ma, Y; Nenkov, M; Petersen, I; Zhou, Z | 1 |
| Amendt, C; Blaukat, A; Dahmen, H; Fuchss, T; Grombacher, T; Kirkin, V; Pehl, U; Sirrenberg, C; Vassilev, LT; Wilm, C; Zenke, FT; Zimmermann, A | 1 |
| Chen, YJ; Jiang, HG; Jin, J; Li, J; Li, MY; Shu, Y; Wu, JN; Xiang, M; Zhu, YM | 1 |
| Bach, DH; Hu, R; Kim, D; Lee, SK; Luu, TT; Park, HJ | 1 |
| Cheng, Z; Chu, J; Ke, M; Liu, S; Liu, X; Liu, Y; Miao, S; Sun, X; Wang, K; Wang, Y; Wu, L; Xiao, Y; Yang, L; Yu, C; Yu, L; Zhang, Q | 1 |
| Hsu, JC; Lee, YC; Lin, PC; Lu, CY; Wei, CF; Yang, SC | 1 |
| Liu, L; Liu, S; Wang, Y; Yuan, Y | 1 |
| Guo, C; Li, W; Pangeni, RP; Raz, DJ; Sun, T; Wang, J; Yang, L; Yun, X; Zhang, K | 1 |
| Harada, T; Inoue, S; Jingu, D; Nakagawa, T; Nakamura, A; Saito, R; Sugawara, S; Suzuki, A; Tanaka, H; Yamada, T | 1 |
| Che, X; Chen, Y; Cheng, Y; Deng, M; Hou, K; Hu, X; Liu, Y; Qu, X; Wang, Y; Wu, J; Yan, H; Yang, Y; Zhang, Y; Zou, D | 1 |
| Bai, C; Cao, L; Chang, J; Chen, G; Chen, Y; Chen, Z; Cheng, Y; Fang, J; Gong, Y; Guan, S; He, J; Hu, C; Hu, Y; Huang, D; Huang, Y; Jie, Z; Li, W; Liang, L; Liao, W; Liu, M; Liu, X; Liu, Z; Lu, J; Lu, S; Ma, R; Ma, S; Mao, W; Pan, H; Peng, M; Qin, S; Qiu, F; Shan, L; Shi, J; Song, Y; Su, W; Sun, S; Sun, Y; Tao, M; Wang, B; Yang, J; Yang, Z; Yao, Y; Ye, F; Zhang, Y; Zheng, Z; Zhou, J | 1 |
| Bohra, GK; Kumar, D; Meena, DS; Midha, N | 1 |
| Chen, J; Fan, Y; Hua, H; Huang, DC; Shu, Y; Wang, H; Zhang, J; Zhou, C | 1 |
| Ding, HW; Fan, YH; Hong, JY; Kim, D; Lee, SK; Liu, JY; Wang, D; Xu, YN; Yang, XS | 1 |
| Wang, J; Wu, S; Xie, X; Zeng, F; Zhan, C | 1 |
| Cai, J; Jiang, X; Li, X; Sun, L; Tu, L; Wei, M; Wu, Z | 1 |
| Bedir, S; Celik, E; Cikman, DI; Degerli, E; Demirci, NS; Demirelli, FH; Derin, S; Karadag, M; Oruc, K; Oztas, NS; Samanci, NS | 1 |
| Arrieta, O; Bosch-Barrera, J; Caro, RB; Dómine, M; Drozdowskyj, A; Garcia-Campelo, R; Granados, ALO; Guirado, M; Insa, A; Karachaliou, N; Lianes, P; Majem, M; Massuti, B; Molina-Vila, MA; Reguart, N; Rodriguez-Abreu, D; Rosell, R; Sala, MÁ; Vázquez-Estevez, S; Verdú, A; Vicente, D | 1 |
| Chen, X; Guo, Z; Hou, X; Li, J; Li, M; Liu, L; Sun, M; Wang, Q; Xi, N; Xie, C; Xie, N | 1 |
| Guo, Y; Ma, K; Qiu, S; Shao, J; Sun, C; Sun, M; Wang, X; Xu, Y | 1 |
| Chang, C; Fan, XX; Huang, JM; Jiang, ZB; Lai, HL; Leung, EL; Wang, MF; Wang, W; Wu, QB; Xie, C; Xie, YJ; Yao, XJ; Zhang, YZ | 1 |
| Lian, X; Liao, M; Quan, J; Wang, G; Wu, Y; Xie, W; Yang, ZZ; Zhang, Z | 1 |
| Ahn, MJ; Ham, SY; Kim, JH; Lee, JW; Moon, JW; Park, K; Yi, CA | 1 |
| Chen, S; Li, S; Li, W; Wang, G; Wang, M; Wang, Q; Xia, J; Xu, Y; Zhang, D | 1 |
| Feng, LX; Ge, H; Wang, J; Yu, Z; Zhang, LW; Zhang, Y | 1 |
| Ballet, S; De Grève, J; Elsocht, M; Giron, P; Gutierrez, GJ; Maes, L; Versées, W | 1 |
| Geat, D; Girolomoni, G; Gisondi, P; Lombardo, F; Mattiucci, A; Santo, A | 1 |
| Goto, K; Ikeno, T; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Nosaki, K; Sato, A; Satouchi, M; Seto, T; Tsuta, K; Wakabayashi, M; Yamamoto, N; Yoh, K | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Bottiglieri, A; Brambilla, M; de Braud, F; De Toma, A; Ferrara, R; Galli, G; Gallucci, R; Ganzinelli, M; Garassino, MC; Greco, GF; Labianca, A; Lo Russo, G; Lobefaro, R; Manglaviti, S; Nichetti, F; Occhipinti, M; Prelaj, A; Proto, C; Signorelli, D; Torri, V; Viscardi, G; Zilembo, N | 1 |
| Gan, L; Guo, M; Guo, Z; Liu, Z; Si, J; Xie, Y; Zhang, H; Zhang, J; Zhao, J | 1 |
| Cheng, G; Li, L; Nie, X; Wu, XN; Zhang, P | 1 |
| Ji, YX; Mu, XY; Sun, L; Zhang, L | 1 |
| Singh Badhan, RK; Yu, H | 1 |
| Jiang, Z; Li, Y; Pan, Z; Sun, H; Wang, C; Zhang, J; Zhang, Y | 1 |
| Jia, Y; Li, W; Peng, Y; Sun, C; Yang, Y; Zhao, H; Zheng, J | 1 |
| Ahmad, I; Ansari, A; Belamkar, S; Nath Kundu, C; Nayak, D; Patel, H; Patil, C; Pawara, R; Surana, S; Wadkar, A; Wagh, S | 1 |
| Fan, Y; Fang, L; Gong, L; Han, N; Huang, Z; Lu, H; Qin, J; Qiu, G; Xie, F; Xu, Y | 1 |
| Berghmans, T; Besse, B; De Maio, E; Dziadziuszko, R; Hasan, B; Menis, J; Novello, S; Peric, A; Reck, M; Remon, J; Wasag, B | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Agarwal, SM; Gupta, M; Pal, D; Saini, R | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Ansari, A; Noolvi, M; Patel, HM; Pawara, R; Surana, S | 1 |
| Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C | 1 |
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Asano, M; Hasegawa, Y; Ito, H; Kobayashi, H; Miura, H; Miura, M; Niioka, T; Okuda, Y; Sano, M; Sato, K; Sudo, K; Takeda, M; Watanabe, H | 1 |
| Huang, S; Jiang, Y; Li, Y; Liu, K; Ma, X; Meng, Q; Shu, X; Song, Z; Sun, H; Wang, C; Yu, H | 1 |
| Bai, Y; Chen, H; Chen, ZH; Chuai, S; Gan, B; Gao, H; Gou, LY; Han-Zhang, H; Jiang, BY; Li, A; Liu, SY; Su, J; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xie, Z; Xu, CR; Yang, JJ; Yang, XN; Yang, Z; Zhang, Q; Zhang, XC; Zhang, Z; Zhong, WZ; Zhou, Q | 1 |
| Mitsudomi, T | 2 |
| Aggarwal, C; Borghaei, H | 1 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Boyer, M; Dodd, N; Fan, J; Hirsh, V; Kim, DW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, DH; Lee, KH; Lu, S; Märten, A; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shi, Y; Tan, EH; Yang, JC; Zhang, L | 1 |
| Bai, H; Hong, C; Mei, TH; Wang, J | 1 |
| Dai, PC; Lai, GX; Lin, XH; Liu, DL; Wang, Q; Ye, J; Zhang, HW; Zhang, L | 1 |
| Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Cui, S; Jiang, L | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Cochin, V; Godbert, Y; Gross-Goupil, M; Le Moulec, S; Ravaud, A | 1 |
| Acunzo, M; Coppola, V; Croce, CM; Fadda, P; Fassan, M; Fattore, L; Kladney, R; Laganà, A; Nigita, G; Rizzotto, L; Romano, G; Veneziano, D; Zanesi, N | 1 |
| Kai, W; Shen, B; Song, Y; Sun, X; Xiao, Z | 1 |
| Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ | 1 |
| Bivona, TG; Chaib, I; Codony-Servat, C; Codony-Servat, J; de Los Llanos Gil, M; Karachaliou, N; Molina, MA; Ramirez, JL; Rosell, R; Solca, F | 1 |
| Chic, N; Mayo-de-Las-Casas, C; Reguart, N | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Höllhumer, R; Jacob, K; Moloney, G | 1 |
| Chen, H; Hu, J; Li, D; Li, J; Shi, M; Wang, X; Zhang, H; Zhang, L; Zhang, R | 1 |
| Asano, M; Ito, H; Kobayashi, H; Miura, M; Okuda, Y; Sato, K; Takeda, M; Yokota, H | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Burbridge, MF; Cattan, V; Chargari, C; Clémenson, C; Deutsch, E; Ferté, C; Jacquet-Bescond, A; Liu, W; Mondini, M | 1 |
| Bosch-Barrera, J; Costa, EC; Insa, A; Isla, D; Kraemer, S; Lee, C; Majem, M; Moran, T; Palmero, R; Provencio, M; Puig, M; Reguart, N; Rosell, R; Schnell, D | 1 |
| Chang, CH; Chang, LY; Ko, JC; Lee, CH; Lee, MC; Wang, JY; Yu, CJ | 1 |
| Honkanen, T; Koivunen, JP; Koivunen, P; Wilenius, E | 1 |
| Chen, SF; Zhang, JL; Zhang, ZY | 1 |
| Bennouna, J | 1 |
| Fan, XX; Fu, J; He, JX; Huang, J; Jiang, ZB; Kam, RK; Leung, EL; Liu, L; Liu, ZQ; Lu, LL; Luo, LX; Wei, CL; Wu, JL; Xiao, DK; Xie, Y; Yao, XJ; Yuan, ZW; Zheng, YF; Zhou, YL | 1 |
| Bernatowicz, PL; Pancewicz-Wojtkiewicz, J | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K | 1 |
| Bai, P; Chen, L; Li, W; Luo, H; Peng, A; Tang, M; Wan, L; Wang, F; Wen, J; Wu, W; Yang, J; Yang, L; Yang, S; Ye, H; Zheng, L | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Chen, KC; Chen, PC; Cheng, CH; Huang, YH; Lan, CH; Lee, WY; Lin, CW; Wu, HC; Wu, WS | 1 |
| Cao, Y; Jiang, AY; Jiang, XF; Jin, H; Wang, H; Wu, Y | 1 |
| Chiba, R; Kudo, K; Moriguchi, S; Morikawa, N; Nihei, S; Saito, H; Sato, J; Yamauchi, K | 1 |
| Beretta, GD; Caprioli, A; Ceresoli, GL; Codignola, C; Fraccon, AP; Meriggi, F; Ogliosi, C; Prochilo, T; Scartozzi, M; Zaniboni, A | 1 |
| Chen, G; Cheng, Y; Feng, J; Hu, C; Huang, C; Huang, Y; Liu, X; Lu, S; Song, Y; Tan, FL; Wu, G; Wu, YL; Yan, HH; Yang, JJ; Zhang, L; Zhong, W; Zhou, C | 1 |
| Atagi, S; Hirashima, T; Imai, K; Isa, SI; Iwazaki, A; Nakao, K; Nishihara, T; Okamoto, N; Okishio, K; Omachi, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Cui, Y; Flamini, V; Jiang, WG | 1 |
| Bennouna, J; Chouaid, C; de Pouvourville, G; Do, P; LeLay, K; Luciani, L; Moro-Sibilot, D; Perol, M; Vergnenègre, A | 1 |
| Fei, Z; Jiang, H; Wang, H | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Akiyama, N; Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Inui, N; Iwaizumi, M; Karayama, M; Kono, M; Kusama, Y; Nakamura, Y; Suda, T; Suzuki, Y | 1 |
| Guo, R; Jin, S; Min, H; Shu, Y; Wen, W; Wu, H; Xu, T; Zhang, Z | 1 |
| Cao, B; Li, F; Liang, L; Wang, J; Zhu, T | 1 |
| Benveniste, MF; de Groot, PM; Papadimitrakopoulou, VA; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC | 1 |
| Arulananda, S; Do, H; Dobrovic, A; John, T; Mitchell, P; Musafer, A | 1 |
| Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, S; Zhang, W | 1 |
| Fujii, I; Hagiwara, M; Katayama, M; Kobayashi, SS; Nakase, I; Sugiyama, A; Takatani-Nakase, T; Takenaka, T | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Chen, CY; Lee, H; Lin, PL; Wang, L; Wu, DW; Wu, TC | 1 |
| Baek, YM; Hwang, YE; Jang, D; Kim, DE; Park, H | 1 |
| Li, J; Tang, C; Zhou, B | 1 |
| Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Bejjanki, H; Bishnoi, R; Reisman, D | 1 |
| Ando, M; Fujiwara, T; Hasegawa, Y; Inoue, A; Katakami, N; Nagase, K; Shimizu, S; Takahashi, T; Takeuchi, S; Yano, S; Yoshimura, K | 1 |
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Migliorino, MR; Mok, TS; Nadanaciva, S; Nakagawa, K; Niho, S; Pluzanski, A; Rosell, R; Sandin, R; Sbar, EI; Tsuji, F; Wang, T; White, JL; Wu, YL; Zhou, X | 1 |
| Arqués, O; Cedrés, S; Fasani, R; Felip, E; Guillaumet-Adkins, A; Heyn, H; Martinez de Castro, A; Martinez-Marti, A; Matito, J; Mereu, E; Miquel, JM; Nadal, E; Navarro, A; Nuciforo, P; Palmer, HG; Pardo, N; Remon, J; Rodriguez-Esteban, G; Villanueva, A; Vivancos, A | 1 |
| Planchard, D | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Goldman, JW; Harrop, B; John, T; Kao, S; Kim, DW; Kim, HR; Kim, SW; Kim, TM; Lee, JS; Lin, CC; Natale, R; Overend, P; Rabbie, S; Su, WC; Yang, JC; Yang, Z | 1 |
| Hou, S; Li, Y; Liu, Q; Liu, Y; Qi, M; Shao, L; Zhang, J | 1 |
| Epistolio, S; Forcella, M; Frattini, M; Freguia, S; Fusi, P; Monti, E; Oldani, M | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Gotoda, H; Hotta, K; Ichihara, E; Ichimura, K; Kato, Y; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ohashi, K; Tamura, T; Tanaka, T | 1 |
| Chen, Z; Feng, X; Gao, Y; He, J; Li, X; Liu, T; Lv, Z; Pan, H; Wang, Y; Xie, S; Yang, W; Yang, X; Zhang, J | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Diao, L; Fan, Y; Gomez, D; Haddad, V; Herbst, R; Heymach, JV; Hong, WK; Howells, K; Hung, MC; Kim, ES; Lee, JJ; Li, L; Lim, SO; Liu, D; Nilsson, MB; Pena, GA; Poteete, A; Sequist, LV; Sood, AK; Sun, H; Tong, P; Tran, H; Wang, J; Wistuba, I; Yang, JC | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A | 1 |
| Kodama, K; Maniwa, T; Takeda, M; Yamamoto, Y | 1 |
| Bai, XY; Chen, HJ; Chen, ZH; Dong, ZY; Jiang, BY; Ke, EE; Luo, DL; Mei, P; Su, J; Sun, YL; Tu, HY; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zheng, MY; Zhong, WZ; Zhou, Q | 1 |
| Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Lungershausen, J; Märten, A; Massey, D; Mok, T; O'Byrne, K; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Gao, XX; Han, B; Jiang, ZM; Li, C; Wang, P; Wang, XH; Yang, RF; Yu, B; Zhang, L; Zhang, RQ; Zhang, Y | 1 |
| Cho, HJ; Choi, CM; Choi, YD; Hur, JY; Kim, TO; Kim, YC; Lim, JH; Oh, IJ; Park, CK; Shin, HJ | 1 |
| Wu, X | 1 |
| Fukumoto, S; Harada, M; Kiuchi, S; Oizumi, S; Watanabe, M; Yamada, N; Yokouchi, H | 1 |
| Li, Z; Lu, C; Ma, L; Wang, J; Zhang, K; Zhang, T; Zhang, Y; Zhu, M; Zhuang, X | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| Fan, T; Liu, XL; Song, YJ; Wei, YN; Yang, H; Zhou, J | 1 |
| Wang, N; Zhang, T | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Bowman, RV; Fong, KM; Sim, EH; Wood-Baker, R; Yang, IA | 1 |
| Girard, N | 2 |
| Chen, J; Guo, R; Wang, X; Yao, J | 1 |
| Bommu, UD; Konidala, KK; Pamanji, R; Yeguvapalli, S | 1 |
| Chiba, M; Gemma, A; Ishikawa, A; Kobayashi, K; Kubota, K; Kunugi, S; Noro, R; Seike, M; Zou, F | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Loong, HHF; To, KKW; Wu, WKK | 1 |
| Amador, M; Andrade Santiago, JM; Aparisi, F; Arriola, E; Artal, A; Barneto, I; Diz, P; García Gómez, R; Gutierrez, V; Isla, D; Majem, M; Martínez Aguillo, M; Paredes, A; Peralta Muñoz, S; Ponce, S; Provencio, M; Sánchez-Torres, JM; Valdivia, J; Vicente Baz, D | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
| Bai, R; Bode, AM; Dong, Z; Fan, S; Liu, K; Lu, B; Yang, R; Yeung, YT; Yin, S; Zhang, C | 1 |
| Dietel, M; Eberhardt, WEE; Muehlenhoff, L; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Baba, K; Hasegawa, Y; Ishioka, Y; Itoga, M; Nakagawa, H; Taima, K; Takanashi, S; Tanaka, H; Tanaka, Y; Tasaka, S | 1 |
| Li, X; Wang, J; Wang, Y; Xing, L; Yang, Z; Yu, J; Zhang, T; Zheng, L | 1 |
| Feng, M; Li, L; Li, Y; Liu, W; Liu, Z; Ma, X; Wang, L; Yi, Y; Zhang, W | 1 |
| Hirashima, T; Iwata, K; Masuhiro, K; Morishita, N; Morita, S; Nasu, S; Okamoto, N; Ryota, N; Shiroyama, T; Suzuki, H; Takata, SO; Tanaka, A; Ueda, Y | 1 |
| Lokhande, KB; Murthy, PS; Nagar, S; Reddy, PS; Reddy, VD; Swamy, KV | 1 |
| Lee, VHF | 1 |
| Lee, VHF; Yan, H; Zou, B | 1 |
| Alqahtani, S; Ashby, CR; Bates, SE; Chen, ZS; Deng, T; Gupta, P; Kaddoumi, A; Lei, YX; Wang, YJ; Wurpel, JND; Zhang, GN; Zhang, YK | 1 |
| An, T; Chang, J; Chen, M; Hua, Y; Li, W; Liu, X; Liu, Z; Lu, S; Lu, Y; Shi, J; Su, W; Wang, J; Yang, JJ; Yang, L; Zhou, J; Zhou, X | 1 |
| Miyoshi, S; Namba, K; Sakaguchi, M; Sato, H; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Yamamoto, H; Yoshioka, T | 1 |
| Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P | 1 |
| Chen, M; Tong, B; Wang, M; Xing, J; Xu, Y; Zhao, J; Zhong, W | 1 |
| Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y | 1 |
| Arimoto, T; Chihara, Y; Date, K; Imabayashi, T; Iwasaki, Y; Kaneko, Y; Morimoto, Y; Seko, Y; Takayama, K; Takemura, Y; Tanimura, K; Ueda, M | 1 |
| Feng, W; Ji, Y; Jin, L; Li, C; Liu, S; Wang, C; Xie, Q | 1 |
| Gao, F; Jiang, AY; Luo, HL; Lv, YF; Zhang, J | 1 |
| Hutton, D; Li, Q; Wen, F; Zhang, P; Zheng, H | 1 |
| Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W | 1 |
| Altan, M; Brahmer, JR; Carter, BW; Chen, T; Doebele, RC; Elamin, YY; Estrada-Bernal, A; Goldberg, SB; Heymach, JV; Le, AT; Li, S; Liu, S; Lu, C; Nilsson, MB; Papadimitrakopoulou, V; Politi, K; Poteete, A; Roarty, E; Robichaux, JP; Sun, H; Tan, Z; Truini, A; Wong, KK; Zhang, S | 1 |
| Chang, E; Gambhir, SS; Hori, SS; Hughes, NP; Kani, K; Kjær, A; Lee, S; Mallick, P; Natarajan, A; Nielsen, CH; Wang, SX; Xu, L | 1 |
| Fukui, T; Harada, S; Igawa, S; Kasajima, M; Katagiri, M; Kubota, M; Kusuhara, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ozawa, T; Sasaki, J; Sugita, K; Yokoba, M | 1 |
| Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J | 1 |
| Romero, D | 1 |
| Gao, MY; Lin, C; Qin, Y; Wang, YF; Zhang, H | 1 |
| Ghaedi, K; Mojtabavi Naeini, M; Tavassoli, M | 1 |
| Bao, Y; Chen, Q; Liu, L; Sun, X; Wang, Y; Xu, Y | 1 |
| Burslem, K; Earnshaw, S; Graham, J; Lim, J | 1 |
| Goto, Y; Hasegawa, Y; Hosomi, Y; Inoue, A; Isobe, H; Kaburagi, T; Kato, T; Kim, YH; Kunitoh, H; Minato, K; Mori, Y; Nishio, M; Ohashi, Y; Sakai, H; Tanai, C; Tomizawa, Y; Yamada, K; Yoh, K | 1 |
| Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M | 1 |
| Che, X; Hou, K; Hu, X; Kang, J; Liu, Y; Qu, X; Wang, J; Wang, Y; Zhang, T; Zheng, C | 1 |
| Li, F; Liang, L; Wang, J; Yue, Y; Zhu, T; Zhu, X | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Bai, C; Chang, M; Hu, J; Kwak, KJ; Lee, LJ; Li, J; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhou, J | 1 |
| Che, X; Fan, Y; Hou, K; Hu, X; Kang, J; Liu, Y; Qu, X; Wang, J; Zhang, T; Zhang, Y; Zhao, H; Zheng, C | 1 |
| Graziano, S; Sharma, N | 1 |
| Chen, J; Kang, C; Li, Y; Liu, H; Liu, M; Ren, D; Wang, R; Zhang, H | 1 |
| Goto, K; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Maeda, Y; Makimoto, G; Matsumoto, S; Ninomiya, K; Ninomiya, T; Ohashi, K; Sato, A; Tabata, M; Tomida, S; Toyooka, S; Umemura, S; Watanabe, H | 1 |
| Aarons, L; Martin, EC; Yates, JWT | 1 |
| Ishimoto, O; Kawashima, Y; Kikuchi, T; Kobayashi, K; Maeno, Y; Masumoto, AI; Nukiwa, T; Sugawara, S; Watanabe, S; Yamaguchi, OU; Yoshizawa, H | 1 |
| Bai, C; Chang, M; Fang, T; Hong, Q; Li, J; Zhang, G; Zhou, J | 1 |
| Charles Victor, J; Cheema, PK; Cheng, SY; Khanna, S; Leake, J; Thawer, A | 1 |
| Choi, CM; Hur, JY; Kim, HJ; Kim, SJ; Kim, YC; Lee, JC; Lee, KY; Lee, MK; Oh, IJ; Park, CK | 1 |
| Jassem, J | 1 |
| Chung, JG; Hsu, FT; Lin, SS; Wu, JY | 1 |
| Endo, T; Furukawa, K; Hayashihara, K; Hizawa, N; Ichimura, H; Inagaki, M; Kaburagi, T; Kikuchi, N; Kimura, M; Kurishima, K; Miyazaki, K; Nakamura, H; Nawa, T; Saito, K; Satoh, H; Tamura, T; Yamashita, T | 1 |
| Liu, S; Lv, X; Sun, K; Yang, X; Yin, J | 1 |
| Harada, T; Kawano, Y; Kimura, S; Liu, R; Nakanishi, Y; Okamoto, I; Shibahara, D; Tanaka, K | 1 |
| Chihara, Y; Hasegawa, I; Hiranuma, O; Hiraoka, N; Kaneko, Y; Kubota, Y; Shiotsu, S; Takayama, K; Takeda, T; Takumi, C; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, A | 1 |
| Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Wang, Y; Zhou, L; Zhou, S | 1 |
| Bonner, M; Kim, JY; Liu, Z; Pangeni, R; Raz, DJ; Tong, TR; Wang, J; Wu, J; Yang, L; Yuan, YC; Yuchi, T; Yun, X; Zhang, K | 1 |
| Shirley, M | 1 |
| Dagogo-Jack, I; Ferris, L; Gainor, JF; Lin, JJ; Nagy, R; Shaw, AT; Stevens, SE | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Chiba, M; Fujino, T; Jänne, PA; Kobayashi, Y; Koga, T; Kosaka, T; Mitsudomi, T; Nishino, M; Ohara, S; Sesumi, Y; Shimoji, M; Suda, K; Suzuki, M; Takemoto, T; Tomizawa, K | 1 |
| Dai, L; Lu, L; Lv, D; Su, X | 1 |
| Aisa, HA; Cao, JG; Huang, GZ; Liu, FZ; Nie, LF; Wang, SS; Xiamuxi, H | 1 |
| Ikeuchi, T; Ishikawa, S; Tokuyasu, H | 1 |
| Chen, SM; Chen, X; Han, SW; Long, SQ; Wu, WY; Yang, XB | 1 |
| Golabiewska, E; Holownia, A; Niechoda, A; Rybak, A; Zarzecki, M | 1 |
| Kawai, S; Kitazono, M; Murata, K; Ohashi, K; Takahashi, Y; Takamori, M; Wada, A; Yamamoto, M | 1 |
| Jing, Z; Wang, XJ; Zhang, N; Zhou, RJ | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Liu, J; Qu, G; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhang, G; Zhou, J | 1 |
| Hu, Y; Peng, L; Wang, C; Xu, S; Zhang, B; Zhang, H; Zheng, P; Zhu, W | 1 |
| Fang, Y; Pan, HM; Ren, YL; Sheng, J; Zhou, XY | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Barasa, L; Gupta, V; Kulkarni, NS; Muth, A; Parvathaneni, V; Perron, JC; Shukla, SK; Yoganathan, S | 1 |
| Bertran-Alamillo, J; Burbridge, M; Cantero, F; Cardona, AF; Castellví, J; Cattan, V; Codony-Servat, C; Codony-Servat, J; García-Román, S; Giménez-Capitán, A; Karachaliou, N; Molina-Vila, MA; Rodríguez, S; Roman, R; Rosell, R; Schoumacher, M; Teixidó, C; Viteri, S | 1 |
| Ji, YX; Nie, KK; You, YH; Zhu, C | 1 |
| Liu, X; Shi, F; Su, L; Sun, W; Sun, X; Wang, Y; Yao, S; Zhang, Y | 1 |
| Jin, B; Liu, J; Liu, Y; Qu, X; Su, H | 1 |
| Cressey, R; Khaodee, W; Kunnaja, P; Udomsom, S | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Ahsmann, EJ; Eshuis, M; van Egmond, NH | 1 |
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Díaz-Rubio, E; González-Larriba, JL; Hernández, S; Manzano, A; Pérez, P; Puente, J; Sanz, J; Sotelo, M; Zugazagoitia, J | 1 |
| Huber, RM; Reck, M; Thomas, M | 1 |
| Bastida, C; Falchook, GS; Fu, S; Hong, DS; Jiang, Y; Kurzrock, R; Morgan-Linnell, SK; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
| Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ | 1 |
| Braakhuis, BJ; Brakenhoff, RH; Martens-de Kemp, SR; Nagel, R; Stigter-van Walsum, M; van Beusechem, VW; van der Meulen, IH | 1 |
| Akerley, WL; Cowie, RH; Hornberger, J; Nelson, RE; Spinella, DG | 1 |
| Alesini, D; Bria, E; Cantile, F; Ciardiello, F; Cortesi, E; Fasano, M; Morgillo, F; Passaro, A; Pellegrino, A | 1 |
| Brekken, RA; Buettner, R; Chatterjee, S; Christofori, G; Frasca, D; Heukamp, LC; Koker, M; König, K; Meder, L; Neumaier, B; Peifer, M; Rauh, D; Schöttle, J; Siobal, M; Thomas, RK; Ullrich, RT; Wieczorek, C; Wolf, J | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Hu, CP; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Sterman, DH | 1 |
| Altavilla, G; De Pas, TM; Rosell, R; Santarpia, M; Spaggiari, L | 1 |
| Juhász, E; Kim, JH; Klingelschmitt, G; Walzer, S | 1 |
| Araya, T; Demura, Y; Kasahara, K; Matsuoka, H; Nishi, K; Nishitsuji, M | 1 |
| Eckert, R; Faehling, M; Griese, U; Kamp, T; Kuom, S; Ott, G; Spengler, W; Sträter, J | 1 |
| Bayne, M; Cherrett, L; Davis, R; Fenton, P; Laurence, V | 1 |
| Atagi, S; Fukuoka, M; Imai, M; Katakami, N; Kudoh, S; Matsui, S; Ogiwara, A; Ueda, M; Yoshioka, H | 1 |
| Armand, JP; Bahleda, R; Baselga, J; Berman, D; Calvo, E; Felip, E; Hanna, N; Harbison, CT; Herbst, RS; Kurland, JF; Laurie, SA; Park, JS; Pathak, AK; Shepherd, FA; Soria, JC; Vakkalagadda, B; Zhang, S | 1 |
| Adachi, E; Matsugo, S; Matsumoto, K; Michikoshi, H; Nakamura, T; Sakai, K; Suzuki, Y | 1 |
| Cai, J; He, C; Lin, B; Shao, L; Song, Z; Yu, X; Zhang, B; Zhang, Y | 1 |
| Akashi, M; Chin, TM; Doan, NB; Koeffler, HP; Mori, S; Said, JW; Sudo, M | 1 |
| Ke, S; Pan, G; Zhao, J | 1 |
| Irifune, K; Ito, R; Miyawaki, S; Sayama, K; Tohyama, M | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S | 1 |
| Chen, Y; Huang, Y; Mei, Q; Xia, S; Yu, S | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Noor, A; Teugels, E; Umelo, IA | 1 |
| Fukudo, M; Ikemi, Y; Inui, K; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Terada, T; Teramukai, S; Togashi, Y | 1 |
| Giuliani, J; Marzola, M | 2 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Nakayama, S; Naoki, K; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Burton, L; Cowan, KJ; Hampton, GM; Hegde, PS; Lackner, MR; Li, C; Merchant, M; Parab, V; Patel, P; Penuel, E; Peterson, A; Yauch, RL | 1 |
| Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ | 1 |
| Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, JI; Kim, JY; Kim, S; Kim, TM; Koh, Y; Lee, JK; Lee, S; Lee, SH; Min, HS; Park, C; Shin, JY | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Kurokawa, M; Omi, K | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Ettinger, DS; Kris, MG | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B; Schwartz, EL; Sironi, J; Zou, Y | 1 |
| Alden, CM; Blumenschein, GR; Davis, SE; Herbst, R; Heymach, J; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Tang, X; Tran, H; Tsao, AS; Wistuba, I | 1 |
| Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N | 1 |
| Hou, K; Hu, X; Kang, J; Liu, Y; Mu, X; Qu, X; Zhang, Y | 1 |
| Chao, T; Chen, Y; Chu, Q; Gui, Q; Han, N; Peng, P; Xia, S; Yu, S; Zhuang, L; Zou, M | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Chen, G; Guo, Y; Li, Z; Liu, H; Wang, Y; Zhang, L | 1 |
| Bae, S; Jeong, JH; Kang, S; Kim, CH; Kim, EJ; Lim, YB | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Aragane, N; Harada, T; Ichinose, Y; Kawakami, S; Kishimoto, J; Morinaga, R; Nagata, S; Nakanishi, Y; Saruwatari, K; Takayama, K; Yamada, K | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Kishi, A; Kiyohara, Y; Yamazaki, N | 1 |
| Blanchet, B; Boudou-Rouquette, P; Dupin, N; Goldwasser, F; Mortier, L; Sakji, L; Thomas-Schoemann, A; Vidal, M; Zhen, Y | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Chouaid, C; Pérol, D; Pérol, M | 1 |
| Liang, JQ; O'Connell, J; Ramalingam, SS | 1 |
| Cappuzzo, F; D'Arcangelo, M | 1 |
| Brenner, R; Hirsch, FR; Ikeda, N; Ilouze, M; Kato, Y; Mascaux, C; Ohira, T; Peled, N; Qian, J; Wynes, MW; Yoshida, K | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Evans, T; Gettinger, S; Hensing, TA; Ireland, B; Socinski, MA; Stinchcombe, TE; VanDam Sequist, L | 1 |
| Agelaki, S; Agelidou, M; Christofillakis, C; Georgoulias, V; Giassas, S; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Rapti, A; Samonis, G; Souglakos, J; Vamvakas, L; Voutsina, A | 1 |
| Chen, X; Liu, Y; Pei, D; Schuler, M; Shu, Y; Yin, Y; Zhu, L; Zhu, Q | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Imamura, F; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Mori, M; Namba, Y; Nonen, S; Otani, Y; Tachibana, I; Takimoto, T; Tsuruta, N; Uchida, J; Yokota, S | 1 |
| Cho, YS; Kim, HU; Kim, JI; Nam, KH; Park, J; Yun, SK | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S | 1 |
| Barzotti, E; Crinò, L; Drudi, F; Mangianti, M; Papi, M; Poggi, B; Ravaioli, A; Salvi, M; Santelmo, C | 1 |
| Aisner, J; Dakhil, SR; Manola, JB; Schiller, JH; Sovak, MA; Stella, PJ | 1 |
| Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D | 1 |
| Fang, X; Gu, P; Huang, B; Liang, A; Liu, F; Ren, S; Wu, Y; Yi, X; Zeng, Y; Zhang, Z; Zhao, Y; Zhou, C | 1 |
| Lazarus, DR; Ost, DE | 1 |
| Chen, PC; Chu, CY; Shih, YH | 1 |
| Carr, LL; Jett, JR | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Bode, AM; Byun, S; Dong, Z; Farrand, L; Jeong, CH; Kim, JY; Lee, HJ; Lee, J; Lee, MH; Lee, SY; Lim, S; Reddy, K; Won Lee, K | 1 |
| Arpin, D; Bringuier, PP; Couraud, S; Locatelli-Sanchez, M; Riou, R; Souquet, PJ | 1 |
| Fukuoka, J; Ichihara, E; Iioka, H; Kiura, K; Kondo, E; Kuwahara, K; Ohtani, N; Saito, K; Takigawa, N; Tomita, Y; Ueda, R | 1 |
| Ho, JC; Lam, SK; Li, YY; Mak, JC; Zheng, CY | 1 |
| Gao, H; Guo, W; Liu, X | 1 |
| Costanzo, R; De Lutio, E; Franco, R; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rachiglio, AM; Rocco, G; Sandomenico, C | 1 |
| Idowu, MO | 1 |
| Bellevicine, C; Carlomagno, C; De Luca, C; de Rosa, N; De Stefano, A; Iaccarino, A; Illiano, A; Malapelle, U; Micheli, P; Pepe, F; Piantedosi, FV; Rocco, D; Russo, S; Salatiello, M; Troncone, G; Vitiello, F | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Kieszko, R; Kowalski, DM; Krawczyk, KW; Krawczyk, P; Krzakowski, M; Milanowski, J; Mlak, R; Rolski, A; Szczyrek, M; Szudy, A; Winiarczyk, K | 1 |
| Chen, MJ; Li, LY; Wang, MZ; Zhang, L; Zhao, J; Zhong, W | 1 |
| Baas, P; Blumenschein, GR; Butts, CA; Chao, RC; Chmielowska, E; Gao, F; Gridelli, C; Groen, HJ; Grossi, F; Harmon, C; Juhasz, E; Selaru, P; Socinski, MA; Tye, L; Usari, T; Williams, JA | 1 |
| Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J | 1 |
| Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH | 1 |
| Cheng, F; Chu, DT; Du, CX; Li, WG; Liu, ZD; Mi, YL; Peng, Y; Tang, KK; Wang, Y; Xi, XM; Yang, HY; Zhang, XR; Zhao, LM; Zheng, YQ | 1 |
| Belani, CP; Benner, RJ; Chachoua, A; Cuevas, JD; Eisenberg, PD; Mather, CB; Meech, SJ; Nemunaitis, JJ; Raez, LE | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Han, ZG; Shan, L; Wang, Q; Zhang, Y | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, E; Lee, SH | 1 |
| Castellanos-Rizaldos, E; Guha, M; Makrigiorgos, GM | 1 |
| Hayakawa, H; Honda, Y; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kudo, K; Minami, D; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 2 |
| Barry, ST; Bradford, JR; Brown, H; Carr, TH; Delpuech, O; Dry, JR; Farren, M; Gibson, NJ; Powell, SJ; Runswick, S; Smith, NR; Wappett, M; Weston, SL | 1 |
| Gavine, P; Huang, XS; Ji, Q; Li, M; Su, X; Wu, YL; Xie, L; Yang, XN; Zhan, P; Zhang, J; Zhang, L; Zhang, XC; Zheng, L; Zhong, WZ; Zhou, M; Zhu, G | 1 |
| Grossman, S; Mehta, M; O'Neill, A; Robins, HI | 1 |
| Sperduto, PW | 1 |
| Chen, S; Ding, W; Gu, J; Kim, S; Li, X; Pan, M; Tian, W; Zhang, L; Zheng, L | 1 |
| Aoki, Y; Fujii, T; Ishii, N; Kondoh, O; Mio, T; Ono, N; Sakata, K; Suda, A; Tsukaguchi, T; Tsukuda, T; Yamazaki, T | 1 |
| An, J; Gao, H; Guo, W; Li, J; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, W | 1 |
| Aloj, SM; Chiaviello, A; Palumbo, G; Postiglione, I | 1 |
| Piccart, M | 1 |
| Gao, FH; Guo, YH; Jiang, B; Shi, J; Yuan, HH | 1 |
| Cho, BC; Hong, YK; Kim, HJ; Kim, JH; Kim, SM; Solca, F; Yun, MR | 1 |
| Jacobson, BA; Jay-Dixon, J; Kratzke, RA; Patel, MR; Sadiq, AA | 1 |
| Dziadziuszko, R; Jassem, J | 2 |
| Bettini, A; Bianchi, F; Broggini, M; Farina, G; Floriani, I; Ganzinelli, M; Garassino, MC; Giaccone, G; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Scanni, A; Tomirotti, M; Torri, V; Veronese, S | 1 |
| He, C; Li, Y; Liu, M; Xu, J; Xu, Y; Zheng, L | 1 |
| Ellis, PM; Leighl, NB; Sehdev, S; Verma, S; Younus, J | 1 |
| Altug, S; Digumarti, R; Han, B; Kim, HK; Kim, SW; Lee, DH; Lee, JS; Orlando, M; Rodrigues-Pereira, J; Sahoo, TP; Song, XQ; Wang, J; Wang, X | 1 |
| Chen, ZG; Curran, WJ; Deng, X; Hu, Z; Khuri, FR; Li, R; Owonikoko, TK; Ramalingam, SS; Sica, GL; Sun, SY | 1 |
| Bhatt, VR; Ganti, AK; Kedia, S; Kessinger, A | 1 |
| Chamberlain, MC | 1 |
| Thompson, CA | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Havel, L; Hrnciarik, M; Krejci, J; Minarik, M; Pesek, M; Salajka, F | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Chikamori, K; Fukuyama, T; Goto, K; Hida, T; Katakami, N; Kozuki, T; Maemondo, M; Nishio, M; Seto, T; Tamura, T; Yamamoto, N; Yoshioka, H | 1 |
| Bradbury, PA; Hilton, JF; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH | 1 |
| Chen, B; Li, B; Xiao, F; Xie, B; Zhang, W; Zheng, J; Zhou, J | 1 |
| Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A; Visa, J | 2 |
| He, CS; Wei, SH; Xie, M; Zhang, L | 1 |
| Stinchcombe, TE; Weiss, JM | 1 |
| Gao, BL; Hang, JB; Hu, JA; Xu, ZH | 1 |
| Bedi, A; Chang, X; Chatterjee, A; Goodman, SN; Harari, PM; Hidalgo, M; Izumchenko, E; Kim, MS; Ling, S; Monitto, CL; Sidransky, D; Solis, LM; Wistuba, II | 1 |
| Brown, PD; Komaki, R; McGovern, SL; Soh, HE; Wefel, JS; Welsh, JW | 1 |
| Chen, W; Dai, H; Xia, C; Xu, L | 1 |
| Aisner, DL; Berge, EM; Doebele, RC | 1 |
| Camidge, DR | 1 |
| Bai, C; Chen, J; Cheng, Y; Dai, H; Ding, L; Feng, J; Hu, C; Jiao, S; Jin, Y; Li, Q; Liang, L; Liu, W; Liu, X; Luo, R; Qin, S; Shi, Y; Song, Y; Sun, Y; Tan, F; Wang, D; Wang, J; Wang, Y; Wei, Z; Wu, YL; Xu, N; Zhang, H; Zhang, L; Zhang, S; Zhang, W; Zhang, Y; Zhou, C; Zhou, J | 1 |
| Pao, W; Yu, HA | 1 |
| Chen, JJ; Chen, X; Ma, SN; Zhao, J; Zhou, JY | 1 |
| Falchook, GS; Fok, JY; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, RG | 1 |
| Chen, JQ; Giaccone, G; Goldsmith, PK; Heldman, MR; Herrmann, MA; Lee, JH; Park, KS; Wang, Y | 1 |
| Butts, C; Choy, H; Ding, K; Edelman, MJ; Gandara, D; Goss, GD; Hensing, TA; Jett, J; Kernstine, K; Khuri, F; Lilenbaum, R; Lorimer, I; Masters, GA; Noble, J; O'Callaghan, C; Pisters, K; Rowland, K; Schiller, J; Shepherd, FA; Tsao, MS | 1 |
| Dungo, RT; Keating, GM | 1 |
| Alberti, AM; Apolone, G; Cammilluzzi, E; Cesario, A; D'Angelillo, RM; De Quarto, AL; Fiore, M; Greco, C; Ippolito, E; Ramella, S; Ramponi, S; Trodella, L | 1 |
| Aerts, JG; Biesma, B; Burgers, S; Codrington, H; Dalesio, O; Dingemans, AM; Groen, HJ; Lankheet, NA; Smit, EF; Vincent, AD | 1 |
| Chen, L; Fan, W; He, G; Lei, K; Lin, Y; Mo, Y; Xiang, M; Yang, M | 1 |
| Gao, HJ; Liu, H; Qin, HF; Qu, LL; Wang, SS | 1 |
| Amoroso, D; Chao, TY; Chung, CY; Ciuleanu, T; Groen, HJ; Heo, DS; Klingelschmitt, G; Klughammer, B; Middleton, G; Milanowski, J; Szczesna, A; Thatcher, N; Tsai, CM; Tsao, CJ; Zeaiter, A | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Koba, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Torres-Garcia, VZ; Vazquez-Martin, A; Visa, J | 1 |
| Chen, Y; Wang, M; Zhao, J; Zhong, W | 1 |
| Imamura, F; Kijima, T; Komuta, K; Kumagai, T; Kumanogoh, A; Minami, S; Mori, M; Morita, S; Nakazawa, Y; Namba, Y; Nishino, K; Okuyama, T; Tachibana, I; Takahashi, R; Uchida, J; Yamamoto, S; Yano, Y | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Diao, P; Wang, LY; Wei, Y; Xie, H; Yao, WX; Zeng, C; Zhao, X; Zhou, H; Zhou, J | 1 |
| Boisdron-Celle, M; Fey, L; Hureaux, J; Morel, A; Rieux, C; Urban, T | 1 |
| An, C; Xuan, X; Zhou, C | 2 |
| Baty, F; Betticher, D; Brutsche, M; Bubendorf, L; Cathomas, R; Crowe, S; Dröge, C; Früh, M; Gautschi, O; Pless, M; Rauch, D; Rothschild, S; Zappa, F | 1 |
| Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL | 1 |
| Shen, W; Turchi, JJ; Xu, J; Zeng, LF; Zhang, ZY | 1 |
| Barrajón-Catalán, E; Bosch-Barrera, J; Corominas-Faja, B; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A | 1 |
| Chen, CH; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
| Bai, F; Ding, K; Ku, X; Li, H; Liu, X; Tu, Z; Xu, Y; Zhang, L; Zhao, Z; Zhou, W | 1 |
| Chang, KT; Chen, JT; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Chen, YM; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, WS | 1 |
| Cho, SY; Choi, J; Hwang, JJ; Jang, SJ; Kim, CS; Lee, G; Lee, JH; Lee, SW; Lim, C; Seo, J; Song, JY | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Digumarthy, S; Goldberg, SB; Jackman, DM; Lennes, IT; Muzikansky, A; Oxnard, GR; Sequist, LV | 1 |
| Ahn, JS; Ahn, MJ; Cho, EK; Kang, ES; Kang, JH; Kim, SW; Lee, DH; Lee, GW; Lee, JS; Lee, JW; Lee, KH; Park, K; Sun, JM | 1 |
| Bowles, DW; Jimeno, A; Weickhardt, A | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Deng, CH; Li, HQ; Li, L; Li, MY; Lu, W; Wu, Q; Zhou, TY | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Barlesi, F; Blumenschein, GR; Daniel, DB; Ervin, TJ; Godbert, B; Goldschmidt, JH; Govindan, R; Krzakowski, MJ; Orlov, SV; Patel, PH; Patel, T; Peterson, AC; Phan, SC; Ramlau, RA; Robinet, G; Spigel, DR; Wertheim, MS; Yauch, RL; Yu, W; Zha, J | 1 |
| Bowden, C; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Kressel, B; Lin, CY; Marsland, T; Miller, V; Patel, T; Polikoff, J; Rubin, M; White, L; Yang, JC | 1 |
| Hao, X; Li, J; Lin, L; Shi, Y; Wang, B; Zhang, X | 1 |
| Chen, S; Hao, X; Li, J; Lin, L; Shi, Y; Wang, B; Zhang, X | 1 |
| Baudrin, L; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Herman, D; Lavolé, A; Mennecier, B; Milleron, B; Molinier, O; Moreau, L; Morin, F; Moro-Sibilot, D; Pichon, E; Poudenx, M; Quoix, E; Sennelart, H; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Fukuda, M; Iida, T; Ikeda, T; Ikegami, Y; Kohno, S; Mizoguchi, K; Motoshima, K; Nagashima, S; Nakamura, Y; Sano, K; Takemoto, S; Tsukamoto, K | 1 |
| Dai, B; Fang, B; Gao, W; Hofstetter, WL; Lu, H; Meng, J; Minna, J; Roth, JA; Swisher, SG; Wang, L; Wu, S | 1 |
| Li, YQ; Sun, H; Xue, D | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Abraham, I; Bustin, F; De Vos, L; Galdermans, D; Lechat, I; Van Meerbeeck, J | 1 |
| Cai, HR; Ding, JJ; Liu, L; Miao, LY; Ren, SX; Schmid-Bindert, G; Wang, YS; Zhou, CC | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Gatti, R; Giovannetti, E; La Monica, S; Petronini, PG; Saccani, F; Sirangelo, R; Tiseo, M | 1 |
| Goss, GD; Hirsh, V; Laurie, SA; Leighl, NB; Nicholas, G; Oza, A; Philip, L; Reaume, MN; Schwock, J; Shepherd, FA; Tsao, MS; Wang, L; Wright, JJ | 1 |
| Akinaga, S; Fujisaka, Y; Hayashi, H; Hirashima, T; Miyoshi, K; Murakami, H; Nakagawa, K; Satouchi, M; Takahashi, T; Takeda, K; Yamamoto, N | 1 |
| Mennecier, B; Quoix, A; Sakhri, L | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Bosdet, I; Ho, C; Ionescu, D; Karsan, A; Laskin, JJ; Mariano, C; Melosky, B; Murray, N; Sun, S; Zhai, Y | 1 |
| Fujimoto-Ouchi, K; Furugaki, K; Harada, N; Iwai, T; Moriya, Y | 1 |
| Li, X; Shen, Y; Tang, D; Wang, M; Wang, Y; Yao, R; Yao, Y; Zhang, H | 1 |
| Gröschel, A; Reck, M; Reinmuth, N | 1 |
| Costa, DB; de Figueiredo-Pontes, LL; Gonzalez, DA; Kobayashi, S; Lucena-Araujo, AR; Nakayama, S; Yamaguchi, N; Yasuda, H | 1 |
| Ahmad, A; Bao, B; Gadgeel, SM; Ginnebaugh, KR; Li, Y; Maitah, MY; Sarkar, FH | 1 |
| Bennouna, J; Dansin, E; Favrel, S; Hiret, S; Kowalski, D; Krzakowski, M; Penel, N; Tourani, JM | 1 |
| Hishima, T; Hosomi, Y; Kato, K; Nagamata, M; Okamura, T; Okuma, Y; Sekihara, K; Yamada, Y | 1 |
| Koyama, N; Uchida, Y | 1 |
| Azuma, K; Hoshino, T; Itoh, K; Kasama-Kawaguchi, Y; Kim, J; Matsueda, S; Muta, E; Nishio, K; Sasada, T; Sugawara, S; Yamada, T; Yamashita, T; Yamashita, Y; Zhang, GL | 1 |
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Brahmer, JR; Guaglianone, PP; Hidalgo, MM; Keppen, MD; Kolesar, JM; Lee, JW; Patel, JD; Schiller, JH; Siegfried, JM; Traynor, AM | 1 |
| Fang, X; Gu, P; Luo, BF; Ren, SX; Wu, YJ; Yi, XH; Zeng, Y; Zhao, YM; Zhou, CC; Zhu, XY | 1 |
| Song, Z; Zhang, Y | 1 |
| Gemma, A; Kitamura, K; Kubota, K; Matsuda, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Noro, R; Okano, T; Seike, M | 1 |
| Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M | 1 |
| Ciuleanu, T; Cobo, M; Douillard, JY; McCormack, R; Milenkova, T; Ostoros, G; Webster, A | 1 |
| Han, JY; Kim, H; Kim, HT; Lee, GK; Lee, YJ; Yun, T | 1 |
| Chen, Q; Li, Q; Liu, J; Qian, X; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, R; Xu, T; Zheng, J | 1 |
| Lee, VH; Lee, VW; Schwander, B | 1 |
| Gu, YF; Mo, ML; Song, P; Su, D; Zhang, F; Zhang, H; Zhang, SC | 1 |
| Ito, S; Itoh, K; Nishimura, Y; Takiguchi, S | 1 |
| Molina-Pinelo, S; Pastor, MD; Paz-Ares, L | 1 |
| Jang, SH; Jang, TW; Kim, HJ; Kim, HR; Kim, KS; Kim, SY; Kim, YC; Lee, GH; Lee, JC; Lee, JE; Lee, KY; Lee, MK; Lee, SY; Oh, IJ; Ryu, JS; Shin, KC; Son, JW | 1 |
| Besse, B; Bonardel, G; Chargari, C; Farace, F; Gontier, E; Hadoux, J; Helissey, C; Lamand, V; Le Moulec, S; Soria, JC; Tanz, R; Vedrine, L | 1 |
| Deng, HB; Gong, YB; Kang, XH; Wang, LF; Wang, ZQ; Wu, J; Xu, ZY; Zhao, XZ | 1 |
| Gauler, TC; Harbeck, N; Solca, F | 1 |
| Chen, M; Chen, X; Fan, L; Fei, K; Gao, G; Garfield, D; He, Y; Kuang, P; Li, B; Li, X; Ren, S; Schmit-Bindert, G; Su, C; Wang, Y; Zhou, C; Zhou, S | 1 |
| Liu, Z; Shi, L; Tang, J; Tong, L | 1 |
| Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR | 1 |
| Baio, G | 1 |
| Eicheler, W; Holler, M; Meier, F; Minjgee, M; Rodemann, HP; Saki, M; Toulany, M | 1 |
| Afonso-Afonso, FJ; Alonso-Jáudenes, G; Amenedo, M; Barón-Duarte, FJ; Campos-Balea, B; Casal Rubio, J; Fírvida-Pérez, JL; Huidobro, G; Lázaro-Quintela, M; López-Vázquez, MD; Santomé, L; Vázquez, S | 1 |
| Arcila, ME; Chaft, JE; Cohen, DW; Costa, DB; Eck, MJ; Hanna, M; Huberman, MS; Ishioka, K; Kobayashi, SS; Lathan, CS; Lucena-Araujo, AR; Meyerson, M; Moran, T; Nakayama, S; Oxnard, GR; Park, E; Riely, GJ; Sequist, LV; Sng, NJ; Soo, RA; Yamaguchi, N; Yasuda, H; Yeo, WL; Yun, CH | 1 |
| Arnold, AM; Boyer, MJ; Bradbury, PA; Chen, EX; Clingan, P; Ding, K; Ellis, PM; Fenton, D; Goss, GD; Hirsh, V; Laberge, F; Laurie, SA; Lee, CW; Montenegro, A; Seymour, L; Shepherd, FA; Solomon, BJ; Stockler, MR; Zukin, M | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Nakagawa, T; Yano, S | 1 |
| Afonso, J; Amenedo, M; Casal, J; Fírvida, JL; Lázaro, M; Santomé, L; Vázquez, S | 1 |
| Bannerji, R; Edelman, MJ; Jou, YM; Joy, AA; Martin, JC; Nemunaitis, J; Small, K; Statkevich, P; Stephenson, JJ; Yao, SL; Zhang, D; Zhou, H; Zhu, Y | 1 |
| Hager, H; Khalil, AA; McCulloch, T; Meldgaard, P; Mellemgaard, A; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Andreoli, R; Ardizzoni, A; Azzoni, C; Bartolotti, M; Bortesi, B; De Palma, G; Gelsomino, F; Goldoni, M; Mozzoni, P; Mutti, A; Silini, EM; Tiseo, M | 1 |
| Dhanda, R; Mallick, R; Nadler, E; Pan, IW | 1 |
| Bai, Q; Chen, X; Du, Y; Hou, J; Nan, J; Wang, Q; Wang, Y; Yang, J; Zhang, J; Zhang, X; Zhu, N | 1 |
| An, J; Gao, H; Li, J; Li, X; Liu, X; Liu, Y; Qin, H; Qu, L; Tang, C; Wang, W; Yang, S | 1 |
| Baresic, T; Basso, SM; Del Conte, A; Lumachi, F; Minatel, E; Schinella, D | 1 |
| Antoine, M; Cadranel, J; Duruisseaux, M; Lacave, R; Lavole, A; Leprieur, EG; Rabbe, N; Rozensztajn, N; Ruppert, AM; Vieira, T; Wislez, M | 1 |
| Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Narita, C; Niioka, T; Sato, K | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Ishii, Y; Isobe, H; Kobayashi, K; Maemondo, M; Minegishi, Y; Sugawara, S; Watanabe, S; Yoshizawa, H | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 2 |
| Fang, MH; Li, RC; Yu, SY; Zheng, LJ | 1 |
| Yaqub, F | 1 |
| Akar, A; Altiok, S; Bepler, G; Chiappori, A; Gray, JE; Haura, E; Kish, JA; Kreahling, J; Lush, R; Neuger, A; Pinder-Schenck, M; Schell, MJ; Tanvetyanon, T; Tetteh, L; Williams, CC; Zhao, X | 1 |
| Keating, GM | 2 |
| He, C; Lin, B; Lou, G; Shao, L; Song, Z; Yu, X; Zhang, B; Zhang, Y | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Garassino, MC; Torri, V | 1 |
| Harada, D; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Ju, L; Zhou, C | 1 |
| Chen, CY; Chiu, HC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Wo, TY | 1 |
| Horn, L; Lammers, PE; Lovly, CM | 1 |
| Fukihara, J; Hasegawa, Y; Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Taniguchi, H; Watanabe, N; Yokoyama, T | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Cao, X; Hong, Z; Lan, L; Li, N; Luo, L; Pan, X; Shen, L; Yin, Z; Zhang, Y; Zhou, Y | 1 |
| Barry, ST; Eberlein, C; Farren, M; Rooney, C; Ross, SJ; Weir, HM | 1 |
| Hashimoto, M; Iwakami, S; Kato, M; Kobayashi, I; Koizumi, F; Minakata, K; Moriyama, H; Moriyama, M; Murakami, A; Nara, T; Nurwidya, F; Shimada, N; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Bertran-Alamillo, J; Bivona, T; Carcereny, E; Costa, C; Drozdowskyj, A; Felip, E; Garcia-Campelo, R; Gervais, R; Giannikopoulos, P; Giménez-Capitán, A; Karachaliou, N; Majem, M; Massuti, B; Molina, MA; Moran, T; Ono, M; Rosell, R; Taron, M; Viteri, S; Wei, J | 1 |
| Chan, DC; Jensen, RT; Mantey, SA; Moody, TW; Moreno, P | 1 |
| Azuma, K; Hattori, S; Hoshino, T; Itoh, K; Kawahara, A; Komatsu, N; Matsueda, S; Sasada, T | 1 |
| Camidge, DR; Campbell, AK; Engelman, JA; Gadgeel, SM; Gernhardt, D; Giaccone, G; Jänne, PA; Khuri, FR; Koczywas, M; Letrent, S; Liang, J; O'Connell, JP; Rajan, A; Reckamp, KL; Ruiz-Garcia, A; Taylor, I | 1 |
| Couturier, O; Fosse, P; Hachemi, M; Hureaux, J; Lacœuille, F; Urban, T; Vervueren, L | 1 |
| Fan, X; Jiang, L; Li, S; Liu, Z; Wu, X; Zhao, H; Zhu, F | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dong, XL; Dong, Z; Li, G; Li, XL; Mu, XY; Ni, YH; Sun, EL; Sun, J; Yi, Z | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Bader, AG; Kelnar, K; Zhao, J | 1 |
| Bohnet, S; Deppermann, KM; Eiff, MV; Fischer, JR; Heigener, DF; Koester, W; Kortsik, C; Pawel, JV; Reck, M; Schnabel, PA; Thomas, M | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Deng, Y; Fan, X; Fu, X; Gao, Y; Li, W; Ping, W | 1 |
| Heideman, DA; Kuiper, JL; Postmus, PE; Smit, EF; Thunnissen, E; van Wijk, AW | 1 |
| Hirata, M; Kagawa, S; Kanai, Y; Kawai, K; Naka, S; Nishii, R; Ohmomo, Y; Yoshimoto, M | 1 |
| Fang, Q; Li, N; Ou, W; Sun, HB; Wang, BX; Wang, SY; Ye, X; Zhang, L; Zhang, SL | 1 |
| Chen, G; Li, J; Lu, Q; Peng, L; Tan, C; Wan, X; Wang, Y; Yi, L; Zeng, X | 1 |
| Beltran-Alamillo, J; Benlloch, S; Bordogna, W; Botero, ML; Chen, D; de Aguirre, I; Gimenez-Capitán, A; Klughammer, B; Kovach, B; Lawrence, HJ; Mayo, C; Palma, JF; Queralt, C; Ramirez, JL; Ramón y Cajal, S; Schlegel, M; Shieh, F; Taron, M; Wu, L; Zhang, G | 1 |
| Guan, YS; He, Q; Li, M | 1 |
| Liu, J; Sun, W; Zhou, YM | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Weber, AM | 2 |
| Karachaliou, N; Morales-Espinosa, D; Rosell, R; Viteri, S | 1 |
| Rerknimitr, P; Rungtrakulchai, R | 1 |
| Katanasaka, Y; Kitamura, Y; Kodera, Y; Koizumi, F; Tamura, T; Yunokawa, M | 1 |
| Chi, HS; Cho, YU; Jang, S; Kim, SW; Kim, YJ; Park, CJ; Park, SH | 1 |
| Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Hwang, KE; Jeong, ET; Kim, BR; Kim, HR; Kim, YS; Kwon, SJ; Park, DS; Yoon, KH | 1 |
| Kato, M; Kobayashi, I; Murakami, A; Nurwidya, F; Shimada, N; Shukuya, T; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Carcereny, E; Cardenal, F; Cardona, AF; De Castro, J; Insa, A; Isla, D; Majem, M; Molina, MA; Moran, T; Pallarès, MC; Palmero, R; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Taron, M | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Burrafato, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Truini, A | 1 |
| Baumann, M; Benes, CH; Chowdhury, D; Efstathiou, JA; Greninger, P; Hülskötter, M; Kern, AM; Krause, M; Pan, Y; Settleman, J; Singh, A; Wang, M; Willers, H | 1 |
| Fan, XX; He, JX; Leung, EL; Li, N; Liu, L; Wu, JL; Zhou, YL | 1 |
| Adamczak, J; Chatterjee, S; Florin, A; Franz, T; Heukamp, LC; Hinze, Y; Neumaier, B; Schöttle, J; Siobal, M; Ullrich, RT; Wieczorek, C | 1 |
| Lin, CC; Tsai, CM; Wang, SY | 1 |
| Pan, YY; Wu, M; Yuan, Y; Zhang, Y | 2 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Dafni, U; Karlis, D; Peters, S; Smit, E | 1 |
| Amler, L; Desai, R; Do, A; Filvaroff, E; Fu, L; Huang, J; Januario, T; Koeppen, H; Lazarov, M; Lipkind, M; Louie, SG; Mohan, S; Pandita, A; Parab, V; Patel, P; Patel, R; Penuel, E; Peterson, A; Phan, SC; Raja, R; Ramakrishnan, V; Rangell, L; Shames, DS; Wistuba, I; Xia, X; Yauch, RL; Yu, W; Zha, J | 1 |
| Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N | 1 |
| Catania, C; de Marinis, F; Passaro, A | 1 |
| Koh, Y; Murakami, H; Serizawa, M; Takahashi, T; Watanabe, M; Yamamoto, N | 1 |
| Behringer, D; Desaiah, D; Dittrich, C; Hartmann, JT; Kazeem, G; Leschinger, MI; Papai-Szekely, Z; Sederholm, C; Vinolas, N; von Pawel, J | 1 |
| Chang, CX; Li, P; Qi, JL; Shi, SB; Tang, XY; Tian, J | 1 |
| Bajaj, PS; Carlson, JJ; Goertz, HP; Veenstra, DL | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Chang, JY; Hsiao, CJ; Liou, JP; Pai, HC; Pan, SL; Teng, CM; Tsai, AC; Wang, CY; Wang, JC | 1 |
| Chang, YW; Chen, HA; Chen, JC; Chiu, CF; Su, JL; Su, YH; Tseng, CF; Yu, YH | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Ali, CW; Bates, AT; Button, M; Califano, R; Chan, S; Chaudhuri, A; Danson, SJ; Dorey, N; Dua, D; Ellis, S; Khan, F; Lee, L; Mulvenna, P; Nicolson, M; Ottensmeier, C; Popat, S; Shaw, HM; Szabo, M; Upadhyay, S | 1 |
| Fang, Q; Jiang, Y; Yuan, Q | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Ding, D; Huang, H; Jia, X; Song, J; Sun, E; Yan, H; Zhang, Z; Zhong, R | 1 |
| Fujiwara, K; Hosokawa, A; Ichiba, Y; Kajiume, S; Kiba, T; Kimoto, S; Nakano, K; Nakashima, T; Ogawa, Y; Okada, Y; Taniguchi, H | 1 |
| Hayakawa, Y; Kaneto, N; Kato, S; Saiki, I; Sakurai, H; Yokoyama, S | 1 |
| Audigier Valette, C; Cadranel, J; Chabaud, S; Moro-Sibilot, D; Perol, D; Perol, M | 1 |
| Köhler, J; Schuler, M | 1 |
| Chang, J; Feng, Y; Luo, Z; Peng, W; Qiao, J; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, J | 1 |
| Geissler, M; Steins, M; Thomas, M | 2 |
| Hong, W; Lin, B; Mao, W; Zhang, B; Zhang, Y | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Harada, D; Honda, Y; Ichihara, E; Kiura, K; Murakami, T; Ninomiya, T; Ochi, N; Ohashi, K; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Bexon, AS; Boyd, TE; Conkling, P; de La Bourdonnaye, G; Mita, AC; Nemunaitis, JJ; Richards, DA; Smith, DA; Wages, D | 1 |
| Hager, H; Khalil, A; Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L | 1 |
| Fang, H; Huang, S; Li, S; Liu, R; Pan, H; Wang, Z; Zhou, J | 1 |
| Wu, YL; Yan, HH; Yang, JJ; Zhang, XC; Zhao, N | 1 |
| Aimiuwu, J; Blachly, JS; Gao, Y; Hicks, WJ; Li, J; Otterson, GA; Papp, A; Phelps, MA; Poi, M; Schaaf, LJ; Socinski, MA; Starrett, SL; Stinchcombe, TE; Villalona-Calero, MA; Wang, D; Wei, L; Zhao, W | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Chun, KS; Hong, YS; Jang, WJ; Jeong, CH | 1 |
| Kassem, MG; Korashy, HM; Rahman, AF | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Kuang, K; Yang, K; Yang, X | 1 |
| Aukema, TS; Burgers, SA; Klomp, HM; Rijna, H; Schaake, EE; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Farias-Hesson, E; Finigan, JH; Heasley, LE; Kang, J; Kern, JA; Kim, J; Leach, SM; Mason, RJ; Mishra, R; Ramamoorthy, P; Singleton, KR; Tan, AC; Vasu, VT; Yoo, M | 1 |
| Garzon, F; Geater, SL; Gopalakrishna, P; Iannotti, N; Lee, V; Lim, WT; Mok, TS; Reyderman, L; Reynolds, C; Smith, D; Spira, A; Thongprasert, S; Wang, B; Xu, L | 1 |
| Chang, JY; Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Butts, CA | 1 |
| Aieta, M; Bachi, A; Barni, S; Bearz, A; Bulotta, A; Cattaneo, A; de Marinis, F; De Pas, T; Doglioni, C; Floriani, I; Foti, S; Gregorc, V; Grigorieva, J; Grossi, F; Lazzari, C; Levra, MG; Mencoboni, M; Novello, S; Petrelli, F; Roder, H; Roder, J; Torri, V; Tsypin, M; Viganò, M | 1 |
| Cai, H; Chen, X; Miao, L; Wang, Y; Xia, H; Zhuang, Z | 1 |
| Chen, X; Gu, Y; Guo, R; Liu, L; Liu, P; Liu, Y; Lu, K; Røe, OD; Shu, Y; Wang, J; Wang, Z; Yin, Y; Zhu, L; Zhu, Q | 1 |
| Asada, M; Funahashi, Y; Ito, K; Semba, T; Uenaka, T; Wakabayashi, T | 1 |
| Ando, M; Asami, K; Endo, T; Fukuda, M; Ibata, H; Isa, S; Kamimura, M; Kawaguchi, T; Kozuki, T; Kubo, A; Nakagawa, H; Okano, Y; Saka, H; Sakamoto, K; Soejima, Y; Takada, M; Tamura, A; Tomizawa, Y; Yoshimi, M | 1 |
| Leighl, NB; Zer, A | 2 |
| Agrawal, R; Kumar, S | 1 |
| Aukema, TS; Burgers, SA; Codrington, HE; Klomp, HM; Rijna, H; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Wakelee, HA | 1 |
| Al-Batran, SE; Allgäuer, M; Atmaca, A; Jäger, E | 1 |
| He, C; Hong, W; Lou, G; Shao, L; Song, Z; Xie, F; Zhang, B; Zhang, Y; Zheng, L | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| DiPiro, PJ; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Kim, M; Kim, SW; Lee, DH; Massey, D; Park, K; Shi, Y; Sun, JM | 1 |
| Blumenthal, GM; Boyd, K; He, K; Jiang, X; Justice, R; Keegan, P; Khozin, S; Murgo, A; Pazdur, R | 1 |
| Fore, M; Mennecier, B; Prim, N | 1 |
| Ding, HR; Han, SY; Li, PP; Teng, F; Zhao, W | 1 |
| Han, Y; Jiang, T; Li, Q; Shang, Y; Wang, P; Yong, X; Yu, W; Zhang, P | 1 |
| Aisner, DL; Berge, EM; Damek, D; Doebele, RC; Poonia, S | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, C; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Ambudkar, SV; Chen, ZS; Fu, LW; Kathawala, RJ; Patel, A; Sodani, K; Talele, TT; Wang, YJ; Zhang, H; Zhang, YK; Zhu, H | 1 |
| Bianco, C; Giaccone, G; Lee, LC; Luo, J; Mitsudomi, T; Mok, T; Moon, YW; Okamoto, I; Park, KS; Pham, T; Raffeld, M; Rosell, R; Salomon, DS; Subramaniam, D; Wang, Y; Xi, L; Yatabe, Y | 1 |
| Alden, CM; Bashoura, L; Eapen, GA; Faiz, SA; Herbst, RS; Hong, WK; Jack Lee, J; Jimenez, CA; Liu, DD; Marom, EM; Massarelli, E; Mino, B; Morice, RC; Onn, A; Tran, HT; Wistuba, II | 1 |
| Lam, KC; Mok, TS | 1 |
| Altiok, S; Doshi, P; Fulp, W; Haura, EB; Sasser, K; Smith, MA; Song, L | 1 |
| Koh, Y; Kusuhara, M; Serizawa, M; Takahashi, T; Urakami, K; Watanabe, M; Yamaguchi, K; Yamamoto, N; Zangiacomi, V | 1 |
| Ardizzoni, A; Artioli, F; Bersanelli, M; Lucchi, L; Tiseo, M | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 2 |
| Ardizzoni, A; Cappuzzo, F; Cortinovis, D; de Marinis, F; Fontanini, G; Galetta, D; Gridelli, C; Grossi, F; Iurlaro, M; Lorusso, V; Novello, S; Santo, A | 1 |
| Hu, G; Liu, D; Long, G; Sun, W; Wang, J | 1 |
| Baty, F; Betticher, DC; Brauchli, P; Brutsche, M; Droege, C; Früh, M; Gautschi, O; Joerger, M; Klingbiel, D; Ochsenbein, A; Pless, M; Rothschild, S; Stahel, RA; von Moos, R; Zappa, F | 1 |
| Fonseca, T; Griebsch, I; Lungershausen, J; Mok, T; Paz-Ares, L; Popat, S; Stammberger, U; Wu, YL; Yang, JC | 1 |
| Li, H; Ma, D; Qu, Y; Wu, X; Yang, Y; Yin, Y | 1 |
| Choi, DY; Freeman, MR; Jung, JH; Kim, J; Kim, KP; Lee, JC; Lee, KY; Rho, JK; You, S | 1 |
| Ahn, MJ; Altug, S; Barraclough, H; Kang, JH; Kim, DW; Lin, CC; Mok, T; Orlando, M; Park, K; Srimuninnimit, V; Tsai, CM; Yang, JC | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| Chang, FY; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Banerji, U; Bhosle, J; de Bono, JS; O'Brien, ME; Popat, S; Puglisi, M; Stewart, A; Thavasu, P | 1 |
| Aieta, M; Gregorc, V; Lazzari, C; Lerose, R; Tartarone, A | 1 |
| Bode, AM; Chen, H; Dong, Z; Jeong, CH; Jung, SK; Kim, JE; Lee, HJ; Lee, KW; Lee, MH; Lee, SY; Lim, DY; Lim, TG | 1 |
| Bennouna, J; Bensadoun, RJ; Dielenseger, P; Malka, D; Moro-Sibilot, D; Mortier, L; Rey, JB; Scotté, F; Sicard, J; Wislez, M | 1 |
| Bao, Z; Chen, X; Liu, ZF; Zhang, P; Zhao, J; Zhou, JY | 1 |
| Escudero-Vilaplana, V; Gonzalez-Haba, E; Ribed, A; Sanjurjo, M | 1 |
| Ayoubi, JM; Broutin, S; Couderc, LJ; Friard, S; Gil, S; Goetgheluck, J; Paci, A; Picone, O; Tcherakian, C | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH; Sim, SH | 1 |
| Li, M; Lv, L; Lv, S; Lv, W; Song, B; Wang, J; Wei, H; Zhao, B | 1 |
| Meldgaard, P; Nissen, PH; Sorensen, BS; Weber, B; Winther Larsen, A | 1 |
| De, S; Dermawan, JK; Dowlati, A; Gurova, K; Narla, G; Pink, J; Sharma, N; Stark, GR | 1 |
| Krainhöfer, J; Reissig, A; Steinert, M; Walther, M | 1 |
| Bates, A; Counsell, N; Faivre-Finn, C; Hackshaw, A; Lee, SM; Lewanski, CR; Ngai, Y; Ottensmeier, C; Patel, N; Wadsworth, C | 1 |
| Asakuma, M; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Masuda, N; Otani, S; Sasaki, J | 1 |
| Iwata, T; Kim, YH; Mishima, M; Nagai, H; Nishimura, T; Ozasa, H; Sakamori, Y; Sunadome, H | 1 |
| Arakawa, H; Fukuoka, M; Harada, R; Johkoh, T; Kudoh, S; Kusumoto, M; Sakai, F; Ueda, M | 1 |
| Brunetti, A; De Rosa, V; Del Vecchio, S; Fonti, R; Gargiulo, S; Gramanzini, M; Greco, A; Iommelli, F; Monti, M; Ortosecco, G; Panico, M | 1 |
| Herbst, RS; Heymach, JV; Johnson, BE; Lockwood, SJ; Ryan, AJ | 1 |
| Chen, Q; Jiang, B; Li, Q; Liu, J; Pei, D; Qian, Y; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, T; Zheng, J; Zhu, F | 1 |
| Bunn, PA; Herbst, RS; Hirsch, FR | 1 |
| Auliac, JB; Berard, H; Bizieux, A; Bota, S; Chouaid, C; Corre, R; Descourt, R; Falchero, L; Fournel, P; Greiller, L; Greillier, L; Labrunie, A; Le Caer, H; Marin, B; Monnet, I; Schott, R; Vergnenegre, A | 1 |
| Ando, M; Hasegawa, Y; Kimura, T; Kojima, E; Nomura, F; Ogasawara, T; Saito, H; Shindoh, J; Sugino, Y; Suzuki, R; Takahashi, K; Yamamoto, M; Yoshida, N | 1 |
| Ali, SK; Chakraborty, C; Doss, GP; NagaSundaram, N; Rajith, B; Zhu, H | 1 |
| Meldgaard, P; Nexo, E; Sorensen, BS; Tsai, J; Weber, B; Wei, W; Wu, L | 1 |
| Jänne, PA; Paweletz, CP | 1 |
| Hayashi, H; Nakagawa, K; Nishio, K; Togashi, Y | 1 |
| Azuma, K; Hoshino, T; Izumi, H; Kage, M; Kawahara, A; Kuwano, M; Nakashima, K; Ono, M; Sonoda, K; Tashiro, K; Watari, K | 1 |
| Bae, MK; Hong, YS; Jang, WJ; Jeong, CH; Jeong, JW; Joo, SH; Jung, SK; Kang, JS; Kundu, JK; Park, GH | 1 |
| Ciuleanu, T; Cobo, M; Cole, R; Dearden, S; Douillard, JY; McCormack, R; McWalter, G; Milenkova, T; Ostoros, G; Walker, J; Webster, A | 1 |
| Colburn, D; Fehrenbacher, L; Hainsworth, J; Johnson, BE; Kabbinavar, F; Kasubhai, S; Klughammer, B; Kressel, B; Marsland, T; Miller, V; Patel, T; Rubin, M; White, L; Yang, JC | 1 |
| Bode, AM; Chen, H; Dong, Z; Li, H; Li, W; Lim, DY; Liu, K; Ma, WY; Oi, N; Peng, C; Reddy, K; Sheng, Y; Yao, K; Zhu, F | 1 |
| Akiyama, Y; Fujita, K; Hirose, T; Kusumoto, S; Nakashima, M; Sasaki, Y; Shirai, T; Sugiyama, T | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Brandes, AA; Buttitta, F; Centi, I; Chella, A; Crinò, L; Cuccurullo, F; De Pas, T; Del Grammastro, M; Felicioni, L; Filice, G; Malatesta, S; Marchetti, A; Santoro, A; Venturino, P | 1 |
| Ahn, HK; Cho, EK; Hong, J; Kim, YS; Lee, HY; Lee, JH; Park, I; Park, J; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Hata, A; Imai, Y; Katakami, N; Masago, K; Yatabe, Y | 1 |
| Carretero, J; Costa, DB; Hayashi, Y; Kobayashi, SS; Li, D; Nakayama, S; Sng, N; Soejima, K; Soo, RA; Tan, AJ; Welner, R; Wong, KK; Yamaguchi, N; Yamamoto, M; Yasuda, H | 1 |
| Asakuma, M; Harada, S; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Kusuhara, S; Masuda, N; Niwa, H; Otani, S; Sasaki, J | 1 |
| Rosell, R | 1 |
| Atagi, S; Fukuoka, M; Goto, K; Harada, R; Hida, T; Hosomi, Y; Kato, T; Maemondo, M; Nagase, S; Nakagawa, K; Nishio, M; Okamoto, I; Seto, T; Tajima, K; Yamamoto, N; Yamanaka, T | 1 |
| Chao, TT; Chen, KF; Chen, PT; Chen, YL; Huang, YC; Lai, CC; Lin, HI; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Bustos, D; Kirkpatrick, DS; Lin, E; Nicholes, K; Settleman, J; Song, Q; Stephan, JP; Wilson, C | 1 |
| Kim, EO; Kim, J; Kim, JH; Kim, SH; Lee, D; Lee, H; Lee, J; Yun, M | 1 |
| Luo, J; Shen, L; Zheng, D | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Arai, M; Hayashihara, K; Iwasawa, T; Kato, T; Ogura, T; Ohashi, K; Okudela, K; Saito, T; Satoh, H; Sekine, A; Tamura, K | 1 |
| Cecconi, M; Lane, K; Thomas, C | 1 |
| Dai, B; Fang, B; Gao, W; Gold, KA; Heymach, JV; Hofstetter, WL; Lu, H; Minna, J; Ou, Z; Roth, JA; Swisher, SG; Wang, L; Wang, M; Wu, S; Zhang, L | 1 |
| Chai, S; Ke, CQ; Lin, G; Tang, C; To, KK; Wang, YZ; Yao, S; Ye, Y; Yin, C | 1 |
| Bai, C; Chen, S; Ning, X; Sun, Z; Wang, Y; Yang, XD; Ying, H | 1 |
| Fang, W; Hong, S; Hu, Z; Kang, S; Liang, W; Qin, T; Sheng, J; Wu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, DY; Tan, FL; Wang, YX; Wu, YW; Zhao, Q; Zheng, X | 1 |
| Ahn, SH; Jeong, EH; Kim, CH; Kim, HR; Kim, SY; Lee, TG | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Berrino, L; Capuano, A; Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F; Sasso, FC | 1 |
| Banna, G; Cappuzzo, F; Catino, A; Chiari, R; Cortinovis, D; Crinò, L; D'Incecco, A; de Marinis, F; Facchinetti, F; Galetta, D; GiajLevra, M; Haspinger, ER; Landi, L; Milella, M; Minuti, G; Novello, S; Ricciardi, S; Rossi, E; Salvini, J; Santo, A; Tibaldi, C; Tiseo, M | 1 |
| Groen, HJ; Grünberg, K; Heideman, DA; Kuiper, JL; Smit, EF; Würdinger, T | 1 |
| Basappa, N; Butts, CA; Chambers, CR; Chu, MP; Chu, Q; Fenton, D; Ghosh, S; Joy, AA; Sangha, R; Sawyer, MB; Smylie, M | 1 |
| Dickgreber, NJ; Hoffknecht, P; Maria Huber, R; Märten, A; Pelzer, T; Schütz, M; Serke, M; Stöhlmacher-Williams, J; Tufman, A; Wehler, T; Wiewrodt, R | 1 |
| Demura, Y; Fujita, Y; Gemma, A; Harada, M; Ishii, Y; Ishimoto, O; Kobayashi, K; Maemondo, M; Matsumoto, Y; Miura, S; Morikawa, N; Okudera, K; Saijo, Y; Sato, I; Takamura, K; Usui, K | 1 |
| Ding, L; Gu, A; Han, B; He, J; Hu, X; Jia, X; Jiao, SC; Ma, K; Peng, J; Sun, Y; Tan, F; Wang, CL; Wang, J; Wang, Y; Wu, M; Ying, K; You, C; Zhang, L; Zhang, S; Zhang, Y | 1 |
| Boukovinas, I; Briasoulis, E; Dimopoulos, MA; Fountzilas, G; Kalogera-Fountzila, A; Karavasilis, V; Klouvas, G; Kosmidis, P; Kotoula, V; Mavropoulou, P; Papandreou, CN; Pectasides, D; Syrigos, KN | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Fukuoka, M; Imamura, F; Komuta, K; Kudoh, S; Seki, A; Yoshioka, H | 1 |
| Chen, HJ; Chen, JH; Chen, ZH; Cheng, Y; Feng, WN; Liu, YP; Song, Y; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhao, MF; Zhong, WZ; Zhou, Q | 1 |
| Ando, M; Arakawa, H; Ebina, M; Fukuda, Y; Fukuoka, M; Gemma, A; Inoue, Y; Ishii, T; Johkoh, T; Kudoh, S; Kusumoto, M; Kuwano, K; Nakagawa, K; Ohe, Y; Sakai, F; Seki, A; Taniguchi, H; Yamazaki, N | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Leung, JS | 1 |
| Hong, SS; Jang, WJ; Jeong, CH; Jeong, GS; Park, B | 1 |
| Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Alama, A; Ballestrero, A; Barletta, G; Boccardo, F; Carminati, E; Coco, S; Dal Bello, MG; Garuti, A; Genova, C; Grossi, F; Rijavec, E; Sini, C; Truini, A; Venè, R | 1 |
| Bai, F; Han, R; Jiang, F; Liu, Y; Pang, W; Shen, H; Tian, X; Wang, J; Xing, L; Yan, X; Zhang, X | 1 |
| Akamatsu, H; Endo, M; Hisamatsu, Y; Imai, H; Kenmotsu, H; Ko, R; Mori, K; Murakami, H; Naito, T; Nakashima, K; Ohde, Y; Omori, S; Ono, A; Oyakawa, T; Shukuya, T; Taira, T; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Furuyama, K; Gotanda, K; Harada, T; Ieiri, I; Iwama, E; Li, H; Nakanishi, Y; Okamoto, I; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Engle, JA; Kolesar, JM | 2 |
| Abdulrahman, R; Ahn, C; Bunn, PA; Camidge, DR; Choy, H; Doebele, RC; Dowell, J; Gaspar, LE; Gerber, DE; Hughes, R; Iyengar, P; Kavanagh, BD; Smith, I; Timmerman, R; Wardak, Z | 1 |
| Jabbour, SK | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Kanai, Y; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H | 1 |
| Chen, XQ; Lin, GN; Liu, DY; Liu, PP; Peng, JW; Xiao, JJ | 1 |
| Bastida, CC; Falchook, GS; Gaido, L; Jackson, T; Karp, DD; Miller, VA; Ordóñez, NG; Stephens, PJ | 1 |
| Gao, HM; Gao, Z; Jia, YF; Tan, W; Tian, YL; Wang, YS; Zhang, MX; Zhang, N; Zhang, RX; Zhao, JQ | 1 |
| Cui, J; Guo, QQ; Han, LL; Jiang, LL; Jing, L; Liang, X; Liu, Y; Liu, ZY; Ma, JQ; Nan, KJ; Wang, J; Wang, MC; Wu, T; Yang, CC; Yao, Y | 1 |
| Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
| Byeon, JH; Jung, YH; Kim, HR; Kim, TJ; Lim, JU; Park, CK; Woo, IS | 1 |
| Bogart, J; Bradley, J; Hodgson, L; Jänne, PA; Katragadda, S; Kong, FM; Lilenbaum, R; Masters, G; Samuels, M; Vokes, E; Wang, X | 1 |
| Jang, C; Li, J; Wang, J; Wu, F; Xiong, J | 1 |
| Li, ZX; Qiu, XS; Qu, LY; Wang, EH; Wen, H; Xu, K; Zhong, HS | 1 |
| Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK | 1 |
| Choi, DY; Jung, JH; Kim, J; Kim, KP; Lee, JW; Lee, KY; Lee, MY; You, S | 1 |
| Du, YJ; Hu, YM; Li, J; Qian, H; Shi, WL; Wu, Y; Zhu, LR | 1 |
| Liu, Z; Mao, JH; Wang, Q; Wang, Y; Wei, G; Wen, M; Yuan, H; Zhang, P | 1 |
| Jain, P; Khanal, R; Sharma, A; Sharma, N; Yan, F | 1 |
| Chen, LK; Dinglin, XX; Hou, X; Huang, JJ; Ma, SX; Qin, T; Wang, Z; Zeng, YD | 1 |
| Enoki, H; Katahira, K; Teraoka, A; Tsuchiya, Y; Yoshikawa, T | 1 |
| Jenks, S | 1 |
| Peters, S; Smit, E | 1 |
| Bennouna, J; Boyer, MJ; Docampo, LI; Doherty, JP; Goldberg, Z; Jänne, PA; Liang, JQ; Mather, CB; Mok, T; O'Byrne, K; O'Connell, J; Paz-Ares, L; Pluzanski, A; Ramalingam, SS; Shtivelband, M; Taylor, I; Von Pawel, J; Zhang, H | 1 |
| Guo, S; Li, Z; Liu, Y; Ren, G; Ren, J; Song, G; Wang, Y; Zhang, L | 1 |
| Guo, R; Huang, X; Shu, Y; Wu, H; Xiang, C; Yin, Y; Yu, Q; Yu, S; Zhang, B | 1 |
| Deng, H; Long, SQ; Pan, ZQ; Wu, WY; Yang, XB | 1 |
| Agarwal, VR; Ahmed, T; Bhatia, D; Bose, J; Choudhari, S; Damre, A; Deore, V; Joshi, A; Kumar, S; Lad, VJ; Pandey, PK; Sahu, B; Sangana, R; Sharma, S; Sonawane, V; Srivastava, A; Tannu, P; Venkataraman, M; Venkatesha, VA | 1 |
| Frank, M; Golpon, H; Lange, A; Prenzler, A; von der Schulenburg, JM; Welte, T | 1 |
| Huang, J; Ji, LJ; Liu, H; Liu, Y; Ma, W; Qi, X; Xu, M; Zhu, Y | 1 |
| Chen, B; Li, B; Xie, B; Zeng, Y; Zhang, W; Zheng, J; Zhou, J | 1 |
| Assaraf, YG; Azzariti, A; Giovannetti, E; Jansen, G; Kathman, I; Paradiso, A; Peters, GJ; Porcelli, L; Scheffer, GL | 1 |
| Byers, L; Coombes, KR; Date, H; Diao, L; Girard, L; Giri, U; Heymach, JV; Komaki, R; Lin, SH; Menju, T; Minna, JD; Saintigny, P; Wang, J; Weinstein, JN; Wistuba, II; Wu, CC; Zhang, J | 1 |
| Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L | 1 |
| Sheng, Z; Zhang, Y | 1 |
| Bortlicek, Z; Bruha, F; Fiala, O; Minarik, M; Mukensnabl, P; Pesek, M; Racek, J; Svaton, M | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Aokage, K; Hishida, T; Nagai, K; Tsuboi, M; Yoshida, J | 1 |
| Bidoli, P; Cappuzzo, F; Clementi, L; Cseh, A; Favaretto, A; Finocchiaro, G; Grossi, F; Marchetti, A; Massey, D; Santoro, A; Valente, ML | 1 |
| Balikó, Z; Sárosi, V | 2 |
| Abe, M; Aoki, M; Fujii, T; Fujimoto-Ouchi, K; Hashimoto, E; Motegi, H; Nagahashi, S; Nakatani, N; Sakata, K; Sano, Y; Sasaki, E; Satoh, Y; Sugimoto, M; Yatabe, Y | 1 |
| Cappuzzo, F; Landi, L | 1 |
| Koeffler, HP; Leong, G; Madan, V; Mori, S; Sudo, M; Yang, H | 1 |
| Nakamoto, Y; Nakatsura, T; Ofuji, K; Saito, K; Shimomura, M; Tada, Y; Yoshikawa, T; Yoshimura, M | 1 |
| Chang, FY; Chao, CH; Chao, TT; Chen, KF; Chen, YL; Huang, YC; Lai, CC; Shiau, CW; Tsai, YT; Wang, CY; Yu, CJ | 1 |
| Cheng, Y; Fan, Y; Han, B; Huang, C; Liu, X; Liu, Y; Lu, S; Ma, S; Song, X; Wang, J; Wang, M; Yang, S; Zhang, L; Zhang, S; Zhao, H; Zhou, C | 1 |
| Bugés, C; Capdevila, L; Carcereny, E; Cardona, AF; Cros, S; Moran, T; Reguart, N; Rosell, R | 1 |
| Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Niioka, T; Sato, K | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| Amadori, D; Burgio, MA; Calistri, D; Capelli, L; Casanova, C; Chiadini, E; Crinò, L; Dazzi, C; Delmonte, A; Dubini, A; Gamboni, A; Mariotti, M; Papi, M; Puccetti, M; Ragazzini, A; Ulivi, P; Verlicchi, A | 1 |
| Chen, Y; Liu, J; Wang, C; Wang, M; Zhang, L; Zhao, X | 1 |
| Pirker, R | 1 |
| Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M | 1 |
| Chang, H; Chang, WC; Ho, CL; Hsu, HH; Hsu, YC; Huang, TW; Ko, KH; Tung, HJ; Wu, YC | 1 |
| Ma, H; Tian, JH; Tian, X; Wang, F; Wang, X; Wang, Y; Zhang, Y; Zhou, JG | 1 |
| Biswas, B | 1 |
| Socinski, MA; Spitzer, G | 1 |
| Ando, M; Kawaguchi, T; Kubo, A | 1 |
| Chen, X; Zhou, C; Zhou, F | 1 |
| Chang, YL; Chao, SW; Chen, CC; Huang, WJ; Lin, YC; Shih, JY | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Kobayashi, K; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Sugawara, S | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Asano, H; Furukawa, M; Hashida, S; Kanazawa, S; Maki, Y; Miyoshi, S; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Liao, BC; Lin, CC; Yang, JC | 2 |
| Barberis, M; Catania, C; Conforti, F; de Marinis, F; De Pas, T; Lazzari, C; Noberasco, C; Spitaleri, G; Stufano, V; Toffalorio, F; Vecchio, F | 1 |
| Atagi, S; Hirashima, T; Kurata, K; Minomo, S; Nakatani, T; Okamoto, N; Okishio, K; Omachi, N; Saijo, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Reguart, N; Remon, J | 1 |
| Andratschke, N; Hildebrandt, G; Kuhnt, T; Lewitzki, V | 1 |
| Chen, J; Han, H; Hu, H; Liu, C; Lu, H; Yang, Y; Yin, H; Zhang, P; Zhou, W; Zhu, L | 1 |
| Chang, CH; Ho, CC; Lee, CH; Wang, JY; Yu, CJ | 1 |
| Dhillon, S | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Chen, T; Qin, X; Wu, H; Xiong, H; Zhu, F; Zou, Y | 1 |
| Beijersbergen, RL; Bernards, R; Grernrum, W; Hölzel, M; Huang, S; Knijnenburg, TA; Nijkamp, W; Papadakis, AI; Sun, C; Wessels, LF; Xue, Y | 1 |
| Becker, A; Heideman, DA; Kuiper, JL; Ronden, MI; Smit, EF; Thunnissen, E; van Hengel, P; Ylstra, B | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Bahleda, R; Burris, H; Jiang, J; Lager, J; Liu, L; LoRusso, P; Macé, S; Martini, JF; Soria, JC | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H | 1 |
| Ding, L; Shi, Y; Sun, Y; Tan, F; Wang, Y; Yuan, X | 1 |
| Carcereny, E; de Marinis, F; Drozdowskyj, A; Dubos-Arvis, C; Passaro, A; Perez-Moreno, P; Rosell, R; Vergnenegre, A; Zeaiter, A | 1 |
| Alama, A; Barisione, G; Bello, MG; Ferrini, S; Gangemi, R; Grossi, F; Orengo, AM; Truini, M | 1 |
| Fujii, A; Furuyama, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Okamoto, I; Okamoto, T; Ota, K; Takayama, K | 1 |
| Aoe, K; Bessho, A; Chikamori, K; Fujii, M; Harada, D; Hisamoto-Sato, A; Hosokawa, S; Hotta, K; Ichihara, E; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Nogami, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Berghmans, T; Grigoriu, B; Meert, AP | 1 |
| Kaneko, T; Lau, MR; Lunec, J; Margetts, J; Novello, S; Nutt, J; Plummer, R; Ramlau, R; Reck, M; Scagliotti, GV; Thomas, M | 1 |
| de Velasco, MA; Fujita, Y; Fumita, S; Hayashi, H; Nakagawa, K; Nishio, K; Okamoto, K; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Belani, CP; Joshi, M; Liu, X; Miller, B; Rice, SJ | 1 |
| Chen, X; Huang, H; Ma, S; Wang, B; Wu, K; Zhang, S; Zheng, X | 1 |
| Cai, N; Chen, X; Kong, X; Liu, P; Xu, L; Zhang, Y; Zhou, Y; Zou, H | 1 |
| Fujita, Y; Fukuhara, T; Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Cai, X; Chen, S; Deng, H; Fang, Y; Hu, M; Li, J; Li, Z; Vaughn, A; Wan, W; Wu, S; Xiao, J; Xu, L; Yang, X | 1 |
| Aerts, JG; Boons, CC; Boven, E; Hugtenburg, JG; Moes-Ten Hove, J; Smit, EF; Swart, EL; Timmers, L; van de Ven, PM | 1 |
| Azuma, H; Sakai, K; Suzuki, S; Takahashi, N | 1 |
| Chang, WA; Chong, IW; Chou, SH; Huang, MS; Hung, JY; Kuo, TY; Lee, JY; Liu, TC; Shen, CH; Tsai, MJ; Wu, KL; Yang, CJ; Yen, CJ | 1 |
| Fan, ZW; Li, J; Liu, Y; Xu, GG | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Bae, SY; Hong, JY; Lee, HJ; Lee, SK; Park, HJ | 2 |
| Beom, SH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH; Sim, SH | 1 |
| Ahn, HK; Cho, EK; Hong, J; Jeong, SH; Kang, SM; Kim, YS; Kyung, SY; Lee, JH; Park, I; Park, J; Park, JW; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Cioffredi, LA; Jackman, DM; Jacobs, L; Johnson, BE; Kesari, S; Lucca, J; Lynch, TJ; Marcoux, PJ; Morse, LK; Plotkin, SR; Rabin, MS; Sharmeen, F | 1 |
| Chen, LK; Dinglin, XX; Liang, JZ; Liao, H; Ma, SX; Qin, T; Wei, WD; Xu, F; Zeng, YD; Zhang, L | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Baumann, M; Brammer, I; Can, Y; Dikomey, E; Dorniok, F; Gal, A; Grob, TJ; Gurtner, K; Kasten-Pisula, U; Krause, M; Kriegs, M; Laban, S; Oertel, R; Petersen, C; Rieckmann, T; Wysocki, M | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Chang, YT; Huang, HJ; Hwang, MH; Lin, AM; Tang, MC; Wu, MY; Yang, JC | 1 |
| Han, S; Pu, R; Shi, LW; Zhao, YL | 1 |
| Liang, J; Su, N; Xie, Y | 1 |
| Castellanos, EH; Horn, L; Rivera, G; Wakelee, H | 1 |
| Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Seo, YH | 1 |
| Chung, C | 2 |
| Bai, C; Huang, Y; Liao, M; Luo, F; Ma, S; Qin, S; Shi, Y; Wang, C; Yu, S; Zhang, L; Zhang, Q; Zhi, X; Zhou, C | 1 |
| Che, XF; Hiramoto, M; Ito, K; Miyazawa, K; Moriya, S; Sugita, S; Yamashiro, Y; Yokoyama, T | 1 |
| Banno, E; Hayashi, H; Kobayashi, Y; Mitsudomi, T; Nishio, K; Togashi, Y | 1 |
| Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS | 1 |
| Dahlberg, SE; Jackman, DM; Jänne, PA; Johnson, BE; Lo, PC; Nishino, M; Oxnard, GR; Sequist, LV | 1 |
| Han, X; Liu, M; Lv, G; Ma, L; Shi, Y; Wang, S; Zeng, C | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Bigley, G; Blockley, L; Cresswell, C; Dale, A; Davies, A; de Boer, R; Donald, E; Elvin, P; Fan, S; Fu, H; Gladwin, A; Gray, N; Harrod, G; Herbst, RS; Ji, Q; Lee, JS; Morten, J; Platt, A; Read, J; Stevens, J; Su, X; Vasselli, J; Williams, V; Womack, C; Ye, Q; Zhang, T; Zheng, L | 1 |
| Chudacek, Z; Pesek, M; Svaton, M; Vosmiková, H | 1 |
| Arrieta, O; Bacon-Fonseca, L; de la Garza-Salazar, J; Flores-Estrada, D; López-Macías, D; Macedo-Pérez, EO; Martínez-Hernández, JN; Ramírez-Tirado, LA; Vega-González, MT | 1 |
| Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC | 1 |
| Huang, Y; Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Bassett, P; Chicklore, S; Chua, S; Cook, GJ; Goh, V; Loi, HY; O'Brien, ME; Punwani, R; Sharma, B; Siddique, M | 1 |
| Ahn, JS; Ahn, MJ; Chang, WJ; Choi, MK; Choi, YL; Do, IG; Hong, JY; Jung, HA; Kim, MJ; Kim, SM; Park, K; Sun, JM | 1 |
| Fujita, S; Hata, A; Hayashi, M; Katakami, N; Kawamura, T; Takeshita, J; Tomii, K | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Lee, KY; Li, W; Lu, S; Lungershausen, J; Palmer, M; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Hu, C; Li, M; Wang, Q | 1 |
| Gao, C; Gao, Y; He, W; Qu, W; Yu, Y; Zhang, S; Zhang, Y; Zhu, S | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y | 1 |
| Delaney, C; Frank, S; Huang, RS | 1 |
| Busto, ME; Koch, H; Kramer, K; Kuster, B; Médard, G | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Fan, LL; Gao, S; Li, WC; Li, XQ; Liu, JT; Sun, GP; Wang, F; Wang, H; Wei, W; Yu, HQ | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Daito, H; Ishikawa, R; Kawashima, A; Kobayashi, K; Maeno, Y; Masumoto, A; Murayama, Y; Okano, T; Shiono, A; Utsugi, H; Yamaguchi, O | 1 |
| An, G; Han, SY; Li, PP; Sun, H; Zhao, W; Zhou, F; Zhou, N | 1 |
| Ali, SM; Berry, J; Cascone, T; Guha-Thakurta, N; Heymach, JV; McMahon, C; Miller, V; Pai, S; Roxas, M; Subbiah, IM; Subbiah, V; Tang, Z | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Fujiwara, Y; Goto, Y; Hamada, A; Horinouchi, H; Kanda, S; Katsuya, Y; Nokihara, H; Ohe, Y; Osawa, S; Sunami, K; Takashima, Y; Tamura, T; Utsumi, H; Yamamoto, N | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Kim, H; Kim, M; Kim, S; Ku, BM; Lee, JY; Lee, MY; Lim, SH; Park, K; Sun, JM | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, F; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Rosano, C; Truini, A; Vanni, I; Venè, R | 1 |
| Asada, K; Imokawa, S; Inoue, Y; Inui, N; Karayama, M; Kasamatsu, N; Koshimizu, N; Matsuda, H; Shirai, T; Suda, T; Yamada, T; Yokomura, K | 1 |
| Doyle, KP; Flores, EJ; Kamdar, MM; Maytal, G; Mino-Kenudson, M; Rinehart, TJ; Sequist, LV | 1 |
| Cho, S; Kang, YK; Kim, BY; Kwon, T; Lee, JC; Park, YH; Rho, JK; Shin, HJ; Yoon, DY; Yu, DY | 1 |
| Gao, BL; Hang, JB; Hu, JA; Shun, WW; Xu, ZH | 1 |
| Hotta, K; Ichihara, E; Iwasaku, M; Kato, Y; Kiura, K; Kudo, K; Kunimasa, K; Oze, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Yoshioka, H | 1 |
| Ciardiello, F; Della Corte, CM; Fasano, M; Morgillo, F; Papaccio, F | 1 |
| Aydiner, A; Ciftci, R; Sen, F | 1 |
| Hall, PE; Popat, S; Spicer, J | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Chicchinelli, N; De Luca, A; Fenizia, F; Forgione, L; Franco, R; Iannaccone, A; Lambiase, M; Morabito, A; Normanno, N; Pasquale, R; Piccirillo, MC; Rocco, G; Rossi, A; Sacco, A | 1 |
| Chang, SN; Hsu, KH; Lin, CH; Pan, HC; Sheehan, J; Sheu, ML; Tsou, HK | 1 |
| Broggini, M; Garassino, MC; Torri, V | 1 |
| Geater, SL; Massey, D; Mok, TS; Ou, SH; Schuler, M; Sequist, LV; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Yu, CJ; Zazulina, V; Zhou, C | 1 |
| James, M; Jeong, JH; Lee, Y; Wang, Y; You, M | 1 |
| Busch, TM; Cengel, KA; Gallagher-Colombo, SM; Miller, J; Putt, ME; Vinogradov, SA | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Carpentier, O; Jégu, J; Prim, N; Purohit, A; Quoix, E; Selvaggi, L; Velten, M | 1 |
| Addison, CL; Bar, J; Bradbury, PA; Dimitroulakos, J; Ding, K; Goss, GD; Han, L; Laurie, SA; Seymour, L; Shepherd, FA; Zhao, H | 1 |
| Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Kramchaninov, MM; Moiseenko, FV; Moiseenko, VM | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, S; Bottoni, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Sambuceti, G; Truini, A; Vanni, I | 1 |
| Asano, H; Hatakeyama, S; Jida, M; Kawahara, E; Kiura, K; Kubo, T; Miyoshi, S; Naomoto, Y; Otani, H; Sakaguchi, M; Soh, J; Takaoka, M; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
| Hida, T; Kato, T; Kiura, K; Massey, D; Okamoto, I; Seki, Y; Seto, T; Yamamoto, N; Yokoyama, A; Yoshioka, H | 1 |
| An, T; Bai, H; Ding, X; Duan, J; Li, Z; Liu, Z; Shen, Z; Sun, Y; Wang, J; Wang, S; Wang, Y; Wang, Z; Wu, M; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Chen, HL; Hsiao, FY; Lu, HM; Shen, LJ; Wei, CP | 1 |
| Li, Y; Qian, K; Wang, R; Yao, S; Zhang, Y | 1 |
| Vignot, S; Zalcman, G | 1 |
| Guckenberger, M | 1 |
| Hirsh, V | 2 |
| Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kaneda, T; Katakami, N; Mori, M; Morita, S; Negoro, S; Nishino, K; Otsuka, T; Tachihara, M; Uchida, J; Urata, Y; Yano, Y; Yokota, S | 1 |
| Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ | 1 |
| Bagust, A; Beale, S; Boland, A; Dickson, R; Dundar, Y; Dwan, K; Greenhalgh, J; Hockenhull, J; Marshall, E; Mullard, A; Proudlove, C; Richardson, M | 1 |
| Hata, A; Katakami, N | 1 |
| Fang, WF; Hong, SD; Huang, Y; Ma, YX; Sheng, J; Tian, Y; Xue, C; Yang, YP; Zhang, L; Zhao, YY | 1 |
| Fan, Y; Gong, L; Huang, Z; Miao, L; Xiong, M | 1 |
| Fan, Y; Fang, L; Gong, L; Huang, Z; Lei, T; Mao, W; Miao, L; Yang, H; Yu, H | 1 |
| Eisele, DW; McCormick, F; Phuchareon, J; Tetsu, O | 1 |
| Ahn, MJ; Atagi, S; Jiang, H; Kim, SW; Lee, DH; Liu, Y; Lu, Y; Mok, TS; Nakagawa, K; Ponce, S; Shi, X; Soria, JC; Wang, J; Webster, A; Wu, YL; Yang, JC; Yang, JJ; Yoh, K; Zhou, JY | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
| Hu, P; Jiang, J; Liu, D; Liu, Y; Tan, F; Wang, Y; Wu, Y; Zhang, L | 1 |
| Cao, W; Chen, H; Huang, L; Liu, Y; Mei, L; Ming, P; Wang, T; Zhang, B; Zhang, H; Zhang, R; Zhu, X | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Akerley, W; Barlesi, F; Favaretto, A; Hirsh, V; Novello, S; Orlov, S; Ramlau, R; Ross, JS; Sandler, A; Santoro, A; Scagliotti, G; Schwartz, B; Sequist, LV; Shepherd, FA; Shuster, D; Spigel, D; von Pawel, J; von Roemeling, R; Wang, Q | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Arrieta, O; Baracos, VE; De la Torre-Vallejo, M; López-Macías, D; Macedo-Pérez, EO; Orta, D; Ramírez-Tirado, LA; Sánchez-Lara, K; Turcott, J | 1 |
| Aono, H; Azuma, K; Hosomi, Y; Kato, T; Komase, Y; Kunitoh, H; Morita, S; Nakahara, Y; Nishikawa, M; Oba, MS; Okamoto, H; Okuma, Y; Sato, A; Takeoka, H; Watanabe, K; Yamada, K | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Wadekar, R; Weber, AM | 1 |
| Bai, C; Chen, G; Ding, C; Feng, J; Gu, A; Han, B; He, J; Huang, C; Jian, H; Jiao, S; Li, F; Ling, Y; Liu, X; Luo, H; Luo, R; Pang, Q; Shi, Y; Shu, Y; Sun, Y; Wang, C; Wang, Z; Wu, M; Yang, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, Q; Zhou, C; Zhou, Y | 1 |
| Chu, W; Gao, L; Liu, J; Lv, B; Tan, G; Wang, R; Zhang, Y; Zhao, X; Zhen, Q | 1 |
| Cheong, JG; Choi, J; Jung, JW; Kang, M; Kim, HJ; Kim, TY; Lee, GH; Lee, HY; Lee, JW; Nam, SH; Ryu, J | 1 |
| Erasmus, JJ; Gold, KA | 1 |
| Chung, DH; Chung, JK; Heo, DS; Jeon, YK; Kang, KW; Keam, B; Kim, DW; Kim, TM; Lee, SH; Lee, SJ; Paeng, JC | 1 |
| Kim, YH; Mishima, M | 1 |
| Zhang, L; Zhao, H | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Miyoshi, Y; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Chen, J; Li, L; Luo, M; Pan, L; Qin, G; Qin, S; Yang, J; Zhang, Q | 1 |
| Kempf, E; Lacroix, L; Soria, JC | 1 |
| Asakuma, M; Fukui, T; Hamada, A; Hayashi, N; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katagiri, M; Katono, K; Kimura, M; Kubota, M; Maki, S; Masuda, N; Mitsufuji, H; Otani, S; Ryuge, S; Saito, H; Sasaki, J; Takakura, A; Toyooka, I; Wada, M; Yamamoto, M; Yokoba, M | 1 |
| Cao, X; Dong, W; Feng, W; Hong, S; Jia, J; Li, N; Lin, D; Peng, J; Wang, S; Xue, C; Zhang, H; Zhang, L; Zhang, W | 1 |
| Huang, XE; Shi, B; Xu, J; Zhang, XB | 1 |
| Chen, L; Guo, Y; Hu, Z; Huang, M; Huang, Y; Li, H; Li, J; Ma, Y; Wang, X; Xin, S; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Cascone, T; Heymach, JV | 1 |
| Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kudoh, S; Matusura, K; Mitsuoka, S; Nakai, T; Oka, T; Suzumira, T; Tochino, Y; Yoshimoto, N; Yoshimura, N | 1 |
| Li, E; Li, J; Qiao, H; Ren, K; Shi, H; Zhao, D | 1 |
| Hisada, T; Imai, H; Ishihara, S; Ishizuka, T; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Seki, K; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Utsugi, M; Yamada, M; Yoshino, R | 1 |
| Chiba, K; Kurokawa, T; Matsushima, Y; Nakanishi, Y; Narita, Y; Shiroiwa, T; Urushihara, H | 1 |
| Boone, E; Breyne, J; De Laere, E; Dedeurwaerdere, F; Demedts, I; Oyaert, M; Vandorpe, J | 1 |
| Becker, C; Engel, J; Eppmann, S; Getlik, M; Grütter, C; Heil, J; Heuckmann, JM; Hoffgaard, F; Kast, SM; Keul, M; Kibies, P; Krüll, J; Lategahn, J; Mayer-Wrangowski, S; Menninger, S; Ortiz-Cuaran, S; Rauh, D; Richters, A; Schaumann, N; Schultz-Fademrecht, C; Sos, ML; Termathe, M; Thomas, RK; Tinnefeld, V; Tomassi, S; Uhlenbrock, N; Zahedi, RP | 1 |
| Al-Shahrour, F; Becker, JH; Capelletti, M; Carretero, J; Jänne, PA; Kikuchi, E; Kuang, Y; Patel, TB; Paweletz, CP; Pulido, I; Shapiro, GI; Shimamura, T; Soucheray, M; Wong, KK; Xu, C | 1 |
| Bora-Singhal, N; Chellappan, S; Nguyen, J; Perumal, D | 1 |
| Chan, CH; Chan, HL; Chen, JT; Chou, HC; Chung, TW; Lin, CC; Lin, MW; Lyu, KW; Wen, YF; Wu, SB | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Fang, L; Li, F; Lin, N; Ma, S; Song, Y; Sun, X; Xu, Y; Zhang, Y | 1 |
| Marquez-Medina, D; Popat, S | 1 |
| Bianco, R; Carillio, G; Costanzo, R; Daniele, G; Giordano, P; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Azuma, Y; Futagami, S; Hamaguchi, M; Hikita, A; Hirashima, T; Iwata, K; Morishita, N; Okamoto, N; Ryota, N; Sando, M; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A; Tani, E | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Nomura, S; Ohe, Y; Ohmatsu, H; Sugiyama, E; Tsuboi, M; Umemura, S; Yoh, K | 1 |
| Allen, D; Bokobza, SM; Devery, AM; Jiang, Y; Kersemans, V; Ryan, AJ; Smart, S | 1 |
| Bianco, R; Brillante, S; Cosconati, S; D'Amato, V; De Placido, S; Di Mauro, C; Formisano, L; Marciano, R; Montuori, N; Orsini, RC; Parsons, SJ; Raimondo, L; Randazzo, A; Rosa, R; Servetto, A; Veneziani, BM | 1 |
| Khuri, FR; Ramalingam, SS | 1 |
| Hu, B; Jiang, J; Li, C; Liu, DY; Ni, J; Wang, HP; Zhang, L | 1 |
| Dai, D; Li, XF; Liu, JJ; Wang, J; Wang, Q; Xu, WG; Zhang, Y; Zhu, YJ | 1 |
| Igawa, S; Ishihara, M; Katagiri, M; Masuda, N; Otani, S; Sasaki, J; Takakura, A | 1 |
| Anaya, P; Arrieta, O; Morales-Oyarvide, V; Polanco, AC; Ramírez-Tirado, LA | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Cho, BC; Choi, JM; Choi, YR; Jang, JY; Kim, HR; Lee, HW | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Okuda, C; Otsuka, K; Takeshita, J | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Griesinger, F; Heigener, DF; Lüers, A; Märten, A; Sadjadian, P; Scheffler, M; Schumann, C; Sebastian, M; Stehle, I | 1 |
| Chua, KN; Goh, BC; Huynh, H; Kong, LR; Ng, HC; Ong, WR; Sim, WJ; Thiery, JP | 1 |
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Almeida, GM; Coelho, MA; Coelho, SC; Pereira, MC; Santos-Silva, F | 1 |
| Bessho, A; Hotta, K; Ichinose, Y; Katsui, K; Kishimoto, J; Kiura, K; Nogami, N; Saeki, S; Sasaki, J; Shioyama, Y; Takayama, K; Takigawa, N; Tanimoto, M | 1 |
| Abdel-Sattar, M; Sugay, A; Tien Ho, P; Ting, J; Wilson, L; Xiang, P | 1 |
| Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Di Gennaro, E; Leone, A; Mancini, R; Roca, MS; Terranova-Barberio, M; Vitagliano, C | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Laurie, SA; Seymour, L; Shepherd, FA; Zhao, H | 1 |
| Iwasa, T; Kaneda, H; Kudo, K; Nakagawa, K; Nishida, S; Nishio, K; Okamoto, I; Takahama, T; Takeda, M; Tanaka, K; Yonesaka, K; Yoshida, T | 1 |
| Kiessling, R; Lundqvist, A; Maeda, A; Nakata, M; Nakayama, E; Oka, M; Okita, R; Saisho, S; Seliger, B; Shimizu, K; Wolf, D; Yamaguchi, Y; Yasuda, K; Yukawa, T | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Gong, P; Li, H; Li, J; Li, N; Ma, X; Su, F | 1 |
| Fukusumi, M; Hamamoto, Y; Honma, C; Ibe, T; Kameyama, N; Kamimura, M; Mouri, A; Takeoka, S | 1 |
| Cai, K; Feng, S; Wang, H; Wang, Y; Wu, H; Xiong, G; Zhang, Z | 1 |
| Cui, F; He, X; Wang, M; Wang, W; Wu, D; Wu, J | 1 |
| Ahn, JH; Choi, CM; Choi, YJ; Kim, SW; Lee, DH; Lee, JS; Lee, SJ | 1 |
| Amellal, N; Bahleda, R; Deutsch, E; Farace, F; Gazzah, A; Hollebecque, A; Marzin, K; Massard, C; Ould-Kaci, M; Roux, F; Soria, JC; Varga, A | 1 |
| Alharbi, KK; Chakravarthy, S; Goud, I; Khan, IA; Lakshmi M, AM; Matam, K; Prasad, SV; Ravi, V; Shaik, NA; Sridhar, K; Syed, R; Tabassum, SN; Vijayanand, PR | 1 |
| Bode, AM; Chang, X; Chen, H; Dong, Z; Jiang, Y; Liu, K; Reddy, K; Ryu, J; Shi, C; Yao, K; Zhang, C; Zhang, Y; Zhao, S | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Fan, XX; Jiang, ZH; Leung, EL; Liu, L; Liu, ZQ; Lu, LL; Tin, VP; Wong, MP; Yao, XJ; Yau, LF; Zhou, YL | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; La Monica, S; Mutti, A; Petronini, PG; Saccani, F; Tiseo, M | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Morita, M; Ohtsuka, T; Sakaguchi, M; Soh, J; Suzawa, K; Tomida, S; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H | 1 |
| Cho, KM; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Chao, TT; Chen, KF; Chen, YL; Chu, PY; Hsiao, YJ; Hung, MH; Shiau, CW; Tai, WT; Wang, CY; Yu, HC | 1 |
| Diao, L; Fan, Y; Giri, U; Gudikote, J; Herbst, R; Heymach, JV; Johnson, BE; Koo, A; Lu, W; Nilsson, MB; Rowe, P; Ryan, A; Tang, X; Tong, P; Tran, H; Wang, J; Webster, A; Wistuba, II | 1 |
| Aebersold-Keller, F; Aebi, S; Baumann, C; Betticher, D; Buser, K; Büttner, R; Calderoni, A; Casty, A; Diebold, J; DʼAddario, G; Gautschi, O; Heukamp, LC; Irlé, C; Jehle-Schwertfeger, S; König, K; Mamot, C; Morant, R; Pellicioli, E; Stadelmann, C; Trojan, A | 1 |
| Ding, L; Feng, J; Hu, C; Hu, X; Li, Q; Liu, X; Luo, R; Qin, S; Shi, Y; Song, Y; Sun, Y; Tan, F; Wang, D; Wang, J; Wang, Y; Xv, N; Zhang, L; Zhang, S; Zhou, C; Zhou, J | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Jin, J; Liu, BZ; Wu, ZM | 1 |
| Liu, K; Ma, X; Shu, X; Sun, Y; Wang, C; Wang, Q; Wu, B; Zhen, Y; Zhou, Y; Zhu, X | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Cai, L; Hu, J; Li, C; Liu, W; Lu, H; Meng, Q; Ning, J | 1 |
| Dong, M; He, X; Li, J; Wang, J; Wang, Y; Wang, Z; Wu, Y | 1 |
| Chen, H; Gao, X; He, W; Li, B; Mei, C; Xu, R; Zhu, Y | 1 |
| Inoue, A; Kobayashi, K; Nukiwa, T; Watanabe, S | 1 |
| Bertrán-Alamillo, J; Bosch-Barrera, J; Bria, E; Carcereny, E; Chaib, I; Codony-Servat, C; Codony-Servat, J; Crisetti, E; de Marinis, F; Drozdowskyj, A; Felip, E; Felipe Cardona, A; García-Campelo, R; Gervais, R; Giménez-Capitán, A; González-Cao, M; Karachaliou, N; López-Vivanco, G; Luis Ramírez, J; Majem, M; Massuti, B; Miguel Sánchez, J; Molina-Vila, MA; Morales-Espinosa, D; Morán, T; Pilotto, S; Rosell, R; Sánchez Hernández, JJ; Santarpia, M; Sperduti, I; Teixidó, C; Vergnenegre, A; Verlicchi, A; Viteri, S | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Bae, SY; Hong, JY; Jung, C; Kang, JI; Lee, HJ; Lee, SK; Park, HJ | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Li, X; Lv, J; Nong, J; Qin, N; Wang, J; Wu, Y; Yang, X; Zhang, H; Zhang, Q; Zhang, S; Zhang, X | 1 |
| Chung, DH; Han, JJ; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, SH | 1 |
| Brower, V | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Chonan, M; Narita, N; Tominaga, T | 1 |
| Ahn, MJ; Kim, SW; Lin, CC; Mok, T; Orlando, M; Park, K; Puri, T; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC | 1 |
| Jia, L; Li, S; Li, W; Li, Y; Niu, M; Wang, T; Xu, S; Yang, Z; Zhang, S | 1 |
| Kang, HH; Kim, IK; Lee, HI; Lee, HY; Lee, SH; Mo, JY; Moon, HS; Yeo, CD | 1 |
| Dong, JY; Li, YL; Lin, NM; Mao, SY; Pan, JP; Pan, YN; Sun, J; Wu, WJ; Zhang, C; Zhang, DY; Zhao, YM | 1 |
| Altun, B; Cintosun, U; Tasci, I | 1 |
| Arrieta, O; Baracos, V; de la Torre-Vallejo, M; Turcott, J | 1 |
| Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV | 1 |
| Asai, K; Hirata, K; Isa, S; Kawaguchi, T; Kimura, T; Kubo, A; Kudoh, S; Matsuura, K; Mitsuoka, S; Nakai, T; Oka, T; Sawa, K; Suzumura, T; Tanaka, H; Uji, M; Watanabe, T; Yoshimoto, N; Yoshimura, N | 1 |
| Chiba, M; Gemma, A; Kubota, K; Matsumoto, M; Miyanaga, A; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T | 1 |
| Bao, H; Li, H; Wang, Q; Zhang, H; Zhuang, Y | 1 |
| Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K | 1 |
| Boye, M; Kang, JH; Kim, JS; Orlando, M; Puri, T; Rajan, N; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC | 1 |
| Dong, QZ; Han, Y; Jiang, GY; Liu, Y; Wang, EH; Wang, L; Wang, S | 1 |
| Hirsh, V; Massey, D; Mok, T; O'Byrne, K; Popat, S; Schuler, M; Sequist, LV; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V | 1 |
| Kinomura, A; Misumi, K; Miyata, Y; Okada, M; Sun, J; Tashiro, S | 1 |
| Archibald, HL; Bardelli, A; Bhang, HE; Costa, C; Crystal, AS; Damon, LJ; Engelman, JA; Faber, AC; Getz, G; Gomez-Caraballo, M; Hata, AN; Hu, H; Iafrate, AJ; Ji, F; Kalsy, A; Keating, CL; Krishnamurthy Radhakrishna, V; Lee, D; Lockerman, E; Maruvka, YE; Mulvey, HE; Niederst, MJ; Piotrowska, Z; Raoof, S; Ruddy, DA; Sadreyev, RI; Sequist, LV; Siddiqui, FM; Siravegna, G; Stegmeier, F | 1 |
| Ge, Y; Han, X; Huang, S; Jin, Y; Li, Y; Liu, K; Ma, X; Song, Z; Wang, C; Yu, H; Zhen, Y; Zhou, Y | 1 |
| Ni, J; Zhang, L | 1 |
| Chou, SH; Han, DX; Hu, P; Ruan, RS; Tzeng, CM; Zheng, LM | 1 |
| Groen, HJ; Hiltermann, TJ; Kok, K; Saber, A; van den Berg, A; van der Wekken, AJ | 1 |
| Jang, JY; Jeon, YK; Keam, B; Kim, CW; Kim, TM; Kim, YG; Nam, SJ | 1 |
| Cai, J; Li, QX; Ning, J; Wery, JP; Xu, X; Yang, M | 1 |
| Chan, LW; Cho, WC; Meng, F; Sin, TK; Siu, PM; Wang, F; Wong, SC; Yung, BY | 1 |
| Syed, YY | 1 |
| Fujita, K; Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Sasaki, Y; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Seton-Rogers, S | 1 |
| Choy, TS; Kwong, DL; Lam, KO; Lam, PM; Lee, VH; Leung, DK; Leung, TW | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Ke, EE; Wu, YL | 1 |
| Addeo, A | 1 |
| An, SJ; Bai, XY; Chen, ZH; Gou, LY; Su, J; Wu, YL; Xie, Z; Yang, SQ; Zhang, XC | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Hong, D; Liang, X; Zhang, G; Zhang, X | 1 |
| Lee, VH; Ma, L; Wang, DD; Yan, H; Zhu, G; Zou, B | 1 |
| Fukuoka, M; Imamura, F; Inoue, A; Morita, S; Muto, S; Nakagawa, K; Okamoto, I; Seto, T; Yamamoto, N; Yoshida, K | 1 |
| Blumenthal, GM; He, K; Kazandjian, D; Keegan, P; Pazdur, R; Yuan, W | 1 |
| Hanawa, T; Hyuga, M; Hyuga, S; Itoh, K; Nishimura, Y; Takiguchi, S | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Adamo, V; Alù, M; Bazan, V; Blasi, L; Bronte, G; Celesia, C; De Tursi, M; Franchina, T; Gambale, E; Laudani, A; Natoli, C; Passiglia, F; Picone, A; Rizzo, S; Russo, A; Savio, G; Sortino, G | 1 |
| Hashimoto, M; Hidayat, M; Kobayashi, I; Moriyama, H; Moriyama, M; Murakami, A; Nara, T; Nurwidya, F; Sasaki, S; Shimada, N; Suina, K; Tajima, K; Takahashi, F; Takahashi, K; Yagishita, S; Yoshioka, Y | 1 |
| Chen, X; Fan, XX; He, JX; Huang, J; Leung, EL; Liu, L; Xiao, DK; Xu, JH; Yao, XJ; Zhang, YZ; Zheng, SY; Zhou, YL | 1 |
| Alfieri, R; Ardizzoni, A; Barocelli, E; Bonelli, M; Cavazzoni, A; Cretella, D; Falco, A; Fumarola, C; Galetti, M; Gervasi, A; La Monica, S; Lagrasta, CA; Madeddu, D; Naldi, N; Petronini, PG; Quaini, F; Tiseo, M; Vivo, V | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Ma, A; Shi, J; Wang, D; Yang, J; Zhai, Q; Zhang, C; Zhang, H; Zhang, X | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Bessho, A; Fujii, M; Gemba, K; Harita, S; Hotta, K; Inoue, K; Kiura, K; Kozuki, T; Kudo, K; Kuyama, S; Nogami, N; Oda, N; Okada, T; Takigawa, N; Tanimoto, M | 1 |
| Bowen, JM; Gibson, RJ; Van Sebille, YZ; Wardill, HR | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Contreras-Díaz, M; López-Herrero, F; Martínez-Bernal, G; Medina-Tapia, A; Molina-Socola, FE; Rueda-Rueda, T; Sánchez-Vicente, JL | 1 |
| Cai, F; Cao, W; Duan, C; Fan, C; He, Z; Huang, Q; Liu, Y; Wang, J; Wang, X; Xiao, X; Zhang, L | 1 |
| Arvis, CD; Boyer, M; Hirsh, V; Kim, DW; Kim, M; Kim, SW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, KH; Lu, S; Massey, D; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shahidi, M; Shi, Y; Tan, EH; Tsai, CM; Yang, JC; Zazulina, V; Zhang, L | 1 |
| Chen, L; Huang, M; Li, J; Ma, Y; Wang, X; Xin, S; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y; Zhu, C; Zhu, X; Zhuang, W | 1 |
| Feng, C; Guo, F; Huang, C; Li, X; Liu, X; Qin, Q; Wang, Y | 1 |
| Jiang, X; Wang, W; Zhang, Y | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Cho, EK; Jeong, HC; Kim, EK; Kim, HR; Kim, JH; Lee, JH; Lim, SM; Min, YJ; Park, K | 1 |
| Buiting, HM; de Kanter, W; Linn, SC; Smorenburg, CH | 1 |
| Fei, Z; Jiang, H; Li, J; Xu, J; Zhu, X | 1 |
| An, C; Chu, H; Gu, C; Lu, R; Shi, H; Xiao, F; Yi, X; Zhang, H; Zhang, J; Zhu, F | 1 |
| Ding, L; Ding, Z; He, J; Hou, M; Huang, M; Li, L; Liang, M; Liu, Y; Lu, Y; Ren, L; Tan, F; Xiang, J; Xiong, W; Yu, Q; Zhou, L; Zhou, X; Zhu, J | 1 |
| Ang, MK; Chowbay, B; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Toh, CK; Zhang, Z | 1 |
| Au-Yeung, SC; Fei, R; Lam, AS; Poon, DC; To, KK; Wei, Y | 1 |
| Ikegami, D; Kuzumaki, N; Narita, M | 1 |
| Asano, M; Ito, H; Kobayashi, H; Miura, M; Niioka, T; Okuda, Y; Sato, K; Takeda, M | 1 |
| Chang, N; Duan, Q; Liu, W; Pang, C; Zhang, J | 1 |
| Barone, C; Cassano, A; D'Argento, E; Dadduzio, V; Di Noia, V; Rossi, S; Schinzari, G | 1 |
| Hsiue, EH; Lee, JH; Lin, CC; Yang, JC | 2 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| Choi, YS; Kong, SH; Seong, JY; Suh, HS | 1 |
| David, JM; Dominguez, C; Fernando, RI; Hamilton, DH; McCampbell, KK; Palena, C | 1 |
| Han, W; Jiang, L; Jing, J; Jing, Z; Pan, H; Shou, J; Sui, X; Xie, J; Yao, J; You, L | 1 |
| Arai, J; Matsumoto, K; Miyazaki, T; Mochinaga, K; Nagasaki, T; Nagayasu, T; Nanashima, A; Tominaga, T; Tsuchiya, T; Tsukamoto, K; Yamasaki, N | 1 |
| Lai, FC; Li, X; Lin, JB; Lin, JW; Lin, M; Liu, B; Luo, RG; Qiu, ML; Tu, YR | 1 |
| Cai, XW; Chang, JH; Fu, XL; Huang, QL; Liu, Q; Liu, ZB; Lu, YN; Pan, SY; Wang, JL; Wu, XH; Zhao, XM | 1 |
| Jia, L; Li, S; Li, W; Li, Y; Wang, S; Wang, T; Xu, S; Yang, Z; Zhang, S | 1 |
| Fujita, M; Hirano, R; Hirota, T; Kubo, A; Matsumoto, T; Nabeshima, K; Uchino, J; Watanabe, K; Yamaguchi, E; Yokoi, T | 1 |
| Chin, TM; Lee, JZ; Leow, YN; Lim, B; Lim, EH; Lim, EK; Lim, PX; Lim, WT; Lunny, DP; Malusay, SR; Nga, ME; Pang, YH; Shyh-Chang, N; Soo, RA; Sun, LL; Tai, BC; Tam, WL; Tan, BJ; Tan, DS; Tan, EH; Yang, H; Zhang, WC | 1 |
| Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H | 1 |
| Bai, C; Chen, G; Ding, C; Feng, J; Gu, A; Han, B; He, J; Hu, X; Huang, C; Jian, H; Jiao, S; Li, F; Ling, Y; Liu, X; Luo, H; Luo, R; Pang, Q; Shi, Y; Shu, Y; Sun, Y; Wang, C; Wang, Z; Wu, M; Yang, Y; Zhang, S; Zhang, Y; Zhao, H; Zhao, Q; Zhou, C | 1 |
| Chen, TC; Huang, HS; Lee, H; Wu, DW | 1 |
| Batliner, J; Fey, MF; Gautschi, O; Gugger, M; Rothschild, SI; Tschan, MP | 1 |
| Addeo, A; Di Maio, M | 1 |
| Hu, C; Ma, JA; Wu, F; Zhang, H; Zhang, Y | 1 |
| Barone, C; Calegari, MA; Orlandi, A | 1 |
| Dong, L; Guo, L; Li, L; Li, W; Li, Z; Lin, D; Ling, Y; Qiu, T; Yang, L; Yang, X; Ying, J | 1 |
| Choi, JW; Hua, TN; Jeong, Y; Kim, HW; Kim, KW; Kim, MK; Phan, AN; Rho, JK; Vo, VT | 1 |
| López-Brea, M | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Diz Taín, P; García-Palomo, A; González, AL | 1 |
| Vidal, ÓJ | 1 |
| Alejandro, MÁ; Artal Cortés, Á; Gimeno Pelegrín, J | 1 |
| Cobo, M; Godoy, A; Gutiérrez, V; López, O; Rodelo, L; Ruiz, M | 1 |
| Taus, Á | 1 |
| Hai, P; Wang, YY; Xia, B; Zhang, CY; Zhao, R; Zhe, H; Zhou, S | 1 |
| Karachaliou, N; Rosell, R | 1 |
| Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW | 1 |
| Cajal, R; Calle, C; Clopes, A; Cordero, LA; Crespo, R; Gasol, M; Germà, JR; Gilabert, A; Mora, R; Segú, L; Simon, S | 1 |
| Burghuber, OC; Hochmair, M; Holzer, S | 1 |
| Huang, G; Jia, W; Li, J; Liu, J; Liu, L; Miao, P; Song, S; Sun, X; Yan, H; Yang, H; Zhao, L; Zhao, X; Zhou, X | 1 |
| Butler, R; Davies, RS; Lester, JF; Nelmes, DJ | 1 |
| Fukuhara, T; Maemondo, M; Morita, M; Nukiwa, T; Suzuki, A; Tanaka, N; Terasaki, H; Tsukita, Y; Watanabe, K | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Harada, D; Harita, S; Hotta, K; Ichihara, E; Ichikawa, H; Inoue, K; Inoue, M; Kishino, D; Kiura, K; Kubo, T; Kuyama, S; Minami, D; Murakami, T; Ninomiya, K; Ninomiya, T; Oda, N; Shibayama, T; Takigawa, N; Tanimoto, M; Yokoyama, T | 1 |
| Cheng, Y; Enatsu, S; He, J; Kang, JH; Kim, JH; Murakami, H; Nakagawa, K; Orlando, M; Puri, T; Wang, X; Yang, JC; Yang, PC | 1 |
| He, J; Ma, J; Tan, W; Tang, X | 1 |
| Dietel, M; Eberhardt, W; Griesinger, F; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Fan, S; Wang, W; Zang, H | 1 |
| Jin, Y; Lou, G; Shao, Y; Shi, X; Tong, X; Wu, X; Yu, X; Zhang, Y | 1 |
| Aboagye, EO; Beckley, A; Carroll, L; Kaliszczak, MA; Nguyen, QD; Pisaneschi, F; Slade, RL; Smith, G | 1 |
| Campo, M; Engelman, JA; Fidias, P; Gainor, JF; Gerber, D; Heist, RS; Muzikansky, A; Sequist, LV; Shaw, AT; Temel, JS | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Ohmatsu, H; Sugiyama, E; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Bidoli, P; Buosi, R; Burgio, MA; Cappuzzo, F; Cerea, G; Chiari, R; Cortinovis, D; De Marinis, F; Del Conte, A; Ferrari, S; Finocchiaro, G; Foltran, L; Giannetta, L; Mazzoni, F; Migliorino, MR; Montanino, A; Morabito, A; Normanno, N; Tiseo, M | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
| Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Minami, D; Ninomiya, K; Ninomiya, T; Oda, N; Ohashi, K; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M; Yoshioka, H | 1 |
| Du, Z; Tang, X; Yang, M; Zhou, Y; Zhuang, J | 1 |
| Baty, F; Brutsche, M; Cerny, T; Dutly, A; Ess, S; Früh, M; Hitz, F; Joerger, M; Joos, L; Krähenbühl, S; Neumair, P; Warschkow, R | 1 |
| Demuth, C; Meldgaard, P; Sorensen, BS; Sorensen, SF; Weber, B | 1 |
| Dietel, M; Eberhardt, WE; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Waller, C; Zirrgiebel, U | 1 |
| Chen, DQ; Ding, J; Geng, MY; Liu, HC; Shen, AJ; Shen, JK; Sun, JY; Wang, X; Wang, YQ; Xiong, B; Zhang, MM; Zheng, M | 1 |
| Chen, HJ; Chen, ZH; Su, J; Tu, HY; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Arrieta, O; Barron, F; Cardona, AF; de la Torre-Vallejo, M; Luna-Palencia, RL | 1 |
| Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q | 1 |
| Aerts, HJ; Grossmann, P; Oxnard, GR; Rizvi, N; Schwartz, LH; Tan, Y; Zhao, B | 1 |
| Fukuoka, M; Hohjoh, H; Takahashi, M; Yoshioka, K | 1 |
| Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Grosskurth, SE; Helfrich, BA; Kim, J; Scarborough, HA; Schuller, AG; Tan, AC; Zaberezhnyy, V; Zhang, Z | 1 |
| Chang, YH; Chien, KH; Hsu, CR; Tai, MC | 1 |
| Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS | 1 |
| Cai, H; Miao, L; Qian, D; Tian, Y; Wang, Y; Yang, J; Yang, Z; Zhang, Z | 1 |
| Du, Y; Liu, H; Ma, T; Pan, Y; Shen, Y; Zhu, Y | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 1 |
| Adam, J; Artignan, X; Bardet, E; Lacas, B; Lacroix, L; Le Péchoux, C; Levy, A; Pignon, JP; Verrelle, P | 1 |
| Hu, M; Qian, K; Wang, R; Yao, S; Zhang, Y; Zhi, X | 1 |
| Bi, M; Chen, W; Ding, F; Tang, C; Tang, DJ; Wang, J; Yu, H | 1 |
| Chen, M; Gu, Y; Sun, Y; Wang, M; Xu, Y; Yang, Z; Ye, X; Zhao, J; Zhong, W; Zhu, G | 1 |
| Jeong, JH; Kwon, TK; Oh, YJ; Seo, YH | 1 |
| Chen, J; Ding, L; Hu, X; Liu, J; Shentu, J; Tan, F; Wang, Y; Wu, G; Wu, L; Xu, W; Zhou, H; Zhu, M | 1 |
| Banno, E; Hayashi, H; Kaneda, H; Nakagawa, K; Nishio, K; Sakai, K; Takeda, M; Tanizaki, J; Togashi, Y | 1 |
| Wu, YL; Xu, CR; Yang, JJ; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Lee, JK; Lee, SH; Min, HS; Park, K; Sun, JM | 1 |
| Chai, Y; Zhu, Z | 1 |
| Han, B; Jin, B; Lou, Y; Wang, H; Wu, D; Xu, J; Yang, H; Zhang, X; Zhang, Y; Zhong, H | 1 |
| Li, B; Lin, D; Wan, Y; Yao, Z | 1 |
| Ahn, MJ; Cho, BC; Jang, JS; Jung, I; Kim, DW; Kim, HR; Kim, JH; Kim, SW; Lee, DH; Lee, KH; Sun, JM | 1 |
| Chen, J; Li, Y; Liu, H; Liu, M; Wang, Y; Xu, S; Zhang, H | 1 |
| Shen, B; Song, Y; Sun, X; Wang, K; Xiao, Z | 1 |
| Goto, K; Ishii, G; Kohno, T; Matsumoto, S; Murakami, H; Nishio, M; Nogami, N; Nomura, S; Ohe, Y; Ohtsu, A; Sato, A; Satouchi, M; Seto, T; Tsuchihara, K; Tsuta, K; Yamamoto, N; Yoh, K | 1 |
| Bonetti, A; Giuliani, J; Remo, A | 1 |
| Chang, HY; Chang, YL; Chao, MW; Cheng, CC; Cheng, HC; Hsu, CC; Hsu, JT; Lin, SI; Liu, SJ; Liu, TW; Pan, SL; Tsai, HJ; Tseng, CP; Wang, HY | 1 |
| Fang, S; Han, X; Tang, N; Wang, Z; Zhang, Q | 1 |
| Chow, LW; Fan, XX; Jiang, ZB; Leung, EL; Li, X; Liu, L; Loo, WT; Yao, XJ | 1 |
| Agatsuma, T; Gomi, D; Hachiya, T; Hanaoka, M; Koizumi, T; Koyama, S; Kuraishi, H; Miyahara, T; Ono, Y; Suzuki, T; Tateishi, K; Wada, Y; Yamamoto, R; Yoshiike, F | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 2 |
| Biaoxue, R; Hua, L; Shuanying, Y; Wenlong, G | 1 |
| Brückl, W; Huber, RM; Tufman, A | 1 |
| Asao, T; Hayashi, H; Iihara, H; Imai, H; Itoh, Y; Kaira, K; Kita, Y; Minato, K; Mizusaki, N; Naruse, I; Sugiyama, T; Yamada, M | 1 |
| Ali, SM; Bocharov, EV; Campregher, PV; Chung, J; Gitlitz, BJ; Haddad, CK; Johnson, M; Klempner, SJ; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Steinecker, G; Stephens, PJ; Suh, JH; Velcheti, V | 1 |
| Han, XC; Li, Y; Ma, XW; Xin, QZ | 1 |
| Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H | 1 |
| Ang, MK; Chowbay, B; Jain, A; Kanesvaran, R; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Tan, WL; Toh, CK | 1 |
| Pakkala, S; Ramalingam, SS | 2 |
| Cao, XN; Deng, Y; Hu, FY; Hu, JB; Lai, SY; Ma, J; Xu, QZ | 1 |
| Ahn, MJ; Bai, Y; Chen, K; Cheng, Z; Guo, Q; Kim, DW; Rabbie, S; Wang, Y; Xu, Y; Yang, JC; Yang, Z; Yin, X; Zhang, L; Zhang, X | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Adamo, V; Franchina, T; Ricciardi, GRR; Russo, A | 1 |
| Hann, SS; Li, L; Wang, S; Wu, W; Zheng, F | 1 |
| Chen, Z; Deng, W; Ke, E; Niu, F; Su, J; Wu, Y; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhao, N; Zhou, Q | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Hayama, M; Hirashima, T; Morishita, N; Nishida, T; Nishihara, T; Okamoto, N; Shiroyama, T; Suzuki, H; Tamiya, M; Tanaka, A | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Diebold, J; Froesch, P; Früh, M; Gautschi, O; Jochum, W; Klingbiel, D; Mark, M; Reichegger, H; Rothschild, S; Schmid, S | 1 |
| Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G | 1 |
| Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T | 1 |
| Ding, L; Fu, J; Lu, S; Tan, F; Wu, B; Ye, M | 1 |
| Han, L; He, J; Huang, Z; Li, W; Ma, P; Nie, F; Zhang, M | 1 |
| Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W | 1 |
| Bai, JP; Chen, X; Li, Y; Liu, LR; Liu, YH; Qu, X; Qu, YC; Zhang, FL; Zhang, HB; Zheng, GJ; Zhu, YJ; Zhu, YZ | 1 |
| Chen, HY; He, Y; Kang, J; Li, KL; Li, L; Wang, YB; Zhang, P | 1 |
| Ali, SM; Allen, JM; Erlich, RL; Miller, VA; Ou, SI; Ross, JS; Schrock, AB; Stephens, PJ; Vafai, D | 1 |
| Jiang, H; Li, J; Liu, X; Xu, H; Zheng, R | 1 |
| Al-Khafaji, AS; Davies, MP; Field, JK; Gosney, JR; Koffa, M; Liloglou, T; Marcus, MW; Risk, JM; Shaw, RJ | 1 |
| Bai, XY; Chen, HJ; Jiang, BY; Su, J; Tu, HY; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hagiwara, K; Iwai, Y; Kawamura, R; Koyama, N; Koyama, S; Miwa, C; Nagai, Y; Watanabe, Y | 1 |
| Go, YJ; Han, JY; Joo, J; Lee, GK; Lee, JS; Lee, KH; Lee, SH; Lee, Y; Lim, KY | 1 |
| Abazeed, ME; Khunger, M; Velcheti, V | 1 |
| Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y | 1 |
| Chen, ZY; Dong, ZY; Hou, QY; Li, YS; Liu, SY; Su, J; Wu, YL; Yan, HH; Zhai, HR; Zhong, WZ | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Jiang, T; Qiao, M; Ren, S; Su, C; Zhou, C; Zhou, F | 1 |
| Lee, JK; Lee, SH | 1 |
| Di Maio, M; La Salvia, A; Rossi, A | 1 |
| Jensen, RT; Mantey, SA; Moody, TW; Moreno, P; Ramos-Alvarez, I; Ridnour, L; Wink, D | 1 |
| Gao, QL; Li, L; Li, QJ; Liu, HM; Ma, XH; Shi, B; Tian, TD | 1 |
| Chuang, JC; Das, M; Diehn, M; Huang, J; Liang, Y; Neal, JW; Stehr, H; Wakelee, HA | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wang, Z; Wu, J; Wu, Y; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Li, P; Ma, Z; Wang, H; Yan, X; Zhang, G; Zhang, M | 1 |
| Chewaskulyong, B; Fukuoka, M; Haddad, V; Han, B; Ichinose, Y; Margono, B; Mok, TS; Ohe, Y; Rukazenkov, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ; Young, H | 1 |
| Pi, C; Xu, CR; Zhang, YC; Zhou, Q | 1 |
| Song, Y; Yuan, DM | 1 |
| Aiuchi, T; Arakawa, K; Hamada, Y; Igarashi, K; Ikegami, D; Iwasawa, C; Kuzumaki, N; Nagasawa, A; Narita, M; Ochiya, T; Shimura, E; Suda, Y; Takeshima, H; Ushijima, T; Yoshioka, Y | 1 |
| Ajithkumar, T; Geropantas, K; Glenn, A; Kouroupis, M; Maskell, D | 1 |
| Fraser, A | 1 |
| Chen, Y; Fuller-Pace, FV; Gong, D; Huang, L; Huang, Z; Li, K; Li, Y; Lin, P; Mo, C; Wei, Y; Zhang, J | 1 |
| Hu, Y; Jin, X; Shi, L; Su, Y; Zhang, C; Zhu, X | 1 |
| Akashi, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Obara, T; Ogata, H; Okamoto, I; Yoshimoto, G | 1 |
| Cho, BC; Doherty, JP; Garon, EB; Gernhardt, D; Giri, N; Jatoi, A; Keefe, DM; Kim, DW; Lacouture, ME; Nadanaciva, S; O'Connell, J; Sbar, E; Sonis, S; Wang, T | 1 |
| Chen, YJ; Choong, WK; Hong, TM; Hsu, YL; Kuo, TC; Liao, YC; Pan, SH; Sung, TY; Tsai, CF; Wang, YT; Wu, HY; Yang, PC; Yen, HY | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Giusti, R; Iacono, D; Lauro, S; Marchetti, P; Mazzotta, M | 1 |
| Gettinger, S | 1 |
| Colantuoni, G; Del Gaizo, F; Falanga, M; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A | 1 |
| Bean, J; Chang, YC; Chen, KY; Cheng, AL; Hu, FC; Huang, CJ; Huang, CL; Lin, ZZ; Pao, W; Shih, JY; Shun, CT; Tsai, MC; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Enderlein, E; Gerber, PA; Homey, B | 1 |
| Yang, CH | 2 |
| Jänne, PA | 4 |
| Riely, GJ | 2 |
| Natale, RB | 4 |
| Heymach, JV; Nikolinakos, P | 1 |
| Ding, K; Florescu, M; Hasan, B; Seymour, L; Shepherd, FA | 1 |
| Li, T; Ling, YH; Perez-Soler, R | 1 |
| Khuri, FR; Roman, J | 1 |
| Lin, R; Ling, YH; Perez-Soler, R | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okuda, K; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H | 2 |
| Cheng, CM; Ciou, SC; Hong, JH; Jheng, MY; Ko, JC; Lin, YW; Ling, ST; Wang, LH | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Holmes, AJ; Jänne, PA; Kang, JH; Ki, CS; Kim, HT; Kim, SW; Lee, JS; Park, BB; Park, CK; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS | 1 |
| Baselga, J; Cedres, S; Felip, E; Foernzler, D; Gatzemeier, U; Heller, A; Klughammer, B; Maacke, H; Möcks, J; Parera, M; Peralta, S; Reck, M; Rojo, F; Sala, G; Saura, C | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Fujiwara, Y; Hirano, S; Kiura, K; Kondo, E; Ohashi, K; Osawa, M; Rai, K; Takata, K; Takata, M; Tanimoto, M; Yoshino, T | 1 |
| Altavilla, G; Arrigo, C; Galletti, G; Marabello, G; Picone, G; Pitini, VV; Santarpia, MC; Tomasello, C | 1 |
| Crinò, L; Reck, M | 1 |
| Chang, YC; Chiu, YH; Gow, CH; Hsu, YC; Shih, JY; Wei, PF; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Na, II; Rho, JK; Ryoo, BY; Yang, SH | 1 |
| Aoe, K; Bessho, A; Fujiwara, Y; Gemba, K; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Matsuo, K; Moritaka, T; Segawa, Y; Shibayama, T; Sugimoto, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Hamada, H; Hamaguchi, N; Higaki, J; Ito, R; Kadowaki, T; Miyoshi, S | 1 |
| Cutz, JC; da Cunha Santos, G; Ding, K; Kamel-Reid, S; Liu, N; Marrano, P; Sakurada, A; Seymour, L; Shepherd, FA; Squire, JA; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Brugarolas, A; Eugenieva, E; Farré, J; Fernández Morejón, FJ; González Manzano, R; Martínez Navarro, E | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Kim, SW; Lee, DH; Lee, JS; Suh, C; Yi, EJ; Yoon, DH | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Chang, JW; Chen, CM; Cheung, YC; Hsieh, JJ; Hsu, T; Huang, SF; Lin, G | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Manoloukos, M; Murray, S | 1 |
| Arrieta, O; Castillo-Gonzalez, P; de la Cruz Vargas, J; De la Garza, J; Flores-Estrada, D; Gonzalez, C; Gonzalez-De la Rosa, CH; Guzman, E; Hernandez-Pedro, N; Martinez-Barrera, L; Morales-Barrera, R; Rios-Trejo, MA; Téllez, E; Treviño, S | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Chang, YL; Gow, CH; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Epstein, D; Haley, JD; Petti, F; Sujka-Kwok, I; Thomson, S | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Li, JR; Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 2 |
| Burgers, JA; Haas, RL; Kappers, I; Klomp, HM; van Pel, R; Van Zandwijk, N | 1 |
| Choong, NW; Dancey, JE; Grushko, T; Haraf, DJ; Hoffman, PC; Kozloff, M; Lester, E; Lin, S; Mauer, AM; Olopade, OI; Salgia, R; Szeto, L; Vokes, EE | 1 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Hesketh, PJ; Hirsch, FR; Mack, PC; Marchello, BT; Moon, J; Spreafico, A; Wozniak, AJ | 1 |
| Grünberg, K; Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Chin, TM; Seto, KY; Soo, RA; Wong, AS | 1 |
| Barlési, F | 2 |
| Stewart, DJ | 2 |
| Bhutani, M; Mao, L; Pathak, AK | 1 |
| Dahlberg, SE; Gray, RJ; Johnson, BE | 1 |
| Eguchi, K; Fukuoka, M; Harada, M; Ichinose, Y; Imamura, F; Inoue, A; Itoh, Y; Jiang, H; Maruyama, R; Masuda, N; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Shinkai, T; Takeda, K; Tamura, T; Tomii, K; Tsuboi, M; Yamamoto, N | 1 |
| Armour, AA; Cappuzzo, F; Crinò, L; Cullen, M; Duffield, EL; Ford, HE; Ghiorghiu, S; Hirsch, FR; Pesek, M; Reck, M; Speake, G; Thompson, JC; Varella-Garcia, M; Zatloukal, P | 1 |
| Socinski, MA; Stinchcombe, TE | 2 |
| Hayakawa, K; Jiang, SX; Katagiri, M; Masuda, N; Okayasu, I; Piao, CJ; Saegusa, M; Umezawa, A; Yamamoto, M; Yamashita, K; Yoshida, T | 1 |
| Fandi, A; Giaccone, G; Herbst, RS; Iacona, RB; Janas, M; Johnson, DH; Ochs, JS | 1 |
| Astoul, P; Barlési, F; Breen, D; Fina, F; Martin, PM; Nanni-Metellus, I | 1 |
| Giaccone, G; Gutierrez, M; Rajan, A | 1 |
| Tamura, K | 1 |
| Dias-Santagata, DC; Lynch, TJ; Nanda, A; O'Hara, CJ; Stubbs, H; Willers, H; Zaner, KS | 1 |
| Eguchi, K; Ishizaka, A; Kawada, I; Kawamura, M; Kobayashi, K; Nakachi, I; Naoki, K; Soejima, K; Watanabe, H; Yasuda, H | 1 |
| Alfieri, RR; Ardizzoni, A; Boni, L; Bortesi, B; Bozzetti, C; Camisa, R; Capelletti, M; Cavazzoni, A; De Palma, G; Franciosi, V; Galetti, M; Goldoni, M; Loprevite, M; Mozzoni, P; Petronini, PG; Rindi, G; Tiseo, M | 1 |
| Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H | 1 |
| Bunn, PA; Dziadziuszko, R; Gajapathy, S; Hirsch, FR; Lin, M; O'Neill, V; Skokan, M; Varella-Garcia, M; Xiao, Y | 1 |
| Alloisio, M; Cappuzzo, F; Destro, A; Finocchiaro, G; Incarbone, M; Jänne, PA; Ligorio, C; Roncalli, M; Rossi, E; Santoro, A; Skokan, M; Terracciano, L; Toschi, L; Varella-Garcia, M; Zucali, PA | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Bianchi, F; Neri, I; Patrizi, A | 1 |
| Döme, B; Magyar, M | 1 |
| Ishihara, S; Minato, K; Mogi, A; Naito, Y; Saito, R; Shitara, Y; Suga, T; Takise, A; Tsuchiya, S; Yamabe, K | 1 |
| Hotta, K; Kiura, K; Shirahige, A; Tabata, M; Takata, S; Takigawa, N; Tanimoto, M; Watanabe, H | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Bonomi, PD; Cohen, G; De Braud, F; Eberhardt, WE; Herbst, RS; Heymach, JV; Johnson, BE; Krebs, AD; Paz-Ares, L; Ranade, AA; Sandler, AB; Sebastian, M; Stewart, DJ; Trigo, JM; Vasselli, J | 1 |
| Amoroso, D; Ardizzoni, A; Bearz, A; Belvedere, O; Brandes, AA; Cascinu, S; Crinò, L; Gridelli, C; Grossi, F; Labianca, R; Piantedosi, FV; Siena, S; Tiseo, M; Valentino, B; Venturino, P | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hashimoto, T; Hayashibara, K; Ichimura, H; Inagaki, M; Ishikawa, H; Ishikawa, S; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nawa, T; Satoh, H; Shinohara, Y; Sumi, M | 1 |
| Bertran-Alamillo, J; Botia, M; Carrasco, E; Castellà, E; Costa, C; Llatjós, M; Mate, JL; Mayo, C; Molina-Vila, MA; Moran, T; Pérez-Cano, M; Pradas, A; Queralt, C; Reguart, N; Rosell, R; Taron, M; Tomàs, M | 1 |
| Chin, TM; Haber, DA; Lynch, TJ; Quinlan, MP; Sequist, LV; Settleman, J; Sharma, SV; Singh, A | 1 |
| Homes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, N; Rogers, AM; Yonesaka, K; Zejnullahu, K; Zhao, F | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Copeman, M | 1 |
| Hanagiri, T; Ichiki, Y; Mizukami, M; Onitsuka, T; Oyama, T; Sugaya, M; Sugio, K; Takenoyama, M; Uramoto, H; Yasuda, M; Yasumoto, K | 1 |
| Chen, KY; Cheng, AL; Hu, FC; Huang, CL; Lin, ZZ; Shih, JY; Yang, CH; Yang, PC; Yeh, KH; Yu, CJ | 1 |
| Fukuyama, S; Ichinose, Y; Ikeda, J; Maruyama, R; Nishimura, M; Okamoto, T; Osoegawa, A; Seto, T; Tagawa, T; Wataya, H; Yamanaka, T; Yamazaki, K | 1 |
| Herbst, RS; Sandler, A | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Cheng, CM; Ciou, SC; Hong, JH; Jheng, MY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Donovan, JC; Ghazarian, DM; Shaw, JC | 1 |
| Azzariti, A; Duan, HQ; Galetta, D; Gao, EM; Han, Y; Liu, XQ; Paradiso, A; Toschi, L; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Ahn, BM; Choi, DR; Choi, JS; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kwon, JH; Lee, KM; Park, S; Shin, YC; Song, HH; Zang, DY | 1 |
| Ren, SX; Yan, LH; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Cullen, M; Thatcher, N | 1 |
| Armour, AA; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Li, LY; Liao, ML; Lippman, SM; Lowe, ES; Mok, T; Osterlind, K; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Sun, Y; Watkins, CL; Wu, YL | 1 |
| Balko, JM; Black, EP | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 2 |
| Azzoli, CG; Brahmer, JR; Fogle, M; Ginsberg, M; Kris, MG; Miller, VA; Milton, DT; Riely, GJ; Rizvi, NA; Rosen, N; Rudin, CM; Senturk, E; Seshan, VE; Sirotnak, FM; Solit, DB | 1 |
| Fukuoka, M; Hida, T; Katakami, N; Kawahara, M; Kubota, K; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saijo, N; Takeda, K; Tamura, T; Watanabe, K; Yokoyama, A | 1 |
| Bodenstein, H; Digel, W; Franke, A; Guschall, WR; Gütz, S; Heigener, D; Laack, E; Reck, M; Schmidtgen, C; Schneider, CP; Schott-von-Römer, K | 1 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Pavlidis, N; Pentheroudakis, G; Vassou, A; Voulgaris, E | 1 |
| Backes, H; Borgman, CL; Jacobs, AH; Koker, M; Li, H; Neumaier, B; Shapiro, GI; Shimamura, T; Sos, ML; Tawadros, S; Thomas, RK; Ullrich, RT; Waerzeggers, Y; Winkeler, A; Wolf, J; Zander, T | 1 |
| Chu, DT; Sun, Y; Wang, B; Wang, HJ; Wang, Y; Zhang, XR | 1 |
| Jiang, H | 1 |
| de Boer, R; Godwood, A; Humblet, Y; Milenkova, T; Nogová, L; Ruffert, K; Smith, R; Vansteenkiste, J; Wolf, J | 1 |
| Deng, Q; Ma, S; Xu, Y; Yu, X | 1 |
| Chen, E; Feld, R; Gauthier, I; Goss, G; Laurie, S; Leighl, N; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Barnett, J; Cuthbertson, A; Morrison, MS; Ricketts, SA; Tessier, J; Wedge, SR | 1 |
| Catania, C; Curigliano, G; de Braud, F; De Carlis, L; De Pas, T; Locatelli, M; Lorizzo, K; Pelosi, G; Spitaleri, G; Toffalorio, F | 1 |
| Hirama, M; Ishiwata, T; Miura, K; Miyaji, A; Seyama, K; Shukuya, T; Takahashi, K; Yae, T | 1 |
| Acharya, J; Bottomley, DM; Lyon, C | 1 |
| Hida, T; Horio, Y; Ogawa, S; Park, JC; Park, JY; Shimizu, J; Yoshida, K | 1 |
| Bareschino, M; Colantuoni, G; Falanga, M; Ferrara, ML; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A; Rossi, E; Schettino, C | 1 |
| Chouaid, C; Coudray-Omnès, C; Moser, A; Vergnenègre, A | 1 |
| Boysen, M; Longson, C; Stevens, A | 1 |
| Ailawadhi, S; Derby, L; Fetterly, G; Natarajan, R; Ramnath, N; Reid, M | 1 |
| Mehić, B; Smoljanović, V; Stanetić, M; Tinjić, L | 1 |
| Sakurada, A; Tsao, MS | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Bunn, PA; Dziadziuszko, R; Hedman, K; Hirsch, FR; Varella-Garcia, M; Witta, SE; Yoshida, K | 1 |
| Aoyagi, D; Kanda, S; Kobayashi, N; Koizumi, T; Kubo, K; Nakayama, J; Ushiki, A; Yamamoto, H; Yasuo, M | 1 |
| Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Boinpally, R; Chick, JB; Dunlop, D; Hughes, AN; Nicolson, M; O'Brien, ME; Petty, WJ; Price, A; Rankin, E; Wolf, J; Woll, PJ | 1 |
| Fu, Z; Li, M; Li, X; Liu, N; Ma, L; Meng, X; Yang, G; Yang, Y; Yu, J; Zhao, S | 1 |
| Duchnowska, R; Grala, B; Siemiatkowska, A; Smoter, M | 1 |
| Deng, QF; Su, B; Zhao, YM; Zhou, CC | 1 |
| Xing, LN; Zhang, F | 1 |
| Ito, F; Nishio, K; Shin-ya, T; Takeuchi, K | 1 |
| Ahn, JS; Ahn, MJ; Choi, MK; Hong, JY; Jae Park, M; Lee, J; Lee, SJ; Oh, SJ; Park, K; Park, MJ; Yi, JH | 1 |
| Bradley, J; Feins, RH; Gewanter, RM; Gopal, RS; Komaki, RU; Kong, FM; Langer, CJ; Lee, HK; Movsas, B; Rosenzweig, KE | 1 |
| Frenkel, EP; Gazdar, AF; Minna, JD; Peyton, M; Soh, J; Xie, Y; Zhang, W | 1 |
| Akerley, W; Arbogast, K; Bentz, JS; Boucher, KM; Walters, T | 1 |
| Adamo, B; Adamo, V; Caristi, N; Chiofalo, G; Denaro, N; Franchina, T; Gambadauro, P; Giordano, A; Russo, A; Scimone, A | 1 |
| Date, H; Fujiwara, Y; Hosokawa, S; Hotta, K; Kiura, K; Soh, J; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S; Yoshino, T | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Nakagawa, K; Nishio, K; Okabe, T; Okamoto, I; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Lin, SS; Tsai, TH; Yang, HH | 1 |
| Chu, D; Lin, D; Ma, F; Shi, Y; Sun, T; Sun, Y; Tan, W; Wu, C; Xu, B; Yang, M; Yu, D | 1 |
| Cappuzzo, F; Drabkin, H; Gajapathy, S; Gemmill, R; Rossi, E; Valente, M; Varella-Garcia, M | 1 |
| Jones, D | 1 |
| Costa, DB; Kobayashi, S | 2 |
| Aggarwal, AN; Singh, N | 1 |
| Bergot, E; Zalcman, G | 1 |
| Barletta, E; Cusano, F; Ferrara, G; Ingordo, V | 1 |
| Langer, CJ | 3 |
| Andreu, J; Baselga, J; Cedrés, S; del Campo, JM; Felip, E; Martínez, P; Pallisa, E; Prat, A; Quispe, I; Sala, G | 1 |
| Chang, JW; Hsieh, JJ; Hsu, T; Li, YY; Shen, YC; Wang, CH; Yeh, KY | 1 |
| Gandhi, J; Gazdar, AF; Girard, L; Lam, WL; Lockwood, WW; Minna, JD; Peyton, M; Shigematsu, H; Soh, J; Varella-Garcia, M; Xie, Y; Yamamoto, H; Zhang, J; Zhang, W | 1 |
| Agarwal, S; Christensen, JG; Digiovanna, MP; Harris, LN; Kolmakova, J; Rimm, DL; Stern, DF; Zerillo, C | 1 |
| Deplanque, G; Deray, G; Dreno, B; Janus, N; Launay-Vacher, V; Mateus, C; Morere, JF; Robert, C; Souquet, PJ | 1 |
| Ahn, JS; Ahn, MJ; Jun, HJ; Kim, HS; Kim, S; Lee, J; Lee, S; Park, K; Park, YH; Yi, SY | 1 |
| Bunn, PA; Franklin, WA; Hirsch, FR; Kosaka, T; Mitsudomi, T; Nakajima, E; Skokan, M; Varella-Garcia, M; Xavier, AC; Yatabe, Y; Zeng, C | 1 |
| Atsou, K; Chouaid, C; Hejblum, G; Vergnenegre, A | 1 |
| Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Bayer-Zubek, V; Cordon-Cardo, C; Costa, J; Donovan, MJ; Greco, FA; Hainsworth, JD; Kotsianti, A; Parums, DV; Teverovskiy, M; Verbel, D | 1 |
| Hirai, Y; Kawago, M; Kiyoi, M; Naito, K; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T | 1 |
| Eguchi, K; Fukuoka, M; Ichinose, Y; Imamura, F; Itoh, Y; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Sekine, I; Shinkai, T; Takeda, K; Tamura, T; Tsuboi, M; Yamamoto, N | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Armour, AA; Ataman, OU; Biesma, B; Duffield, E; Ferry, D; Goss, G; Hirsch, FR; Laurie, SA; Thompson, J; Varella-Garcia, M; Wierzbicki, R; Zarenda, M | 1 |
| Chen, XG; Feng, ZQ; Li, J; Li, Y | 1 |
| Boku, N; Fujiwara, Y; Murakami, H; Nokihara, H; Puchalski, TA; Shin, E; Takahashi, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N; Yamazaki, K | 1 |
| Lu, MQ; Wang, J; Wei, Q; Wen, CH; Xu, XH; Zhou, ZT | 1 |
| Bodkin, D; Capó, A; Eberhardt, WE; Germonpré, P; Govindan, R; Kennedy, SJ; Natale, RB; Ranson, M; Rizvi, NA; Sleckman, BG; Stockman, PK | 1 |
| Lin, CC; Yang, CH | 1 |
| Aracil, M; Jimeno, J; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Bryce, J; De Feo, G; De Maio, E; Del Giudice, A; Di Maio, M; Falasconi, F; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC | 1 |
| Distel, RJ; Jänne, PA; Kuang, Y; Makrigiorgos, M; Rogers, A; Thiede, S; Vetrand, K; Wang, L; Yeap, BY | 1 |
| Fischer, F; Frommolt, P; Garraway, LA; Gazdar, AF; Girard, L; Heynck, S; Kashkar, H; Koker, M; Mermel, C; Meyerson, M; Michel, K; Minna, JD; Pao, W; Peifer, M; Peyton, M; Rabinovsky, R; Seeger, JM; Sos, ML; Thomas, RK; Weir, BA; Weiss, J; Zander, T | 1 |
| Horn, L; Sandler, AB | 1 |
| Karapanagiotou, EM; Merikas, I; Saif, MW; Syrigos, KN; Tsimboukis, S | 1 |
| Reck, M | 3 |
| Fujii, Y; Kawano, O; Okuda, K; Sasaki, H; Yano, M; Yukiue, H | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Clark, GM | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Hawkins, N; Scott, DA; Thatcher, N; Woods, BS | 1 |
| Billheimer, D; Brahmer, J; Carbone, D; Chen, H; Chen, S; Dang, TP; Herbst, R; Lee, JW; Massion, P; Salmon, S; Sandler, A; Schiller, J; Shyr, Y; Tran, H; Tsao, A | 1 |
| Bousamra, M; Fan, TW; Higashi, RM; Kloecker, G; Lane, AN; Miller, DM | 1 |
| An, TT; Bai, H; Duan, CJ; Guo, ZQ; Liu, HN; Liu, YX; Mao, L; Wang, HS; Wang, J; Wang, X; Wang, YY; Wu, NM; Yang, L; Zhao, J | 1 |
| Manegold, C | 2 |
| Filipits, M; Minar, W; Pirker, R | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, M; Capelletti, M; Cavazzoni, A; Fumarola, C; Galetti, M; Generali, D; Goldoni, M; La Monica, S; Mutti, A; Petronini, PG; Tagliaferri, S; Tiseo, M | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Hanrahan, EO; Herbst, RS; Heymach, JV; Johnson, BE; Kennedy, SJ; Langmuir, P; Mann, H; Natale, RB; Ryan, AJ | 1 |
| Arellano, J; Leteneux, C | 1 |
| Doral Stefani, S; Giorgio Saggia, M; Vicino dos Santos, EA | 1 |
| Li, T; Perez-Soler, R | 1 |
| Fujii, A; Fujita, F; Fujita, M; Koike, M; Nakamura, H; Ohya, J; Suzuki, T | 1 |
| Fujimoto, T; Ito, T; Kanda, S; Mori, S | 1 |
| Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Ardizzoni, A; Boni, L; Bozzetti, C; Camisa, R; Campanini, N; Capelletti, M; De Palma, G; Franciosi, V; Lagrasta, C; Marchioni, A; Rindi, G; Rossi, G; Sartori, G; Spiritelli, E; Tiseo, M | 1 |
| Dhruva, N; Socinski, MA | 1 |
| Chang, CP; Chao, HS; Chen, YM; Chiu, CH; Chu, LS; Tsai, CM | 1 |
| Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH | 1 |
| Cheng, LC; Chua, DT; Chung, LP; Ho, JC; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
| Kaji, A; Katayama, K; Kawahara, H; Mitsuhashi, J; Noguchi, K; Sugimoto, Y | 1 |
| Beckett, L; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, D; Perkins, N; Scudder, SA | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Becker, M; Fichtner, I; Leschber, G; Merk, J; Rolff, J | 1 |
| Mekhail, T; Pennell, NA | 1 |
| Li, D; Shen, QJ; Wang, F; Xing, WH; Xu, J; Zhang, LN; Zhang, XH; Zhuo, RJ; Zou, ZQ | 1 |
| Ansari, J; Hussain, SA; Palmer, DH; Rea, DW | 1 |
| Demierre, MF; Goldberg, LJ; Pongpudpunth, M | 1 |
| Biasco, G; Boschi, S; Fanti, S; Lollini, PL; Nannini, M; Pantaleo, MA | 1 |
| Brower, SL; Bush, JE; Rice, SD | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| He, C; Liu, M; Ouyang, M; Xu, J; Zhang, J; Zhong, N; Zhou, C | 1 |
| Asahina, H; Fukuoka, M; Hagiwara, K; Hida, T; Hirashima, T; Inoue, A; Kobayashi, K; Mitsudomi, T; Morita, S; Nukiwa, T; Okamoto, I; Sugio, K; Sunaga, N; Yamazaki, K; Yanagitani, N; Yasumoto, K; Yoshida, K | 1 |
| Chen, KY; Ho, CC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Cho, EK; Ha, SY; Hong, J; Kim, YS; Lee, H; Lee, JH; Lee, JI; Park, J; Park, SH; Shin, DB; Sim, H | 1 |
| Clément-Duchêne, C; Merritt, R; Wakelee, HA | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Benedetti, G; Colucci, G; Crinò, L; Galetta, D; Latini, L | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Green, J; Hockenhull, J; Macbeth, F; McLeod, C; Proudlove, C; Stevenson, J; Walley, T | 1 |
| Choe, du H; Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Dorans, K | 1 |
| Hanagiri, T; Nose, N; Onitsuka, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasumoto, K | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Endo, M; Igawa, S; Kaira, K; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
| Bowman, ED; Croce, CM; Gemma, A; Goto, A; Harris, CC; Horikawa, I; Jen, J; Kudoh, S; Mathe, EA; Okano, T; Schetter, AJ; Seike, M; Sugimura, H; Yang, P | 1 |
| Huh, K; Kim, MJ; Kim, SW; Oh, J | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Aono, N; Isa, S; Kawaguchi, T; Koh, Y; Kubo, A; Kurata, T; Nakao, K; Tachibana, K; Takada, M; Tsujino, K | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Arrieta, O; Michel, RM; Rios Trejo, MA | 1 |
| Jiang, W; Wu, JX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Bigelow, RL; Burke, P; Cardelli, JA; Carroll, JL; Coleman, DT; Milligan, SA; Steffan, JJ; Williams, BJ | 1 |
| Friedrich, MJ | 2 |
| Aizawa, H; Azuma, K; Basaki, Y; Hattori, S; Kage, M; Kashihara, M; Kawahara, A; Kuwano, M; Nakano, K; Ono, M; Shirouzu, K; Takamori, S; Terazaki, Y; Yanagawa, T | 1 |
| Date, H; Hotta, K; Jida, M; Kiura, K; Kubo, T; Matsuo, K; Mitsudomi, T; Miyoshi, S; Ohe, Y; Oto, T; Sano, Y; Takano, T; Toyooka, S; Tsukuda, K; Yamamoto, H; Yamane, M; Yatabe, Y | 1 |
| Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y | 1 |
| Anderton, J; Davies, BR; Mark Hickinson, D; Marshall, G; Rukazenkov, Y; Speake, G; Swaisland, A; Wilkinson, RW | 1 |
| Ren, S; Tang, L; Yan, L; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Fujita, Y; Fukai, S; Kawabata, T; Kawahra, M; Saito, R; Shibata, S; Shibayama, T; Shirai, M; Tamura, A; Tomizawa, Y | 1 |
| Chin, TM; Wong, AS; Zee, YK | 1 |
| Admane, S; Chirieac, LR; Costa, DB; Digumarthy, SR; Heist, RS; Iafrate, AJ; Kobayashi, S; Kwak, EL; Lynch, TJ; Mark, EJ; McDermott, U; Mino-Kenudson, M; Rodig, SJ; Settleman, J; Shaw, AT; Solomon, B; Stubbs, H; Yeap, BY | 1 |
| Chang, CC; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Su, YJ | 1 |
| Cheng, LC; Chua, DT; Chung, LP; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
| Cioffredi, LA; Giaccone, G; Jackman, DM; Jänne, PA; Johnson, BE; Miller, VA; Riely, GJ; Ruiz, MG; Sequist, LV; Yeap, BY | 1 |
| Ding, J; Hu, G; Li, J; Qian, X; Wang, Z; Zhang, W | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Gazdar, AF | 3 |
| Cappuzzo, F; Hirsch, FR; Varella-Garcia, M | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, WK; Lo, AI; Wong, MK | 1 |
| Ahn, JS; Ahn, MJ; Cho, JY; Choi, JH; Kang, JH; Kim, HT; Kim, SW; Lee, J; Lee, JS; Park, BB; Park, K; Park, SH; Shin, SW; Sohn, CH; Song, HS; Uhm, JE | 1 |
| Tsai, CC; Wang, HC; Wang, PH | 1 |
| Armour, AA; Chewaskulyong, B; Chu, DT; Duffield, EL; Fukuoka, M; Han, B; Ichinose, Y; Jiang, H; Margono, B; Mok, TS; Nishiwaki, Y; Ohe, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Watkins, CL; Wu, YL; Yang, CH; Yang, JJ | 1 |
| Bastus, R; Bertran-Alamillo, J; Bover, I; Camps, C; Cardenal, F; Catot, S; Garcia-Campelo, R; Gonzalez-Larriba, JL; Insa, A; Isla, D; Lopez-Vivanco, G; Majem, M; Massuti, B; Mayo, C; Molina, MA; Moran, T; Moreno, MA; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rolfo, C; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M | 1 |
| Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Gold, KA; Kim, ES; William, WN | 1 |
| Arai, S; Fukui, T; Hataishi, R; Iwasaki, M; Katagiri, M; Katono, K; Kobayashi, H; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Onoda, S; Otani, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Lazzari-Agli, L; Sartori, S; Tassinari, D; Tombesi, P | 2 |
| Mendoza, L | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Hsu, JY; Wakelee, HA | 1 |
| Kim, YH; Mio, T; Mishima, M | 1 |
| Han, JY; Jung, JI; Kim, JY; Park, IH | 1 |
| Miller, AA; Petty, WJ; Waller, LL | 1 |
| Auclair, PL; Battelli, C; Carrier, K; Emery, IF; Hayes, DM | 1 |
| Hida, T; Horio, Y; Matsuo, K; Mitsudomi, T; Ogawa, S; Park, J; Park, JY; Shimizu, J; Yatabe, Y; Yoshida, K | 1 |
| Herbst, RS | 5 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 1 |
| Da Silva, S; Decaestecker, C; Demetter, P; Mathieu, A; Salmon, I; Verbeken, E; Weynand, B | 1 |
| Cameron, MD; Kamenecka, TM; Li, X | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Yamada, Y; Yoshida, T | 1 |
| Carlson, JJ | 1 |
| Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Niang, C; Sancey, L | 1 |
| Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Khochbin, S; Niang, C; Sancey, L | 1 |
| Chen, F; Lu, Y; Luo, R; Luo, X; Zhang, J | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Gandara, DR; Lara, PN; Li, T; Mack, PC; Perez-Soler, R | 1 |
| Ichinose, Y; Maruyama, R; Seto, T; Wataya, H | 1 |
| Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY | 1 |
| Sanford, M; Scott, LJ | 1 |
| Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| Boerner, S; Chung, CT; Joshua, AM; Lara-Guerra, H; Leighl, NB; Liu, G; Ludkovski, O; Ma, C; Paul, N; Sakurada, A; Salvarrey, MA; Shepherd, FA; Squire, J; Tsao, MS; Waddell, TK | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Kappers, I; Klomp, HM | 1 |
| Anisimov, VV; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Moiseyenko, VM; Semionov, II; Yargnian, SM | 1 |
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Yano, S | 1 |
| Bessho, A; Harita, S; Hayashi, H; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Umemura, S; Yoshioka, H | 1 |
| Blakely, J; Houts, AC; Reyes, CM; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Beganovic, S | 1 |
| Arnold, A; Ciuleanu, TE; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Frymire, E; Gauthier, I; Goss, GD; Ho, C; Laberge, F; Laurie, SA; Lee, CW; Leighl, NB; Noble, J; Seymour, L; Shepherd, FA; Vincent, MD; Walde, D; Zukin, M | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Ito, F; Takeuchi, K | 1 |
| Engelman, JA; Jackman, D; Jänne, PA; Johnson, BE; Kris, MG; Lynch, T; Miller, VA; Pao, W; Riely, GJ | 1 |
| Benlloch, S; Molina, MA; Rosell, R; Taron, M; Viteri, S | 1 |
| Afifi, Y; Benomar, S; Bouhllab, J; Boutayeb, S; Errihanni, H; Hamada, S; Hassam, B | 1 |
| Atoyan, R; Bao, R; Borek, M; Cai, X; DellaRocca, S; Forrester, J; Lai, CJ; Qian, C; Qu, H; Samson, M; Tao, X; Wang, DG; Wang, J; Xu, GX; Yin, L; Zhai, HX; Zifcak, B | 1 |
| Kawana, S; Mitsuishi, T; Motoki, T | 1 |
| Büttner, R; Heukamp, LC | 1 |
| Gao, W; Shen, H; Shu, YQ; Sun, J; Yuan, Y | 1 |
| Inoue, F; Momosaki, N; Morizono, G; Takenaka, T; Tanaka, T; Tomisaki, S | 1 |
| Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB | 1 |
| Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
| Lyseng-Williamson, KA | 2 |
| Asami, K; Fukuoka, M; Hirashima, T; Katakami, N; Kudoh, S; Mitsudomi, T; Morita, S; Nakagawa, K; Negoro, S; Okamoto, I; Saito, H; Satouchi, M; Seto, T; Shibata, K; Shimizu, E; Tada, H; Takada, M; Toyooka, S; Tsurutani, J; Yatabe, Y; Yoshioka, H | 1 |
| Baba, N; Fujio, K; Kimura, S; Kohno, M; Kosugi, M; Ozaki, K; Sakamoto, T; Tanimura, S | 1 |
| Besse, B; Soria, JC; Vignot, S | 1 |
| Ayala, D; Blackstock, AW; Capellari, J; Center, B; Hinson, WH; Lovato, J; Miller, AA; Oaks, T; Petty, WJ | 1 |
| Amann, JM; Brahmer, J; Carbone, DP; Gonzalez, A; Lee, JW; Roder, H; Schiller, JH | 1 |
| Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S | 1 |
| Billheimer, D; Carbone, DP; Chen, H; Dang, TP; Herbst, RS; Roder, H; Roder, J; Salmon, JS; Sandler, A; Tran, HT; Tsao, AS; Tsypin, M | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Armour, AA; Bischoff, H; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Liao, ML; Mok, T; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Speake, G; Watkins, CL | 1 |
| Ando, M; Fukuoka, M; Hida, T; Ichinose, Y; Iwamoto, Y; Kashii, T; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Nakagawa, K; Okamoto, I; Sasaki, J; Sato, T; Satouchi, M; Sawa, T; Seto, T; Takayama, K; Takeda, K; Yamamoto, N | 1 |
| Huang, MS; Hung, HC; Hung, JY; Lai, CL; Lai, YF; Lin, MC; Shieh, JM; Yang, CT | 1 |
| Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK | 1 |
| Ganti, AK | 1 |
| Freidlin, B; Korn, EL; McShane, LM | 1 |
| Beika, Y; Enomoto, T; Fujii, T; Kishi, K; Kurosaki, A; Miyamoto, A; Morokawa, N; Takaya, H; Uruga, H; Yoshimura, K | 1 |
| Ma, PC; Manson, GV | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Neal, JW | 2 |
| Blumenschein, GR; Herbst, RS; Kim, ES; Lu, C; Lum, BL; Malik, M; Oh, YW; Papadimitrakopoulou, VA; Tran, HT; Zinner, RG | 1 |
| Chen, L; Ma, X; Sun, C; Zhong, M | 1 |
| Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H | 1 |
| Chen, TH; Fischer, F; Getlik, M; Greulich, H; Heuckmann, JM; Heynck, S; Klüter, S; Koker, M; Pawar, VG; Peifer, M; Rabiller, M; Rauh, D; Reuter, C; Rode, HB; Ruddigkeit, L; Simard, JR; Sos, ML; Thomas, RK; Weiss, J; Yuza, Y | 1 |
| Chen, YM; Chou, KT; Fan, WC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Wu, CH | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Sung, JH; Yun, T | 1 |
| Carney, D; Forde, P; Murphy, C; O'Sullivan, C | 1 |
| Akimov, M; Au, JS; Baselga, J; Damyanov, D; Delmar, P; Essioux, L; Felip, E; Hillenbach, C; Klughammer, B; Kuo, HP; McLoughlin, P; Milanowski, J; Orlov, S; Pluzanska, A; Ramlau, R; Reck, M; Tan, EH; Yang, PC | 1 |
| Neal, JW; Sequist, LV | 2 |
| Brown, A; Capelletti, M; Christensen, JG; Engelman, JA; Ercan, D; Jänne, PA; Kwiatkowski, DJ; Lee, C; Lifshits, E; Rogers, A; Xiao, Y; Yonesaka, K; Zejnullahu, K | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Ahn, JS; Ahn, MJ; Kang, JH; Kim, JH; Kim, SW; Lee, DH; Lee, JS; Park, K; Shin, SW; Suh, C | 1 |
| Hirte, H; Hotte, SJ; Kavsak, PA | 1 |
| Alfieri, RR; Ardizzoni, A; Bordi, F; Carmi, C; Cavazzoni, A; Galetti, M; La Monica, S; Lodola, A; Mor, M; Petronini, PG; Rivara, S; Silva, C; Vacondio, F; Vezzosi, S | 1 |
| Fujimoto, H; Hashimoto, K; Ishizuka, H; Kameyama, Y; Oyama, T; Suito, T; Yasuda, H | 1 |
| Caicun, Z; Jian, G; Jie, Z; Liang, T; Ling, Z; Qinfang, D; Songwen, Z | 1 |
| Burgers, JA; Cortesi, F; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Peters, GJ; Santoro, A; Smit, EF; Tibaldi, C; Zucali, PA | 1 |
| Ramsey, SD | 1 |
| Bradbury, PA; Evans, WK; Isogai, PK; Leighl, NB; Mittmann, N; Ng, R; Seymour, L; Shepherd, FA; Tsao, MS; Tu, D; Zhu, L | 1 |
| Hilbe, W; Pircher, A; Ploner, F; Popper, H | 1 |
| Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS | 1 |
| Han, YH; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Arakawa, M; Hasegawa, T; Honda, N; Nakamura, K; Rosser, CJ; Saito, H; Tobiume, M; Yamada, Y | 1 |
| Adam Willardsen, J; Anderson, MB; Cai, SX; Drewe, J; Jiang, S; Kasibhatla, S; Mather, G; Pervin, A; Pleiman, CM; Sirisoma, N; Tseng, B; Zhang, H | 1 |
| Ke, QH; Su, XY; Xu, XM; Yang, JY; Yuan, GJ | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Chen, L; Shi, YX; Wang, F; Zhang, L; Zhang, Y; Zhao, H | 1 |
| Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y | 1 |
| Gao, ZQ; Gu, AQ; Han, BH; Shi, CL; Wang, HM; Xiong, LW | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Barabasz, A; Fadden, P; Foley, B; Hall, S; Huang, K; Rice, JW; Scott, A; Steed, P; Veal, JM | 1 |
| Fujita, S; Fukudo, M; Ikemi, Y; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Aizawa, H; Akiba, J; Azuma, K; Basaki, Y; Hattori, S; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kono, S; Kuwano, M; Nakashima, K; Ono, M; Takamori, S; Yanagawa, T | 1 |
| Hang, J; Li, Z; Su, B; Su, C; Zhang, L; Zhao, Y; Zhou, C; Zhou, S | 1 |
| Choi, PJ; Kim, KN; Lee, KN; Lee, SK; Roh, MS; Son, C; Um, SJ; Yang, DK | 1 |
| Belani, CP | 3 |
| Eguchi, K; Fukuoka, M; Horai, T; Ichinose, Y; Masuda, N; Mitsudomi, T; Mori, K; Nukiwa, T; Saijo, N; Segawa, Y; Takahashi, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Hansen, O; Schytte, T | 1 |
| Borrill, J; Edwards, SJ | 1 |
| Lind, JS; Postmus, PE; Smit, EF | 1 |
| Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; La Monica, S; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Berna, MJ; Chan, D; Giaccone, G; Jensen, RT; Mantey, S; Moody, TW; Ridnour, L; Sancho, V; Wink, DA | 1 |
| Belani, CP; Owonikoko, TK; Ramalingam, SS | 1 |
| Athanasiou, A; Bardi, G; Chandrinou, H; Stathopoulos, GP; Trafalis, D | 1 |
| Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Doi, S; Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Takasu, M; Takatani, H; Tomonaga, N; Tsukamoto, K; Yamaguchi, H | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Liao, ML; Qin, SK; Sun, Y; Wu, YL; Zhou, CC | 1 |
| Brekken, RA; Carney, DN; Korpanty, G; Smyth, E; Sullivan, LA | 1 |
| Chan, R; Jacks, T; Jasper, PJ; Lane, K; Lauffenburger, DA; Lazzara, MJ; Neel, BG; Sorger, PK; Yaffe, MB | 1 |
| Hotta, K; Inoue, K; Kishino, D; Kiura, K; Okada, T; Suzuki, E; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| De Pas, TM; Delmonte, A; Gregorc, V; Spitaleri, G; Toffalorio, F | 1 |
| Dive, C; Harrison, LR; Mironov, A; Moreira-Leite, FF; Roberts, RA | 1 |
| Blackhall, F; Campbell, L; Thatcher, N | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Hsu, WH; Hung, JJ; Jeng, WJ; Liu, JS; Wu, YC | 1 |
| Cho, BC; Choi, SY; Kim, EM; Kim, HK; Kim, JH; Kim, JS; Kim, SM; Solca, F; Yun, CO | 1 |
| Anthoney, A; Blatter, J; Dean, E; Hanauske, AR; Kletzl, H; Klingelschmitt, G; Melezinek, I; Ranson, M; Reck, M; Twelves, C | 1 |
| Li, LY; Wang, MZ; Xu, LY; Zhang, L; Zhang, XT; Zhang, XY; Zhong, W | 1 |
| Fukuoka, M; Itoh, Y; Jiang, H; Negoro, S; Nishiwaki, Y; Saijo, N; Yamamoto, N | 1 |
| Drillenburg, P; Hoekzema, R | 1 |
| Guo, Y; Jiang, W; Li, S; Liao, H; Shi, YX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Calvo, A; Catena, R; Collantes, M; Diaz, R; Díaz-González, JA; Manrique, I; Nguewa, PA; Parrondo, R; Peñuelas, I; Perez-Stable, C; Redrado, M | 1 |
| Fujita, S; Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Miller, VA; Oxnard, GR | 1 |
| Camps, C; Carcereny, E; Gasco, A; Massuti, B; Moran, T; Quiroga, V; Rosell, R; Viteri, S; Wei, J | 1 |
| Ramalingam, SS; Stinchcombe, TE | 1 |
| Brugger, W; Cappuzzo, F; Cicenas, S; Ciuleanu, T; Esteban, E; Giaccone, G; Juhász, E; Klingelschmitt, G; Klughammer, B; Melezínek, I; Molinier, O; Stelmakh, L; Szczésna, A | 1 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Cheng, H; Dong, S; Guo, AL; Lin, QX; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Fukudo, M; Inui, K; Masago, K; Mishima, M; Togashi, Y | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Fujita, S; Ichikawa, M; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Eckert, R; Faehling, M; Kamp, T; Kuom, S; Schumann, C; Stoiber, KM | 1 |
| Choi, YJ; Kim, CH; Kim, HR; Kim, HT; Kim, YM; Koh, JS; Kook, EH; Lee, JC; Rho, JK | 1 |
| Ambrosio, R; Barbato, V; Bareschino, MA; Falanga, M; Gridelli, C; Maione, P; Rossi, A; Sacco, PC; Schettino, C | 2 |
| Fukuoka, M; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Takezawa, K; Tanizaki, J; Yamaguchi, H | 1 |
| Bartolotti, M; Bordi, P; Gelsomino, F; Tiseo, M | 1 |
| Guo, P; Kris, MG; Ladanyi, M; Moskowitz, CS; Oxnard, GR; Pao, W; Rizvi, NA; Rusch, VM; Schwartz, LH; Zhao, B | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW | 1 |
| Fujikura, Y; Hizawa, N; Homma, S; Kurishima, K; Morishima, Y; Ota, K; Otsuka, S | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Biesma, B; Eberhardt, WE; Germonpré, P; Herbst, RS; Heymach, JV; Ichinose, Y; Johnson, BE; Kabbinavar, F; Kennedy, SJ; Langmuir, P; Li, L; Qin, S; Saijo, N; Sun, Y; Tada, H; Wang, J; Zhang, L; Zhou, C | 1 |
| Hosoda, W; Kitamura, A; Mitsudomi, T; Sasaki, E; Yatabe, Y | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Ando, M; Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Miyazawa, H; Morita, S; Nukiwa, T; Ogura, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Tanaka, T; Yoshimori, K; Yoshizawa, H | 1 |
| Rudman, SM; Spicer, JF | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Döme, B; Ostoros, G; Strausz, J; Tímár, J | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Babineaux, S; Klein, R; Lawson, A; Liepa, AM; Muehlenbein, C; Schwartzberg, L; Wielage, R | 1 |
| Lin, CC; Shao, YY; Yang, CH | 1 |
| Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M | 1 |
| Ackerman, J; Albain, KS; Barlesi, F; Berkowitz, L; Besse, B; Gabrail, N; Hart, LL; Herbst, RS; Leighl, NB; Massarelli, E; Melnyk, O; Miller, VA; Raez, LE; Rosen, PJ; Shepherd, FA; Shun, Z; Sternas, L | 1 |
| Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
| He, C; Li, P; Ma, J; Ma, Z; Wang, H; Wang, Q; Wei, B; Zhu, H | 1 |
| Govindan, R; Stinchcombe, TE | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| De Jonge, M; Guttman-Yassky, E; Iwata, KK; Krueger, JG; Matthews, L; McCarthy, S; Mita, A; Rowinsky, EK; Verweij, J | 1 |
| de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Chang, SH; Hsu, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Antoniou, C; Chasapi, V; Dilana, KD; Karapanagiotou, EM; Matekovits, AE; Stratigos, AJ; Syrigos, KN; Tsimboukis, S; Vergou, T | 1 |
| Ding, YM; Ju, LX; Li, W; Meng, SY; Su, B; Tang, L; Yan, LH; Yang, XJ; Zhao, YM; Zhou, CC | 1 |
| Bokemeyer, C; Laack, E; Sauter, G | 1 |
| Aebersold, DM; Bernier, J; Bucher, SE; Ciernik, IF; Glanzmann, C; Lippuner, T; Lombrieser, N; Lütolf, UM; Ries, G; Rothschild, S; Zouhair, A | 1 |
| Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Sano, K; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishihara, K; Kaji, R; Katakami, N; Nishimura, T; Takahashi, Y; Tomii, K | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Costa, DB; Hamada, A; Kobayashi, S; Yeo, WL | 1 |
| Byers, L; Cai, D; Gao, B; Gazdar, AF; Girard, L; Heymach, J; Kim, YH; Kodadek, T; Mills, G; Minna, JD; Nanjundan, M; Peyton, M; Pollack, JR; Raso, MG; Shames, DS; Sullivan, JP; Wistuba, I; Xie, Y | 1 |
| Chen, L; Li, C; Liu, X; Tian, Q; Wang, P; Xu, Y; Yang, Z; Zhao, W | 1 |
| Lv, P; Zhou, T | 1 |
| Akiyama, H; Hishida, T; Horinouchi, H; Kondo, H; Mitsudomi, T; Nagai, K; Nagayasu, T; Tsuboi, M; Yokoi, K | 1 |
| Chen, J; Liu, H; Wang, Y | 1 |
| Eaton, KD; Martins, RG | 1 |
| Blum, RA; Cheng, CP; Hanifudin, A; Lim, LT | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H | 1 |
| Huang, C; Jiang, K; Wu, B; Xu, Z; Zhang, J; Zhuang, W | 1 |
| Bertran-Alamillo, J; Cardenal, F; Cobo, M; Garrido, P; Isla, D; Lianes, P; Manegold, C; Massuti, B; Molina, MA; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Stahel, R; Taron, M; Trigo, JM | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Altorki, N; Camiolo, M; Fenoglio, S; Gao, DC; Johns, C; Kenner, L; Lindsted, T; Mittal, V; Schlederer, M; Sordella, R; Stiles, B; Yao, Z | 1 |
| Arao, T; Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Tanaka, K; Yamada, Y; Yamaguchi, H | 1 |
| Aukema, TS; Codrington, HE; Kappers, I; Klomp, HM; Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Amarshi, N; Billingsley, A; Nair, BA; Thomas, KS | 1 |
| Ghosh, G; Kron, SJ; Lee, AG; Palecek, SP; Yan, X | 1 |
| Cioffredi, LA; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Van den Abbeele, AD; Yap, JT; Yeap, BY | 1 |
| Kim, YM; Park, SY; Pyo, H | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Ahn, HK; Ahn, JS; Ahn, MJ; Chang, MH; Choi, YL; Jung, CK; Lee, J; Park, K; Park, YH | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Nishiyama, A; Tomii, K; Yoshioka, H | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Murray, S | 1 |
| Fukuoka, M; Nakagawa, K; Nakamatsu, K; Nishimura, Y; Okamoto, H; Okamoto, I; Takahashi, T; Watanabe, K; Yamamoto, N | 1 |
| Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Chang, YC; Chang, YL; Hsu, YC; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC | 1 |
| Alam, N; Dudek, AZ; Gustafson, KS; Kapoor, A; Ladanyi, M; Truskinovsky, AM; Zakowski, MF | 1 |
| Iqbal, SA; Myerson, JS; O'Brien, ME; Popat, S | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Geng, YT; Li, XD; Shen, H; Shu, YQ; Sun, J; Wu, CP; Yin, YM | 1 |
| Fujiwara, K; Kudo, K; Matsuo, K; Mizuta, M; Sato, T; Tsushima, M; Yonei, T | 1 |
| Geng, YT; Hu, XL; Li, W; Shao, YF; Shu, YQ; Wang, ZX; Yin, YM | 1 |
| Fu, XY; Huang, Q; Li, DJ; Lu, MQ; Su, J; Xu, XH; Xue, F | 1 |
| Chiu, YF; Kuo, YH; Lin, YW; Su, YC; Tsai, MS | 1 |
| Eberhardt, W | 1 |
| Arcila, ME; Azzoli, CG; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA | 1 |
| Altomare, G; Bidoli, P; Cazzaniga, ME; Cicchiello, F; Colombo, I; Cortinovis, DL; Crippa, A; Villa, F | 1 |
| Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Shirane, M | 1 |
| Alessandroni, P; Baldelli, AM; Casadei, V; Catalano, V; Dennetta, D; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Ugolini, M | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Albain, KS; Atkins, JN; Chansky, K; Crowley, JJ; Dakhil, SR; Franklin, WA; Gandara, DR; Herbst, RS; Hirsch, FR; Kelly, K; Kim, ES; Mack, PC; Redman, M | 1 |
| Chen, LC; Gitlitz, B; Jezior, D; Milne, G; Patel, R; Reckamp, K; Syto, M; Zaknoen, S | 1 |
| Balemans, C; Mattijssen, V; Ruinemans, GM; Smit, HJ; Wiersma-van Tilburg, AJ | 1 |
| Murashige, N; Oshima, Y; Tanimoto, T | 1 |
| Chang, YH; Lim, KH | 1 |
| Armour, AA; Watkins, CL | 1 |
| Basaki, Y; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kuwano, M; Nakashima, K; Ono, M; Uramoto, H; Yamamoto, C; Yasumoto, K | 1 |
| Chang, CY; Chang, TY; Chao, YS; Chen, CH; Chen, CP; Chen, CT; Chen, YR; Chu, CY; Coumar, MS; Fang, MY; Hsieh, HP; Hsieh, SH; Hsu, H; Hsu, JT; Liao, CC; Lien, TW; Lin, WH; Rafi, S; Shiao, HY; Wang, SY; Wu, CH; Yeh, KC; Yeh, TK | 1 |
| Bryce, J; Carillio, G; Carotenuto, P; Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; La Rocca, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Chiba, M; Fujiwara, M; Goya, T; Kishino, T; Matsushima, S; Morii, T; Ogura, W; Ohnishi, H; Ohtsuka, K; Watanabe, T | 1 |
| Jones, SJ; Milenkova, T | 1 |
| Saijo, N | 3 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Chang, TH; Huang, CP; Lan, CC; Lin, SB; Shih, JY; Su, KY; Tsai, MF; Wu, CP; Wu, SG; Yang, CH; Yang, PC; Yu, SL; Yu, YL | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Minna, JD; Murudkar, C; Shay, JW; Shultz, JC; Wijesinghe, DS | 1 |
| Costanzo, R; Daniele, G; Di Maio, M; Giordano, P; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Riccardi, MG; Rocco, G | 1 |
| Bagust, A; Boland, A; Brown, T; Dickson, R; Dundar, Y; Hockenhull, J; Oyee, J; Proudlove, C; Ramani, VS | 1 |
| Ju, L; Li, W; Yan, L; Zhou, C | 1 |
| Grygárková, Y; Havel, L; Hrnciarik, M; Kolek, V; Koubková, L; Krejcí, J; Pesek, M; Salajka, F; Skalová, B; Skricková, J; Stícha, M; Tomísková, M; Zatloukal, P | 1 |
| Katayama, T; Maehara, Y; Mitsudomi, T; Murakami, I; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Ahn, JS; Ahn, MJ; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM | 1 |
| Chen, Z; Ding, W; Gao, L; Huang, X; Lou, Y; Yang, H; Ye, Z; Yu, Y; Zhang, Y | 1 |
| Duchnowska, R | 1 |
| Addison, CL; Bradbury, PA; Ding, K; Goss, GD; Le Maître, A; Seymour, L; Shepherd, FA; Tsao, MS; Zhao, H | 1 |
| Altiok, S; Bai, Y; Eschrich, S; Fang, B; Haura, EB; Kinose, F; Koomen, J; Li, J; Lin, H; Liu, RZ; Oguz, U; Remily-Wood, ER; Zhang, G | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Liu, X; Nie, J; Tian, G | 1 |
| Ahn, JS; Ahn, MJ; Chung, MJ; Hwang, HS; Kim, TS; Lee, HY; Lee, JW; Lee, KS; Park, K; Yi, CA | 1 |
| Horger, M; Schulze, M; Spengler, W | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Dong, N; Guo, Y; Luan, HL; Sun, BC; Sun, LN; Wang, M; Zang, FL; Zhan, ZL | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Al-Khater, AM; Rasul, KI | 1 |
| Colucci, G; Galetta, D; Millaku, A; Pisconti, S; Rossi, A | 1 |
| Heigener, D; Mok, T; Reck, M; Wolf, J; Wu, YL | 1 |
| Liu, D; Shentu, J; Tan, F; Wang, Y; Xu, N; Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Hui, RC; Ko, JH; Shih, YC; Yang, CH | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Doebele, RC; Heasley, LE; Heasley, LR; Helfrich, BA; Hercule, P; Hinz, TK; Marek, L; Marshall, ME; Ware, KE | 1 |
| Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, K; Okamoto, W; Takezawa, K; Tanaka, K; Yamaguchi, H | 1 |
| Ren, GJ; Wang, MZ; Xia, Y; Zeng, X; Zhang, L; Zhu, YJ | 1 |
| Lee, P | 1 |
| Cortot, AB | 1 |
| Ardizzoni, A; Bartolotti, M; Boggiani, D; Bortesi, B; Bozzetti, C; Gelsomino, F; Sammarelli, G; Thai, E; Tiseo, M | 1 |
| Lin, CC; Yang, JC | 1 |
| Beijnen, JH; Fanggiday, JC; Lankheet, NA; Malingré, MM; Staaks, GH; Ter Heine, R; Van Der Westerlaken, MM | 1 |
| Heigener, DF; Reck, M | 1 |
| Imai, H; Ishizuka, T; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Nakajima, T; Oriuchi, N; Promchan, K; Shimizu, K; Sunaga, N; Tominaga, H; Yamamoto, N; Yanagitani, N | 1 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Chang, HT; Chen, CA; Chen, CY; Chen, YJ; Chong, NS; Hsieh, CH; Hsieh, YP; Lin, SC; Lin, SL; Shueng, PW; Wang, LY | 1 |
| Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
| Erdem, L; Giovannetti, E; Leon, LG; Olcay, E; Peters, GJ | 1 |
| Dobashi, Y; Kanai, Y; Koyama, S; Tetsuka, K | 1 |
| Longo, M; Merlo, V; Novello, S; Scagliotti, GV | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Cappuzzo, F; Cortinovis, D; De Marinis, F; Di Maio, M; Gridelli, C; Mok, T | 2 |
| Alauddin, MM; Balatoni, J; Flores, L; Gelovani, JG; Gonzalez-Lepera, C; Krasnykh, V; Mukhapadhyay, U; Najjar, AM; Ogawa, K; Pal, A; Shavrin, A; Soghomonyan, S; Tong, W; Volgin, AY; Yeh, HH; Young, D | 1 |
| Boss, DS; Britten, CD; Camidge, DR; Eckhardt, SG; Engelman, JA; Garon, EB; Guo, F; Jänne, PA; Letrent, S; Liang, J; Millham, R; Schellens, JH; Taylor, I; Wong, S | 1 |
| Honda, T; Kameda, Y; Kondo, T; Miyagi, Y; Murakami, S; Noda, K; Obata, M; Oshita, F; Saito, H; Sakuma, Y; Yamada, K; Yokose, T | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Ariza, A; Benlloch, S; Bertran-Alamillo, J; Bivona, TG; Carcereny, E; Cardenal, F; Cobo, M; Costa, C; de Aguirre, I; Garcia-Campelo, R; Gimenez-Capitan, A; Insa, A; Isla, D; Majem, M; Massuti, B; Mate, JL; Mayo, C; Mendez, P; Molina, MA; Moran, T; Porta, R; Provencio, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Sawyers, CL; Simonetti, S; Taron, M; Viteri, S | 1 |
| Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Wojas-Krawczyk, K | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| An, SJ; Chen, ZH; Cheng, H; Dong, S; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 2 |
| de Marinis, F; Gridelli, C; Rossi, A; Venturino, P | 1 |
| Amir, E; Bradbury, PA; Douillard, JY; Horgan, AM; Kim, ES; Leighl, NB; Ng, R; Shepherd, FA | 1 |
| Anthoine, G; Berghmans, T; CsToth, I; Mascaux, C; Meert, AP; Paesmans, M; Sculier, JP | 1 |
| Galettis, P; Links, M; Luk, PP | 1 |
| Abratt, RP; Arrieta, Ó; Blackhall, FH; Chan, V; de Boer, RH; de Marinis, F; Gottfried, M; Langmuir, P; Milenkova, T; Raats, J; Read, J; Vansteenkiste, JF; Wolf, J; Yang, CH | 1 |
| Barlesi, F; Ferry, D; Gogov, S; Goss, GD; Greco, FA; Langmuir, P; Mulatero, C; Natale, RB; Rowbottom, JA; Sunpaweravong, P; Thomas, M; Thompson, J; Thongprasert, S; Tsai, CM; Whorf, R | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Farndon, PA; Kobayashi, S; Li-Wan-Po, A; Mitsudomi, T; Potter, VA | 1 |
| Gazdar, AF; Girard, L; Imai, H; Kaira, K; Larsen, JE; Minna, JD; Mori, M; Peyton, M; Sato, M; Shames, DS; Soh, J; Sunaga, N; Xie, Y; Yanagitani, N | 1 |
| Abraham, J; Davis, C | 1 |
| Babu, VC; Harini, VV; Kumar, BS; Nargund, A; Patil Okaly, GV; Rao, R; Rao, S; Sahoo, R; Venkataswamy, E | 1 |
| Hureaux, J; Jeanfaivre, T; Le Maignan, L; Mirebeau-Prunier, D; Urban, T; Vervueren, L | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Hwang, J; Subramaniam, DS | 1 |
| Beinert, T; Binder, D; Buckendahl, AC; Hübner, RH; Schlattmann, P; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Mountzios, G; Syrigos, KN | 1 |
| Assaraf, YG; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Guchelaar, HJ; Lemos, C; Peters, GJ; Santoro, A; Scheffer, GL; Tibaldi, C; van der Straaten, T; Zucali, PA | 1 |
| Behrens, RJ; Cannon, MW; Friedman, EL; Gross, GG; Hillman, SL; Jatoi, A; Mc Kean, H; Rowland, KM; Sborov, MD; Stella, PJ | 1 |
| Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY | 1 |
| Ren, GJ; Shan, B; Xiao, Y; Xu, JS; Zhang, L; Zhao, YY; Zhu, YJ | 1 |
| Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W | 1 |
| Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z | 1 |
| Bergot, E; Creveuil, C; Lechapt, E; Levallet, G; Zalcman, G | 1 |
| De Marinis, F; Karapanagiotou, EM; Oikonomopoulos, G; Saif, MW; Syrigos, KN | 1 |
| Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A | 1 |
| Castel, M; Despas, F; Mazières, J; Pathak, A | 1 |
| Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC | 1 |
| Hirano, S; Ishii, S; Kobayashi, N; Kudo, K; Naka, G; Sugiyama, H; Takeda, Y | 1 |
| Chiu, HC; Chou, DL; Hsu, JT; Huang, CT; Lien, TW; Lin, WH; Yen, KJ | 1 |
| Han, JY; Hyung, LS; Kim, HT; Lee, JS; Lee, SH; Moon, YJ; Yoo, NJ; Yun, T | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Murphy, M; Stordal, B | 1 |
| Heigener, DF; Horwood, K; Mali, P; Reck, M; van Zandwijk, N; Wu, YL | 1 |
| de Marinis, F; Di Maio, M; Gridelli, C; Ricciardi, S; Rossi, A | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Choi, BG; Han, JY; Kim, JY; Lee, SH; Yoo, NJ | 1 |
| Abe, H; Aikawa, E; Akiba, J; Azuma, K; Kage, M; Kawahara, A; Nakashima, K; Sumi, A; Taira, T; Takamori, S; Yamaguchi, T | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Inoue, A; Ishida, T; Isobe, H; Kinoshita, I; Maemondo, M; Nishimura, M; Nukiwa, T; Oizumi, S; Saijo, Y; Sukoh, N | 1 |
| Cabodi, S; Camacho-Leal, MP; Defilippi, P; Morello, V; Papotti, M; Repetto, D; Sigismund, S; Turco, E; Volante, M | 1 |
| Guo, J; Ma, B; Wang, Y; Zhang, Y; Zhou, H | 1 |
| Anadkat, MJ; Hepper, DM; Wu, P | 1 |
| Früh, M | 1 |
| Tuder, RM; Winn, RA | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chen, KY; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Dhillon, S; Muir, VJ | 1 |
| Kimura, H; Nakagawara, A; Nakajima, T; Yasufuku, K; Yoshino, I | 1 |
| Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H | 1 |
| Chang, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Abbate, I; Bongarzone, I; Cremona, M; De Bortoli, M; Galetta, D; Garrisi, VM; Mangia, A; Paradiso, A; Pastorino, U; Quaranta, M; Vaghi, E | 1 |
| Chang, HC; Chao, TY; Chung, YH; Lie, CH; Lin, MC; Wang, CC; Wang, JL | 1 |
| Ardizzoia, A; Bertolini, A; Cortesi, E; Fagnani, D; Farina, G; Farris, A; Garassino, MC; Labianca, R; Locatelli, MC; Longo, F; Mancuso, A; Martelli, O; Moscetti, L; Pavese, I; Rulli, E; Scanni, A; Tomirotti, M; Valmadre, G | 1 |
| Crinò, L; Metro, G | 1 |
| Azzoli, CG; Bains, M; Chaft, JE; Downey, R; Flores, R; Heelan, RT; Kris, MG; Krug, LM; Ladanyi, M; Miller, VA; Pao, W; Park, B; Rizvi, NA; Rusch, V; Shen, R; Singh, B; Zakowski, M | 1 |
| Bosquée, L; Corhay, JL; Thonnard, AS | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Chuu, CP; Kuo, LK; Lin, HP | 1 |
| Hazama, M; Kim, YH; Niimi, M; Sakamori, Y; Tanaka, S; Yanagihara, K | 1 |
| Wang, L; Xiao, F; Zhang, W; Zheng, J | 1 |
| Abdiche, S; Bonnabau, H; Chouaïd, C; Cumin, I; Decroisette, Ch; Ejnaini, CN; Hureaux, J; Lombard, JN; Mazières, J; Monnet, I; Quéré, G; Vergnenègre, A | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
| Banz, K; Bischoff, H; Brunner, M; Chouaid, C; de Castro Carpeño, J; de Marinis, F; Grossi, F; Vergnenègre, A; Walzer, S | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Gruber-Mösenbacher, U; Hilbe, W; Hulla, W; Mohn-Staudner, A; Pirker, R; Ploner, F; Popper, H; Studnicka, M; Wrba, F | 1 |
| Brugger, W; Cappuzzo, F; Ciuleanu, T; Coudert, B; Giaccone, G; Gopalakrishna, P; Park, K; Wu, YL | 1 |
| Ji, Y; Lu, YJ; Ma, SL; Wang, CR; Wu, YM; Zhao, YF | 1 |
| Berghmans, T; Meert, AP; Sculier, JP | 1 |
| Ansari, R; Bustin, F; Flynn, P; Hainsworth, J; Hart, L; Herbst, RS; O'Connor, P; Otterson, GA; Soh, CH; Vlahovic, G | 1 |
| Chalfant, CE; Goehe, RW; Hawkins, AJ; Massiello, A; Mayton, EK; Mukerjee, P; Murudkar, CS; Park, MA; Pinkerman, RL; Shultz, JC; Wijesinghe, DS | 1 |
| Campbell, TC; Hoang, T; Kim, K; Larson, MM; LoConte, NK; Marcotte, SM; O'Mahar, SE; Seo, S; Traynor, AM | 1 |
| Berg, A; Brustugun, OT; Helland, Å; Lund-Iversen, M | 1 |
| Cheon, YH; Jeon, DH; Kang, MG; Kim, CY; Kim, HJ; Kim, MJ; Kim, YE; Lee, GW; Lee, SS | 1 |
| Date, H; Mishima, M; Nagai, H; Niimi, M; Sasaki, T; Seo, N; Tanaka, S; Yanagihara, K; Yasuda, H | 1 |
| Katzumata, A; Kawauchi, M; Kuramoto, S; Matsumoto, Y; Ono, Y; Toyoshima, A; Toyota, Y | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Ma, S; Xu, Y; Zhang, Y | 1 |
| Heneberg, P | 1 |
| Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M | 1 |
| Chen, Y; Feng, L; Ge, W; Han, W; Jin, H; Li, J; Lin, X; Pan, H; Sun, J; Wang, X; Wang, Y | 1 |
| Baselga, J; Felip, E; Hermes, A; Klughammer, B; Reck, M; Tan, EH | 1 |
| Borget, I; Cadranel, J; Chouaid, C; Coudert, B; Daniel, C; Dansin, E; Friard, S; Madelaine, J; Madroszyk, A; Morin, F; Pignon, JP; Quoix, E; Westeel, V | 1 |
| Bryce, J; Carillio, G; Costanzo, R; Daniele, G; De Feo, G; Di Maio, M; Giordano, P; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Agustoni, F; Buzzoni, R; Ducceschi, M; Formisano, B; Gelsomino, F; Pietrantonio, F; Platania, M; Pusceddu, S; Vitali, M; Zilembo, N | 1 |
| Shepherd, FA | 2 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Dallas, J; Jantz, MA; Kaye, FJ | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Okamoto, I; Takeda, M | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Nukiwa, T; Oizumi, S; Saijo, Y; Satoh, H; Yoshizawa, H | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y; Tsuchido, Y | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, ST; Kim, SW; Lee, J; Park, K; Park, YH; Sohn, I; Sun, JM; Uhm, JE | 1 |
| Kosaka, T; Kuwano, H; Mogi, A; Yamaki, E | 1 |
| Fujimoto-Ohuchi, K; Furugaki, K; Iwai, T; Kondoh, K; Mori, K; Moriya, Y; Yanagisawa, M; Yorozu, K | 1 |
| Altavilla, G; Benecchi, S; Magri, I; Pettineo, G; Rosell, R; Salazar, MF; Santarpia, M | 1 |
| Bennouna, J; de Castro, J; Dingemans, AM; Gridelli, C; Griesinger, F; Grossi, F; Langer, C; Rossi, A; Thatcher, N; Wong, EK | 1 |
| Asano, H; Harada, M; Kagawa, S; Kanazawa, S; Katsui, K; Maki, Y; Masuda, H; Miyoshi, S; Muraoka, T; Naito, M; Naomoto, Y; Takemoto, M; Toyooka, S; Tsukuda, K | 1 |
| Belani, CP; Blumenschein, G; Goss, G | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Correa, PD; Rizwanullah, M; Shrimali, RK | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Boons, CC; Boven, E; Hugtenburg, JG; Mangnus, D; Moes, JE; Smit, EF; Swart, EL; Timmers, L | 1 |
| Han, JY; Kim, HT; Lee, GK; Lee, JS; Lim, KY; Park, SY; Won, YW; Yoon, KA; Yun, T | 1 |
| Ameshima, S; Asami, K; Atagi, S; Hirai, K; Kawahara, M; Koizumi, T; Morikawa, A; Morozumi, N; Tsukadaira, A | 1 |
| Cha, MY; Chae, YJ; Kim, M; Kim, MS; Kim, YH; Lee, GS; Lee, KH; Lee, KO; Park, J; Park, SB; Song, JY; Suh, KH | 1 |
| Amato, KR; Arcila, M; Chmielecki, J; de Stanchina, E; Foo, J; Ginsberg, MS; Hutchinson, K; Inoue, A; Kris, MG; Ladanyi, M; Michor, F; Miller, VA; Ohashi, K; Oxnard, GR; Pao, W; Socci, ND; Somwar, R; Sos, ML; Thomas, RK; Viale, A; Wang, L | 1 |
| Blanchet, B; Dauphin, A; Dusser, D; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Schoemann-Thomas, A; Taieb, F; Vidal, M | 1 |
| Han, SY; Li, PP; Zhao, MB; Zhuang, GB | 1 |
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Akerley, WL; Arthur, S; Brugger, W; Chen, Y; Costa, DB; Ferrari, D; Garmey, EG; Gerber, DE; Gorbachevsky, I; Orlov, S; Ramlau, R; Schiller, JH; Schwartz, B; Sequist, LV; von Pawel, J | 1 |
| Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y | 1 |
| Moro-Sibilot, D | 1 |
| Douillard, JY; Lokiec, F | 1 |
| Besse, B; Zalcman, G | 1 |
| Giroux Leprieur, E; Planchard, D | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 1 |
| Becker, A; Crombag, L; Heideman, DA; Postmus, PE; Smit, EF; Thunnissen, FB; van Wijk, AW | 1 |
| Barratt, BJ; Fukuoka, M; Hada, S; Jawaid, A; Kamatani, N; Kato, H; Kudoh, S; March, R; Mushiroda, T; Nakamura, Y; Nakata, K; Nyberg, F; Ohe, Y; Takahashi, A; Umemura, T | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Huang, YS; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Yin, XL; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Houwing, RH; Koster, ME; Lips, IM; Vonk, EJ | 1 |
| Akimoto, S; Clausen, IG; Dobashi, T; Fukuoka, M; Harbron, CG; Higenbottam, T; Kato, H; Kawakami, T; Kihara, M; Komatsu, Y; Kudoh, S; Kyono, Y; Marko-Varga, G; Nagasaka, K; Nakata, K; Nishimura, T; Nyberg, F; Ogiwara, A; Ohe, Y; Otsuji, M; Peers, IS; South, MC; Takami, S; Tu, HK; Wada, K | 1 |
| Gaafar, RM; Hasan, B; Papamichael, D; Scagliotti, GV; Surmont, VF; Torri, V; Van Klaveren, RJ; van Meerbeeck, JP; Welch, JJ | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Hotta, K; Kiura, K | 1 |
| Amihai, D; Gilad, Y; Gorzalczany, Y; Hammel, I; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Aziz, F; Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T | 1 |
| de Boer, RH; Wong, HL | 1 |
| Bunn, PA; Camidge, DR; Camidge, R; Dziadziuszko, R; Eisen, T; Franklin, WA; Hirsch, FR; Kabbinavar, F; Martins, R; Richardson, F; Richardson, K; Rusk, J; Schnell, FM; Sternberg, DW; Varella-Garcia, M; Wacker, B | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Chen, X; Geng, Y; Hu, X; Li, W; Shu, Y; Wang, R; Yin, Y | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Kawano, Y; Kawasaki, M; Kitasato, Y; Mizuta, Y; Sakoda, Y; Takata, S | 1 |
| Erasmus, JJ; Stewart, DJ | 1 |
| Keiding, S; Meldgaard, P; Memon, A; Nexo, E; Sorensen, BS; Sorensen, L; Weber, B; Winterdahl, M | 1 |
| Baumann, M; Benes, C; Dahm-Daphi, J; Dikomey, E; Gheorghiu, L; Krause, M; Kriegs, M; Morsbach, F; Nanda, A; Sander, D; Settleman, J; Wang, M; Willers, H | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Hsieh, WY; Lee, JY; Lee, YM; Yang, PC; Yu, SL | 1 |
| Lin, D; Ma, F; Shi, Y; Sun, T; Xu, B | 1 |
| Colomer, R; Quintela-Fandino, M | 1 |
| Clarke, JL; Grommes, C; Holodny, AI; Kris, MG; Lassman, AB; Miller, VA; Oxnard, GR; Pao, W | 1 |
| Gong, Y; Pao, W | 1 |
| Fiegl, M; Hack, R; Hilbe, W; Jamnig, H; Pall, G; Pircher, A; Sterlacci, W; Ulsperger, E; Zelger, B | 1 |
| Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
| Hao, XZ; Hu, XS; Li, B; Li, JL; Shi, YK; Wang, B; Wang, L; Wang, Y; Zhang, XR; Zhu, HX | 1 |
| Li, L; Liu, JL; Su, H; Xu, CA; Zou, HW | 1 |
| Chu, QS; de Jonge, MJ; Hamilton, M; Iwata, K; McCarthy, S; Mita, AC; Mita, MM; Papadopoulos, K; Ricart, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Verweij, J; Wacker, B; Witt, K; Wood, L | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Azuma, K; Hattori, S; Kage, M; Kawahara, A; Kinoshita, T; Kuwano, M; Nakagawa, K; Nakashima, K; Okamoto, I; Ono, M; Taira, T; Takamori, S; Takeda, M | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Lara, PN; Lau, D; Li, T; Mack, PC; Perkins, N; Sangha, R | 1 |
| Duffield, E; Fukuoka, M; Goto, K; Ichinose, Y; Itoh, Y; Jiang, H; McCormack, R; Mok, T; Negoro, S; Nishio, K; Ohe, Y; Saijo, N; Yamamoto, N | 1 |
| Loo, BW; Ma, L; Meng, X; Murphy, JD; Sun, X; Yu, J | 1 |
| Cappuzzo, F; D'Incecco, A | 1 |
| Custodio, A; de Castro, J | 1 |
| Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F | 1 |
| Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J | 2 |
| Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P | 1 |
| Clark, P; George, E; Rinaldi, F | 1 |
| Chen, ZW; Lu, S; Song, ZB; Yu, YF | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Guo, ZZ; Huang, JJ; Huang, Y; Lin, TY; Tian, Y; Xu, F; Zhang, LL | 1 |
| Kani, K; Mallick, P; Sordella, R | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Liu, YC; Tang, GJ; Wei, YF; Yu, CJ; Yuan, MK | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Bachi, A; Bergamaschi, L; Bulotta, A; Cattaneo, A; Floriani, I; Garavaglia, D; Ghio, D; Gregorc, V; Grigorieva, J; Lazzari, C; Roder, H; Sorlini, C; Spreafico, A; Tsypin, M; Viganò, MG | 1 |
| Choi, CM; Choi, DR; Kim, SW; Lee, DH; Lee, JS; Suh, C | 1 |
| Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Hockenhull, J; Martin Saborido, C; Oyee, J; Ramani, VS | 1 |
| Blasinska-Morawiec, M; Brugger, W; Cappuzzo, F; Curescu, S; Manikhas, GM; Mayne, K; Mazieres, J; Sakalauskas, R; Triller, N; Trunzer, K; Ward, C; Whittom, R | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Ahn, J; Hyon, JY; Lee, JH; Wee, WR | 1 |
| Asuncion, BR; Gaire, F; Gustavson, M; Hirsch, FR; Ikeda, N; Kato, Y; Mascaux, C; Matsubayashi, J; Nagao, T; Ohira, T; Ranger-Moore, J; Tran, C; Wynes, MW; Yoshida, K; Zhao, JM | 1 |
| Lanuti, M; Mino-Kenudson, M; Sequist, LV; Sharma, A | 1 |
| Agus, DB; Choi, NC; Foo, J; Leder, K; Mallick, P; Michor, F; Mumenthaler, SM; Pao, W | 1 |
| Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Doheny, S; Hughes, D | 1 |
| Chen, C; Fujioka, N; Gupta, K; Gupta, V; Johnson, KN; Kratzke, RA; Li, Y; Nguyen, J; Niehans, G; Pasrija, T | 1 |
| Knap, MM; Madsen, HH; Meldgaard, P; Nexo, E; Sorensen, BS; Weber, B | 1 |
| Chen, W; Qiao, J | 1 |
| Armour, A; Chen, YM; Chu, DT; Duffield, E; Fukuoka, M; Kuo, HP; Lam, KC; Liao, M; Magill, P; Negoro, S; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| Li, B; Sheng, ZX; Wang, F; Wang, LD | 1 |
| Brownstein, CM; Chen, D; Crino, L; Eberhardt, WE; Engelman, JA; Habben, K; Jänne, PA; Liu, L; Novello, S; Ramalingam, SS; Reck, M; Schneider, CP; Spigel, DR; Steins, MB | 1 |
| Li, H; Schmid-Bindert, G; Su, B; Wang, D; Yang, X; Zhao, Y; Zhou, C | 1 |
| Levêque, D | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA | 1 |
| Cromwell, I; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Hatashita, E; Kita, A; Kuwata, K; Nakagawa, K; Okamoto, I; Okamoto, K; Ono, M; Yamaguchi, H; Yamanaka, K | 1 |
| Brugarolas, A; Evgenyeva, E; Fernández, FJ; Forteza, J; González-Manzano, R; Martínez-Navarro, EM; Rebollo, J; Sureda, M; Valenzuela, B | 1 |
| Groen, HJ; Hiltermann, TJ; Schuuring, E; Timens, W | 1 |
| Hu, P; Jiang, J; Ren, GJ; Tan, FL; Wang, HP; Wang, MZ; Wang, YX; Xia, Y; Xiao, Y; Zhang, L | 1 |
| Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A | 1 |
| Basu, S; Batus, M; Bonomi, PD; Buckingham, L; Coon, J; Fidler, MJ; Jacobson, KK; Jewell, SS; Morrison, LE; Walters, K | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Chen, Y; Deng, J; Zhuang, L | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; Galvani, E; La Monica, S; Mari, E; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M; Tramonti, S | 1 |
| Chung, CT; Hwang, DM; Lara-Guerra, H; Leighl, NB; Pintilie, M; Schwock, J; Tsao, MS; Waddell, TK | 1 |
| Fang, W; Gu, XY; Jiang, Z | 1 |
| Ashley, S; Chua, S; Cook, G; Coward, JI; Gunapala, R; Myerson, JS; O'Brien, ME; Popat, S; Puglisi, M; Sharma, B; Trani, L; Wotherspoon, A | 1 |
| Cappuzzo, F; Jänne, PA; Mok, TS; Soria, JC | 1 |
| Forsyth, M; Nadler, E; Reyes, C; Satram-Hoang, S | 1 |
| Jirillo, A; Trojniak, MP | 1 |
| Arpin, D; Ernesto, S; Nesme, P; Pérol, M | 1 |
| Bischoff, H; Chouaid, C; de Castro Carpeño, J; Grossi, F; Heigener, D; Nuijten, MJ; Vergnenègre, A; Walzer, S | 1 |
| Bar, J; Onn, A | 1 |
| Aleknavičius, E; Cicėnienė, A; Drobnienė, M; Grigienė, R; Lachej, N; Steponavičienė, L; Zelvienė, TP | 1 |
| Chen, YM; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Alder, H; Cascione, L; Condorelli, G; Croce, CM; Di Leva, G; Engelman, JA; Garofalo, M; Jeon, YJ; Lovat, F; Nephew, KP; Ngankeu, A; Nuovo, G; Ono, M; Rho, JK; Romano, G; Sun, J; Volinia, S | 1 |
| Cheng, H; De Luo, B; Liu, ZG; Ren, Y; Zhang, YF; Zhu, H | 1 |
| Ren, SX; Zhang, L; Zhou, CC; Zhou, SW | 1 |
| Hong, D; Kurzrock, R; Munoz, J | 1 |
| Funada, Y; Hatakeyama, Y; Hori, S; Kasai, D; Kobayashi, K; Kondoh, T; Kotani, Y; Nagano, T; Nishimura, H; Nishimura, Y | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Nambara, D; Omi, K | 1 |
| Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Chang, CY; Chang, TY; Chao, YS; Chen, CH; Chen, YR; Chu, CY; Fang, MY; Hsieh, HP; Hsu, JT; Huang, YW; Lien, TW; Lin, WH; Song, JS; Wu, SH; Yen, KJ | 1 |
| Goozner, M | 1 |
| Cromwell, I; Malfair Taylor, SC; Melosky, B; Peacock, S; van der Hoek, K | 1 |
| Abolhoda, A; Ahn, JS; Ahn, MJ; Cui, Z; Kim, Y; Ko, J; Ou, SH; Park, K | 1 |
| Chen, ZG; Fan, S; Khuri, FR; Koo, J; Li, Y; Owonikoko, TK; Ramalingam, SS; Sun, SY; Yue, P | 1 |
| Chen, Z; Cheng, D; Ding, K; Le Maitre, A; Liu, G; Liu, N; Patel, D; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Adjei, A; Brown, A; Camidge, DR; Doebele, R; Dy, G; Fetterly, G; Franklin, W; Hirsch, FR; Jackson, MK; Lettieri, J; Lu, X; Maxson, D; Oton, A; Reynolds, M; Varella-Garcia, M; Weickhardt, A; Wynes, MW; Youssoufian, H | 1 |
| Ou, SH | 1 |
| Gubish, CT; Henry, C; Rothstein, ME; Siegfried, JM; Stabile, LP | 1 |
| Bekele, BN; Biernacka, A; Erez, B; Herbst, RS; Hosho, K; Jacoby, JJ; Jürgensmeier, JM; Komaki, R; Korshunova, MV; O'Reilly, MS; Ryan, A; Smith, PD; Takahashi, O; Wistuba, II | 1 |
| Paz-Ares, L | 1 |
| Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L | 1 |
| Agatsuma, T; Eda, S; Hachiya, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Kuraishi, H; Ohura, N; Tsushima, K; Yasuo, M | 1 |
| Govindan, R; Subramanian, J | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Argast, GM; Davies, A; Epstein, DM; Mercado, P; Richardson, F; Sennello, R; Wacker, B; Wolf, J; Young, GD | 1 |
| Abe, T; Aoki, T; Furuya, N; Hayama, N; Hisata, J; Igawa, S; Katagiri, M; Masuda, N; Mineshita, M; Miyazawa, T; Tajiri, S; Urano, T | 1 |
| Kaira, K; Yamamoto, N | 1 |
| Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Adachi, K; Burioka, N; Chikumi, H; Igishi, T; Kanamori, Y; Miyake, N; Nanba, E; Shimizu, E; Takata, M; Yamasaki, A | 1 |
| Ansén, S; Bass, AJ; Beer, DG; Brace, LE; Brambilla, C; Brambilla, E; Brustugun, OT; Cho, J; Clement, JH; Deng, X; Dutt, A; Eck, MJ; Gabler, F; Gray, NS; Greulich, H; Groen, H; Hammerman, PS; Hanna, M; Hatton, C; Haura, EB; Helland, A; Heuckmann, JM; Heynck, S; Janne, PA; Johnson, BE; Koker, M; Lawrence, MS; Leenders, F; Lim, SM; Lin, W; Lorimier, P; Meyerson, M; Moch, H; Onofrio, RC; Peifer, M; Petersen, I; Querings, S; Ramos, AH; Rauh, D; Salvesen, HB; Seidel, D; Sietsma, H; Simard, JR; Soltermann, A; Sos, ML; Stoelben, E; Thomas, RK; Timens, W; Tsao, MS; Winckler, W; Wolf, J; Wong, KK; Woods, BA; Xu, C; Zander, T; Zhang, J; Zhou, W | 1 |
| Akazawa, Y; Imamura, F; Kumagai, T; Nishino, K; Okyuama, T; Uchida, J | 1 |
| Del Vecchio, S; Iommelli, F; Salvatore, M; Speranza, A; Zannetti, A | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Takaiwa, T; Yoshioka, H | 1 |
| Ban, HJ; Kim, KS; Kim, YC; Oh, IJ | 1 |
| Li, Y; Song, L | 1 |
| Böker, B; Grohé, C; Lüders, H | 1 |
| Jaśkiewicz, P; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Mlak, R; Winiarczyk, K; Wojas-Krawczyk, K | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Huang, B; Huang, YS; Wu, YL | 1 |
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Nagase, H; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
| Chen, L; Fujimoto, T; Handa, N; Kawa, S; Kobayashi, T; Kukimoto-Niino, M; Liu, ZJ; Parker, L; Sano, S; Sato, M; Semba, K; Shirouzu, M; Tanaka, T; Terada, T; Terazawa, Y; Wakiyama, M; Wang, BC; Yamamoto, T; Yokoyama, S; Yoshikawa, S | 1 |
| Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Blajman, CR; Chen, YM; Emerson, L; Hirsh, V; Langmuir, P; Lee, JS; Manegold, C; Park, K; Perng, RP; Qin, S | 1 |
| Lin, TC; Wu, PY | 1 |
| Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J | 1 |
| Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S | 1 |
| Eberhardt, WE; Groneberg, M; Kübler, D; Pöttgen, C; Sak, A; Stuschke, M | 1 |
| Bai, H; Han, B | 1 |
| Bai, C; He, J; Li, H; Qin, Y; Song, H; Wang, C; Wei, L; Wu, C; Wu, M; Xu, J; Zhang, X; Zhu, T | 1 |
| Agatsuma, T; Ameshima, S; Hayasaka, M; Ikegami, K; Kanda, S; Kobayashi, T; Koizumi, T; Kubo, K; Matsuo, A; Morikawa, M; Shiina, T; Suzuki, T; Takasuna, K; Yoshikawa, S | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Bengtsson, T; Hicks, RJ; Peterson, A; Port, RE | 1 |
| Tao, L; Yang, F; Zhu, B; Zhuo, W | 1 |
| Ghosh, G; Kron, SJ; Lian, X; Palecek, SP | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 2 |
| Hirsh, V; Novello, S; Sandler, AB; Scagliotti, GV; Schiller, JH; Schwartz, B; Sequist, LV; Soria, JC; von Pawel, J; Von Roemeling, R | 1 |
| de Marinis, F; del Signore, E; Fulvi, A; Gori, B; Ricciardi, S | 1 |
| Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Bai, CX; Garfield, D; Ge, HY; Song, YL; Wang, X; Wang, XY; Xu, N; Yang, P; Zhang, X | 1 |
| Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J | 1 |
| Fujii, S; Hamada, A; Inaba, M; Isobe, T; Iwamoto, N; Kai, Y; Kashiwabara, K; Kishi, H; Kohrogi, H; Saeki, S; Saito, H; Sasaki, J; Semba, H; Tsubata, Y; Urata, M; Ushijima, S | 1 |
| Cinieri, S; Lorusso, V | 1 |
| Bischoff, HG; Eberhardt, WE; Fischer, JR; Gottschling, S; Heigener, DF; Herpel, E; Klein, P; Köhne, CH; Kortsik, C; Kuhnt, T; Meister, M; Moldenhauer, I; Muley, T; Penzel, R; Schnabel, PA; Thomas, M | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Chang, X; Chatterjee, A; Horii, A; Kobayashi, T; Koch, WM; Kusuke, D; Levenson, VV; Liggett, TE; Melnikov, AA; Monitto, CL; Ogawa, T; Shiga, K; Sidransky, D | 1 |
| Fu, H; Hu, YD; Liu, XJ; Long, C; Xiao, Y; Zhang, XL | 1 |
| Amler, LC; Atwal, S; Fine, BM; Hampton, GM; Hicks, RJ; Hughes, BG; Lackner, MR; Liu, W; Pirzkall, A; Punnoose, EA; Raja, R | 1 |
| Kim, JH; Klingelschmitt, G; Ng, C; Park, K; Wu, YL; Zaatar, A | 1 |
| Chien, CR; Hsia, TC; Lin, CC | 1 |
| Furukawa, M; Kiura, K; Kubo, T; Maki, Y; Mitsudomi, T; Miyoshi, S; Muraoka, T; Shien, K; Soh, J; Suda, K; Tanaka, N; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
| Bunn, PA; Hirsch, FR; Jotte, RM; Konduri, K; Neubauer, MA; Ruxer, RL; Spira, AI; Varella-Garcia, M; Witta, SE | 1 |
| Cheng, Y; Han, B; Hayashi, N; Huang, C; Liu, X; Liu, Y; Lu, S; Ma, S; Song, X; Wang, J; Wang, M; Yang, S; Zhang, L; Zhang, S; Zhang, X; Zhou, C | 1 |
| Reckamp, KL | 1 |
| Ando, M; Hasegawa, Y; Horio, M; Horio, Y; Kondo, M; Saito, H; Tamura, M; Yamamoto, M | 1 |
| Chang, YC; Chang, YL; Hu, FC; Lee, YC; Shih, JY; Wu, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Ahn, MJ; Blair, JM; Chen, YM; Kang, JH; Liang, J; Linn, C; Orlando, M; Peng, G; Xiu, Q; Yang, JC | 1 |
| Albert, I; Azzoli, CG; Bodkin, D; Iannotti, NO; Jiang, PY; Juhász, E; Kelly, K; Koutsoukos, T; Patel, JD; Pereira, JR; Weems, G; Zatloukal, P | 1 |
| Burger, JA; Saintigny, P | 1 |
| Juergens, R; Levine, MN | 1 |
| Gao, W; Guo, R; Shen, H; Shu, Y; Sun, J; Xu, R | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Albert, I; Chao, RC; Govindan, R; Karaseva, N; Krzakowski, M; Makhson, A; Miziara, JE; Papai, ZS; Portulas, ED; Reck, M; Scagliotti, GV; Selaru, P; Strausz, J; Szczesna, A; Thomas, M; Thongprasert, S; Tye, L; von Pawel, J; Wierzbicki, RF; Zhang, K | 1 |
| Ayoola, A; Barochia, A; Belani, CP; Belani, K | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Kato, T; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yokomizo, Y; Yoshizawa, H | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Basu, S; Batus, M; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; McCormack, S; Walters, K | 1 |
| Bertran-Alamillo, J; Costa, C; Giménez-Capitán, A; Mayo, C; Molina-Vila, MÁ; Rosell, R | 1 |
| Chai, F; Ferrari, D; Garmey, EG; Goldman, JW; Just, RG; Laux, I; Rosen, LS; Savage, RE | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Kuo, LC; Lai, YC; Liu, YC; Yu, CJ; Yuan, MK | 1 |
| Brewster, M; Cedrés, S; Dean, E; Felip, E; Galdermans, D; Martínez, P; McNally, V; Ranson, M; Ross, G | 1 |
| Ando, M; Fukuoka, M; Johkoh, T; Kudoh, S; Nakagawa, K; Ohe, Y; Seki, A; Takemoto, S; Yamazaki, N | 1 |
| Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
| Guo, Z; Li, J | 1 |
| Au, JS; Cheng, CK; Merimsky, O; Reck, M; von Pawel, J | 1 |
| Mason, DP | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| Chen, LK; Dinglin, XX; Liang, Y; Liao, H; Liu, JL; Xu, F; Zeng, YD; Zhang, L | 1 |
| Gerber, DE; Hamann, HA; Lee, SJ; Rasco, DW; Woodruff, S | 1 |
| Asrani, K; Bremner, R; Cheng, E; Hostetter, G; Inge, L; Jameson, NM; Kingsley, CB; Loftus, JC; Tran, NL; Weiss, GJ; Whitsett, TG; Winkles, JA | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Chu, CT; Kim, ES; Sada, YH | 1 |
| Ahn, JS; Ahn, MJ; Hwang, IG; Jo, SJ; Kim, BS; Kim, HK; Kim, SW; Kim, YH; Lee, DH; Lee, JW; Lee, K; Lee, KH; Min, YJ; Park, K; Song, HS; Sun, JM; Yun, HJ | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Fukuda, A; Sonoda, T; Takenaka, T; Yamagata, M | 1 |
| Chen, Y; Gao, Z; Zhuang, L | 1 |
| Chen, J; Chen, L; Guan, Z; Han, B; Jiang, G; Li, L; Li, W; Liao, M; Liu, X; Luo, R; Tao, M; Wang, M; Wu, Y; Xu, J; Xu, N; Yu, S; Zhao, X; Zhong, W | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Le Caer, H; Locher, C; Monnet, I; Vergnenegre, A | 1 |
| El-Modir, A; Stevenson, R | 1 |
| Chen, J; Cui, IH; Gong, Y; Jin, Y; Tang, C; Wu, X; Xu, Z; Zhang, X; Zhang, Y | 1 |
| Keshtgarpour, M; Ma, PC; Pennell, NA; Yin, L | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| Cappuzzo, F | 2 |
| Perez-Soler, R; Piperdi, B | 1 |
| Califano, R; D'arcangelo, M; Mok, TS | 1 |
| Jett, JR; Pao, W; Yatabe, Y | 1 |
| Azzoli, CG; Beumer, JH; Dowlati, A; Gadgeel, SM; Kris, MG; Krug, LM; Lynch, TJ; Miller, VA; Mitchell, B; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA; Rowland, KM; Salgia, R; Tonda, M; Wertheim, MS | 1 |
| Brown, MP; Cheetham, G; Scott, HS; Sharma, A; Tan, TH | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Nakao, S; Ohmori, T; Sakai, A; Sone, T | 1 |
| Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Gao, D; Helfrich, BA; Kim, J; Porter, CC; Scarborough, HA; Tan, AC; Zhang, Z | 1 |
| Blumenschein, GR; Chao, RC; Ciuleanu, T; Groen, HJ; Juhasz, E; Robert, F; Ruiz-Garcia, A; Tye, L; Usari, T | 1 |
| Abdel-Rahman, M; Arcila, M; Au, V; Bivona, TG; Boggon, TJ; Choi, CM; Choi, YJ; Costa, C; Halmos, B; Jang, SJ; Kim, SW; Kim, WS; Ladanyi, M; LaFramboise, T; Lee, DH; Lee, JC; Lee, JS; Levine, AD; Lin, L; Ma, PC; Miller, VA; Moonsamy, P; Olivas, V; Park, YS; Rho, JK; Rosell, R; Sawyers, C; Taron, M; Wang, X; Zhang, Z | 1 |
| Cai, L; Cao, M; Gemma, A; Kitamura, K; Minegishi, Y; Mizutani, H; Noro, R; Seike, M; Soeno, C; Yoshimura, A | 1 |
| Burgers, JA; Codrington, HE; Kappers, I; Klomp, HM; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Barrios, CH; Blackhall, F; Bover, I; Boyer, M; Campbell, AK; Frank, R; Krzakowski, M; Letrent, SP; Liang, JQ; O'Connell, J; Park, K; Ramalingam, SS; Rosell, R; Ruiz-Garcia, A; Seog Heo, D; Talbot, DC; Taylor, I | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Gu, H; Li, X; Liu, S; Wang, D | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Anand, S; Bachi, A; Floriani, I; Gregorc, V; Lazzari, C; Milan, E; Sorlini, C; Torri, V | 1 |
| Furcht, CM; Lazzara, MJ; Muñoz Rojas, AR; Nihalani, D | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| A't Hart, N; Stigt, JA; van der Wekken, AJ | 1 |
| Huang, JA; Min, DL; Shen, Z; Tang, LN; Yang, Y; Yue, L; Zhou, XH | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Dong, XR; Huang, J; Liu, L; Lu, HD | 1 |
| Hamaguchi, M; Kawase, I; Kida, H; Kijima, T; Komuta, K; Minami, S; Nagatomo, I; Nakatani, T; Tachibana, I; Takahashi, R; Takeuchi, Y; Yamamoto, S | 1 |
| Bernstein, ED; Clément-Duchêne, C; Dudek, AZ; Jahan, T; Krupitskaya, Y; Latz, JE; Natale, RB; Osarogiagbon, R; Sanborn, RE; Shi, P; Wakelee, HA | 1 |
| Bill, A; Famulok, M; Hannam, JS; Heukamp, LC; König, K; Schmitz, A | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Li, H; Ren, XB; Wang, CL; Wang, M; Yu, JP; Zhang, LM; Zhao, J | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Horn, L; Lovly, CM | 1 |
| Nagpal, S; Riess, J; Wakelee, H | 1 |
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
| Chen, RC; Halle, J; Higginson, DS; Marks, LB; Morris, DE; Pham, E; Rosenman, JG; Socinski, MA; Stefanescu, M; Tracton, G | 1 |
| Itoh, K; Nakabeppu, Y; Nishimura, Y; Takiguchi, S; Yoshioka, K | 1 |
| Hashimoto, M; Koizumi, F; Minakata, K; Moriyama, H; Murakami, A; Nara, T; Nishio, K; Nurwidya, F; Seyama, K; Tajima, K; Takahashi, F; Takahashi, K; Yae, S | 1 |
| Chang, J; Cho, BC; Hong, S; Jung, M; Kang, YA; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Rha, SY | 1 |
| Jänne, PA; Oxnard, GR | 1 |
| Shi, YK | 1 |
| Gao, W; Huang, P; Liu, L; Liu, P; Shao, X; Shu, Y; Wang, R; Yin, Y; Zhang, Z | 1 |
| Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Novik, AV; Protsenko, SA; Rudakova, AV; Semënov, II; Togo, AV | 1 |
| Cho, BC; Christensen, JG; Ha, SJ; Hong, YK; Kim, JH; Kim, SM; Kwon, OJ; Lee, JH; Solca, F; Soo, RA | 1 |
| Galvani, E; Giovannetti, E; Peters, GJ | 1 |
| Gemma, A; Gemmah, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kobayashi, K; Kudoh, S; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Tanaka, T | 1 |
| Kris, MG; Ladanyi, M; Moreira, AL; Paik, PK; Rekhtman, N; Sima, CS; Varghese, AM | 1 |
| Chen, HM; Kuo, R; Lai, MS; Lin, ZZ; Shao, YY; Shau, WY; Yang, JC | 1 |
| Abell, F; Boyer, M; De Souza, P; Horwood, K; Johnston, M; Millward, M; Pavlakis, N; Rischin, D; Stein, B | 1 |
| Beculic, H; Dervisevic, S; Imsirovic, B; Mekic-Abazovic, A | 1 |
| Benešová, L; Bortlíček, Z; Brůha, F; Fiala, O; Fínek, J; Krejčí, J; Minárik, M; Pešek, M | 1 |
| Fujii, N; Fujimoto, N; Kato, T; Nagao, T; Nakanishi, G; Tanaka, T; Toda, N | 1 |
| Badurak, P; Janowicz-Żebrowska, A; Jaśkiewicz, P; Knetki-Wróblewska, M; Kowalski, DM; Krzakowski, M; Płużański, A; Zajda, K | 1 |
| Cei, M; Mumoli, N; Vitale, J | 1 |
| Daw, H; Haddad, A; Petrosyan, F; Spiro, T | 1 |
| Chen, ZH; Cheng, H; Dong, S; Wu, YL; Xie, Z; Zhang, XC; Zhang, YF; Zhu, JQ | 1 |
| Cai, J; Chen, T; Chen, Y; Deng, J; Du, Z; Li, Q; Lu, J; Shan, B; Song, X; Wery, JP; Yang, M; Zhang, L | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yoshimori, K; Yoshizawa, H | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Carlson, JJ; Yeung, K | 1 |
| Hashemi-Sadraei, N; Pennell, NA | 1 |
| Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM | 1 |
| Biaoxue, R; Shuanying, Y; Wei, L; Wei, Z; Zongjuan, M | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Chmielecki, J; Foo, J; Michor, F; Pao, W | 1 |
| Ackerman, A; Costa, DB; Goldstein, MA; Kobayashi, S | 1 |
| Chen, Z; Li, Z; Liao, M; Lu, S; Niu, X; Shen, L; Shen, S; Yu, Y | 1 |
| Ahn, JH; Kim, EJ; Kim, SW; Kim, SY; Lee, HJ; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS | 1 |
| Chen, M; Li, L; Wang, M; Xia, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Karavasilis, V; Kosmidis, P; Murray, S; Papadopoulos, S; Razis, E | 1 |
| Hasegawa, S; Kondo, N; Tanaka, F; Uramoto, H; Yamada, T; Yano, S | 1 |
| Maemondo, M | 1 |
| Katsura, Y; Ko, R; Koyama, R; Minakata, K; Murakami, A; Muraki, K; Namba, Y; Ohashi, R; Sakuraba, S; Shukuya, T; Takahashi, F; Takahashi, K; Yagishita, S | 1 |
| Cho, BC; Lee, JH; Park, JH; Shin, JU | 1 |
| Chen, J; Dassarath, M; Gu, R; Wang, Q; Wu, G; Yang, K; Yin, Z | 1 |
| Betticher, D; Brauchli, P; Bubendorf, L; Crowe, S; Droege, C; Froesch, P; Gautschi, O; Hess, T; Mayer, M; Ochsenbein, A; Oppliger Leibundgut, E; Pless, M; Rauch, D; Ribi, K; Schmid, P; Stahel, R; von Moos, R; Zappa, F | 1 |
| Berry, DA; Gong, J; Janku, F; Kurzrock, R; Parsons, HA; Stewart, DJ | 1 |
| Chohnabayashi, N; Inoue, A; Mochizuki, S; Murakami, K; Nishimura, N; Nukiwa, T | 1 |
| Chang, PM; Chen, CC; Chen, KY; Chiou, JF; Ho, CC; Hsiao, M; Huang, CY; Kuo, YL; Lai, JM; Lee, PY; Liu, YW; Lu, PJ; Wang, LS; Wu, AT; Wu, CH; Yang, CN; Yang, PC; Yang, SC; Yeh, CT; Yen, CC | 1 |
| Clark, P; Dillon, B; Knight, H; Naidoo, B | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Dang, NH; Hayashi, Y; Hosono, O; Ichihara, H; Inoue, Y; Iwata, S; Kamiya, K; Katayose, T; Kawasaki, H; Kichikawa, Y; Kondo, S; Morimoto, C; Sakamoto, M; Souta-Kuribara, A; Tanaka, H; Yamada, T; Yamazaki, H | 1 |
| Blackstock, AW; Decker, RH; Gettinger, SN; Khandani, A; Lankford, S; Moore, DT; Morris, DE; Petty, WJ; Schwartz, G; Socinski, MA; Stinchcombe, TE | 1 |
| Hallek, M; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
| Carbone, DP; Ding, K; Grigorieva, J; Roder, H; Roder, J; Seymour, L; Shepherd, FA; Tsao, MS | 1 |
| Edelman, MJ; Mok, T; O'Byrne, K; Paz-Ares, L; Rittweger, K; Spigel, DR; Thurm, H; Yu, W | 1 |
| Jiao, W; Luo, Y; Shen, Y; Sui, A; Tang, D; Wang, M; Wang, Y; Wang, Z; Yang, R | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M; Ricar, J | 1 |
| Brandão, EP; Cruz, M; Pantarotto, MG | 1 |
| Riely, GJ; Yu, HA | 1 |
| Boshoff, C; Bulley, S; Chao, D; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Khan, I; Lal, R; Lee, SM; Lewanski, C; Marshall, E; Middleton, G; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Chen, HJ; Dong, S; Huang, YS; Jiang, BY; Liao, RQ; Nie, Q; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Griesinger, F; Overbeck, TR | 1 |
| Bortlíček, Z; Coupková, H; Grygárková, Y; Havel, L; Hejduk, K; Hrnčiarik, M; Kolek, V; Košatová, K; Koubková, L; Pešek, M; Roubec, J; Salajka, F; Sixtová, D; Skřičková, J; Spelda, S; Tomíšková, M; Zatloukal, P; Zemanová, M | 1 |
| Baghdadi, TA; Bhatia, S; Hanna, N; Harb, W; Jalal, SI; Johnson, C; McClean, J; Riggs, H; Taber, D; Yu, M | 1 |
| Liu, BN; Meng, ZW; Pan, ZH; Wu, X; Xu, K; Yan, HQ; Zhou, QH; Zhu, Y | 1 |
| Lee, JG; Wu, R | 1 |
| Baty, F; Brutsche, M; Bubendorf, L; Carbone, D; Crowe, S; Dingemans, AM; Gautschi, O; Grigorieva, J; Hsu Schmitz, SF; Na, KJ; Peters, S; Pless, M; Roder, H; Roder, J; Smit, E; Stahel, R; Zappa, F | 1 |
| Chen, MS; Chi, CW; Hsu, CC; Huang, YC; Kuo, CD; Lee, HC; Lee, LM; Lee, YC; Liao, JF; Lin, AM; Yang, CH; Yin, PH | 1 |
| Chen, GY; Cheng, Y; Huang, C; Huang, YS; Liu, Y; Lu, S; Ren, S; Wu, YL; Yan, HH; Yang, JJ; Zhou, C | 1 |
| Bidkhori, G; Masoudi-Nejad, A; Moeini, A | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Bahce, I; Heideman, DA; Hendrikse, NH; Lammertsma, AA; Lubberink, M; Postmus, PE; Schuit, RC; Smit, EF; Thunnissen, E; van der Veldt, AA; Windhorst, AD; Yaqub, M | 1 |
| Chen, SS; Falchook, GS; Fok, JY; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, SA; Stephen, B; Tsimberidou, AM; Wheler, JJ | 1 |
| Alesini, D; Cortesi, E; Passaro, A; Pochesci, A | 1 |
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Aburatani, H; Endo, S; Fukayama, M; Ishikawa, S; Kanai, Y; Kataoka, H; Matsubara, D; Murakami, Y; Niki, T; Oguni, S; Ohara, S; Sakatani, T; Tamura, T; Yoshimoto, T | 1 |
| Teh, BW; Worth, LJ | 1 |
| Li, X; Lü, JL; Qin, N; Sun, YF; Wu, YH; Yang, XJ; Zhang, H; Zhang, Q; Zhang, SC | 1 |
| Amler, LC; Armstrong, EA; Harari, PM; Huang, S; Li, C; Peet, CR; Saker, J; Sliwkowski, MX | 1 |
| Chambers, CR; Sheikh, N | 1 |
| Liu, HB; Lv, TF; Shi, Y; Song, Y; Xiao, YY; Yuan, DM; Zhan, P | 1 |
| Guirgis, HM | 1 |
| Guo, LX; Jiao, J; Li, GQ; Liu, Y; Yao, ZJ; Zhang, B; Zhou, B; Zhou, GB | 1 |
| Kobayashi, K | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Arakawa, K; Fukatsu, M; Kataoka, K; Katsuno, S; Kimura, T; Kondoh, Y; Nakamura, N; Nishiyama, O; Takashima, N; Taniguchi, H; Umemura, T; Watanabe, N | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Hou, B; Jiang, WR; Kong, QT; Li, B; Li, J; Liu, ZB; Shen, TZ; Wang, Y; Wang, Z; Wu, XH; Zhu, XX | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yasuda, K; Yukawa, T | 1 |
| Cioffi, P; Fanizza, C; Giglioni, A; Grappasonni, I; Marotta, V; Natoli, C; Petrelli, F | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Jeon, WI; Lee, SY; Ryu, PD | 1 |
| Baqir, W; Husband, A; Mahony, M; Todd, A; Williamson, S | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Barocelli, E; Bonelli, M; Carbognani, P; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Graiani, G; La Monica, S; Madeddu, D; Mozzoni, P; Mutti, A; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Hirashima, T; Kawase, I; Kitai, K; Morishita, N; Okamoto, N; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, M; Yamadori, T | 1 |
| Bailey, AS; Canepa, HM; Costa, DB; Goldstein, MA; Huberman, MS; Kobayashi, S; Nakayama, S; Yamaguchi, N | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Chen, Z; Han, R; Sun, L; Wang, J; Wang, X; Zhang, J; Zhao, J; Zhong, D | 1 |
| Gridelli, C; Maione, P; Rossi, A | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Krejci, J; Minarik, M; Pesek, M | 1 |
| Chang, H; Cho, BC; Cho, J; Ha, SJ; Hong, YK; Jeong, JH; Kim, HR; Kim, JH; Kim, SH; Kim, SM; Shim, HS; Sung, JH; Tania, C | 1 |
| Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawahara, M; Okishio, K; Okuma, T; Omachi, N; Takeuchi, N | 1 |
| Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Chen, Y; Sun, C; Zhang, X | 1 |
| Li, H; Li, X; Schmid-Bindert, G; Wang, D; Wang, Y; Zhou, C; Zhou, S | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T | 1 |
| Ichihara, E; Kataoka, I; Kiura, K; Minami, D; Ochi, N; Ohashi, K; Takeda, H; Takigawa, N; Tanimoto, M | 1 |
| Higami, Y; Kato, M; Kobayashi, T; Koshimo, Y; Marumo, S; Takeda, M; Teranishi, T | 1 |
| Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Chen, Y; Du, XJ; Yang, M; Yu, S; Yuan, X; Zhang, L | 1 |
| Agatsuma, T; Hachiya, T; Hirai, K; Ichiyama, T; Koizumi, T; Koyama, S; Morozumi, N; Shiina, T; Tateishi, K | 1 |
| Ji, L; Pei, Y | 1 |
| Endo, H; Higashiyama, M; Imamura, F; Inoue, M; Kondo, J; Kumagai, T; Nishizawa, Y; Okami, J; Okuyama, H; Takehara, T; Uchida, J | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Bastida, CC; Falchook, GS; Janku, F; Kurzrock, R; Stewart, DJ; Tsao, AS | 1 |
| Bridge, S; Dharamshi, K; Jäkel, A; Johns, A; Modha, R; Plested, M | 1 |
| Koh, Y; Serizawa, M; Takahashi, T; Yamamoto, N | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Chang, SS; Chen, CT; Du, Y; Herbst, R; Hsu, JL; Hsu, MC; Hung, MC; Ko, HW; Wang, YN; Yamaguchi, H | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Brooks, MB | 1 |
| Broggini, M; De Braud, F; Garassino, MC; Platania, M; Torri, V | 1 |
| Duyster, J; Kancha, RK; Kunst, PW; Reinten, RJ; van der Ven, WH; van Noesel, CJ; van Noesel, J; van Os, TA; Weegenaar, J | 1 |
| Alfieri, R; Ardizzoni, A; Carmi, C; Cavazzoni, A; Dekker, H; Galvani, E; Giovannetti, E; Leon, LG; Mor, M; Peters, GJ; Petronini, PG; Saccani, F | 1 |
| Majem, M; Pallarès, C | 1 |
| Cai, J; Li, T; Wang, X; Wu, B; Xu, Y; Ye, M; Zhu, J | 1 |
| Crawford, M; Fabbri, M; Friedman, A; Garofalo, M; Kang, HW; Nana-Sinkam, SP; Nuovo, G | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Augustin, A; Avila, DW; Duchateau-Nguyen, G; Essioux, L; Golling, S; Hermann, JC; Klughammer, B; Lamerz, J; Langen, H; Meistermann, H; Scheiblich, S; Tzouros, M | 1 |
| Kuiper, JL; Smit, EF | 1 |
| Besse, B; Chaubet-Houdu, M | 1 |
| Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Goyal, A; Singh, N | 1 |
| Pallis, AG; Syrigos, KN | 1 |
| Kaur, J; Tikoo, K | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Fang, Z; Li, B; Zang, YS | 1 |
| Dering, J; Desai, AJ; Dubinett, SM; Finn, RS; Garon, EB; Hosmer, W; Kamranpour, N; Márquez-Garbán, DC; Pietras, RJ; Pitts, S; Slamon, DJ; von Euw, EM | 1 |
| Herbst, RS; Kies, MS | 1 |
| Natale, RB; Zaretsky, SL | 1 |
| Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H | 1 |
| Jänne, PA; Johnson, BE; Salgia, R; Taffaro, ML | 1 |
| Coll, JL; Dubrez, L; Favrot, MC; Hurbin, A | 1 |
| Wilkinson, E | 1 |
| Culy, CR; Faulds, D | 1 |
| Couzin, J | 2 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Koty, PP; Lei, W; Levitt, ML | 1 |
| Baselga, J; Hammond, LA | 1 |
| Bunn, PA; Franklin, W | 1 |
| Baldwin, J | 1 |
| Burton, A | 1 |
| Ebina, M; Gomi, K; Inoue, A; Kikuchi, T; Kimura, Y; Maemondo, M; Moriya, T; Nukiwa, T; Saijo, Y; Tokue, Y | 1 |
| Thomas, M | 2 |
| Dummer, R; Follath, F; Jacky, E; Trojan, A | 1 |
| Tamura, T | 1 |
| Lorusso, PM | 1 |
| Cella, D | 1 |
| Schiller, JH | 2 |
| Mauer, AM; Villano, JL; Vokes, EE | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ranson, M; Thatcher, N | 1 |
| Lavelle, F | 1 |
| Arteaga, CL; Johnson, DH | 2 |
| Averbuch, S; Baselga, J; Dong, RP; Douillard, JY; Eek, R; Feyereislova, A; Fukuoka, M; Giaccone, G; Horai, T; Kudoh, S; Macleod, A; Nakagawa, K; Nishiwaki, Y; Noda, K; Rischin, D; Smit, E; Takata, I; Tamura, T; Vansteenkiste, J; Yano, S | 1 |
| Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L | 1 |
| Androulakis, N; Bozionelou, V; Georgoulias, V; Kouroussis, C; Mavroudis, D; Pallis, AG; Souglakos, J; Vlachonikolis, IG | 1 |
| Fujii, K; Kihara, N; Kohrogi, H; Matsumoto, M; Okamoto, I; Suga, M; Terasaki, Y | 1 |
| Daigo, Y; Hirata, K; Kakiuchi, S; Katagiri, T; Kikuchi, T; Nakamura, Y; Nishime, C; Ohnishi, Y; Zembutsu, H | 1 |
| Patrick-Miller, LJ | 1 |
| Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Herbst, RS; Heyes, A; Kaye, S; Kieback, D; LoRusso, PM; Maddox, AM; Ochs, J; Ranson, M; Raymond, E; Rischin, D; Rothenberg, ML; Rubin, EH; Small, EJ | 1 |
| Giaccone, G; Janmaat, ML; Kruyt, FA; Rodriguez, JA | 1 |
| Hanajiri, K; Maruyama, T; Mitsui, H; Nakajima, J; Omata, M | 1 |
| Graham, J; Kirkpatrick, P; Muhsin, M | 1 |
| Seymour, L; Shepherd, FA; Sridhar, SS | 1 |
| Dancey, JE; Freidlin, B | 1 |
| Bartolini, S; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, G; Crino, L; de Rosa, M; Gregorc, V; Lombardo, L; Magrini, E; Paties, CT; Rossi, E; Villa, E | 1 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L | 1 |
| Bunn, PA; Ciardiello, F; Helfrich, B; Raben, D | 1 |
| Johnson, DH | 1 |
| Bonomi, P | 2 |
| Ardizzoni, A; Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L; Gridelli, C; Maione, P; Santoro, A; Soto-Parra, H; Tiseo, M | 1 |
| Behnken, D; Govindan, R; McLeod, H; Read, W | 1 |
| Ieki, R; Saitoh, E; Shibuya, M | 1 |
| Kelly, K | 1 |
| Chen, G; Cohen, MH; Pazdur, R; Sridhara, R; Williams, GA | 1 |
| Muguruma, H; Sone, S; Yano, S | 1 |
| Genma, A; Kudo, S; Yoshimura, A | 1 |
| Gemma, A; Kudoh, S; Yoshimura, A | 1 |
| George, SL | 1 |
| Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D | 1 |
| Liu, CY; Seen, S | 1 |
| Albain, KS; Averbuch, SD; Belani, CP; Cella, D; Herbst, RS; Kay, AC; Kelly, K; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JJ; Prager, D; Sandler, A; Schiller, JH; Spiridonidis, H; Wolf, MK | 1 |
| Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Mottolese, M; Vocaturo, A | 1 |
| DeGrendele, H | 1 |
| Okamoto, I; Suga, M | 1 |
| Castaldo, V; Gridelli, C; Maione, P; Rossi, A | 1 |
| Sandler, AB | 3 |
| Khuri, FR | 1 |
| Goldman, B | 1 |
| Cortes-Funes, H; Soto Parra, H | 1 |
| van Zandwijk, N | 1 |
| Katz, A; Zalewski, P | 1 |
| Bernardo, MM; de Braud, F; Gridelli, C; Kosimidis, P; Parra, HS; Petruzelka, L; Rossi, A; Souquet, PJ; Stahel, R | 1 |
| Miller, VA; Shah, NT | 1 |
| Bunn, PA; Herbst, RS | 1 |
| Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Gatzemeier, U | 1 |
| Hidalgo, M | 1 |
| Sandler, A | 2 |
| Soulières, D | 1 |
| Pérez-Soler, R | 5 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Lombardo, L; Spreafico, A; Tamberi, S; Toschi, L; Villa, E | 1 |
| Jones, S | 1 |
| Bonomi, PD | 1 |
| Vansteenkiste, J | 2 |
| Kris, MG; Miller, VA; Pao, W | 1 |
| Averbuch, S; Blackledge, G | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Kita, T; Nakao, S; Yoshimoto, A | 1 |
| Belani, CP; Ramalingam, S | 2 |
| Ochs, JS | 1 |
| Abraham, S; Baird, A; Chen, G; Cohen, MH; Liang, C; Lostritto, R; McGuinn, WD; Morse, D; Pazdur, R; Rahman, A; Sridhara, R; Williams, GA | 1 |
| Glover, KY; Papadimitradopoulou, VA; Perez-Soler, R | 1 |
| Averbuch, S; Kelly, K | 1 |
| Baselga, J | 2 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK | 1 |
| Hasegawa, S; Ishibashi, O; Kambayashi, T; Tanaka, F; Wada, H; Yanagihara, K | 1 |
| Azzoli, C; Ben-Porat, L; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Memoli, N; Miller, VA; Pao, W; Patel, J; Pizzo, B; Rizvi, N; Rusch, V; Shah, N; Tyson, L; Venkatraman, E; Zakowski, M | 1 |
| Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ | 1 |
| Shimizu, E | 1 |
| Ranson, M; Wardell, S | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Fujii, T; Hirata, A; Kinoshita, H; Kometani, T; Kuwano, M; Miyagawa, M; Ono, M; Ueda, S | 1 |
| Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY | 1 |
| Perras, C | 1 |
| Krozely, P | 1 |
| Baas, P; Haringhuizen, A; Vaessen, HF; van Tinteren, H; van Zandwijk, N | 1 |
| Fukuoka, M; Horai, T; Imamura, F; Katakami, N; Kiura, K; Kudoh, S; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saka, H; Sawa, Y; Sugiura, T; Takada, M; Takata, I; Takeda, K; Tamura, T; Uchida, H; Watanabe, K; Yano, S; Yokoyama, A | 1 |
| Green, MR | 1 |
| Bell, DW; Brannigan, BW; Christiani, DC; Gurubhagavatula, S; Haber, DA; Haluska, FG; Harris, PL; Haserlat, SM; Louis, DN; Lynch, TJ; Okimoto, RA; Settleman, J; Sordella, R; Supko, JG | 1 |
| Boggon, TJ; Eck, MJ; Fujii, Y; Gabriel, S; Greulich, H; Herman, P; Jänne, PA; Johnson, BE; Kaye, FJ; Lee, JC; Lindeman, N; Meyerson, M; Naoki, K; Paez, JG; Sasaki, H; Sellers, WR; Tracy, S | 1 |
| Marx, J | 1 |
| Choy, H; Kim, DW | 1 |
| Campiglio, M; Di Maio, M; Normanno, N; Perrone, F | 1 |
| Dancey, JE | 2 |
| Cersosimo, RJ | 2 |
| Fischman, J | 1 |
| Argiris, A; Mittal, N | 1 |
| Abe, S; Inomata, S; Nagata, M; Saitoh, T; Sato, T; Satoh, M; Shiratori, M; Takahashi, H; Tanaka, H; Yamada, G | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Chabner, BA | 1 |
| Gazdar, AF; Herz, J; Minna, JD; Sprang, SR | 1 |
| Campagnoli, E; Cavina, R; Grimaldi, GC; Latteri, F; Morenghi, E; Parra, HS; Roncalli, M; Santoro, A; Zucali, PA | 1 |
| Kodama, T; Kunitoh, H; Kusumoto, M; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Yamamoto, N; Yamamoto, S | 1 |
| Igarashi, T; Imamura, F; Nakamura, S; Ueno, K; Yamamoto, S; Yoshimura, M | 1 |
| Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E | 1 |
| Giaccone, G | 4 |
| Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, JY; Kim, K; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Park, BB; Park, J; Park, JO; Park, K; Park, SH; Park, YS | 1 |
| Behnken, D; Coplin, MA; Gao, F; Govindan, R; Kommareddy, A; Read, W; Romvari, E | 1 |
| McNeil, C | 1 |
| Cheng, ZW; Gao, JM; Zhang, L | 1 |
| Averbuch, S; Swaisland, H; Wolf, M | 1 |
| Eccles, SA; Harrington, KJ; Nutting, CM; Rogers, SJ | 1 |
| Nakagawa, K | 2 |
| Bell, DW; Haber, DA; Settleman, J; Sordella, R | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Fujiwara, M; Ishikawa, H; Nakayama, M; Ohtsuka, M; Satoh, H; Sekizawa, K | 1 |
| Kris, MG; Miller, VA; Pao, W; Venkatraman, E | 1 |
| Bartolini, S; Bellezza, G; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crinò, L; Damiani, S; Gregorc, V; Ligorio, C; Lombardo, L; Ludovini, V; Magrini, E; Paties, CT; Rossi, E; Spreafico, A; Tonato, M | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G | 1 |
| Price, N; Reddy, GK | 1 |
| Bonomi, P; Chachoua, A; Clark, GM; Hammond, LA; Huberman, M; Karp, D; Pérez-Soler, R; Rigas, J; Rowinsky, EK; Santabárbara, P | 1 |
| Chocholska, S; Krawczyk, P; Milanowski, J | 1 |
| Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT | 2 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Camus, P; Ebina, M; Kudoh, S | 1 |
| Pizzo, B | 1 |
| Vastag, B | 1 |
| Sorscher, SM | 1 |
| Longo, L; Marchioni, A; Rossi, G | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, NK; Kim, TY; Kim, YT | 1 |
| Zhang, L | 1 |
| Bencardino, KB; Cappuzzo, F; Ceresoli, GL; Crinò, L; Ferraldeschi, M; Floriani, I; Gregorc, V; Ludovini, V; Mihaylova, Z; Pistola, L; Spreafico, A; Tofanetti, FR; Tonato, M; Torri, V; Villa, E | 1 |
| del Giglio, A; Ito, C | 1 |
| Barthorpe, A; Bignell, G; Blow, M; Brackenbury, L; Brasseur, F; Butler, A; Chenevix-Trench, G; Clarke, O; Cole, J; Cooper, CS; Davies, H; Dicks, E; Dike, A; Drozd, A; Edkins, S; Edwards, K; Flanagan, AM; Forbes, S; Foster, R; Futreal, PA; Goldstraw, P; Gray, K; Greenman, C; Halliday, K; Harris, G; Hills, K; Hunter, C; Knowles, M; Kosmidou, V; Leung, SY; Looijenga, LH; Louis, DN; Lugg, R; Malkowicz, B; Menzies, A; Nicholson, AG; O'Meara, S; Parker, A; Perry, J; Petty, R; Pierotti, MA; Raine, K; Ratford, L; Shepherd, R; Small, A; Smith, R; Stephens, P; Stephens, Y; Stevens, C; Stratton, MR; Teague, J; Teh, B; Tofts, C; Varian, J; Weber, BL; West, S; Widaa, S; Wooster, R; Yates, A; Yuen, ST | 1 |
| Ishida, A; Iwamoto, Y; Kanoh, K; Kohno, N; Miyazawa, T; Miyazu, Y; Nishisaka, T | 1 |
| Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Tamura, K; Uejima, H | 1 |
| Fujiwara, K; Hisamoto, A; Hotta, K; Kiura, K; Kozuki, T; Okada, T; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ito, M; Iwasaki, T; Kawamura, S; Kijima, T; Kimura, H; Maeda, H; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Okumura, Y; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Easthope, SE; Frampton, JE | 2 |
| Hansen, M; Jänne, PA; Johnson, BE; Meyerson, M; Mukohara, T; Tracy, S | 1 |
| Daigo, Y; Fukuoka, M; Furukawa, C; Ishikawa, N; Kakiuchi, S; Kohno, N; Nakagawa, K; Nakamura, Y; Sone, S; Tsunoda, T; Tsuruo, T; Yano, S | 1 |
| Bando, M; Hosono, T; Nakazawa, S; Ohno, S; Oshikawa, K; Sohara, Y; Sugiyama, Y | 1 |
| Lyle, J | 1 |
| Saeed, M | 1 |
| Chang, GC; Chen, KC; Hsu, JY; Kuo, BI; Lin, CP; Yang, TY; Yin, MC | 1 |
| Senior, K | 1 |
| Ho, SS; Mok, TS; Poon, AN; Yeo, W | 1 |
| Chang, GC; Chen, KC; Lin, YC; Wang, RC; Yang, TY; Yin, MC | 1 |
| Ando, Y; Nagashima, F; Narabayashi, M; Ohyanagi, F; Sasaki, Y | 1 |
| Faulkner, K; Forsythe, B | 1 |
| Adjei, A; Belani, CP | 1 |
| Ben-Porat, L; Heelan, RT; Heinemann, MH; Kris, MG; Miller, VA; Pao, W; Pizzo, BM; Sachs, DL; Shah, NT; Tyson, LB | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Dennis, PA; Tsurutani, J | 1 |
| Baselga, J; Fukuoka, M; Herbst, RS | 1 |
| Von Pawel, J | 1 |
| Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
| Astoul, P; Barlési, F; Doddoli, C; Kleisbauer, JP; Tchouhadjian, C; Torre, JP | 1 |
| Chen, YM; Chiang, SC; Chiu, CH; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Alfaro, V; Tanović, A | 1 |
| Birnbaum, A; Ready, N | 1 |
| Blandin, S; Gérinière, L; Girard, N; Perrot, E; Souquet, PJ | 1 |
| Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC | 1 |
| Brave, S; Kendrew, J; Stratford, IJ; Telfer, BA; Wedge, SR; Whittaker, L; Williams, KJ | 1 |
| Arnheim, K | 1 |
| Cho, D; Halmos, B; Janne, PA; Kocher, O; Lee, JC; Meyerson, ML; Tenen, DG | 1 |
| Fuster, LM; Sandler, AB | 1 |
| Bakoyannis, C; Briasoulis, E; Dimopoulos, M; Efstathiou, H; Fountzilas, G; Kopterides, P; Kosmidis, P; Lambropoulos, S; Makatsoris, T; Papadopoulos, S; Pectasides, D; Razis, E; Rigatos, S; Skarlos, D; Tzamakou, E; Varthalitis, G | 1 |
| Akita, H | 1 |
| Curigliano, G; De Braud, F; De Pas, T; Dodaro, L; Manzoni, S; Noberasco, C; Pelosi, G; Spaggiari, L | 1 |
| Normanno, N | 1 |
| Dowell, J; Kirkpatrick, P; Minna, JD | 1 |
| Belani, C; Price, N | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Belani, CP; Cella, D; Herbst, RS; Heyes, A; Kay, AC; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JS; Prager, D; Schiller, JH; Wolf, MK | 1 |
| Boyer, M; Clarke, S; Millward, M; Sharma, R | 1 |
| Aoe, M; Date, H; Gazdar, AF; Ichimura, K; Kiura, K; Shigematsu, H; Shimizu, N; Tabata, M; Tanimoto, M; Tokumo, M; Tomii, K; Toyooka, S; Tsuda, T; Tsukuda, K; Ueoka, H; Yano, M | 1 |
| Bang, YJ; Choi, IS; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeong, S; Kim, DW; Kim, J; Kim, JH; Kim, NK; Kim, TY; Kim, YT; Lee, JS; Oh, DY | 1 |
| Castaldo, V; Del Gaizo, F; Gridelli, C; Guerriero, C; Maione, P; Rossi, A | 1 |
| Twombly, R | 1 |
| Belani, CP; Gooding, W; Lin, Y; Mohamed, MK; Ramalingam, S | 1 |
| Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG | 1 |
| Dowell, JE; Minna, JD | 3 |
| Matsuo, K; Tanimoto, M; Uchida, A | 1 |
| Cantley, LC; Cichowski, K; Engelman, JA; Fleet, C; Jänne, PA; Johnson, BE; Mermel, C; Mukohara, T; Pearlberg, J | 1 |
| Chang, KL; Lau, SK | 1 |
| Chu, DT; Wang, B; Zhang, XR | 2 |
| Gatzemeier, U; Reck, M | 3 |
| Grandis, JR; Gubish, CT; Lyker, JS; Siegfried, JM; Stabile, LP; Zhang, W | 1 |
| Antonella, P; Augusto, P; Busi, G; Giancarla, B; Palumbo, A; Pedrazzini, A; Roggero, E | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Endoh, H; Hatooka, S; Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Mori, S; Shinoda, M; Takahashi, T; Yatabe, Y | 1 |
| Blumenschein, G; Carbone, DP; Eberhard, DA; Henderson, T; Herbst, RS; Hong, WK; Johnson, DH; Kelley, SK; Kim, ES; Lee, JJ; Liu, DD; Mass, R; Mininberg, E; Ramies, DA; Sandler, A; Seshagiri, S; Tran, H; Truong, MT; Tsao, A; Xie, D | 1 |
| Coppola, D; Cress, D; Haura, EB; Livingston, S; Song, L | 1 |
| Burdak-Rothkamm, S; Feldmann, K; Ludwig, D; Nguyen, TP; Rübe, C; Rübe, CE; Wiegel, T | 1 |
| Frantz, S | 1 |
| Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Taguchi, F | 1 |
| Miller, VA; Pao, W | 1 |
| Curigliano, G; de Braud, F; De Pas, T; Noberasco, C; Pelosi, G; Spaggiari, L; Veronesi, G | 1 |
| Yatabe, Y | 1 |
| Karjalainen, EM; Knuuttila, A; Mali, P; Rouhos, A | 1 |
| Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
| Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC | 1 |
| Golsteyn, RM | 1 |
| Desai, AA; Ratain, MJ | 1 |
| Armstrong, E; Chinnaiyan, AM; Chinnaiyan, P; Harari, PM; Huang, S; Tomlins, SA; Vallabhaneni, G; Varambally, S | 1 |
| Blankenburg, T; Brust, D; Nagel, S; Schaedlich, S; Schütte, W | 1 |
| Abrey, LE; Franceschi, E; Kris, MG; Miller, VA; Milton, DT; Omuro, AM; Shah, N | 1 |
| Chiu, CH; Perng, RP; Shih, YN; Tsai, CM | 1 |
| Alberola, V; Camps, C; Cardenal, F; Castellanos, D; Cortes-Funes, H; Diz, P; Garcia-Giron, C; Gomez, C; Gonzalez-Larriba, JL; Izquierdo, A; Maeztu, I; Mayo, C; Mendez, P; Moran, T; Queralt, C; Rosell, R; Sanchez, JJ; Taron, M; Valero, P; Velasco, A; Vieitez, JM | 1 |
| Kaye, FJ | 1 |
| Bartolini, S; Bemis, L; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Danenberg, K; Doglioni, C; Domenichini, I; Franklin, WA; Gregorc, V; Haney, J; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Sidoni, A; Tonato, M; Varella-Garcia, M; Witta, S | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, K; Nishio, M; Ohyanagi, F; Okumura, S; Satoh, Y | 1 |
| Gemma, A; Kataoka, K; Kokubo, Y; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Shibuya, M; Yoshimura, A | 1 |
| Edelman, MJ | 2 |
| Fujimura, M; Hourai, T; Kasahara, K; Kimura, H; Nakao, S; Nishio, M; Sone, T; Yoshimoto, A | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Kiura, K; Mitsudomi, T; Toyooka, S | 1 |
| Dietrich, GM; Fischer, JR; Geiger, D; Haffner, U; Lahm, H; Spahlinger, B | 1 |
| Astoul, P; Barlési, F; Doddoli, C; Greillier, L; Kleisbauer, JP; Tchouhadjian, C; Thomas, P; Villani, P | 1 |
| Hsu, HS; Huang, BS; Huang, MJ; Lim, KH; Tzen, CY; Yen, Y | 1 |
| Kanazawa, S; Kinoshita, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 1 |
| Anderson, H; Bebb, G; Ho, C; Laskin, J; Melosky, B; Murray, N | 1 |
| Heymach, JV | 1 |
| Campagnoli, E; Cavina, R; De Vincenzo, F; Latteri, F; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Ichinose, Y; Ikeda, J; Maruyama, R; Miyake, T; Nakamura, T; Okamoto, T; Shoji, F; Wataya, H | 1 |
| Chuah, KL; Leong, SS; Lim, ST; Lim, WT; Tan, EH; Tay, MH; Toh, CK; Wong, EH | 1 |
| Reddy, GK | 2 |
| Tyagi, P | 1 |
| Buchholz, E; Fandi, A; Gatzemeier, U; Manegold, C; Smith, RP | 1 |
| Byrne, BJ; Garst, J | 1 |
| Costello, G; Holloway, B; Speake, G | 1 |
| Fukuoka, M; Tamura, K | 1 |
| Blackhall, FH; Rehman, S; Thatcher, N | 1 |
| Chang, XY; Cui, QC; Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Buter, J; Giaccone, G | 2 |
| Cui, QC; Feng, RE; Guo, BQ; Li, LY; Mu, XL; Wang, MZ; Zhang, XT; Zhou, HS | 1 |
| Lilenbaum, R; Lopes, G; Raez, LE | 1 |
| Dowell, J; Minna, JD | 1 |
| Gooding, WE; Grandis, JR; Lui, VW; Siegfried, JM; Thomas, SM; Wentzel, AL | 1 |
| Haber, DA; Settleman, J | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Bunn, PA; Crowley, J; Franklin, WA; Gandara, DR; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sakiyama, T; Sekine, I; Shibata, T; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yamamoto, S; Yoshida, T | 1 |
| Gallegos-Ruiz, M; Giaccone, G; Janmaat, ML; Kruyt, FA; Rodriguez, JA | 1 |
| Abe, T; Hagiri, S; Ishii, K; Katagiri, M; Kato, E; Kobayashi, H; Kuboto, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Takada, N; Tanaka, N; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Soda, H | 1 |
| Besse, B; Cirauqui, B; Ichinose, Y; Mate, JL; Mendez, P; Moran, T; Nishiyama, K; Perez, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sarries, C; Taron, M | 1 |
| Bezjak, A; Campos, D; Ciuleanu, T; Clark, G; Dediu, M; Findlay, B; Hirsh, V; Johnston, D; Maoleekoonpiroj, S; Martins, R; Rodrigues Pereira, J; Santabárbara, P; Seymour, L; Shepherd, FA; Smylie, M; Tan, EH; Thongprasert, S; Tu, D; van Kooten, M | 1 |
| Doroshow, JH | 1 |
| Gow, CH; Shih, JY; Yang, PC | 1 |
| Cutz, JC; da Cunha Santos, G; Daneshmand, M; Ding, K; Kamel-Reid, S; Lagarde, A; Liu, N; Lorimer, I; Marrano, P; Pater, J; Richardson, F; Sakurada, A; Seymour, L; Shepherd, FA; Squire, J; Tsao, MS; Whitehead, M; Zhang, T; Zhu, CQ | 1 |
| Ready, N | 1 |
| Ettinger, DS | 1 |
| Choi, JH; Hyun, MS; Kim, MK; Lee, JK; Lee, KH | 1 |
| Hiddemann, W; Krych, M; Ostermann, H; Schoenberg, SO; Stemmler, HJ; Weigert, O | 1 |
| Friess, T; Hasmann, M; Scheuer, W | 1 |
| Gandara, DR; Gumerlock, PH | 1 |
| Amler, LC; Eberhard, DA; Goddard, AD; Heldens, SL; Herbst, RS; Hillan, KJ; Ince, WL; Jänne, PA; Januario, T; Johnson, BE; Johnson, DH; Klein, P; Miller, VA; Ostland, MA; Ramies, DA; Sebisanovic, D; Seshagiri, S; Stinson, JA; Zhang, YR | 1 |
| Fehrenbacher, L; Herbst, RS; Hermann, R; Johnson, BE; Johnson, DH; Klein, P; Kris, MG; Li, X; Miller, VA; Prager, D; Ramies, D; Sandler, A; Tran, HT | 1 |
| Bartolini, S; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Gazdar, AF; Gregorc, V; Hirsch, FR; Ludovini, V; Rossi, E; Shigematsu, H; Toschi, L; Varella-Garcia, M | 1 |
| Engelman, JA; Jänne, PA | 1 |
| Chen, YF; Cohen, MH; Johnson, JR; Pazdur, R; Sridhara, R | 1 |
| Comis, RL | 1 |
| Chu, DT; Guan, ZZ; Jiang, GL; Li, LY; Li, W; Liu, XY; Zhang, L; Zhao, HY | 1 |
| Bradley, J; Govindan, R; Hope, A; Kreisel, D; Krupnick, AS; Meyers, B | 1 |
| Afar, DE; Agus, DB; Aronson, N; Curran, J; Galkin, A; Hunter, JB; Jain, A; Laux, I; Natale, RB; Shak, S; Tindell, CA | 1 |
| Alavi, J; Algazy, K; Bearn, L; Eaby, B; Evans, T; Shults, J; Stevenson, JP; Veronese, ML | 1 |
| Bearz, A; Berretta, M; Spazzapan, S; Tirelli, U; Vaccher, E | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Fukuyama, S; Hagiwara, K; Kanazawa, M; Kato, M; Kobayashi, K; Miyazawa, H; Nagai, Y; Tanaka, T; Udagawa, K; Yokote, A | 1 |
| Gazdar, AF; Minna, JD; Peyton, MJ | 1 |
| Cantley, LC; Engelman, JA; Halmos, B; Hanna, NH; Jänne, PA; Johnson, BE; Kobayashi, S; Lindeman, N; Mukohara, T; Pearlberg, J; Tenen, DG; Tsuchihashi, Z; Yeap, BY | 1 |
| Blanke, CD | 1 |
| Harper, P; Spicer, J | 1 |
| Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Hsue, V; Ichinose, Y; Jablons, D; Jahan, T; Manegold, C; Massuti, B; Mate, JL; Mok, T; Moran, T; Ono, M; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Zamora, L | 1 |
| Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S | 1 |
| Ganti, AK; Potti, A | 1 |
| Govindan, R; Pillot, G; Viswanathan, A | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Hasegawa, Y; Imaizumi, K; Kataoka, K; Kawabe, T; Kimura, T; Kondoh, Y; Kume, H; Nishiyama, O; Shimokata, K; Taniguchi, H | 1 |
| Fukui, T; Hasegawa, Y; Imaizumi, K; Kondo, M; Kume, H; Nagasaka, T; Sekido, Y; Shimokata, K; Yokoi, K; Yokoyama, T; Yoshioka, H | 1 |
| Burt, PA; Lee, LW | 1 |
| Chang, YL; Chen, KY; Gow, CH; Hsu, YC; Shih, JY; Su, WP; Tsai, MF; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Kasahara, K; Kimura, H; Nishio, K; Sekijima, M; Tamura, T | 1 |
| Hotta, K; Inoue, A; Kiura, K; Nukiwa, T; Tanimoto, M; Ueoka, H | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Benson, K; Booth, B; Chen, YF; Chidambaram, N; Cohen, M; Duan, J; Gobburu, J; Hsieh, LS; Johnson, JR; Leighton, J; Pazdur, R; Sridhara, R; Williams, GM; Zimmerman, P | 1 |
| Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P | 1 |
| Binns, D; Cullinane, C; Hicks, RJ; McArthur, GA; Roselt, P; Solomon, B; Weibe, LI | 1 |
| Beijnen, JH; Schellens, JH; Siegel-Lakhai, WS | 1 |
| Lee, D | 1 |
| Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA | 1 |
| Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Moreno, M; Perez-Gracia, JL; Zubieta, JL | 1 |
| Leighl, NB; Nematollahi, M; Shepherd, FA; Tsao, WS; Zawisza, DL | 1 |
| Hsu, C; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Hanagiri, T; Morita, M; Ono, K; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Dobashi, K; Iijima, H; Ishizuka, T; Minna, JD; Mori, M; Nakajima, T; Otani, Y; Saito, R; Sato, K; Suga, T; Sunaga, N; Takise, A; Tanaka, S; Tomizawa, Y | 1 |
| Baselga, J; Bell, DW; Brannigan, BW; Fukuoka, M; Giaccone, G; Haber, DA; Harris, PL; Haserlat, SM; Herbst, RS; Iacona, RB; Johnson, DH; Krebs, AD; Kris, MG; Lynch, TJ; Manegold, C; Muir, B; Ochs, JS; Okimoto, RA; Riemenschneider, MJ; Sgroi, DC | 1 |
| Chen, YR; Chen, YT; Fu, YN; Hu, SF; Huang, SF; Lin, CH; Tsai, SF; Yang, ST | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Fukuoka, M; Ichinose, Y; Jiang, H; Kato, H; Nagai, K; Tada, H; Tsuboi, M; Tsuchiya, R; Wada, H | 1 |
| Kakiuchi, S; Sone, S; Yano, S | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T | 1 |
| Daigo, Y; Hayama, S; Inai, K; Ishikawa, N; Kato, T; Kohno, N; Murakami, H; Nakamura, Y; Nishimura, H; Takano, A; Takeshima, Y; Taniwaki, M; Tsuchiya, E | 1 |
| Brown, E; Buck, E; Gibson, N; Griffin, G; Haley, JD; Iwata, KK; Petti, F; Ramnarine, N; Thomson, S | 1 |
| Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, XT | 1 |
| Garfield, DH | 2 |
| Bitran, JD; Nabhan, C | 1 |
| Ladanyi, M; Miller, VA; Pao, W | 1 |
| Ohe, Y; Takano, T | 1 |
| Fujii, T; Kuwano, M; Nakamura, H; Ono, M; Shirouzu, K; Takamori, S; Yamana, H | 1 |
| D'Amico, TA | 1 |
| Carbone, DP | 1 |
| Berdel, WE; Hoffknecht, P; Lange, T; Müller-Tidow, C; Serve, H; Thomas, M | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Kabasawa, K; Kawasaki, N; Nakamura, H; Taguchi, M | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Bartolini, S; Bemis, L; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Toschi, L; Varella-Garcia, M | 1 |
| Dudek, AZ; Keshtgarpour, M; Kmak, KL; Koopmeiners, J | 1 |
| Anderson, F; Bebb, G; Davis, J; Ho, C; Murray, N | 1 |
| Bunn, PA; Hirsch, FR | 1 |
| Endo, K; Fujii, Y; Fukai, I; Mizuno, K; Sasaki, H; Yamakawa, Y; Yano, M | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Bepler, G; Cantor, A; Haura, EB; Song, L; Zheng, Z | 1 |
| Apolone, G; Garattini, S; La Vecchia, C | 1 |
| Smith, J | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Rivera, MP; Silvestri, GA | 1 |
| Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
| Garfield, D; Kashef, G | 1 |
| Cardiff, RD | 1 |
| Amler, LC; Cavet, G; Eberhard, DA; Fu, L; Januario, T; Lin, CY; Modrusan, Z; O'Neill, V; Pham, TQ; Seshagiri, S; Soriano, R; Stinson, J; Yauch, RL; Zhu, W | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kuroki, T; Nishio, K; Ohmori, T; Okuda, K; Saijo, N; Shirai, T | 1 |
| Fukuoka, M; Hirata, K; Kimura, T; Kudoh, S; Matsui, K; Matsuura, K; Mitsuoka, S; Nakagawa, K; Negoro, S; Yoshimura, N | 1 |
| Chan, SK; Gullick, WJ; Hill, ME | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Hur, GY; In, KH; Jung, HC; Jung, KH; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Baldwin, PD; Lundberg, AS; Tammaro, KA | 1 |
| Boshoff, C; Falzon, M; Lai, CS; Lee, SM | 1 |
| Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
| Eguchi, K; Koboyashi, T; Seki, N; Seto, T; Shioya, S; Tanigaki, T; Uematsu, K; Umemura, S | 1 |
| Baron, A; Bunn, PA; Chan, DC; Chan, Z; Coldren, CD; Drabkin, HA; Dziadziuszko, R; Franklin, W; Gazdar, AF; Gemmill, RM; Girard, L; Hedman, K; Helfrich, B; Hirsch, FR; Minna, JD; Ravdel, L; Sugita, M; Witta, SE | 1 |
| Chen, YM; Perng, RP; Tsai, CM | 1 |
| Song, ST; Wang, Y; Xu, JM | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Kim, TY; Moriguchi, H; Sato, C | 1 |
| Journagan, S; Obadiah, J | 1 |
| Buttitta, F; Felicioni, L; Marchetti, A | 1 |
| Gatzemeier, U; Kranich, AL; Reck, M; Steinbach, AK | 1 |
| Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Cascone, T; Ciardiello, F; Gridelli, C; Morelli, MP; Troiani, T | 1 |
| Polk, B | 1 |
| Borras, AM; Distel, RJ; Halmos, B; Jänne, PA; Johnson, BE; Joshi, VA; Kuang, Y; Lee, JC; Lindeman, N; Liyanage, H; Maher, EA; Meyerson, M; Rogers, AM | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S | 1 |
| Shepherd, FA; Tsao, MS | 1 |
| Hatano, H; Ishii, D; Kosaka, T; Mitsudomi, T; Mizuno, M; Nakahara, N; Natsume, A; Shimato, S; Wakabayashi, T; Yatabe, Y; Yoshida, J | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
| He, YM; Lai, RS; Shen, LS; Xie, L; Zhu, CL | 1 |
| Schwartz, LM; Woloshin, S | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Cufer, T; Erensoy, I; Gaafar, R; Pemberton, K; Vrdoljak, E | 1 |
| Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 2 |
| Kris, MG; Moryl, N; Obbens, EA; Ozigbo, OH | 1 |
| Hayashi, T; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Tsukamoto, K; Uchida, K; Urabe, S | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Febbo, PG; Riedel, RF | 1 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Goto, K; Park, K | 1 |
| Bartolini, S; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Finocchiaro, G; Franklin, WA; Hirsch, FR; Magrini, E; Metro, G; Santoro, A; Tallini, G; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
| Hashizume, T; Kobayashi, N; Kozawa, S; Miyazawa, N; Ogura, T; Tagawa, A; Takahashi, H; Watanuki, Y | 1 |
| Govindan, R; Morgensztern, D | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Garfield, D | 2 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Gumerlock, PH; Lau, DH; McCoy, J; Vance, R; West, HL | 1 |
| Felip, E; Rosell, R | 1 |
| Fujiwara, Y; Hotta, K; Ishimaru, F; Kiura, K; Kubonishi, S; Matsuo, K; Nakajima, H; Niiya, D; Ogino, A; Shinagawa, K; Tabata, M; Tanimoto, M; Uchida, A; Ueoka, H | 1 |
| Altavilla, G; Rosell, R; Salazar, F; Santarpia, M; Tarón, M | 1 |
| Bakri, K; Bůzková, P; Choksi, J; Gillenwater, H; Jones, PE; Mears, A; Socinski, MA; Stinchcombe, TE; Taylor, M; Tynan, M | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, KH | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Herbst, RS; Kies, MS; Lee, JJ; Liu, D; Pisters, KM; Schaerer, R; Thomas, SK; Tsao, AS; Zinner, RG | 1 |
| Baba, K; Hasegawa, Y; Imaizumi, K; Kato, K; Matsumoto, S; Oishi, T; Saito, H; Saka, H; Shimokata, K; Suzuki, R; Taniguchi, H; Yamamoto, M | 1 |
| Adams, D; Fernanadez, EM; Seiverling, EV | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Sikic, BI | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Goodin, S | 1 |
| Barón, AE; Bunn, PA; Cappuzzo, F; Crino, L; Danenberg, KD; Danenberg, PV; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Park, S; Tanaka, K; Varella-Garcia, M; Witta, SE | 1 |
| Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M | 1 |
| Pérol, M | 2 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Costa, DB; Schumer, ST | 1 |
| Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
| Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
| Aoe, M; Date, H; Ichihara, S; Ichimura, K; Kiura, K; Ohashi, K; Sano, Y; Shimizu, N; Tabata, M; Tokumo, M; Toyooka, S; Tsukuda, K | 1 |
| Johnston, PG; Karaiskou-McCaul, A; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, SA; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Ando, M; Ariyoshi, Y; Fukuoka, M; Okamoto, I; Seto, T; Takeda, K; Tamura, K; Yamamoto, N | 1 |
| Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C | 1 |
| Blackhall, F; Ranson, M; Thatcher, N | 1 |
| Arteaga, CL | 1 |
| von Eyben, FE | 1 |
| Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S | 1 |
| Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H | 1 |
| Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Ramalingam, S; Sandler, AB | 1 |
| Belani, CP; Govindan, R; Hensing, T; Herbst, R; Kelly, K; Krebs, A; Natale, R; Ochs, J; Reiling, R; Wade, J; Wozniak, A | 1 |
| Gadgeel, SM | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| Clark, GM; Ding, K; Santabarbara, P; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Buchholz, E; Gatzemeier, U; Krutzfeldt, K; Manegold, C; Reck, M; Romer, KS | 1 |
| Costa, DB; Huberman, MS | 1 |
| Eguchi, K; Seki, N; Shibakuki, R; Uematsu, K | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Glatt, KA; Greulich, H; Ji, H; Lowell, AM; Meyerson, M; Minami, Y; Shah, K; Shapiro, GI; Shimamura, T; Thomas, RK; Wong, KK | 1 |
| Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY | 1 |
| Holloway, B; Kasahara, K; Kawaishi, M; Kimura, H; Kunitoh, H; Nishio, K; Tamura, T | 1 |
| Pedersen, MW; Poulsen, HS | 1 |
| Hasegawa, Y; Hashimoto, N; Honda, T; Imaizumi, K; Kawabe, T; Nagasaka, T; Shimokata, K | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JS | 1 |
| Baribaud, F; Caudler, E; Fridman, JS; Friedman, SM; Gazdar, AF; Girard, L; He, B; Jablons, DM; Li, Y; Liu, C; Lo, Y; Mikami, I; Minna, JD; Newton, RC; Peyton, M; Reguart, N; Scherle, PA; Vaddi, K; Yang, G; Yao, W; Zhou, BB | 1 |
| Graves, JE; Heffernan, MP; Jones, BF; Lind, AC | 1 |
| High, WA | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Ishikawa, S; Ito, H; Onizuka, M; Ozawa, Y; Sakai, M; Sakakibara, Y; Yamamoto, T | 1 |
| Charoentum, C | 1 |
| Cozzani, E; Parodi, A; Santoro, F | 1 |
| Herbst, R; Sandler, A | 1 |
| Endo, K; Fujii, Y; Haneda, H; Kawano, O; Kobayashi, Y; Sasaki, H; Suzuki, E; Yano, M; Yukiue, H | 1 |
| Bell, DW; Godin-Heymann, N; Haber, DA; Kwak, EL; Lynch, TJ; Settleman, J; Sharma, SV; Sordella, R | 1 |
| Amler, LC; Goddard, AD; Hillan, KJ | 1 |
| Hirsch, FR | 2 |
| Chang, WC; Chang, YH; Chen, HC; Chen, YT; Fang, YF; Hsi, BL; Hsieh, MH; Huang, SF; Ku, YC; Kuo, HP; Lin, SY; Liu, CL; Liu, HP; Tsai, SF | 1 |
| Bach, JP; Faoro, C; Gorg, C; Kiessling, AM; Kleinhans, A; Neubauer, A; Riera-Knorrenschild, J; Schwella, N; Wagner, HJ | 1 |
| Barón, A; Bunn, PA; Coldren, CD; Franklin, WA; Geraci, MW; Helfrich, BA; Hirsch, FR; Lapadat, R; Sugita, M; Witta, SE; Zeng, C | 1 |
| Azzoli, CG; Dunne, M; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Rizvi, NA; Venkatraman, E | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kitahara, N; Kobayashi, Y; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yukiue, H | 1 |
| Bruno, R; Eppler, SM; Hamilton, M; Lu, JF; Lum, BL; Rakhit, A; Wolf, J | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Ichihara, S; Inukai, M; Ito, S; Kiura, K; Ouchida, M; Shimizu, N; Soh, J; Suehisa, H; Toyooka, S | 1 |
| Katakami, N | 1 |
| Ayoub, J; Bezjak, A; Chan, RT; Clark, G; Cyjon, A; de Albuquerque Ribeiro, R; Fenton, D; Gerogianni, A; Laberge, F; Lago, S; Noble, J; Reck, M; Seymour, L; Shepherd, FA; Trajkovic, A; Tu, D; von Pawel, J; Zukin, M | 1 |
| Nieder, C | 1 |
| Buck, E; Cagnoni, P; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Segawa, Y; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S | 1 |
| Bailey, C; Borras, AM; de Jong, F; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Kesari, S; Lindeman, N; Wen, PY | 1 |
| Hirata, K; Iwao, H; Kimura, T; Kudoh, S; Matsuura, K; Mitsuoka, S; Yoshikawa, J; Yoshimura, N | 1 |
| Chang, GC; Chen, KC; Gow, CH; Hsu, C; Lin, CP; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Chiu, CH; Lin, WC; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Azerad, MA; Bosquée, L; Canon, JL; Collard, P; De Greve, J; Duplaquet, F; Galdermans, D; Germonpré, P; Goeminne, JC; Meert, AP; Nackaerts, K; Schallier, D; Tits, G; van Puijenbroek, R; Vandenhoven, G; Vansteenkiste, J | 1 |
| Gerdes, S; Mrowietz, U | 1 |
| Das, AK; Gazdar, AF; Girard, L; Graves, R; Minna, JD; Nirodi, CS; Peyton, M; Redpath, S; Sato, M; Shay, JW; Story, MD | 1 |
| Krohn, KA; Linden, HM; Livingston, RB; Mankoff, DA | 1 |
| Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W | 1 |
| Endoh, H; Hida, T; Kosaka, T; Kuwano, H; Mitsudomi, T; Tada, H; Tsuboi, M; Yatabe, Y; Yoshida, K | 1 |
| Fujiwara, M; Ito, M; Kakemizu, N; Kido, Y; Kusano, N; Momiyama, M; Nishikawa, M; Nozaki, M; Yoshimoto, N | 1 |
| Hsiao, YP; Shih, HC; Wu, MF; Yang, JH | 1 |
| Azim, HA; Ganti, AK | 1 |
| Hong, WK; Kim, ES; Lee, HY; Morgillo, F; Woo, JK | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Kameda, Y; Matsukuma, S; Miyagi, Y; Ohgane, N; Oshita, F; Saito, H; Sakuma, Y; Tsuchiya, E; Yamada, K; Yoshihara, M | 1 |
| Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N | 1 |
| Heelan, RT; Kris, MG; Miller, VA; Milton, DT; Pao, W; Riely, GJ | 1 |
| Kato, T; Nishio, K | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T | 1 |
| Bunn, PA | 2 |
| Gallegos Ruiz, M; Giaccone, G; Janne, P; Le Chevalier, T; Oulid-Aissa, D; Rodriguez, JA; Smit, E; Soria, JC; Thatcher, N | 1 |
| Fujimoto, K; Kawai, S; Masui, K; Nishi, N; Yonezawa, T | 1 |
| Bearz, A; Berretta, M; Fratino, L; Giacalone, A; Simonelli, C; Spazzapan, S; Tirelli, U | 1 |
| Botwood, N; Bunn, PA; Chang, A; Ciuleanu, T; Donald, E; Dziadziuszko, R; Ellison, G; Flannery, A; Franklin, WA; Hirsch, FR; Holloway, B; Knight, L; Parikh, P; Parums, D; Pereira, JR; Thatcher, N; Varella-Garcia, M; von Pawel, J; Watkins, C | 1 |
| Döme, B; Ostoros, G | 1 |
| Hagiwara, K; Kanazawa, M; Kobayashi, K; Koyama, N; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Sutani, A; Tanaka, T; Uchida, Y; Udagawa, K | 1 |
| Gross, GE; Schäd, SG; Zoller, A | 1 |
| Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J; Su, ZZ | 1 |
| Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F | 1 |
| Giaccone, G; Oudejans, JJ; Rodriguez, JA; Vischioni, B; Vos, W | 1 |
| Pujol, JL | 1 |
| Herbst, R; Sandler, A; Vokes, E | 1 |
| Barón, A; Bemis, L; Bunn, PA; Chan, DC; Coldren, C; Franklin, WA; Gazdar, A; Gustafson, D; Helfrich, BA; Hirsch, FR; Minna, J; Raben, D; Varella-Garcia, M; Zeng, C | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Yu, SY; Zhang, L | 1 |
| Chen, M; Gemma, A; Kataoka, K; Kokubo, Y; Kosaihira, S; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| An, TT; Fang, J; Liu, XY; Wu, MN; Yang, L | 1 |
| Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A | 1 |
| Chang, A; Zhang, X | 1 |
| Guan, ZZ; Pan, ZK; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Han, Y; Li, YM; Paradiso, A; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Hanagiri, T; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Ichimura, K; Kiura, K; Shigematsu, H; Shimizu, K; Shimizu, N; Soh, J; Tokumo, M; Toyooka, S | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H | 1 |
| Chen, G; Huang, YJ; Liao, RQ; Lin, JY; Wang, K; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Yang, XN; Zhang, GC; Zhou, Q | 1 |
| Fujimoto, N; Fujiwara, K; Hisamoto, A; Hotta, K; Katayama, H; Kiura, K; Kozuki, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Boye, K; Bras-Gonçalves, RA; Chapelier, A; de Cremoux, P; Defrance, R; Judde, JG; Livartowski, A; Poupon, MF; Rebucci, M; Tran-Perennou, C; Vogt, N | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Borras, AM; Fidias, P; Freidlin, B; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, NI; Lucca, J; Lynch, TJ; Meyerson, M; Ostler, PA; Rabin, MS; Skarin, AT; Temel, J; Yeap, BY | 1 |
| Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Tsutsui, N | 1 |
| Grenier, J; Soria, JC | 1 |
| Chou, LS; Garey, J; Kim, E; Oishi, K | 1 |
| Zalcman, G | 1 |
| Bréchot, JM | 1 |
| Quoix, E | 1 |
| Soria, JC | 1 |
| Guitart, J; Lacouture, ME; Lai, SE; Luu, M; Patel, J | 1 |
| Scagliotti, GV; Selvaggi, G | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Na, II; Rho, JK; Ryoo, BY; Yang, SH | 1 |
| Akita, RW; Schaefer, G; Shao, L; Totpal, K | 1 |
| Gong, SJ; Gong, YF; Hu, XH; Jiang, B; Liu, F; Wang, ML; Yao, BD; Zhang, WY; Zhu, GS; Zhu, ZZ | 1 |
| Fidias, P; Haber, DA; Jänne, PA; Johnson, BE; Joshi, VA; Kucherlapati, R; Lynch, TJ; Meyerson, M; Muzikansky, A; Sequist, LV | 1 |
| Bell, DW; Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Bemis, L; Bunn, PA; Cappuzzo, F; Chansky, K; Crino, L; Dziadziuszko, R; Franklin, WA; Gandara, DR; Gazdar, AF; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| van de Vijver, MJ; van Zandwijk, N | 1 |
| Fukuoka, M; Nakagawa, K; Okabe, T; Okamoto, I; Satoh, T; Takada, M; Tamura, K; Terashima, M; Yoshida, T | 1 |
| Serke, M | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Carlisle, DL; Gaither-Davis, A; Grandis, JR; Liu, X; Siegfried, JM; Swick, MC | 1 |
| Chen, YM; Chou, TY; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Blaukat, A; Funk, JO; Irmer, D | 1 |
| Bereczky, B; Nishimura, Y; Ono, M | 1 |
| Dobashi, K; Hisada, T; Iijima, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Shimizu, K; Suga, T; Sunaga, N; Tanaka, S; Tomizawa, Y; Yanagitani, N | 1 |
| Akie, K; Asahina, H; Dosaka-Akita, H; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Konishi, J; Munakata, M; Nishimura, M; Ogura, S; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Asomaning, K; Christiani, DC; Gurubhagavatula, S; Heist, R; Liu, G; Lynch, TJ; Su, L; Wang, Z; Yeap, BY; Zhou, W | 1 |
| Gabizon, A; Gipps, M; Grenader, T; Shavit, L | 1 |
| Adachi, S; Funada, Y; Kotani, Y; Mitsudomi, T; Negoro, S; Sakuma, T; Satouchi, M; Shimada, T; Takada, Y; Urata, Y; Watanabe, H; Yatabe, Y; Yoshimura, S | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shibata, K; Sone, T; Waseda, Y | 1 |
| Sequist, LV | 1 |
| Armando, E; Bertetto, O; Bonello, L; Bussolati, G; Ciuffreda, L; Daniele, L; Dongiovanni, D; Macrì, L; Sapino, A; Schena, M | 1 |
| Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
| Aoe, M; Date, H; Kiura, K; Kosaka, T; Mitsudomi, T; Ogino, A; Ouchida, M; Shigematsu, H; Soh, J; Takata, M; Toyooka, S; Uchida, A | 1 |
| Argiris, A; Gooding, W; Hensing, T; Kolesar, J; Masters, G; Patel, S; Pins, M; Raji, A; Sturgis, C; Yeldandi, A | 1 |
| Fujimura, M; Ichikawa, Y; Ishiura, Y; Kasahara, K; Kashii, T; Kimura, H; Kita, T; Kobayashi, M; Kunitoh, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shiarasaki, H; Shibata, K; Sone, T; Tamura, T; Waseda, Y; Watanabe, K; Yoshimoto, A | 1 |
| Evans, WK; Feld, R; Mackay, JA; Shepherd, FA; Sridhar, SS | 1 |
| Deneulin, A; Fandi, A; Feld, R; Laurie, SA; Pujol, JL; Rebattu, P; Viens, P | 1 |
| Chang, GC; Chen, KC; Chiu, CH; Hsu, JY; Lin, CP; Perng, RP; Shih, JY; Tsai, CM; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Bedano, PM; Hanna, NH | 1 |
| Kishi, K; Nakata, K; Yoshimura, K | 1 |
| Clark, GM; Culbertson, JL; Savoie, M; Seymour, L; Shepherd, FA; Whitehead, M; Zborowski, DM | 1 |
| Botwood, N; Chang, A; Ganzon, D; Parikh, P; Perng, RP; Tan, EH; Thatcher, N; Thongprasert, S; Tsao, CJ; Watkins, C; Yang, CH | 1 |
| Hanna, N | 1 |
| Carser, JE; Summers, YJ | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Hida, T; Horio, Y; Kosaka, T; Matsuo, K; Mitsudomi, T; Park, JY; Shimizu, J; Yatabe, Y; Yoshida, K | 1 |
| Galetta, D; Gridelli, C; Maione, P; Rossi, A | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Keam, B; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY | 1 |
| Yoneda, S | 1 |
| Inuzuka, K; Kasahara, K; Kawashima, A; Kita, T; Yoshimoto, A | 1 |
| Beckett, LA; Davies, AM; Gandara, DR; Hesketh, PJ; Ho, C; Lara, PN; Lau, DH | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Huang, YJ; Huang, YS; Liao, RQ; Lin, JY; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Zhou, Q | 1 |
| Chen, YM; Chiu, CH; Liou, JL; Perng, RP; Shih, YN; Tsai, CM | 1 |
| Chowbay, B; Goh, JW; Lee, P; Mancer, K; Tan, PH; Toh, CK | 1 |
| Fischer, JR; Geiger, D; Haffner, UJ; Lahm, H | 1 |
| Haigentz, M; Li, T; Ling, YH; Perez-Soler, R; Weber, TK; Yuan, Z | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Cantley, LC; Cappuzzo, F; Christensen, J; Engelman, JA; Gale, CM; Holmes, AJ; Hyland, C; Jänne, PA; Johnson, BE; Kosaka, T; Lee, C; Lindeman, N; Mitsudomi, T; Mok, T; Park, JO; Rogers, AM; Song, Y; Zejnullahu, K; Zhao, X | 1 |
| Esmaili, A; Vahid, B | 1 |
| Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C | 1 |
| Ciardiello, F; Hong, WK; Kim, ES; Kim, WY; Lee, HY; Morgillo, F | 1 |
| Basu, S; Bonomi, P; Buckingham, LE; Coon, JS; Gale, M; Jacobson, KK; Jewell, SS; Kaiser, KA; Mauer, AM; Morrison, LE; Muzzafar, T; Polowy, C; Villaflor, VM | 1 |
| Jiang, B; Li, LY; Lin, JY; Liu, W; Mok, T; Mu, XL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhang, L; Zhang, XT; Zhong, WZ; Zhou, CC; Zhou, Q | 1 |
| Fujisaka, Y; Horiike, A; Murakami, H; Shimoyama, T; Tamura, T; Yamada, Y; Yamamoto, N | 1 |
| Aoe, K; Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Ichimura, K; Kiura, K; Kobayashi, N; Soh, J; Suehisa, H; Toyooka, S | 1 |
| Hanibuchi, M; Sone, S; Tomimoto, H; Yano, S | 1 |
| Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC | 1 |
| Hwang, C; Lacouture, ME; Marymont, MH; Patel, J | 1 |
| Jablons, DM; Raz, DJ | 1 |
| De Tursi, M; Grassadonia, A; Iacobelli, S; Innominato, PF; Irtelli, L; Iurisci, I; Lévi, F; Rich, T; Tinari, N | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Ciardiello, F; Crino, L; Finocchiaro, G; Holmes, AJ; Jänne, PA; Ligorio, C; Magrini, E; Paioli, D; Patelli, M; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Bunn, PA; Chan, D; Coldren, CD; Frederick, BA; Helfrich, BA; Raben, D; Zheng, D | 1 |
| Goldman, ID; Li, T; Ling, YH; Perez-Soler, R | 1 |
| Beckett, LA; Gandara, DR; Shelton, DK; Yoneda, KY | 1 |
| Han, WD; Hao, HJ; Li, Q; Li, XH; Si, YL; Wu, ZQ; Zhao, YL | 1 |
| Liu, G; Shepherd, FA; Tsao, MS | 1 |
| Brahmer, J; Bunn, PA; Caprioli, R; Carbone, DP; Duncan, MW; Dziadziuszko, R; Gray, R; Gregorc, V; Grigorieva, J; Hirsch, FR; Hunsucker, SW; Kasahara, K; Ludovini, V; Massion, PP; Nishio, M; Roder, H; Schiller, J; Solomon, B; Spreafico, A; Taguchi, F; Tsypin, M | 1 |
| Chouaid, C; Fournel, P; Monnet, I; Perol, M; Robinet, G; Vergnenegre, A | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Di Todaro, F; Gaudenzi, P; Manfredini, R; Morandi, P; Nielsen, I; Salmi, R | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Costa, DB | 1 |
| Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y | 1 |
| Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Azzoli, CG; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Pizzo, B; Riely, GJ; Rizvi, NA | 1 |
| Brahmer, J; Juergens, R | 1 |
| An, SJ; Gan, B; Guo, AL; Huang, Y; Li, R; Lin, JY; Mok, TS; Nie, Q; Wang, Z; Wu, YL; Zhang, GC | 1 |
| Calhoun, R; Gandara, DR; Jablons, D; Wakelee, H | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Soh, J; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S | 1 |
| Bolognesi, A; Dell'Oca, I; Ghio, D; Giovannini, M; Gregorc, V; Spreafico, A; Viganò, MG; Villa, E | 1 |
| Costa, DB; Huberman, MS; Kobayashi, S; Tenen, DG | 1 |
| Araujo, N; Armand, JP; de La Motte Rouge, T; Dessen, P; Galluzzi, L; Harel-Belan, A; Harper, F; Kroemer, G; Lazar, V; Olaussen, KA; Pierron, G; Pinna, G; Ripoche, H; Robert, T; Soria, JC; Tasdemir, E; Wong, TW; Zermati, Y | 1 |
| Chang, JW; Cheung, YC; Chou, CL; Hsieh, JJ; Hsu, T; Huang, SF; Wang, HM | 1 |
| Furukawa, K; Ichinose, S; Imai, K; Inoue, T; Kato, H; Kubota, M; Maehara, S; Ohira, T; Ohtani, K; Oikawa, T; Okunaka, T; Suga, Y; Sugimoto, Y; Tsunoda, Y; Tsutsui, H; Usuda, J | 1 |
| Jänne, PA; Liu, W; Makrauer, FL; Odze, RD; Qamar, AA | 1 |
| Barclay, L; Bebb, G; English, J; Fee, J; Ho, C; Horsman, D; Laskin, JJ; Marra, MA; Melosky, B; Murray, N; O'Connor, R; Pugh, TJ; Salski, C; Sutcliffe, M; Vielkind, J | 1 |
| Brahmer, JR; Hann, CL | 1 |
| Cabebe, E; Wakelee, H | 1 |
| Akimoto, S; Anyoji, H; Fujii, K; Fukuoka, M; Hada, S; Harbron, CG; Higenbottam, T; Hirano, T; Jiang, H; Kanazawa, M; Kato, H; Kawakami, T; Kawamura, T; Kudoh, S; Kunito, H; Kyono, Y; Marko-Varga, G; Nakata, K; Nishimura, T; Nishio, K; Nishiwaki, Y; Nyberg, F; Ogiwara, A; Peers, IS; South, MC; Tsuboi, M; Tu, HK | 1 |
| Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT | 1 |
| Chen, YR; Cheng, HH; Fu, YN; Huang, SF; Tsai, SF; Yang, CH; Yeh, CL | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F | 1 |
| Hanrahan, EO; Heymach, JV | 1 |
| Jackman, D; Jänne, PA; Johnson, BE | 1 |
| Bareschino, MA; Ciardiello, F; Gridelli, C; Maione, P; Rossi, A; Schettino, C | 1 |
| Thatcher, N | 1 |
| Hirano, S; Ishiai, M; Kitao, H; Kiura, K; Kozuki, T; Ogino, A; Takata, M; Takigawa, N; Tanimoto, M; Uchida, A | 1 |
| Abe, S; Chiba, H; Hasegawa, T; Igarashi, Y; Inokuchi, J; Iseki, K; Ishii, A; Kabayama, K; Kaneko, M; Noguchi, M; Saitoh, M; Satoh, M; Shiratori, M; Suzuki, T; Tagami, S; Takahashi, H; Watanabe, A | 1 |
| Baker, SD; Cusatis, G; Ghio, D; Gregorc, V; Hidalgo, M; Ingersoll, RG; Ludovini, V; Marsh, S; Sparreboom, A; Spreafico, A; Steinberg, SM; Viganò, MG; Villa, E | 1 |
| Al Hammadi, A; Gerstein, W; Tangri, N | 1 |
| Hao, HJ; Li, Q; Li, XH; Zhao, YL | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Song, ST; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Date, H; Fujiwara, Y; Hotta, K; Kanehiro, A; Kato, K; Kiura, K; Soh, J; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Toyooka, S | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Long, J; Thotathil, Z | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Kimura, H; Koizumi, F; Miyamoto, K; Nakao, S; Nishio, K; Sone, T; Suminoe, M; Tamori, S | 1 |
| Azzoli, CG; Ginsberg, MS; Kris, MG; Liu, V; Miller, VA; Travis, W; White, DA; Zakowski, MF | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yoshida, T | 1 |
| de Gunst, MM; Gallegos-Ruiz, MI; Giaccone, G; Rodriguez, JA | 1 |
| Belani, CP; Bodrogi, I; Csada, E; Gadgeel, S; Herbst, RS; Heymach, JV; Hou, J; Johnson, BE; Kennedy, SJ; Pesek, M; Prager, D; Roubec, J; Spásová, I | 1 |
| Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM | 1 |
| Pan, M; Santamaria, M; Wollman, DB | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Moldvay, J | 1 |
| Boelke, E; Budach, W; Enderlein, E; Gerber, PA; Homey, B; Muller, A | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Fan, Z; Li, X; Liang, K; Lu, Y | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Besse, B; Italiano, A; Planchard, D; Soria, JC | 1 |
| Boggon, TJ; Costa, DB; Halmos, B; Huberman, MS; Kobayashi, S; Kumar, A; Schumer, ST; Tenen, DG | 1 |
| Cragg, MS; Huang, DC; Kuroda, J; Puthalakath, H; Strasser, A | 1 |
| Ardizzoni, A; Bortesi, B; Bozzetti, C; Camisa, R; Campanini, N; Capelletti, M; Chiaramondia, M; Dadati, P; Franciosi, V; Grossi, F; Kunkl, A; Lagrasta, C; Loprevite, M; Naldi, N; Nizzoli, R; Rindi, G; Spiritelli, E; Tiseo, M; Zennaro, D | 1 |
| Briasoulis, E; Georgoulias, V; Kalikaki, A; Koutsopoulos, A; Mavroudis, D; Murray, S; Pallis, AG; Souglakos, J; Stathopoulos, E; Tripaki, M; Voutsina, A | 1 |
| Hizawa, N; Ishikawa, H; Kurishima, K; Ohara, G; Satoh, H | 1 |
| Bang, YJ; Han, SW; Kim, TY | 1 |
| Schalock, PC; Zug, KA | 1 |
| Dowlati, A; Halmos, B; Kern, JA; Kluge, A; Nethery, D | 1 |
| Fregoni, V; Pavesi, L; Ponchio, L; Prada, GA; Sagrada, P; Zambelli, A | 1 |
| Miyazaki, M; Nakagawa, K | 1 |
| Bell, DW; Brannigan, BW; Morabito, A; Moscato, M; Normanno, N; Zampa, G | 1 |
| Amoroso, D; Baldari, M; Bearz, A; Bettoli, V; Cammilluzzi, E; Crinò, L; De Marinis, F; Di Pietro, FA; Gridelli, C; Grossi, F; Innocenzi, D; Maione, P; Micali, G; Piantedosi, FV; Scartozzi, M | 1 |
| Cai, D; Carlson, NE; Deng, J; Letai, A; Perera, S; Shapiro, GI; Shimamura, T; Wong, KK | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Knabl, A | 1 |
| Dizdar, O; Gököz, O; Yalçin, B; Yalçin, S | 1 |
| Chen, L; He, Y; Huang, H; Liao, H; Wei, W | 1 |
| Higashiyama, M; Kato, K; Kodama, K; Koizumi, K; Maeda, J; Oda, K; Okami, J; Orita, N; Taniguchi, K | 1 |
| Comb, MJ; Guo, A; Gygi, SP; Innocenti, G; Kornhauser, J; Lee, KA; MacNeill, J; Mitchell, J; Nardone, J; Polakiewicz, RD; Possemato, A; Rikova, K; Rush, J; Stokes, MP; Villén, J; Wang, Y; Wetzel, R | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Holland, W; Lara, PN; Mack, PC; Mahaffey, CM; Pryde, B | 1 |
| Danesi, R; Giaccone, G; Giovannetti, E; Lemos, C; Nannizzi, S; Peters, GJ; Ricciardi, S; Rodriguez, JA; Smid, K; Tekle, C | 1 |
| Alligood, K; Cable, L; Carter, HL; Gallagher, KT; Gilmer, TM; Rusnak, D; Shewchuk, L; Spehar, G; Truesdale, AT; Woldu, E; Wood, ER | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Iwanami, H; Kataoka, K; Kobayashi, K; Kosaihira, S; Kudoh, S; Minegishi, Y; Miyanaga, A; Miyazawa, H; Nara, M; Noro, R; Okano, T; Tanaka, T; Tsuboi, E; Yoshimura, A | 1 |
| Chen, L; Zhang, PL | 1 |
| Bunn, PA; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Holloway, B; Mann, H; Parums, DV; Speake, G; Thatcher, N; Watkins, C | 1 |
| Miller, VA | 1 |
| Ano, T; Miyazaki, K; Nakazawa, K; Ohtsuka, M; Satoh, H | 1 |
| Lindsley, CW; Thomas, AL | 1 |
| Addeo, A; Barone, C; Birocco, N; Buffoni, L; Bussolati, G; Ciuffreda, L; Daniele, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Gaspari, F; Grillo, R; Macrì, L; Sapino, A; Schena, M | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Sun, Y; Wang, B; Wang, Y; Xu, NZ; Zhang, XR; Zhu, HX | 1 |
| Belani, C; Ramalingam, S | 1 |
| de Marinis, F; Grossi, F | 1 |
| Curiel, DT; Dent, P; Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J | 1 |
| Hagiwara, K; Hirama, T; Ikebuchi, K; Kanazawa, M; Kobayashi, K; Koyama, N; Matsuoka, M; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Nukiwa, T; Sutani, A; Takenoshita, S; Tanaka, T; Udagawa, K; Zhang, J | 1 |
| Aoe, K; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Kiura, K; Kosaka, T; Matsuo, K; Mitsudomi, T; Ohe, Y; Otani, H; Soh, J; Takano, T; Toyooka, S; Yatabe, Y | 1 |
| Ding, K; Pater, J; Seymour, L; Shepherd, FA; Whitehead, M | 1 |
| Alfieri, RR; Bonelli, M; Bordi, F; Carmi, C; Cavazzoni, A; Frazzi, R; Fumarola, C; Galetti, M; Lodola, A; Mor, M; Petronini, PG; Zuliani, V | 1 |
| Brooks, C; Hobbs, ML; Liu, J; Meyn, RE; Munshi, A; Tanaka, T | 1 |
| Albert, D; Axelrod, R; Botkin, D; Dowlati, A; Lilenbaum, R; Seigel, L; Thomas, S; Witt, K | 1 |
| Gipps, M; Goldberg, A; Grenader, T | 1 |
| Chu, CY; Hsiao, CH; Sheen, YS | 1 |
| Ebi, N; Fukuoka, J; Fukuoka, M; Hirashima, T; Ichinose, Y; Kashii, T; Katakami, N; Kudoh, S; Negoro, S; Nishimura, T; Okamoto, I; Satoh, T; Sawa, T; Shibata, K; Shimizu, E; Tamura, K | 1 |
| Banville, M; Bourget, L; Collins, C; Jaramillo, ML; O'Connor-McCourt, M; Paul-Roc, B | 1 |
| Antonia, SJ; Begum, M; Bepler, G; Chiappori, A; Extermann, M; Haura, EB; Ismail-Khan, R; Kapoor, R; Schell, MJ; Simon, GR; Williams, CC | 1 |
| Dohadwala, M; Dubinett, SM; Elashoff, D; Figlin, RA; Gardner, BK; Inge, L; Krysan, K; Mao, J; Rajasekaran, A; Reckamp, KL; Sharma, S | 1 |
| Claasen, J; Sos, ML; Staratschek-Jox, A; Thomas, RK; Wolf, J; Zander, T | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Bemis, LT; Birks, DK; Bunn, PA; Franklin, WA; Haney, J; Helfrich, BA; Hirsch, FR; Kato, H; Nakajima, E; Robinson, WA; Sugita, M; Varella-Garcia, M; Weiss, GJ | 1 |
| Armstrong, DK; Brahmer, JR; Carducci, MA; Chen, P; Das, S; Desai, A; Fackenthal, DL; Fleming, GF; Janisch, L; Jiang, X; Karrison, T; Liu, W; Poonkuzhali, B; Ramirez, J; Ratain, MJ; Rudin, CM; Schuetz, E; Vokes, EE | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Belani, CP; Evans, T; Forster, J; Lu, H; Naret, C; Ramalingam, S; Sulecki, M; Teegarden, P; Weber, MR | 1 |
| Fong, T; Govindan, R; Morgensztern, D | 1 |
| Brueckl, WM; Hahn, EG; Murray, S; Schoeberl, A; Wiest, GH; Wirtz, RM | 1 |
| Chang, AY | 1 |
| Duell, T; Poellinger, B; von Pawel, J; Wagner, H | 1 |
| Higashiyama, M; Kato, K; Kodama, K; Okami, J; Taniguchi, K | 1 |
| Armour, A; Fukuoka, M; Higenbottam, T; Ichinose, Y; Itoh, Y; Jiang, H; Kato, H; Kudoh, S; Nakagawa, K; Nakata, K; Nishiwaki, Y; Nyberg, F; Suga, M; Tsuboi, M; Watkins, C; Yokota, S | 1 |
| Asahina, H; Konishi, J; Nishimura, M; Suzuki, M; Yamazaki, K | 1 |
| Fukuoka, M; Hatashita, E; Iwasa, T; Nakagawa, K; Okabe, T; Okamoto, I; Satoh, T; Tamura, K; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, SH; Kim, TY; Oh, DY | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M | 1 |
| Advani, S; Aggarwal, S; Babu, G; Bhattacharyya, GS; Chacko, RT; Chang, AY; Digumarti, R; Doval, DC; Hargreaves, L; Jagannathan, R; Nag, S; Parikh, P; Ranade, A; Thatcher, N | 1 |
| Eguchi, K; Fukuoka, M; Jiang, H; Kiura, K; Nakagawa, K; Nishio, K; Ohe, Y; Saijo, N; Seto, T; Shinkai, T; Tsuboi, M; Yamamoto, N; Yokota, S | 1 |
| Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Kim, CH; Koh, JS; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH | 1 |
| Argiris, A; Basu, S; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; Johnson, DH; Kaiser, K; Patel, JD; Sandler, A; Villaflor, VM | 1 |
| Chalfe, N; Plestina, S; Samarzija, M; Zuljević, E | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Toschi, L; Trisolini, R | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| An, SJ; Guo, AL; Li, R; Mok, TS; Wu, YL; Zhang, GC; Zhang, XC; Zhang, YF; Zhong, WZ; Zhu, JQ | 1 |
| Ambrogio, L; Baum, A; Chirieac, LR; Greulich, H; Himmelsbach, F; Kubo, S; Li, D; Meyerson, M; Padera, RF; Rettig, WJ; Shapiro, GI; Shimamura, T; Solca, F; Takahashi, M; Wong, KK | 1 |
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Guo, AL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhou, Q | 1 |
| Chen, LK; Huang, H; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Chan, KA; Chang, CH; Chen, KY; Kurth, T; Orav, EJ; Yang, PC; Young-Xu, Y | 1 |
| Chang, GC; Chang, WC; Chen, CH; Chen, HC; Chen, YM; Chu, NM; Chung, CY; Ho, ML; Hsia, TC; Hsieh, RK; Huang, MS; Kao, WY; Kuo, HP; Lai, RS; Lin, MC; Lin, ZZ; Perng, RP; Su, WC; Tsao, CJ; Wang, JL; Yang, CH; Yu, CJ; Yu, CT | 1 |
| Hainsworth, JD; Lin, M; O'Neill, V; Spigel, DR | 1 |
| Lazzari, G; Lovecchio, M; Palazzo, C; Silvano, G | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Engelman, JA; Evans, TL; Goldberg, JS; Grunberg, SM; Haber, DA; Han, M; Iafrate, AJ; Jänne, PA; Johnson, BE; Joshi, VA; Kuhlmann, GL; Lynch, TJ; Martins, RG; McCollum, D; Muzikansky, A; Sequist, LV; Settleman, J; Spigel, D; Spira, A | 1 |
| Ceresoli, GL; Comoglio, P; Destro, A; Floor, K; Garassino, I; Giaccone, G; Giovannetti, E; Rodriguez, JA; Roncalli, M; Ruiz, MG; Santoro, A; Varella-Garcia, M; Zucali, PA | 1 |
| Clark, GM; Ding, K; Seymour, L; Shepherd, FA; Wheatley-Price, P | 1 |
| Lee, CB; Socinski, MA | 1 |
| Li, AW; Xu, JF; Zhou, CC | 1 |
| Li, LY; Wang, HZ; Wang, MZ; Wang, SL; Wu, C; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Buhl, R; Fischer, B | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Buchler, T; Joseph, T; Lai, C; Lee, SM | 1 |
| Akita, H; Kinoshita, I | 1 |
| Bereczky, B; Itoh, K; Nishimura, Y; Yoshioka, K | 1 |
| Böhmer, FD; Fernández, LE; Greiser, U; Lage, A; Perez, R; Sánchez, B; Suarez Pestana, E | 1 |
| Averbuch, SD; Baselga, J | 1 |
| Norman, P | 1 |
| Bunn, PA; Chan, D; Helfrich, BA; Johnson, G; Raben, D | 1 |
| Buchholz, E; Kloeppel, R; Kreisel, C; Manegold, C; Smith, M | 1 |
| Fukuoka, M | 1 |
| Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
| Albanell, J; Baselga, J | 1 |
| Sobel, RK | 1 |
| Kawate, N | 1 |
| Kajanti, M; Kinnula, V; Maasilta, P; Mattson, K; Niiranen, A | 1 |
| Maasilta, PK; Mattson, KV; Mattson, MT; Rautonen, JK | 1 |
| Burke, MT; D'Acquisto, RW; Fanucchi, MP; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD | 1 |
| Maroun, J | 1 |
| Grove, W; Holsti, LR; Maasilta, P; Mattson, K; Tammilehto, L | 1 |
| Maroun, JA; Natale, RB; Robert, F | 1 |
500 review(s) available for quinazolines and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
An appraisal of anticancer activity with structure-activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines; Quinazolinones; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Vascular Endothelial Growth Factor A | 2022 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patents as Topic; Quinazolines | 2023 |
Icotinib: efficacy in different solid tumors and gene mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasms; Quinazolines | 2020 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Purines; Pyridones; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion | 2017 |
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Disease-Free Survival; Drug Approval; Endpoint Determination; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Sulfones | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Targeted Therapy and Imaging Findings.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; Diagnostic Imaging; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Non-Small-Cell Lung; Exanthema; Humans; Incidence; Inflammatory Breast Neoplasms; Neoplasm Staging; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2017 |
Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines | 2017 |
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2017 |
Gefitinib for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure | 2018 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2018 |
Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2018 |
Fruquintinib: First Global Approval.
Topics: Antineoplastic Agents; Benzofurans; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Quinazolines; Smoking | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Patient Education as Topic; Pruritus; Quinazolines | 2013 |
Erlotinib in the first-line treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Clinical perspective of afatinib in non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
How and when to use genetic markers for nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Targeted therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pyrazoles; Pyridines; Quinazolines | 2013 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Databases, Bibliographic; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Second-Line Therapy for Advanced NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Afatinib: first global approval.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Approval; European Union; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Grading; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Taiwan; United States; United States Food and Drug Administration | 2013 |
Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluation, Preclinical; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2013 |
A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Edema; Erythema; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
[Hemolytic anemia under erlotinib treatment].
Topics: Aged, 80 and over; Anemia, Hemolytic; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
[New developments in treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Imaging; Quinazolines | 2013 |
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis | 2014 |
Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2014 |
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Icotinib: activity and clinical application in Chinese patients with lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Crown Ethers; Drug Interactions; ErbB Receptors; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Randomized Controlled Trials as Topic | 2014 |
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2014 |
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2014 |
Afatinib for the treatment of advanced non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Erlotinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Gefitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Solubility | 2014 |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2014 |
Second-line therapy in non-small-cell lung cancer: the DELTA between different genotypes widens.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA-Binding Proteins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Genotype; Glutamates; Guanine; Humans; Keratin-7; Lung Neoplasms; Middle Aged; Palliative Care; Pemetrexed; Pleural Effusion, Malignant; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Taxoids; Transcription Factors; Treatment Failure | 2014 |
Next generation tyrosine kinase inhibitor (TKI): afatinib.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Patents as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
[Afatinib (BIBW 2992)].
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Approval; ErbB Receptors; France; Humans; Lung Neoplasms; Quinazolines | 2014 |
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Proteomics; Quinazolines | 2014 |
Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and safety of gefitinib during pregnancy: case report and literature review.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Mutation; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography Scanners, X-Ray Computed | 2014 |
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines | 2014 |
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve | 2014 |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Proportional Hazards Models; Quinazolines | 2014 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Afatinib and lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2014 |
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2014 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?
Topics: Antibodies, Anti-Idiotypic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Platinum Compounds; Quinazolines | 2015 |
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Quality of Life; Quinazolines; Retrospective Studies | 2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2015 |
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crown Ethers; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
[Pharmacological and clinical profile of afatinib (Giotrif®)].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Long QT Syndrome; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Risk | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines | 2015 |
Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Humans; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4 | 2015 |
EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking | 2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate | 2016 |
Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Incidence; Lung Diseases; Lung Neoplasms; Models, Statistical; Odds Ratio; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment | 2016 |
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Research Design; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
[Living with incurable cancer].
Topics: Aged; Anxiety; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Depression; Emotions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Psychotherapy; Quality of Life; Quinazolines | 2016 |
Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled | 2016 |
Safety of gefitinib in non-small cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
[Mechanism of action and preclinical development of afatinib].
Topics: Afatinib; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Treatment Outcome | 2016 |
[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Evidence on afatinib in patients progressing on a first-line treatment].
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Administration Schedule; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Topics: Administration, Oral; Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Genes, erbB; Genetic Markers; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Molecular Targeted Therapy; Quinazolines; Receptor Protein-Tyrosine Kinases | 2017 |
The safety of afatinib for the treatment of non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quality of Life; Quinazolines; Risk Factors | 2016 |
Rapid onset of radiation maculopathy after whole-brain radiation therapy: A case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dose-Response Relationship, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Macular Degeneration; Middle Aged; Quinazolines; Radiation Injuries; Visual Acuity | 2016 |
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA | 2016 |
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
Efficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2016 |
Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non-Small-cell Lung Cancer on Progression-free and Overall Survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2017 |
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Quinazolines | 2017 |
Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs?
Topics: Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
New insights in drug development for the non-small cell lung cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2008 |
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Disease Models, Animal; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Risk Assessment; Survival Analysis; Thoracic Neoplasms | 2008 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Medical Oncology; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Targeted therapies for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Gene Targeting; Humans; Lung Neoplasms; Patient Selection; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2008 |
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2008 |
Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
Topics: Antineoplastic Agents; Asia, Eastern; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Gefitinib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
New avenues for second-line treatment of metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Taxoids | 2009 |
Predictive biomarkers for EGFR therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines | 2009 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Signal Transduction | 2009 |
Economics of treatments for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2009 |
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bias; Carcinoma, Non-Small-Cell Lung; Data Interpretation, Statistical; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids; Young Adult | 2009 |
New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Platinum Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Skin toxicities associated with epidermal growth factor receptor inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3 | 2009 |
Investigational agents in the management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Survival Rate | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Growth Factor; Sequence Deletion; Treatment Outcome | 2009 |
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2009 |
Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Quinazolines; Ramucirumab; Vascular Endothelial Growth Factor A | 2009 |
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking; Smoking Cessation | 2010 |
EGFR inhibition in NSCLC: the emerging role of cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Taxoids | 2004 |
Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2010 |
Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2009 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
[Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; ErbB Receptors; Gefitinib; Humans; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
[Molecular diagnostics in lung carcinoma for therapy stratification].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Early Detection of Cancer; ErbB Receptors; Europe; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; United States; White People | 2010 |
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hemorrhage; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2010 |
The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines | 2010 |
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2010 |
Gefitinib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2010 |
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer.
Topics: BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Clinical Trials, Phase II as Topic; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Histone Chaperones; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Neoplasm Staging; Nuclear Proteins; Quinazolines; RNA, Messenger | 2010 |
Erlotinib in the treatment of non-small cell lung cancer: current status and future developments.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Discovery; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance chemotherapy in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids | 2010 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; White People | 2011 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Factors driving the choice of the best second-line treatment of advanced NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Docetaxel; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids; Thymidylate Synthase | 2011 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Precision Medicine; Quinazolines | 2010 |
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines | 2010 |
New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Drug Discovery; Humans; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
[Consolidation therapy in advanced non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Prognosis; Quinazolines; Risk Assessment | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Reviewing the safety of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2011 |
[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Exanthema; Gefitinib; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2011 |
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases | 2011 |
EGFR pathway in advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Quality of Life; Quinazolines | 2011 |
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Quinazolines | 2011 |
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quinazolines; Retrospective Studies; Risk Assessment; Technology Transfer | 2011 |
BIBW 2992 in non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2011 |
[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quinazolines; Salvage Therapy | 2011 |
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2011 |
[Adverse effects of new biological therapies for non-small-cell bronchial cancer].
Topics: Angiogenesis Inhibitors; Biological Products; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Interdisciplinary Communication; Lung Neoplasms; Neoplasm Staging; Patient Care Team; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
[Gefitinib for non-small cell lung cancer: a meta analysis].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quality Control; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Precision Medicine; Protein-Tyrosine Kinases; Quinazolines; Quinolines | 2011 |
Erlotinib: as maintenance monotherapy in non-small-cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2011 |
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Therapy; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Smoking; Survival Analysis | 2011 |
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance | 2011 |
[Indication of EGFR kinase inhibitors should be refined].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2011 |
Tissue sampling in lung cancer: a review in light of the MERIT experience.
Topics: Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Practice Guidelines as Topic; Precision Medicine; Quinazolines; Tissue and Organ Harvesting; Tissue Array Analysis | 2011 |
Gefitinib in non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor | 2011 |
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Quinazolines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2012 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Vandetanib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2011 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Gefitinib for non-small-cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan | 2012 |
Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer: a pooled analysis of three randomized trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2011 |
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 2011 |
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
[Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2012 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms | 2012 |
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2011 |
Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2012 |
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Recent advances in non-small cell lung cancer biology and clinical management.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2012 |
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2012 |
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines | 2012 |
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Vandetanib for the treatment of lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Vascular Endothelial Growth Factor A | 2012 |
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Neoplasms; Piperidines; Quinazolines; Thyroid Neoplasms; Treatment Outcome | 2012 |
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Clinical outcomes with erlotinib in patients with epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
Topics: Aged; Alopecia; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Scalp Dermatoses | 2012 |
Targeted therapy for lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2012 |
Clinical and economic review of erlotinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; MEDLINE; Mutation; Quinazolines | 2012 |
Two cases of psoriasis responding to erlotinib: time to revisiting inhibition of epidermal growth factor receptor in psoriasis therapy?.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Treatment Outcome | 2012 |
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2013 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Taxoids | 2013 |
Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.
Topics: Administration, Oral; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; White People | 2013 |
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2013 |
[Brain metastases of non small cell lung cancers: systemic treatments].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
ZD1839 (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2002 |
ZD1839 (Iressa): what's in it for the patient?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Patients; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Research Design; Treatment Outcome | 2002 |
Gefitinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Cells, Cultured | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2002 |
Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Oncology Nursing; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
[Molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Erlotinib (Tarceva): an update on the clinical trial program.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2003 |
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Rate | 2003 |
Targeting epidermal growth factor receptor--are we missing the mark?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure | 2003 |
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Research Design; Treatment Outcome | 2003 |
Gefitinib (Iressa) trials in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: a new therapeutic approach for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Tumor Cells, Cultured | 2003 |
The benefits of achieving stable disease in advanced lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survivors | 2003 |
Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Random Allocation; Treatment Outcome | 2003 |
[Non-small cell lung cancer: 1) Molecular-target therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
[Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines | 2003 |
[Iressa (gefitinib)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Gefitinib therapy for advanced non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Molecular targeted agents in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Quinazolines; Treatment Outcome | 2003 |
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Quinazolines | 2003 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome | 2003 |
Erlotinib: preclinical investigations.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transplantation, Heterologous | 2003 |
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Patient Selection; Predictive Value of Tests; Quinazolines | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2004 |
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2004 |
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
Gefitinib, a novel, orally administered agent for the treatment of cancer.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines | 2004 |
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2004 |
Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2004 |
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Severity of Illness Index; Sickness Impact Profile; Survival Analysis | 2004 |
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids | 2004 |
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
The role of gefitinib in lung cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2004 |
[New advance of the molecular targeting agents in advanced non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Keratinocytes; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Tissue Distribution; Treatment Outcome | 2004 |
Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Gefitinib in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Humans; Lung Neoplasms; Quinazolines; Receptor, ErbB-3; Receptor, ErbB-4; Trastuzumab | 2003 |
Interstitial lung disease associated with drug therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Respiratory Distress Syndrome; Risk Factors | 2004 |
New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Patient Education as Topic; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Half-Life; Humans; Intestinal Absorption; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Brain metastasis responding to gefitinib alone.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gingival Neoplasms; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2004 |
Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib--a novel targeted approach to treating cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
Gefitinib: current status in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Therapy, Combination; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Quinazolines | 2004 |
Gefitinib therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2005 |
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
[Molecular diagnosis of solid tumors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Trastuzumab | 2005 |
[Gefitinib as targeted treatment for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Female; Finland; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2005 |
Spotlight on gefitinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Metaphor; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
ZD6474--clinical experience to date.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methionine; Mutation; Quinazolines; Sex Factors; Threonine | 2005 |
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Recent developments related to the EGFR as a target for cancer chemotherapy.
Topics: Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2005 |
Erlotinib in non-small cell lung cancer: a review.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2005 |
Medical treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib hydrochloride.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Factors predicting response to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines | 2005 |
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2005 |
Recent advances and future perspectives in the management of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Forecasting; Gefitinib; Humans; Interleukin-2; Lung Neoplasms; Lung Transplantation; Mass Screening; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Smoking | 2005 |
Targeted therapies for non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Mutation; Quinazolines; Survival Rate | 2005 |
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2005 |
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2005 |
Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Radiography | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2005 |
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Survival Analysis | 2006 |
Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genetic Therapy; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
EGFR inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines; Treatment Failure | 2005 |
[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines; Survival Rate | 2005 |
Antiangiogenic drugs in non-small cell lung cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Erlotinib. A new option for non-small cell lung cancer].
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2005 |
Targeting HER1/EGFR in cancer therapy: experience with erlotinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2006 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Gefitinib: an adverse effects profile.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Clinical experience with erlotinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
From the bench to the bed: individualizing treatment in non-small-cell lung cancer.
Topics: 14-3-3 Proteins; Adenocarcinoma; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; DNA Damage; DNA Repair; Epistasis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Genes, BRCA1; Genes, cdc; Genes, erbB-1; Genes, ras; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines | 2006 |
Nondermatologic adverse events associated with anti-EGFR therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Where next for gefitinib in patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction | 2006 |
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Denmark; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Structure, Tertiary; Quinazolines; Signal Transduction | 2006 |
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Topics: Antineoplastic Agents; Biological Products; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Protein Kinase Inhibitors; Quinazolines | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Synergism; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Vascular Endothelial Growth Factor A | 2006 |
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; In Vitro Techniques; Lung Neoplasms; Male; Models, Molecular; Mutation; Oncogenes; Quinazolines | 2005 |
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Smoking | 2005 |
Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Second-line therapeutic options in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
[Erlotinib in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Angiogenesis inhibition in the treatment of lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Erlotinib Hydrochloride; Hemorrhage; Humans; Lung Neoplasms; Neovascularization, Pathologic; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Genes, erbB-1; Genes, p53; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Mutation; Mutation, Missense; Protein Structure, Tertiary; Quinazolines; Randomized Controlled Trials as Topic; Sequence Deletion; Smoking | 2007 |
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2006 |
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2007 |
EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2007 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Morpholines; Organic Chemicals; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2007 |
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
Salvage therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids | 2006 |
Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
Topics: Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; China; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis | 2007 |
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2007 |
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Medical Oncology; Mutation; Quinazolines; ras Proteins; Smoking | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Bevacizumab in non small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Erlotinib in non-small cell lung cancer treatment: current status and future development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Treatment Outcome | 2007 |
The place of targeted therapy in the patient management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
Erlotinib in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2007 |
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.
Topics: Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2007 |
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids; Treatment Outcome | 2008 |
Considerations for second-line therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Quinazolines; Trastuzumab; Treatment Outcome | 2006 |
The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Quinazolines | 2008 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
[Non-small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Advances in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
ZD1839 ('Iressa') as an anticancer agent.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Mice; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Tyrosine kinase inhibitors-ZD1839 (Iressa).
Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Disease Progression; Dogs; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Neoplasms; Quinazolines; Rats | 2001 |
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Chemoprevention; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Up-Regulation | 2002 |
[Progress in diagnosis and treatment of lung cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Endothelial Growth Factors; Enzyme Inhibitors; Gefitinib; Genetic Therapy; Humans; Hydroxamic Acids; Lung Neoplasms; Lymphokines; Mass Screening; Metalloendopeptidases; Quinazolines; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Targeting epidermal growth factor receptor in lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2002 |
[ZD1839].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
[Latest therapeutic strategy for stage IV non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Gefitinib; Humans; Hyperthermia, Induced; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Quinazolines; Radiotherapy; Stents | 2002 |
607 trial(s) available for quinazolines and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Poziotinib for Patients With
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Survival Rate | 2022 |
Poziotinib in Non-Small-Cell Lung Cancer Harboring
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate | 2022 |
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
Topics: Acrylamides; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Small Cell Lung Carcinoma | 2022 |
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2022 |
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2022 |
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
Topics: Carcinoma, Non-Small-Cell Lung; Central Nervous System; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Central Nervous System; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
Topics: Adult; Aged; Alleles; Amino Acid Substitution; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2020 |
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2020 |
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2020 |
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Goals; Humans; Lung Neoplasms; Mexico; Mutation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spain | 2020 |
Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines | 2021 |
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Humans; Lung Neoplasms; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2021 |
Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiosurgery | 2017 |
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Substitution; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Liquid Biopsy; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Research Design; Response Evaluation Criteria in Solid Tumors | 2017 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Mutation Rate; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Dacomitinib Beats Gefitinib for EGFR
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2017 |
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2017 |
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Cerebrospinal Fluid Penetration Rate and Efficacy of Afatinib in Patients with EGFR Mutation-positive Non-small Cell Lung Cancer with Leptomeningeal Carcinomatosis: A Multicenter Prospective Study.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2017 |
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Hydroxamic Acids; Lung Neoplasms; Mutation; Quinazolines; Vorinostat | 2017 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Prognosis; Quinazolines; Quinazolinones; Survival Analysis; Treatment Outcome | 2017 |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Piperazines; Quinazolines; Republic of Korea; Taiwan; Treatment Outcome; United States | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Health Status; Humans; Lung Neoplasms; Male; Patient Reported Outcome Measures; Polymorphism, Single Nucleotide; Quality of Life; Quinazolines; Survival Analysis | 2018 |
Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Quinazolines; Reproducibility of Results; Retrospective Studies; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2017 |
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Economics, Pharmaceutical; ErbB Receptors; Exanthema; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Outcome Assessment, Health Care; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2018 |
A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mutation; Prognosis; Quinazolines; Survival Rate | 2018 |
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.
Topics: Aged; Asian People; Benzofurans; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Progression-Free Survival; Quinazolines | 2018 |
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Massachusetts; Protein Kinase Inhibitors; Quinazolines | 2018 |
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Young Adult | 2018 |
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2013 |
Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661).
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Tandem Mass Spectrometry | 2013 |
Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Metastasis; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Neoplasm Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplastic Cells, Circulating; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines | 2013 |
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tetrahydronaphthalenes; Treatment Outcome | 2013 |
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.
Topics: Acute-Phase Proteins; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Amplification; Genes, erbB-1; Humans; Interleukin-9; Kaplan-Meier Estimate; Lipocalin-2; Lipocalins; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival; Treatment Outcome | 2013 |
Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9 | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Proportional Hazards Models; Quinazolines | 2013 |
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome | 2013 |
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2013 |
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2013 |
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Placebos; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pemetrexed; Quinazolines; Recurrence; Taxoids | 2013 |
A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Quinazolines; Retreatment; Risk Factors; Treatment Outcome | 2013 |
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Piperidines; Platinum Compounds; Quinazolines; Vascular Endothelial Growth Factor A | 2013 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2013 |
ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2013 |
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Survival Rate | 2014 |
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Disease Progression; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2013 |
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Platinum Compounds; Population Groups; Quinazolines | 2014 |
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Vinblastine | 2014 |
Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Exanthema; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; White People; Young Adult | 2014 |
A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Survival Analysis; Young Adult | 2014 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cyclic N-Oxides; Cyclin-Dependent Kinases; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indolizines; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pyridinium Compounds; Quinazolines | 2014 |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2014 |
A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Panobinostat; Quinazolines; Treatment Outcome | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Treatment Outcome | 2014 |
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Quinazolinones; Treatment Failure | 2014 |
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiography; Radiopharmaceuticals; Survival Rate; Time Factors | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Pneumonectomy; Prospective Studies; Quinazolines; Survival Rate | 2014 |
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hydroxamic Acids; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Quinazolines; Treatment Outcome; Vorinostat | 2014 |
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger | 2014 |
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Treatment Outcome | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biotin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Treatment Outcome | 2014 |
A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chromogranins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Oligonucleotides; Protein Kinase Inhibitors; Quinazolines; Toll-Like Receptor 9; Treatment Outcome | 2014 |
Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Biopsy; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2014 |
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Furans; Humans; Ketones; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2014 |
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Topics: Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Proportional Hazards Models; Quinazolines; Taxoids; Treatment Outcome | 2014 |
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Remission Induction; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Erlotinib Hydrochloride; Esophagitis; Genes, erbB-1; Humans; Lung Neoplasms; Paclitaxel; Prospective Studies; Quinazolines; Radiation Injuries; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis; Taxoids | 2014 |
MO06.03 Bevacizumab and erlotinib or bevacizumab, cisplatin and pemetrexed in patients with metastatic non-small cell lung cancer: EGFR mutation based treatment allocation and repeat biopsy at progression in the SAKK19/09 (BIOPRO) trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Genes, erbB-1; Genes, ras; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2014 |
Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Iohexol; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Treatment Outcome; Tumor Burden | 2014 |
Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Republic of Korea | 2014 |
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catheters, Indwelling; Humans; Lung Neoplasms; Middle Aged; Piperidines; Pleural Effusion, Malignant; Pleurodesis; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recurrence; Survival Rate; Time Factors; Treatment Outcome | 2014 |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2014 |
Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cranial Irradiation; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recovery of Function; Treatment Outcome | 2014 |
Phase II study of pemetrexed and erlotinib in pretreated nonsquamous, non-small-cell lung cancer patients without an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neutropenia; Pemetrexed; Quinazolines; Thrombocytopenia; Treatment Outcome | 2013 |
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gene Dosage; Humans; Male; Mutation; Piperidines; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2014 |
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2014 |
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Monitoring; Drug Screening Assays, Antitumor; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Quinazolines | 2014 |
Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Single-Blind Method; Treatment Outcome | 2014 |
Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; United States; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Topics: Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Expression; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2014 |
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Carcinoma, Non-Small-Cell Lung; Cooking; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Inhalation Exposure; Life Style; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Disease-Free Survival; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Treatment Outcome; Young Adult | 2015 |
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Topics: Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis; Withholding Treatment | 2015 |
A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retreatment; Treatment Outcome | 2014 |
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2014 |
Efficacy and safety of erlotinib in elderly patients in the phase IV POLARSTAR surveillance study of Japanese patients with non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2014 |
Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Treatment Outcome | 2014 |
Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Gefitinib; Humans; Male; Melphalan; Middle Aged; Prednisolone; Quinazolines; Radiotherapy, Intensity-Modulated; Treatment Outcome; Vindesine | 2015 |
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Colorado; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Risk Factors; Texas; Time Factors; Treatment Outcome | 2014 |
Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant | 2015 |
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2014 |
Personalized biomarkers to monitor disease progression in advanced non-small-cell lung cancer patients treated with icotinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Monitoring; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immunity, Humoral; Inflammation; Lung Neoplasms; Male; Middle Aged; Precision Medicine; Quinazolines; Time Factors | 2015 |
Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Survival Rate; Treatment Outcome; Vorinostat | 2015 |
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Asian People; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Quinazolines | 2015 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Tegafur; Treatment Outcome | 2015 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinoxalines; Sulfonamides; Treatment Outcome | 2015 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Incidence; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Thymidylate Synthase; Treatment Outcome | 2015 |
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines | 2016 |
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Middle Aged; Quinazolines | 2015 |
[Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; International Cooperation; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Clinical Protocols; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drugs, Chinese Herbal; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2015 |
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Quinazolines; Retrospective Studies; Time-to-Treatment; Treatment Failure | 2015 |
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Prevalence; Proto-Oncogene Proteins c-ret; Quinazolines; Retrospective Studies; Translocation, Genetic; Treatment Outcome | 2015 |
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pre-Exposure Prophylaxis; Quinazolines; Risk Factors; Skin Diseases; Tetracycline | 2015 |
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2015 |
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Quinazolines; Treatment Outcome | 2015 |
A randomized phase II study of erlotinib plus nab-paclitaxel versus erlotinib alone as second-line therapy for Chinese patients with advanced EGFR wild-type non-small-cell lung cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Quinazolines | 2015 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
Comparison of the pharmacokinetics of erlotinib administered in complete fasting and 2 h after a meal in patients with lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Cross-Over Studies; Erlotinib Hydrochloride; Fasting; Female; Food-Drug Interactions; Humans; Lung Neoplasms; Male; Middle Aged; Postprandial Period; Protein Kinase Inhibitors; Quinazolines | 2015 |
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Deletion; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
Topics: Aldosterone; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Canada; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Peptidyl-Dipeptidase A; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
[Experience with the use of gefitinib in patients with inoperable non-squamous cell lung cancer with activating EGFR mutations].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2015 |
[Oligoprogression].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure | 2015 |
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Quinazolines; Treatment Outcome; Young Adult | 2015 |
A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Europe; Female; Gefitinib; Genetic Predisposition to Disease; Glutamates; Guanine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2015 |
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pyrrolidinones; Quinazolines; Quinolines; Young Adult | 2015 |
Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer.
Topics: Afatinib; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Nutritional Status; Quinazolines | 2015 |
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Erysipelas; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2015 |
Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2015 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neutropenia; Patient Dropouts; Quinazolines; Taxoids | 2015 |
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines | 2015 |
Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines | 2015 |
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Taxoids | 2016 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcino
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quinazolines | 2015 |
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2015 |
The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Female; Humans; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2015 |
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
[Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2015 |
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2016 |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Rand
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Female; Gefitinib; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Smoking; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Organoplatinum Compounds; Quinazolines; Treatment Outcome | 2016 |
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erloti
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Crown Ethers; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pleural Effusion, Malignant; Quinazolines | 2017 |
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Rate | 2016 |
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Young Adult | 2017 |
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2016 |
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenomic Testing; Point Mutation; Prevalence; Quinazolines; Radiation Injuries; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retreatment; Treatment Outcome | 2016 |
Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Gefitinib; Humans; Least-Squares Analysis; Lung Neoplasms; Male; Mass Spectrometry; Metabolomics; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Subgroup Analysis of the Non-interventional REASON Study: PFS and OS According to Age, Smoking History, Gender, and Histology in NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Prevalence; Quinazolines; Risk Factors; Sex Distribution; Smoking; Survival Analysis; Treatment Outcome | 2016 |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Disease-Free Survival; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoadjuvant Therapy; Pilot Projects; Quinazolines; Tomography, X-Ray Computed | 2016 |
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome | 2016 |
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2017 |
A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines | 2016 |
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome; Tumor Burden | 2017 |
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Quinazolines | 2017 |
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gene Order; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2017 |
A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Survival Analysis; Young Adult | 2017 |
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retreatment; Simvastatin; Survival Analysis; Treatment Outcome | 2017 |
Efficacy and influence factors of icotinib hydrochloride in treating advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2017 |
Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Quinazolinones; Republic of Korea; Treatment Outcome | 2017 |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Survival Analysis | 2008 |
A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Ontario; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors | 2008 |
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Ethnicity; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Time Factors; Treatment Outcome | 2008 |
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Erlotinib Hydrochloride; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2008 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Environmental Exposure; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Particulate Matter; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2008 |
[Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Smoking; Survival Rate | 2008 |
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2008 |
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Health Surveys; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines | 2008 |
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2009 |
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Taxoids | 2008 |
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Smoking; Treatment Outcome | 2009 |
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Dosage; Germany; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2008 |
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Quinazolines | 2009 |
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National C
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Our experiences with erlotinib in second and third line treatment patients with advanced stage IIIB/ IV non-small cell lung cancer.
Topics: Aged; Bosnia and Herzegovina; Carcinoma, Non-Small-Cell Lung; Drug Tolerance; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy | 2008 |
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Smoking | 2009 |
A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2009 |
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2009 |
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Female; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2009 |
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure; Treatment Outcome | 2009 |
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pleural Effusion, Malignant; Prognosis; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2009 |
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; DNA; DNA, Neoplasm; ErbB Receptors; Exons; Feasibility Studies; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2009 |
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Transforming Growth Factor alpha; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Treatment Failure | 2010 |
Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2009 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; STAT3 Transcription Factor | 2009 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Preoperative Period; Protein Kinase Inhibitors; Quinazolines | 2009 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines | 2010 |
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Taxoids | 2010 |
A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taxoids | 2010 |
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Analysis | 2010 |
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Recurrence, Local; Precision Medicine; Predictive Value of Tests; Proteome; Quinazolines | 2010 |
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Mutation; Odds Ratio; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2010 |
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Quinazolines; Time Factors | 2011 |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Prognosis; Quinazolines | 2010 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Retreatment; Taxoids; Time Factors | 2010 |
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Survival; Treatment Outcome | 2011 |
[Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome; Young Adult | 2010 |
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Treatment Outcome | 2011 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
[Efficacy and safety of Erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients].
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Time Factors; Tissue Distribution; Treatment Outcome | 2010 |
[Efficacy and safety of erlotinib as monotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2010 |
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2011 |
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2010 |
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Pilot Projects; Prognosis; Quinazolines; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2010 |
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Dendrites; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome | 2011 |
[Clinical investigation of efficacy of pemetrexed in 32 patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Clinical effect of erlotinib as first-line treatment for Asian elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sex Characteristics; Survival Rate; Treatment Outcome | 2011 |
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Cohort Studies; ErbB Receptors; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome | 2010 |
Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines; Sex Factors; Smoking; Tumor Stem Cell Assay | 2010 |
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Research Design; Southwestern United States; Treatment Outcome | 2010 |
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Prostaglandins; Pyrroles; Quinazolines; Sulfonamides | 2011 |
The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Quinazolines | 2010 |
Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Folliculitis; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Proto-Oncogene Proteins p21(ras); Quinazolines; Treatment Outcome | 2011 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Heptanoic Acids; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Treatment, rationale, and study design of TALISMAN study: a randomized phase II open-label study of second-line erlotinib versus intermittent erlotinib dosing with docetaxel in the treatment of former-smoker men affected by recurrent squamous non-small-ce
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Recurrence; Research Design; Smoking; Taxoids | 2011 |
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Female; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Mexico; Middle Aged; Pemetrexed; Piperidines; Proportional Hazards Models; Quinazolines; Risk Assessment; Risk Factors; South Africa; Time Factors; Treatment Outcome | 2011 |
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Europe; Female; Humans; Lung Neoplasms; Male; Middle Aged; North America; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Quinazolines; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine | 2011 |
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Simvastatin; Treatment Outcome | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum Compounds; Quinazolines | 2011 |
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance; Female; Gefitinib; Genes, erbB-1; Hepatocyte Growth Factor; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2011 |
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mu
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Genes, ras; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Survival Rate; Taxoids; Treatment Outcome | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome; Tyrosine | 2011 |
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Japan; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Research Design; Salvage Therapy; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Platinum Compounds; Prospective Studies; Quinazolines | 2012 |
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Treatment Outcome | 2011 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2012 |
Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2011 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Placebos; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Receptors, Growth Factor; Survival Analysis | 2011 |
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; ErbB Receptors; Europe; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Cadherins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Vimentin | 2011 |
Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mucositis; Neutropenia; Quinazolines; Taxoids | 2011 |
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Topics: Acrylic Resins; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; False Negative Reactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polyvinyls; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2011 |
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Guidelines as Topic; Health Care Costs; Humans; Lung Neoplasms; Models, Economic; Platinum; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom | 2011 |
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Polymorphism, Genetic; Predictive Value of Tests; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2011 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Outcome | 2011 |
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Placebos; Quinazolines; Receptor, IGF Type 1 | 2011 |
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Quinazolines | 2011 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cognition; Cranial Irradiation; Dacarbazine; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survival Analysis; Temozolomide | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cryosurgery; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Treatment Outcome | 2011 |
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2012 |
Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines | 2012 |
A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Retrospective Studies; Treatment Outcome | 2012 |
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Docetaxel; Early Termination of Clinical Trials; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2012 |
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Sequence Deletion; Treatment Outcome | 2012 |
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2012 |
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Smoking; Treatment Outcome | 2012 |
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retreatment; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Time Factors | 2012 |
Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines; Research Design; Salvage Therapy; Survival Rate | 2012 |
Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2012 |
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Quinazolines | 2012 |
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Middle Aged; Pyridines; Quinazolines | 2012 |
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Treatment Outcome | 2012 |
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Folic Acid Antagonists; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Failure; United States | 2012 |
Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Quinazolines; Smoking; Sunitinib; Treatment Outcome | 2012 |
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Endpoint Determination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome | 2012 |
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinazolines; Quinolines | 2012 |
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2012 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Costs and Cost Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Frail Elderly; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2013 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Rate; Tissue Distribution | 2012 |
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Quinazolines; Sunitinib; Survival Rate; Tissue Distribution | 2012 |
Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines; Serum Amyloid A Protein; Survival Rate | 2012 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Risk Factors; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2012 |
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Australia; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Analysis | 2013 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; ras Proteins; Treatment Outcome | 2012 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Esophagitis; Esophagus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy, Conformal; Remission Induction; Tracheoesophageal Fistula; Treatment Failure | 2012 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate | 2012 |
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Po
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis | 2012 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2012 |
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2013 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Efficacy vs. effectiveness: erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2013 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Skin Diseases; Treatment Outcome | 2013 |
[Therapeutic effect of erlotinib in elderly patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2012 |
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis | 2013 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prospective Studies; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2001 |
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2002 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2003 |
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; United States | 2003 |
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2003 |
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2003 |
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Topics: Administration, Oral; Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Approval; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Quinazolines; Reference Values; Survival Analysis; Tablets; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiography; Survival Analysis; Treatment Outcome | 2003 |
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Frail Elderly; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases | 2004 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Quinazolines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Epidermal Growth Factor; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Survival Analysis | 2004 |
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis | 2004 |
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate | 2004 |
Acute lung injury as an adverse event of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Distress Syndrome | 2004 |
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis | 2004 |
Severe myelotoxicity in a combination of gefitinib and vinorelbine.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Quinazolines; Thrombocytopenia; Vinblastine; Vinorelbine | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome | 2004 |
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Staging; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Topics: Acne Vulgaris; Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Remission Induction; Stomatitis; Treatment Outcome | 2004 |
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis | 2005 |
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors | 2004 |
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sensitivity and Specificity; Survival Analysis | 2005 |
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Survival Analysis | 2005 |
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Predictive Value of Tests; Probability; Prognosis; Prospective Studies; Quinazolines; Risk Assessment; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA; Sensitivity and Specificity; Sex Factors; Survival Analysis | 2005 |
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib (Tarceva) for advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Exanthema; Humans; Quinazolines | 2005 |
Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Terminal Care; Treatment Outcome | 2005 |
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Survival Analysis | 2005 |
Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Testosterone | 2005 |
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Quinazolines; Survival Analysis; Taxoids | 2005 |
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2005 |
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib in previously treated non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis | 2005 |
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Predictive Value of Tests; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Placebos; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
FDA drug approval summary: erlotinib (Tarceva) tablets.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Salvage Therapy; Survival Rate; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quinazolines; Survival Rate | 2005 |
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking; Survival Analysis | 2005 |
Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Contraindications; Cystitis; Feasibility Studies; Female; Gastrointestinal Diseases; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonia; Quinazolines; Vomiting | 2005 |
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Topics: Adolescent; Adult; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Analysis; Treatment Failure; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Psychomotor Performance; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost of Illness; ErbB Receptors; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Survival Rate | 2005 |
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Postoperative Period; Quinazolines | 2005 |
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Topics: Administration, Oral; Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organic Chemicals; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed | 2006 |
Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Taiwan; Treatment Failure | 2005 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2006 |
Aspirin reduces adverse effects of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thromboxane B2 | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival; Treatment Outcome; Up-Regulation | 2006 |
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Taxoids | 2006 |
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome | 2006 |
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome | 2006 |
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Topics: Aged; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis | 2006 |
Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.
Topics: Adult; Aged; Algorithms; Analysis of Variance; Area Under Curve; Biotransformation; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasms; Population; Protein Kinases; Quinazolines | 2006 |
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Pain; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2006 |
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Smoking; Survival Analysis; Taxoids | 2007 |
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; DNA Primers; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Tablets | 2006 |
Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2007 |
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Analysis | 2006 |
[Gefitinib in the treatment of advanced non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Analysis | 2006 |
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Quinazolines; Survival Analysis | 2006 |
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Quinazolines; Vinblastine; Vinorelbine | 2007 |
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome | 2007 |
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Homozygote; Humans; Introns; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis | 2007 |
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2006 |
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Vinblastine; Vinorelbine | 2006 |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Patient Selection; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction | 2007 |
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Vinblastine; Vinorelbine | 2007 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
[Gefitinib target treatment in non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2007 |
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2007 |
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
Topics: Adult; Aged; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Half-Life; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quinazolines | 2008 |
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Smoking | 2007 |
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome | 2007 |
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Survival Rate; United States | 2007 |
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Microsatellite Repeats; Middle Aged; Mutation; Polymorphism, Genetic; Quinazolines; Treatment Outcome | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Gefitinib; Humans; Lactones; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proteomics; Quinazolines; Sulfones; Survival Rate; Treatment Outcome | 2007 |
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Lung Neoplasms; Male; Middle Aged; Piperidines; Placebos; Quinazolines; Taxoids | 2007 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Quinazolines | 2008 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Placebos; Predictive Value of Tests; Quinazolines | 2008 |
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Surveys and Questionnaires | 2008 |
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines | 2008 |
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Taxoids | 2008 |
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemokines, CC; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Matrix Metalloproteinase 9; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1 | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Immunohistochemistry; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Treatment Outcome | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate | 2008 |
Clinical experience with gefitinib in Indian patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; India; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; ErbB Receptors; Female; Humans; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperidines; Prognosis; Quinazolines | 2008 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Peptic Ulcer; Predictive Value of Tests; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
[Erlotinib in non-small cell lung cancer: experience of clinical hospital for lung diseases Jordanovac].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Salvage Therapy; Sex Factors; Smoking; Taiwan | 2008 |
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Female; Humans; In Vitro Techniques; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis | 2008 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies | 2008 |
[Gefitinib in the treatment of refractory non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Rate | 2007 |
[Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Survival Rate | 2007 |
Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Thiophenes; Thrombocytopenia | 2002 |
2130 other study(ies) available for quinazolines and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Quinazoline-tethered hydrazone: A versatile scaffold toward dual anti-TB and EGFR inhibition activities in NSCLC.
Topics: A549 Cells; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Humans; Hydrazones; Lung Neoplasms; Models, Molecular; Mycobacterium tuberculosis; Quinazolines; Structure-Activity Relationship; Tuberculosis | 2021 |
Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Dose-Response Relationship, Drug; ErbB Receptors; Exons; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2021 |
Chemical Enhancement Effect of Icotinib-Au Complex Studied by Combined Density Functional Theory and Surface-Enhanced Raman Scattering.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Density Functional Theory; Gold; Humans; Lung Neoplasms; Metal Nanoparticles; Quinazolines; Spectrum Analysis, Raman | 2021 |
Rhabdomyolysis Caused by Gefitinib Overdose.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis | 2022 |
AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
Topics: Acrylamides; Aniline Compounds; Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Piperazines; Quinazolines; Xenograft Model Antitumor Assays | 2022 |
Synergistic inhibitory effect of berberine and icotinib on non-small cell lung cancer cells via inducing autophagic cell death and apoptosis.
Topics: Animals; Apoptosis; Autophagic Cell Death; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mice; Quinazolines; Signal Transduction | 2021 |
Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Therapy, Combination; Endostatins; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2022 |
Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Eosinophilia; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines | 2021 |
Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nanoparticles; Phosphorus; Protein Kinase Inhibitors; Quinazolines | 2022 |
Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Sulfoxides | 2021 |
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Lung Neoplasms; Oxazoles; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2022 |
EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Hospitals; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spain | 2023 |
EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2023 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2022 |
Analysis to determine the effect of mutations on binding to small chemical molecules.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2022 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
In Silico Screening of Synthetic and Natural Compounds to Inhibit the Binding Capacity of Heavy Metal Compounds against EGFR Protein of Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Early Detection of Cancer; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2023 |
Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Evodiamine inhibits stemness and metastasis by altering the SOX9-β-catenin axis in non-small-cell lung cancer.
Topics: Alkaloids; Apoptosis; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cysteine; Humans; Lung Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Reactive Oxygen Species; SOX9 Transcription Factor; Vimentin | 2022 |
Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2022 |
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
Topics: Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nanoparticles; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2022 |
Extracellular Vesicles from
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Vesicles; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP27 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2022 |
Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nucleotides; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies | 2022 |
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report.
Topics: Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines | 2022 |
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chlorpromazine; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; ErbB Receptors; Exosomes; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2022 |
SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition.
Topics: Animals; Apoptosis; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Necrosis Factor-alpha; Vimentin | 2022 |
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mutation; Natural Killer T-Cells; Protein Kinase Inhibitors; Quinazolines | 2022 |
Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Immunity; Leukocytes, Mononuclear; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; T-Lymphocytes | 2022 |
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells.
Topics: Animals; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan | 2022 |
Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; NF-E2-Related Factor 2; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2022 |
Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.
Topics: Adenosine Triphosphate; Allosteric Site; Aniline Compounds; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2022 |
Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2023 |
Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Proof of Concept Study; Quinazolines | 2022 |
Second generation Spautin-1 analogues targeting EGFR-mutant non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2023 |
Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib.
Topics: Afatinib; Aged; beta Catenin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; LIM Domain Proteins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Ultrasonography | 2023 |
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger | 2023 |
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Tetracyclines | 2023 |
In silico target specific design of potential quinazoline-based anti-NSCLC agents.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Ligands; Lung Neoplasms; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2023 |
LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methyltransferases; NLR Family, Pyrin Domain-Containing 3 Protein; Protein Kinase Inhibitors; Pyroptosis; Quinazolines; RNA, Long Noncoding | 2023 |
The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2023 |
Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?
Topics: Carcinoma, Non-Small-Cell Lung; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines; Receptor, ErbB-2 | 2023 |
Methylseleninic acid overcomes gefitinib resistance through asparagine-MET-TOPK signaling axis in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Asparagine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2023 |
BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2023 |
Coevolution-based computational approach to detect resistance mechanism of epidermal growth factor receptor.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2024 |
RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Topics: Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Ligands; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor for Advanced Glycation End Products | 2023 |
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Novel quinazoline-based dual EGFR/c-Met inhibitors overcoming drug resistance for the treatment of NSCLC: Design, synthesis and anti-tumor activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2024 |
Design, synthesis and biological evaluation of structurally new 4-indolyl quinazoline derivatives as highly potent, selective and orally bioavailable EGFR inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2024 |
Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2020 |
Targeting an EGFR Water Network with 4-Anilinoquin(az)oline Inhibitors for Chordoma.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chordoma; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Models, Molecular; Molecular Targeted Therapy; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2019 |
Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines | 2019 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines; Spectroscopy, Fourier Transform Infrared | 2020 |
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Topics: Aged; Asian People; Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2020 |
Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chalcones; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Glycyrrhiza; Humans; Lung Neoplasms; Molecular Docking Simulation; Plant Roots; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2020 |
Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Crown Ethers; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Quinazolines | 2019 |
A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Glucose; Glucose Transporter Type 1; High-Throughput Screening Assays; Humans; Lung Neoplasms; Phenylenediamines; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; RNA Polymerase II; RNA, Messenger; Signal Transduction; Triazines | 2019 |
Efficacy of early combination of local radiotherapy and GM-CSF for advanced non-small cell lung cancer treated with icotinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Young Adult | 2020 |
RET-rearranged non-small-cell lung cancer and therapeutic implications.
Topics: Australia; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Precision Medicine; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines | 2019 |
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Topics: Carcinoma, Non-Small-Cell Lung; China; Circulating Tumor DNA; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2020 |
Cost-effectiveness of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Cranial Irradiation; Crown Ethers; Disease Progression; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Quality of Life; Quinazolines | 2021 |
Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.
Topics: Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Eruptions; Drug Resistance, Neoplasm; Endothelial Cells; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; ras GTPase-Activating Proteins | 2020 |
Evodiamine suppresses Notch3 signaling in lung tumorigenesis via direct binding to γ-secretases.
Topics: A549 Cells; Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Survival; Evodia; Female; Humans; Lung Neoplasms; Mice, Inbred Strains; Molecular Docking Simulation; Quinazolines; Receptor, Notch3; Signal Transduction; Urethane | 2020 |
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gene Rearrangement; Genome, Human; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Republic of Korea; Treatment Outcome | 2020 |
Hybrids of Quinoline and Anilinopyrimidine: Novel EGFRT790M Inhibitors with Antiproliferative Activity against Non-Small Cell Lung Cancer Cell Lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2020 |
Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Quinazolines | 2020 |
Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53 | 2020 |
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA-Activated Protein Kinase; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Radiation, Ionizing; Squamous Cell Carcinoma of Head and Neck; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Bisdemethoxycurcumin Enhances the Sensitivity of Non-small Cell Lung Cancer Cells to Icotinib via Dual Induction of Autophagy and Apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crown Ethers; Diarylheptanoids; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Reactive Oxygen Species; Sp Transcription Factors; Voltage-Dependent Anion Channel 1 | 2020 |
Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Mutation; Neoplasm Invasiveness; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2020 |
Novel anilino quinazoline-based EGFR tyrosine kinase inhibitors for treatment of non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2021 |
Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Interrupted Time Series Analysis; Lung Neoplasms; Quinazolines; Taiwan | 2020 |
Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deubiquitinating Enzyme CYLD; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, Tumor Suppressor; Humans; Inflammation; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2020 |
G9a regulates tumorigenicity and stemness through genome-wide DNA methylation reprogramming in non-small cell lung cancer.
Topics: Animals; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Forkhead Transcription Factors; Heterografts; Histone-Lysine N-Methyltransferase; Histones; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Quinazolines; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, RNA; Up-Regulation | 2020 |
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; GRB2 Adaptor Protein; Humans; Lung Neoplasms; Lymecycline; Male; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2020 |
Gefitinib induced severe hyponatremia: A case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Hyponatremia; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2021 |
The PI3Kα inhibitor DFX24 suppresses tumor growth and metastasis in non-small cell lung cancer via ERK inhibition and EPHB6 reactivation.
Topics: Antineoplastic Agents; Apoptosis; Benzene Derivatives; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Movement; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mitochondria; Morpholines; Neoplasm Metastasis; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Eph Family; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
An Activatable Nano-Prodrug for Treating Tyrosine-Kinase-Inhibitor-Resistant Non-Small Cell Lung Cancer and for Optoacoustic and Fluorescent Imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Lung Neoplasms; Mice; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2020 |
Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2020 |
Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Renal Insufficiency | 2021 |
Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
Evodiamine suppresses non-small cell lung cancer by elevating CD8
Topics: Animals; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Down-Regulation; Female; Humans; Lung Neoplasms; Mice; Mucin-1; Plant Extracts; Programmed Cell Death 1 Receptor; Quinazolines; Transfection | 2020 |
Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
Topics: Animals; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice, Nude; Microtubule-Associated Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Protein Kinase Inhibitors; Quinazolines; Sequestosome-1 Protein; Signal Transduction | 2020 |
Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Pilot Projects; Protein Kinase Inhibitors; Quinazolines | 2021 |
HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2021 |
Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Quinazolines | 2021 |
Structure-Activity Relationship (SAR) Study of Spautin-1 to Entail the Discovery of Novel NEK4 Inhibitors.
Topics: Antineoplastic Agents; Benzylamines; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; NIMA-Related Kinases; Quinazolines; Structure-Activity Relationship | 2021 |
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2021 |
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; Disease Progression; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Time Factors | 2021 |
Cediranib Induces Apoptosis, G1 Phase Cell Cycle Arrest, and Autophagy in Non-Small-Cell Lung Cancer Cell A549 In Vitro.
Topics: A549 Cells; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; MAP Kinase Signaling System; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Vascular Endothelial Growth Factor; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2021 |
Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.
Topics: Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2022 |
Bevacizumab Combined with Icotinib Overcomes Osimertinib Resistance in a Patient of Non-Small Cell Lung Cancer.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crown Ethers; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Gefitinib; Humans; Lung Neoplasms; Mutation; Population Groups; Quinazolines | 2021 |
Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Drug Therapy, Combination; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2021 |
Icotinib Induces Mechanism-Based Inactivation of Recombinant Human CYP3A4/5 Possibly via Heme Destruction by Ketene Intermediate.
Topics: Activation, Metabolic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Activation; ErbB Receptors; Ethylenes; Heme; Humans; Ketones; Microsomes, Liver; Quinazolines; Recombinant Proteins | 2021 |
Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Topics: Acrylamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2021 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction | 2017 |
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Topics: A549 Cells; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2017 |
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Mice; Models, Molecular; Morpholines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2017 |
Acquired
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6.
Topics: A549 Cells; Apoptosis; Astragalus propinquus; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Quinazolines; Saponins; Sirtuins; Triterpenes | 2017 |
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays | 2017 |
[Cabozantinib: Mechanism of action, efficacy and indications].
Topics: Anilides; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Piperidines; Prostatic Neoplasms; Proto-Oncogene Proteins c-ret; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Selective targeting of point-mutated KRAS through artificial microRNAs.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins p21(ras); Quinazolines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2017 |
Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Heterografts; Humans; Lung Neoplasms; Mice; Mutation; Organotechnetium Compounds; Quinazolines; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2017 |
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan | 2017 |
Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Topics: Afatinib; Amides; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Thiophenes | 2017 |
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Piperazines; Prognosis; Quinazolines; Remission Induction | 2017 |
Gefitinib Delays NSCLC Recurrence After Surgery.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Corneal edema with a systemic epidermal growth factor receptor inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Corneal Edema; Dose-Response Relationship, Drug; Drug Substitution; Epithelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2017 |
Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
Topics: A549 Cells; Acetylcysteine; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cigarette Smoking; Drug Resistance, Neoplasm; ErbB Receptors; Free Radical Scavengers; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2017 |
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Gefitinib; Genotype; Histamine H2 Antagonists; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.
Topics: Aurora Kinase B; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comorbidity; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Registries; Retreatment; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Translocation, Genetic | 2017 |
Matrine increases the inhibitory effects of afatinib on H1975 cells via the IL‑6/JAK1/STAT3 signaling pathway.
Topics: Afatinib; Alkaloids; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Matrines; Protein Kinase Inhibitors; Quinazolines; Quinolizines; Signal Transduction; STAT3 Transcription Factor | 2017 |
Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2017 |
Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases.
Topics: AMP-Activated Protein Kinases; Arthritis, Rheumatoid; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Gene Expression Regulation; Humans; Lipogenesis; Oxidation-Reduction; Quinazolines; Reactive Oxygen Species; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Synovial Fluid | 2018 |
The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
Topics: A549 Cells; Afatinib; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction | 2017 |
Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lignans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction | 2017 |
Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
Topics: A549 Cells; Acyltransferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Indoles; Mice; Panobinostat; Proto-Oncogene Proteins p21(ras); Quinazolines; Transcription Factors | 2017 |
Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin B1; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
Case series on the association between blood levels and side effects of afatinib maleate.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Neutrophils; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Pyrazoles; Quinazolines; Quinolines; Signal Transduction; Up-Regulation | 2017 |
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Phytotherapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Saponins; Signal Transduction | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Duodenal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Pyrimidines; Quinazolines; Treatment Outcome | 2017 |
Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines | 2017 |
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Retrospective Studies; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Acrylamides; Adult; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Piperazines; Quinazolines | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Topics: Acetophenones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Aggregation; Cell Count; Cell Line, Tumor; Doxorubicin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Mutation; Quinazolines; Succinate Dehydrogenase | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Metastasis; Nivolumab; Quinazolines; Ramucirumab; Taxoids | 2017 |
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Topics: A549 Cells; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; CCAAT-Enhancer-Binding Protein-beta; Cell Movement; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Protein Stability; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; DNA, Catalytic; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Quinazolines; RNA, Messenger; Toll-Like Receptor 9 | 2018 |
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines | 2017 |
Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Mice, Nude; Pemetrexed; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Triazines; Xenograft Model Antitumor Assays | 2017 |
AZD3759 for CNS metastases in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neuraminidase; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction | 2017 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Interleukin-6; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prevalence; Quinazolines; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pneumonectomy; Point Mutation; Postoperative Period; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers.
Topics: Adrenergic beta-Antagonists; Afatinib; AMP-Activated Protein Kinase Kinases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Drug Resistance, Neoplasm; Epinephrine; ErbB Receptors; Humans; Interleukin-6; Lung Neoplasms; Mutation; Norepinephrine; Protein Kinase C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Receptors, Adrenergic, beta; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Efficacy of Afatinib in a Previously-Treated Patient with Non-Small Cell Lung Cancer Harboring HER2 Mutation: Case Report.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Exons; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Sequence Analysis, DNA; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; China; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcriptional Activation; Up-Regulation | 2018 |
The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2018 |
Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Lung Neoplasms; Metabolic Networks and Pathways; Microsomes, Liver; Quinazolines | 2018 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Lung Cancer with Concomitant Double Gene Mutation.
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Biopsy; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Nivolumab; Pemetrexed; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2018 |
Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transcription Factors; Tripartite Motif Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
[Clinical Observation of Gefitinib with Pericardial Perfusion for
Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Perfusion; Pericardial Effusion; Pericardium; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Ligands; Molecular Docking Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Rosiglitazone; Thiazolidinediones | 2018 |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Spain; Treatment Outcome | 2018 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclopropanes; Drug Resistance, Neoplasm; Enzyme Activation; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Phosphorylation; Pyridines; Quinazolines; Tetraploidy; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
Topics: Animals; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemoradiotherapy; DNA Repair; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mutation; Piperazines; Quinazolines; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays | 2018 |
New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Topics: Acrylamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2018 |
Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Stomatitis; Treatment Outcome | 2018 |
Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer-Aided Design; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Quinazolines; Software | 2018 |
Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2018 |
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Principal Component Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Neoplasm Proteins; Quinazolines; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril | 2018 |
Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Count; Crizotinib; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Rearrangement; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prognosis; Quinazolines | 2018 |
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results | 2018 |
Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Mice, Nude; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Icotinib and whole-brain radiotherapy for the treatment in patients with brain metastases from EGFR-mutant nonsmall cell lung cancer: A retrospective study.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; China; Combined Modality Therapy; Cranial Irradiation; Crown Ethers; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiotherapy Dosage; Retrospective Studies | 2018 |
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Topics: Afatinib; Animals; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mice; Mutagenesis, Insertional; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Tumor Burden | 2018 |
A blood biomarker for monitoring response to anti-EGFR therapy.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Peroxiredoxin VI; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Poziotinib for uncommon ERBB mutations.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Quinazolines | 2018 |
EGF upregulates RFPL3 and hTERT via the MEK signaling pathway in non‑small cell lung cancer cells.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Quinazolines; Telomerase; Tyrphostins | 2018 |
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; ELAV-Like Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Decision Making, Organizational; Disease-Free Survival; ErbB Receptors; Exons; Health Planning; Humans; Lung Neoplasms; Models, Biological; Models, Economic; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; Young Adult | 2018 |
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Prospective Studies; Quinazolines; Survival Rate | 2018 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Interleukin-6; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2018 |
Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process.
Topics: A549 Cells; Animals; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transforming Growth Factor beta1 | 2018 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Survivin | 2018 |
Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA Interference; RNA, Small Interfering; Up-Regulation | 2019 |
HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; E2F Transcription Factors; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; Retinoblastoma Protein; RNA, Long Noncoding; Transplantation, Heterologous | 2018 |
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Topics: Anilides; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Sodium-Phosphate Cotransporter Proteins, Type IIb; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Luminescent Measurements; Lung Neoplasms; Mice; Neoplasm Staging; Piperazines; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Calpain; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.
Topics: Afatinib; Aged; Algorithms; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2019 |
Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Survival Rate | 2018 |
Erlotinib as adjuvant therapy in EGFR-mutant NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Quinazolines; Vinorelbine | 2018 |
Fluoxetine Inhibits DNA Repair and NF-ĸB-modulated Metastatic Potential in Non-small Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; DNA Repair; Fluoxetine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; NF-kappa B; Phenyl Ethers; Quinazolines; Signal Transduction | 2018 |
Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Female; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
[Formulation and Efficacy of Liposome-encapsulated Afatinib for Therapy of Non-small Cell Lung Cancer].
Topics: Afatinib; Capsules; Carcinoma, Non-Small-Cell Lung; Drug Compounding; Liposomes; Lung Neoplasms; Quinazolines | 2018 |
Osimertinib Treats CNS Metastases in NSCLC.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2018 |
Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
Topics: Adult; Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Precision Medicine; Quinazolines; Treatment Outcome | 2018 |
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Quinazolines; Research Design | 2018 |
Clinicopathologic characteristics and outcome of patients with different EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2019 |
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromobox Protein Homolog 5; Chromosomal Proteins, Non-Histone; Cytoskeletal Proteins; Disease Models, Animal; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Lung Neoplasms; Mice; Quinazolines; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2018 |
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines | 2018 |
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Exons; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2018 |
Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2018 |
Straightforward synthesis, characterization, and cytotoxicity evaluation of hybrids of natural alkaloid evodiamine/rutaecarpine and thieno[2,3-
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Indole Alkaloids; Lung Neoplasms; Molecular Structure; Pyrimidinones; Quinazolines; Structure-Activity Relationship | 2020 |
Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib.
Topics: Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Humans; Lung Neoplasms; Mutagenesis, Insertional; Quinazolines; Sequence Deletion | 2019 |
[Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Sialidase Attenuates Epidermal Growth Factor Response and Abolishes Antiproliferative Effects of Erlotinib in A549Alveolar Epithelial Cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cells; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neuraminidase; Protein Kinase Inhibitors; Quinazolines | 2019 |
[Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2019 |
20(S)-ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to icotinib through inhibition of autophagy.
Topics: Animals; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Synergism; Female; Ginsenosides; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Quinazolines; Xenograft Model Antitumor Assays | 2019 |
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycerol Kinase; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2019 |
Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; Drug Liberation; Esterases; Humans; Lung Neoplasms; Lysosomes; Protein Kinase Inhibitors; Quantum Dots; Quinazolines | 2019 |
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; G1 Phase Cell Cycle Checkpoints; Histones; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Organophosphates; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer.
Topics: Acrylamides; Aged; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Quinazolines | 2019 |
Angio-associated migratory cell protein interacts with epidermal growth factor receptor and enhances proliferation and drug resistance in human non-small cell lung cancer cells.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Crown Ethers; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Knockdown Techniques; HEK293 Cells; Heterografts; Humans; Lung Neoplasms; Mice; Phosphorylation; Quinazolines; Transfection; Tumor Burden | 2019 |
Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Topics: Acrylamides; Afatinib; Aged; Aniline Compounds; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2019 |
Knockout of glucosidase II beta subunit inhibits growth and metastatic potential of lung cancer cells by inhibiting receptor tyrosine kinase activities.
Topics: alpha-Glucosidases; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Humans; Lung; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
[Fatal interstitial lung disease associated with erlotinib use].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Topics: Aged; Algorithms; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Mutation; Pemetrexed; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2013 |
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
Functional genetic screens identify genes essential for tumor cell survival in head and neck and lung cancer.
Topics: Animals; Benzamides; beta Karyopherins; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Genes, Essential; Genome-Wide Association Study; Head and Neck Neoplasms; Humans; Kinesins; Lung Neoplasms; Mice; Microtubule-Associated Proteins; Nuclear Proteins; Quinazolines; ran GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mass Spectrometry; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Proteome; Proteomics; Quinazolines; Retrospective Studies | 2013 |
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Diphenylamine; Feedback, Physiological; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Point: should epidermal growth factor receptor mutations be routinely tested for in patients with lung cancer? Yes.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Diagnostic Tests, Routine; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Mutation; Neutropenia; Protein Kinase Inhibitors; Quinazolines | 2013 |
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib in the treatment of patients with multiple metastases from non-small cell lung cancer: clinical case selection for optimal response.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines | 2013 |
α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Topics: Antioxidants; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Thioctic Acid | 2013 |
[Efficacy of icotinib for advanced non-small cell lung cancer patients with EGFR status identified].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Safety; Survival Analysis | 2013 |
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pressure Ulcer; Quinazolines; Wound Healing | 2014 |
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome | 2012 |
Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Topics: Afatinib; Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorometry; Gefitinib; Humans; Indoles; Microscopy, Fluorescence; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectrophotometry; Sulfonamides | 2013 |
Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2013 |
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Topics: Apoptosis; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; RNA, Small Interfering; Signal Transduction | 2013 |
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Transdifferentiation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sequence Analysis, DNA; Sequence Deletion | 2013 |
Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemokine CCL5; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-10; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2013 |
Update: NCCN non-small cell lung cancer clinical practice guidelines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Gefitinib; Humans; Lung Neoplasms; Neoplasm Micrometastasis; Neoplasm Staging; Positron-Emission Tomography; Practice Guidelines as Topic; Quinazolines | 2004 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Topics: Animals; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crown Ethers; ErbB Receptors; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction | 2013 |
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Genes, bcl-2; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Letter to the editor. Probing gender-specific change in IgG1 Fc-galactosylation in non-small cell lung cancer patients treated with epidermal growth factor receptor inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Galactose; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Lung Neoplasms; Male; Mass Spectrometry; Quinazolines; Sex Factors | 2013 |
mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation, Missense; PTEN Phosphohydrolase; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
An HPLC-UV method for the simultaneous quantification of vemurafenib and erlotinib in plasma from cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Humans; Indoles; Liquid-Liquid Extraction; Melanoma; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Vemurafenib | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
Reply to N. Singh et al.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
Reply to M.C. Garassino et al.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2013 |
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; HEK293 Cells; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Tissue Array Analysis | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Patient Selection; Pemetrexed; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines | 2013 |
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Follow-Up Studies; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Hand-foot syndrome induced by erlotinib (Tarceva(Ⓡ) ).
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Hand-Foot Syndrome; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
[Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases | 2013 |
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Metformin; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Quinazolines; Signal Transduction | 2014 |
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
Topics: Aged; Alopecia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cicatrix; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Risk Assessment; Severity of Illness Index | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
USP8 is a novel target for overcoming gefitinib resistance in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Endopeptidases; Endosomal Sorting Complexes Required for Transport; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Protease Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2013 |
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; France; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Survival Rate; Treatment Outcome | 2013 |
Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Intracellular Space; Lung Neoplasms; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Tumor Suppressor Protein p14ARF | 2013 |
Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Humans; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Topics: Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Epidermal growth factor receptor in lung cancer: the amazing interplay of molecular testing and cytopathology.
Topics: Carcinoma, Non-Small-Cell Lung; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome | 2013 |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Individualized treatment of NSCLC: from research to clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Transcriptome | 2013 |
Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Topics: Adult; Aged; Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.
Topics: Alleles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oligonucleotides; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sequence Analysis, DNA | 2013 |
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Size; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Mice; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Sequence Analysis, RNA; Species Specificity; Xenograft Model Antitumor Assays | 2013 |
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, ras; Genetic Variation; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Mutation; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 1; Xenograft Model Antitumor Assays | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320: in regard to Sperduto
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Quinazolines; Radiosurgery | 2013 |
In reply to Robins et al.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dacarbazine; Humans; Lung Neoplasms; Quinazolines; Radiosurgery | 2013 |
Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Topics: Animals; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Janus Kinase 1; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choice Behavior; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2013 |
5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; NF-kappa B; Photochemotherapy; Photosensitizing Agents; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2013 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
[EGFR-ERK signaling pathway down-regulates miRNA-145 in lung cancer cells].
Topics: Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Humans; Lung; Lung Neoplasms; MAP Kinase Signaling System; MicroRNAs; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Phosphorylation; Quinazolines; Tyrphostins | 2013 |
Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation.
Topics: Afatinib; AMP-Activated Protein Kinases; Carcinoma, Non-Small-Cell Lung; Deoxyglucose; Drug Resistance, Neoplasm; ErbB Receptors; Glycolysis; Humans; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Protein Biosynthesis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2013 |
Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-4F; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Quinazolines; RNA Caps; Signal Transduction; Tumor Cells, Cultured | 2013 |
EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2013 |
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2013 |
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Financing, Government; Follow-Up Studies; Gefitinib; Health Plan Implementation; Health Services; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.
Topics: Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mutation; Niclosamide; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Brain metastasis in patients with non-small-cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
New kinase inhibitor approved for metastatic lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib in the treatment of advanced squamous cell NSCLC.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Insulin; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib.
Topics: Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Ranitidine; Retrospective Studies; Stomach Ulcer; Treatment Outcome | 2013 |
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gefitinib; Genes, erbB-1; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, IGF Type 1; Treatment Outcome | 2013 |
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Meglumine; Mice; Mice, Inbred NOD; Plant Extracts; Protein Kinase Inhibitors; Quinazolines; Seeds; Silybin; Silybum marianum; Silymarin; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dipeptides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptor, Notch1; RNA Interference; Signal Transduction; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2013 |
RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Real-Time Polymerase Chain Reaction; Transcriptome | 2013 |
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Reply to v.R. Bhatt et Al and m.C. Chamberlain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Icotinib: kick-starting the Chinese anticancer drug industry.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2013 |
Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines | 2013 |
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Mutation; Pyrazoles; Pyridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Silybin; Silymarin; Treatment Outcome | 2013 |
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoassay; Lung Neoplasms; Lymphatic Metastasis; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasms, Experimental; Oncogene Proteins; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Quinazolines; Quinolines; Small Molecule Libraries | 2013 |
Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2013 |
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Exons; Genes, erbB-1; Humans; Quinazolines; Receptor, IGF Type 1; Sequence Deletion; Treatment Outcome | 2013 |
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines | 2013 |
A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Biological diagnosis of resistance to erlotinib in a malignant pleural effusion].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
[c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Hepatocyte Growth Factor; Humans; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2013 |
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2013 |
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
Topics: Aldehyde Oxidoreductases; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Lung Neoplasms; Mutation; Neoplastic Stem Cells; Phenotype; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Silybin; Silymarin; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Topics: Acetylation; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Mice; Mice, Nude; Propidium; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Computational Biology; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Models, Chemical; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pteridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2013 |
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Quinazolines; Sulfonamides | 2013 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Inbred BALB C; Models, Biological; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
[Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Treatment Failure; Treatment Outcome | 2014 |
In vitro and in vivo anti-tumour effects of MPT0B014, a novel derivative aroylquinoline, and in combination with erlotinib in human non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Caspases; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin B1; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; G2 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Microtubules; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Quinazolines; Quinolines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dasatinib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Female; Focal Adhesion Protein-Tyrosine Kinases; Gene Expression; Humans; Inhibitory Concentration 50; Insulin-Like Growth Factor Binding Protein 2; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with clinical outcome of erlotinib treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cytokines; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Mutation; Quinazolines | 2014 |
microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Analysis | 2013 |
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Hedgehog Proteins; Humans; Lung Neoplasms; MicroRNAs; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; Humans; Immunotherapy; Leukocytes, Mononuclear; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Quinazolines | 2013 |
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
[Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Wnt Signaling Pathway | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Guanylate Kinases; Humans; Lung Neoplasms; Membrane Proteins; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2014 |
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transfection; Up-Regulation | 2014 |
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Gefitinib; Gene Silencing; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Microscopy, Fluorescence; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorting Nexins; Tumor Cells, Cultured | 2014 |
VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
Topics: Algorithms; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Predictive Value of Tests; Prognosis; Proteomics; Quinazolines; Severity of Illness Index; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2014 |
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Survival Analysis | 2014 |
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Endothelial Cells; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Retrospective Studies; Stem Cells | 2013 |
[Effect of bufalin combined gefitinib on lung cancer H1975 cells and its mechanisms research].
Topics: Bufanolides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2013 |
Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Topics: Afatinib; Animals; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Oncogene Proteins v-erbB; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2014 |
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; RNA Interference; RNA-Binding Proteins; Transgenes; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2014 |
Bayesian models for cost-effectiveness analysis in the presence of structural zero costs.
Topics: Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Models, Economic; Multicenter Studies as Topic; Quality-Adjusted Life Years; Quinazolines | 2014 |
ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Furans; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Quinazolines; ras Proteins; Signal Transduction | 2014 |
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Insertional; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Structural Homology, Protein; Translational Research, Biomedical | 2013 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Denmark; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Hydrocortisone; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Skin; Survival Analysis; Treatment Outcome | 2014 |
Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Community Networks; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Medical Oncology; Neoplasm Staging; Pemetrexed; Practice Patterns, Physicians'; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Topics: Amides; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Mutation; NF-kappa B; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Thiophenes | 2014 |
Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Retrospective Studies; Smoking; Treatment Outcome | 2014 |
Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Quinazolines; Remission Induction; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Aged; Aged, 80 and over; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2014 |
A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Specimen Handling; Time Factors | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
Gefitinib and non-small cell lunt cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2013 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2014 |
Afatinib for lung cancer: let there be light?
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Nitrosamines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines | 2014 |
Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Tamoxifen; Thymidine Phosphorylase; Time Factors | 2014 |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Luteolin; Male; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling.
Topics: Afatinib; Antigens, Neoplasm; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Coculture Techniques; Epithelial Cell Adhesion Molecule; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Integrins; Neoplasm Proteins; Quinazolines; Signal Transduction; Stromal Cells; Transforming Growth Factor beta | 2015 |
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Topics: AC133 Antigen; Animals; Antigens, CD; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Lung Neoplasms; Mice, Inbred NOD; Mutation; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Quinazolines; Receptor, IGF Type 1; Spheroids, Cellular; Up-Regulation | 2014 |
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Quinazolines; Quinolines; Receptors, Neurotensin; RNA, Small Interfering; Transcriptional Activation; Transforming Growth Factor alpha | 2014 |
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunity, Humoral; Immunoglobulin G; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Quinazolines | 2014 |
Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Random Allocation; Survivin; Xenograft Model Antitumor Assays | 2013 |
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinazolines; Sulfonamides; Transplantation, Heterologous | 2014 |
In-depth analysis shows synergy between erlotinib and miR-34a.
Topics: Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Quinazolines | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Neoplasm | 2014 |
High-dose, weekly erlotinib is not an effective treatment in EGFR-mutated non-small cell lung cancer-patients with acquired extracranial progressive disease on standard dose erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, Emission-Computed, Single-Photon | 2014 |
Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
Topics: Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Delivery of Health Care; Drug Costs; Gefitinib; Humans; Maintenance Chemotherapy; Models, Economic; Quality-Adjusted Life Years; Quinazolines | 2014 |
Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2014 |
MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2014 |
Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterografts; Histones; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Erlotinib induced target-like purpura.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purpura; Quinazolines | 2014 |
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Ascitic Fluid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catenins; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Simvastatin; Survivin | 2014 |
EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.
Topics: Animals; Apoptosis; Aurora Kinase B; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Chromatin; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase C-alpha; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation Tolerance; ras Proteins; Xenograft Model Antitumor Assays | 2014 |
Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitochondria; Pentacyclic Triterpenes; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Signal Transduction; Triterpenes | 2014 |
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Mice, Nude; Multimodal Imaging; Phthalazines; Piperidines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2014 |
Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Quinazolines; Severity of Illness Index; Symptom Assessment; Taiwan; Treatment Outcome | 2014 |
Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Taxoids | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy; Taxoids | 2014 |
Afatinib in NSCLC harbouring EGFR mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Peroxisome proliferator-activated receptor γ agonist efatutazone impairs transforming growth factor β2-induced motility of epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Smad2 Protein; Thiazolidinediones; Transforming Growth Factor beta2; Wound Healing | 2014 |
Efficacy of erlotinib plus dendritic cells and cytokine-induced killer cells in maintenance therapy of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Erlotinib Hydrochloride; Female; Humans; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
Topics: Adult; Aged; Budgets; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; Erlotinib Hydrochloride; Female; For-Profit Insurance Plans; Humans; Male; Managed Care Programs; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; SEER Program; United States | 2014 |
Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Death; Cell Proliferation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice, Nude; Microtubules; Mitosis; Niacinamide; Paclitaxel; Phosphorylation; Polymerization; Quinazolines; STAT3 Transcription Factor; Sulfonamides; Tubulin; Tumor Suppressor Protein p53; Vincristine | 2014 |
Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Quinazolines; Retrospective Studies; Ribonuclease III; RNA, Messenger | 2014 |
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome; United Kingdom | 2014 |
Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Tumor Cells, Cultured | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Synergism; Endothelial Cells; Epimedium; ErbB Receptors; Gefitinib; Humans; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
The TAILOR study: to agree or to disagree?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Research Design; Salvage Therapy; Taxoids | 2014 |
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Mutation; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Phenotype; Quinazolines; Retrospective Studies | 2014 |
Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Sequence Analysis, RNA | 2014 |
Radiation pneumonitis in patients with non--small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiography; Severity of Illness Index | 2014 |
VeriStrat validated in patients with non-small-cell lung cancer.
Topics: Blood Proteins; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2014 |
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cyclin B1; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Time Factors; Transfection; Tumor Burden; Wnt Proteins; Wnt-5a Protein; Xenograft Model Antitumor Assays | 2014 |
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; Disease-Free Survival; ErbB Receptors; Humans; Kaplan-Meier Estimate; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Paclitaxel; Quinazolines | 2014 |
Afatinib with concurrent radiotherapy in a patient with metastatic non-small cell lung cancer.
Topics: Afatinib; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Humans; Lung Neoplasms; Quinazolines; Radiotherapy, Conformal; Treatment Outcome | 2014 |
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate | 2014 |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2014 |
Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Marsdenia; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Epithelial-Mesenchymal Transition; Fibroblasts; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cognition Disorders; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2014 |
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Humans; Immunoconjugates; Lung Neoplasms; Maytansine; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Quinazolines | 2014 |
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; GPI-Linked Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Comparison is beyond IPASS and OPTIMAL.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Disease Models, Animal; Erlotinib Hydrochloride; Female; Fibroblasts; Humans; Interleukin-6; Lung Neoplasms; Mice; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Serine; STAT3 Transcription Factor; Tyrosine | 2014 |
Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Copy Number Variations; Drug Resistance, Neoplasm; Electrophoresis, Capillary; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Metabolome; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2014 |
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Renal Dialysis | 2014 |
Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Italy; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases | 2014 |
Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Platinum; Prognosis; Prospective Studies; Quinazolines; Reproducibility of Results; Risk Factors | 2014 |
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Topics: Animals; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gefitinib; Humans; Imidazoles; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Matrix; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2014 |
Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Mice; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcription, Genetic | 2014 |
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Mice, Nude; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
[A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Consensus; Drug Administration Schedule; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4 | 2014 |
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Transfection; Xenograft Model Antitumor Assays | 2014 |
Increased INR after gefitinib and acenocoumarol co-administration.
Topics: Acenocoumarol; Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Heart Failure; Humans; International Normalized Ratio; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2014 |
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Vimentin; X-Rays | 2014 |
EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Repetitive Sequences, Nucleic Acid; Risk Factors; Treatment Outcome | 2014 |
Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-κB, and cell-cycle progression in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; High Mobility Group Proteins; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Nude; NF-kappa B p50 Subunit; Quinacrine; Quinazolines; RNA, Small Interfering; Transcriptional Elongation Factors; Xenograft Model Antitumor Assays | 2014 |
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Treatment Outcome | 2014 |
Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; Erlotinib Hydrochloride; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Tomography, X-Ray Computed | 2014 |
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Radiopharmaceuticals; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Analysis | 2014 |
"Companion diagnostics": has their time come and gone?
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Proto-Oncogene Proteins c-met; Quinazolines | 2014 |
Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Neoplasm Proteins; Principal Component Analysis; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines | 2014 |
Monitoring cancer through the blood.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Monitoring, Physiologic; Protein Kinase Inhibitors; Quinazolines | 2014 |
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Nuclear Proteins; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Transfection; Twist-Related Protein 1 | 2014 |
Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Lactams, Macrocyclic; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3 | 2014 |
3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flavonoids; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Burden | 2014 |
High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Quinazolines; Spatio-Temporal Analysis | 2014 |
β-catenin contributes to lung tumor development induced by EGFR mutations.
Topics: Afatinib; Animals; Antineoplastic Agents; beta Catenin; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Doxycycline; ErbB Receptors; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Mice, Transgenic; Mutation, Missense; Protein Stability; Quinazolines; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
What new therapeutic targets exist for EGFR-mutant NSCLC?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2014 |
TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Topics: Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines | 2014 |
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, Nude; Mutation; Pyrimidines; Quinazolines; Signal Transduction; src-Family Kinases; Thiazoles; Xenograft Model Antitumor Assays | 2014 |
Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Melatonin; Mutation; Phosphorylation; Quinazolines | 2014 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Pulmonary embolism with haemorrhagic pericardial effusion and tamponade: a clinical dilemma.
Topics: Anticoagulants; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Diagnosis, Differential; Drainage; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Multiple Organ Failure; Pericardial Effusion; Protein Kinase Inhibitors; Pulmonary Embolism; Quinazolines; Treatment Outcome; Vena Cava Filters | 2014 |
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Methionine; Mice; Mutation; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Threonine | 2014 |
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glycosides; Humans; Marsdenia; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pregnanes; Quinazolines | 2014 |
Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; China; Chromatography, High Pressure Liquid; Crown Ethers; Cytochrome P-450 CYP2C19; Disease-Free Survival; Drug Eruptions; Female; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Tandem Mass Spectrometry | 2014 |
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 8; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Microscopy, Confocal; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Transport; Quinazolines | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome | 2014 |
Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Female; Gastric Acid; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Omeprazole; Population Groups; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.
Topics: Adult; Afatinib; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2015 |
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retreatment; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pulsatilla; Quinazolines; Saponins; Signal Transduction | 2014 |
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Topics: Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins | 2015 |
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Comparative Genomic Hybridization; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Eukaryotic Initiation Factor-4E; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Protein Biosynthesis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-pim-1; Quinazolines; Transcription, Genetic | 2014 |
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies | 2015 |
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Are we expanding oligometastatic non-small-cell lung cancer using advanced radiotherapeutic modalities?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiosurgery | 2014 |
Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Quinazolines; Time Factors | 2015 |
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cytoskeletal Proteins; Female; Humans; Lung Neoplasms; Neoplasm Metastasis; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Treatment Outcome | 2016 |
Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; Quinazolines; Resting Phase, Cell Cycle; Signal Transduction | 2015 |
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Topics: Antigens, CD; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Time Factors; Transfection; Vimentin | 2014 |
Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Proteins | 2014 |
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic | 2015 |
Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Extracts; Cell Line, Tumor; Cytoplasmic Vesicles; Drug Resistance, Neoplasm; Extracellular Space; Gefitinib; Humans; Phospholipids; Quinazolines | 2015 |
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to erlotinib via transcriptional regulation of EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2014 |
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Stevens-Johnson Syndrome | 2015 |
Is the evidence of the Supreme Court Ruling of gefitinib litigation in Japan scientific?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Labeling; Drug Packaging; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
Pan-HER inhibition in EGFR wild-type non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins | 2014 |
Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease-Free Survival; Drugs, Chinese Herbal; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2014 |
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Topics: Activin Receptors, Type II; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Imidazoles; Lung Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Nude; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinolines; ras Proteins; TOR Serine-Threonine Kinases | 2014 |
Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Administration Schedule; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2014 |
The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Chromones; Cytoplasm; Diketopiperazines; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 4 or More Rings; Humans; Lung Neoplasms; Morpholines; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; CpG Islands; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Phenotype; Prognosis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2014 |
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enoxaparin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rac GTP-Binding Proteins; Vimentin; Xenograft Model Antitumor Assays | 2015 |
Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sodium; Treatment Outcome | 2014 |
Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pneumonectomy; Quinazolines | 2016 |
[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2015 |
Nit-picking around second line in EGFRwt NSCLC: just an academic effort.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Quinazolines | 2015 |
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Quinazolines; RNA, Small Interfering; Signal Transduction | 2015 |
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HLA-A2 Antigen; Humans; Immunotherapy; Mutation; Peptides; Quinazolines | 2015 |
Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Topics: Afatinib; Aged; Animals; Apoptosis; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; ets-Domain Protein Elk-1; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Binding; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2015 |
Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; White People | 2015 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Receptor, Notch1; Tumor Suppressor Protein p53 | 2014 |
[Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Crown Ethers; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Signal Transduction | 2014 |
Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epidemiologic Methods; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer in the era of personalized medicine.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2015 |
Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Palliative Care; Quinazolines; Taxoids | 2015 |
Reply to G. Spitzer and M.A. Socinski, F. Zhou et al, and B. Biswas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Palliative Care; Quinazolines; Taxoids | 2015 |
Epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR wild-type lung cancer: when there is a target, there is a targeted drug.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2015 |
Reply to G. Spitzer and M.A. Socinski.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Palliative Care; Quinazolines; Taxoids | 2015 |
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Dual Specificity Phosphatase 1; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols | 2015 |
Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors.
Topics: Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Lung Neoplasms; Male; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Myelitis; Palliative Care; Quinazolines; Radiation Injuries; Spinal Neoplasms; Thoracic Vertebrae | 2015 |
AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827.
Topics: Antineoplastic Agents; Aurora Kinase A; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, erbB-1; Humans; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Quinazolines; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Stromal Cells; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Taiwan; Tuberculosis, Pulmonary | 2015 |
Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway.
Topics: Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction | 2015 |
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Polycomb Repressive Complex 1; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2015 |
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib.
Topics: AC133 Antigen; Afatinib; Antigens, CD; Antigens, Neoplasm; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Epithelial Cell Adhesion Molecule; ErbB Receptors; Glycoproteins; Humans; Lung Neoplasms; Neoplastic Stem Cells; Peptides; Quinazolines | 2015 |
Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; MCF-7 Cells; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2015 |
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Nicotine; Quinazolines; Receptors, Nicotinic; Signal Transduction; Smoking | 2015 |
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; G1 Phase; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidinones; Quinazolines; Sulfonamides; Up-Regulation; Vemurafenib | 2015 |
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Topics: Afatinib; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Shape; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; MAP Kinase Signaling System; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; rho GTP-Binding Proteins | 2015 |
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2015 |
Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Molecular Targeted Therapy; Mutation; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2015 |
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Random Allocation; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2015 |
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Retrospective Studies; Seoul | 2016 |
Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Young Adult | 2015 |
Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
Topics: Adenine; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2015 |
Overcoming Resistance Without the Risk of Reaction: Use of Afatinib and Panitumumab in Two Cases of Epidermal Growth Factor Receptor--Mutated Non--Small-Cell Lung Cancer With T790M Mutations.
Topics: Afatinib; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Panitumumab; Quinazolines | 2015 |
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2015 |
Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; HEK293 Cells; Humans; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2015 |
Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2015 |
Importance of ethnicity and smoking status in EGFR gene testing in lung cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2015 |
An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Mapping; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Signal Transduction | 2015 |
Current two EGFR mutations in lung adenocarcinoma - case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2015 |
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2015 |
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines | 2015 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proteomics; Quinazolines; Receptor, EphA2 | 2015 |
Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
[Hange-Shashin-to for preventing diarrhea during afatinib therapy].
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drugs, Chinese Herbal; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2015 |
Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Drugs, Chinese Herbal; Gefitinib; Male; Marsdenia; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Everolimus; Female; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neuroimaging; Oncogene Proteins, Fusion; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-3; Regression Analysis; Signal Transduction; Structural Homology, Protein; Thermodynamics | 2015 |
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Topics: Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Retrospective Studies | 2015 |
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2015 |
Case records of the Massachusetts General Hospital. Case 17-2015. A 44-year-old woman with intractable pain due to metastatic lung cancer.
Topics: Adult; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Conscious Sedation; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Frameshift Mutation; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Lymphatic Metastasis; Pain Management; Pain, Intractable; Palliative Care; Quinazolines; Radiography | 2015 |
An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Peroxiredoxins; Quinazolines; Reactive Oxygen Species | 2015 |
Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Surface Area; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Glycolysis; Humans; Lung Neoplasms; Male; Quinazolines; Radionuclide Imaging | 2015 |
Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Afatinib (Gilotrif) for advanced non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Comorbidity; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Radiosurgery; Retrospective Studies; Taiwan; Treatment Outcome | 2015 |
EGFR mutations and EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2015 |
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Mice; Mutation; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, Nude; Photochemotherapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Platinum Compounds; Population Groups; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2015 |
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2015 |
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; China; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Male; MCF-7 Cells; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2015 |
Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Decision Making; Drug Utilization; Erlotinib Hydrochloride; Female; Gefitinib; Hospital Administration; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; National Health Programs; Ownership; Quinazolines; Residence Characteristics; Taiwan | 2015 |
[Comparison of the Efficacy and Safety of Icotinib with Standard Second-line
Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
[Molecular targeted therapies and cytotoxics: Friends or foes?].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines | 2015 |
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation | 2015 |
Afatinib for Erlotinib Refractory Brain Metastases in a Patient with EGFR-Mutant Non-Small-Cell Lung Cancer: Can High-Affinity TKI Substitute for High-Dose TKI?
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2015 |
Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Retreatment; Treatment Outcome | 2015 |
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cyclins; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Mutation; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; RNA, Messenger; src-Family Kinases | 2015 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Harringtonines; Homoharringtonine; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Male; Mice; Mice, Nude; Mitochondria; Phosphorylation; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Taxoids; Transplantation, Heterologous | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Consensus; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Quinazolines | 2015 |
MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference | 2015 |
Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Spheroids, Cellular | 2015 |
FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Glycolysis; Humans; Lung Neoplasms; Male; Quinazolines; Radionuclide Imaging | 2015 |
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Survival Rate | 2015 |
Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2015 |
Reply: To PMID 25546556.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2015 |
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
Topics: Afatinib; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retinal Dehydrogenase; Sequence Analysis, DNA; Taxoids | 2015 |
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Chromones; Connexin 26; Connexins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gap Junctions; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Sounds; Treatment Outcome | 2015 |
Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Prognosis; Quinazolines | 2015 |
The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2015 |
Can the Lung Cancer Pie Be Divided into Angiogenic Slices?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2015 |
Gefitinib Approved for EGFR-Mutated NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2015 |
Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Mice; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Drug Monitoring; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Survival Analysis | 2015 |
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Support Techniques; DNA Mutational Analysis; Economics, Pharmaceutical; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Markov Chains; Mutation; Paclitaxel; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2015 |
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane Permeability; Crystallography, X-Ray; Databases, Chemical; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Kinetics; Lung Neoplasms; Models, Molecular; Molecular Conformation; Mutation; Pyrazoles; Pyrimidines; Quinazolines; Small Molecule Libraries; Solubility; src-Family Kinases; Structure-Activity Relationship | 2015 |
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2015 |
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; SOXB1 Transcription Factors; Spheroids, Cellular; Stem Cells; Transcription Factors; Tumor Cells, Cultured; Zinc Finger Protein GLI1 | 2015 |
Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Membrane Proteins; Proteomics; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neurons; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
[Retrospective Analysis of the Afatinib Clinical Pathway during the 28-Day Introductory Period-The Japanese Style of Collaborative Drug Therapy Management(J-CDTM)].
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Medication Therapy Management; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Young Adult | 2015 |
Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; ras Proteins; RNA Interference; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Lung cancer in China: The new frontier?
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Humans; Male; Molecular Targeted Therapy; Quinazolines; Smoking | 2015 |
Predictive efficacy of (11)C-PD153035 PET imaging for EGFR-tyrosine kinase inhibitor sensitivity in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Heterografts; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Nude; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2015 |
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Latin America; Lung Neoplasms; Male; Mexico; Models, Econometric; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2016 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin; Lung Neoplasms; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, IGF Type 1; RNA, Messenger; Signal Transduction | 2015 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2015 |
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2015 |
Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Topics: Animals; Benzamides; Benzodioxoles; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Diphenylamine; Dose-Response Relationship, Drug; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Humans; Immunoblotting; Lung Neoplasms; MAP Kinase Kinase 1; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Functionalized gold nanoparticles improve afatinib delivery into cancer cells.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Gold; Humans; Inhibitory Concentration 50; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Protein-Tyrosine Kinases; Quinazolines | 2016 |
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Markov Chains; Models, Economic; Molecular Targeted Therapy; Mutation; Patient Selection; Pemetrexed; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Uncertainty; United States | 2015 |
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Voltage-Dependent Anion Channel 1; Vorinostat | 2015 |
Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Ligands; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Killer Cells, Natural; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Quinazolines | 2015 |
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Quinazolines; Salvage Therapy; Tegafur | 2015 |
Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cathepsin L; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2016 |
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Hospitals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Smoking | 2015 |
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Mice, Nude; Mice, SCID; Molecular Dynamics Simulation; Mutation; Phenols; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
Topics: Animals; Apoptosis; Benzophenanthridines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Isoquinolines; Lung Neoplasms; Membrane Glycoproteins; Membrane Proteins; Methionine; Mice; Models, Biological; Models, Molecular; Molecular Conformation; NADPH Oxidase 2; NADPH Oxidases; Oxidation-Reduction; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; ErbB Receptors; Gefitinib; Gene Expression Regulation; HEK293 Cells; Humans; Indoles; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Tandem Mass Spectrometry | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
Topics: Afatinib; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Transfection; Xenograft Model Antitumor Assays | 2016 |
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hospitals, University; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Risk Factors; Salvage Therapy; Time Factors; Treatment Failure | 2015 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Female; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice, Nude; Middle Aged; Paclitaxel; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Genetic Markers; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Retrospective Studies; Risk Factors; Sex Distribution; Smoking; Switzerland; Treatment Outcome | 2015 |
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome | 2015 |
Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Novel Quinazoline Derivatives Bearing Various 4-Aniline Moieties as Potent EGFR Inhibitors with Enhanced Activity Against NSCLC Cell Lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Quinazolines; Spectrometry, Mass, Electrospray Ionization | 2016 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2016 |
Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Time Factors | 2016 |
Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Quinazolines; Resveratrol; Stilbenes | 2015 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Topics: Actin Cytoskeleton; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diterpenes; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Afatinib and chemotherapy in non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines | 2016 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Remission Induction | 2016 |
TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; ErbB Receptors; Gefitinib; Heterografts; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Transfection | 2016 |
The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Quinazolines; Simvastatin; Up-Regulation | 2016 |
Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Sarcopenia Is a Condition With Increasing Importance in Medical Oncology.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
In Reply.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Male; Quinazolines | 2016 |
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2016 |
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Phenotype; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
[Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2016 |
The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; p21-Activated Kinases; Protein Kinase Inhibitors; Quinazolines | 2016 |
Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Morpholines; Mutation; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction | 2016 |
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2016 |
Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Quinazolines | 2016 |
Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Topics: Adenine Nucleotide Translocator 2; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Promoter Regions, Genetic; Quinazolines; RNA, Small Interfering; Up-Regulation | 2016 |
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2016 |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome | 2016 |
Resistance: Following different paths.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
What is the clinical impact of the LUX-Lung 5 trial?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Topics: Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cadherins; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Up-Regulation | 2016 |
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastric Acid; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Models, Molecular; Molecular Conformation; Molecular Structure; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2016 |
Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Endocytosis; Ephedra; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Glycoproteins; Humans; Hypoxia; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred NOD; Microscopy, Fluorescence; Mutation; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Phenotype; Quinazolines; Real-Time Polymerase Chain Reaction | 2016 |
Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation.
Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cardiac Glycosides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Digitoxin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Medicine, Chinese Traditional; Microtubules; Mutation; Quinazolines; Tubulin | 2016 |
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2016 |
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.
Topics: Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Markov Chains; Mutation; Quinazolines | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Time Factors | 2016 |
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Choroidal metastasis as a presenting manifestation of a lung adenocarcinoma with response to afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Signal Transduction | 2016 |
Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Topics: A549 Cells; Animals; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 12; Membrane Proteins; Mice; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Mutation; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2017 |
Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
[Clinical Analysis of Icotinib on Beneficiary of
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2016 |
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2016 |
Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Inhibitory Concentration 50; Liliaceae; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Saponins; Signal Transduction | 2016 |
Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Brain Chemistry; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Piperidines; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multivariate Analysis; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prospective Studies; Quinazolines | 2016 |
Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ets-Domain Protein Elk-1; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrolases; Lung Neoplasms; Protein-Arginine Deiminase Type 4; Protein-Arginine Deiminases; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Are TKIs favourable for the elderly with non-small-cell lung cancer?
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Necrolytic Migratory Erythema; Protein Kinase Inhibitors; Quinazolines; Rare Diseases; Risk Assessment; Withholding Treatment | 2016 |
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Interleukin-8; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phenotype; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cyclosporine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NFATC Transcription Factors; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Plicamycin; Quinazolines; Signal Transduction; Sp1 Transcription Factor | 2016 |
PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fimbriae Proteins; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction | 2016 |
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 13; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2016 |
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydroxychloroquine; Lung Neoplasms; Lymphatic Metastasis; Mice; MicroRNAs; Neoplastic Stem Cells; Oligonucleotides; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Consensus; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Quinazolines | 2016 |
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Stem Cell Assay; Ubiquitin; Ubiquitination | 2016 |
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Autophagy-Related Protein-1 Homolog; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Dasatinib; Down-Regulation; Humans; Intracellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; src-Family Kinases | 2017 |
LUX-Lung 7: is there enough data for a final conclusion?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
LUX-Lung 7: is there enough data for a final conclusion?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
LUX-Lung 7: is there enough data for a final conclusion?
Topics: Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Quinazolines | 2016 |
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines | 2016 |
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gallic Acid; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
[Not Available].
Topics: Afatinib; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gossypol; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2016 |
Implications of Blood-Based T790M Genotyping and Beyond in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Genotype; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2016 |
Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Female; Gefitinib; Humans; Interviews as Topic; Male; Middle Aged; Mutation; Qualitative Research; Quinazolines; Reimbursement, Incentive; Spain | 2017 |
Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2016 |
Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxycholesterols; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Pyridines; Quinazolines; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Thiazoles; Triterpenes; Xenograft Model Antitumor Assays | 2016 |
Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Humans; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Wales | 2016 |
EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Variations in EGFR ctDNA Correlates to the Clinical Efficacy of Afatinib in Non Small Cell Lung Cancer with Acquired Resistance.
Topics: Afatinib; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crown Ethers; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Gene Library; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2016 |
Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Contrast Media; Drug Resistance, Neoplasm; ErbB Receptors; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Positron-Emission Tomography; Quinazolines; Substrate Specificity | 2016 |
Acquired Resistance to First-Line Afatinib and the Challenges of Prearranged Progression Biopsies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Middle Aged; Mutation; Pilot Projects; Prospective Studies; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Plasminogen Activator Inhibitor 2; Pseudopodia; Quinazolines | 2016 |
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glucuronosyltransferase; Humans; Lung Neoplasms; Middle Aged; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome | 2016 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Gefitinib; Humans; Liver Function Tests; Lung Neoplasms; Male; Middle Aged; Mutation; Overweight; Quinazolines; Retrospective Studies; Risk Factors | 2016 |
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Propensity Score; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2016 |
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Programmed Cell Death 1 Receptor; Quinazolines; Survival Analysis; Tumor Escape | 2016 |
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterografts; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Oxazoles; Quinazolines; Resorcinols | 2016 |
Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Quinazolines; Receptors, Fibroblast Growth Factor; Signal Transduction; Treatment Outcome | 2016 |
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mice; Neoplasm Recurrence, Local; Quinazolines; Tankyrases; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Transfection | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog.
Topics: A549 Cells; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gefitinib; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; PTEN Phosphohydrolase; Quinazolines | 2016 |
EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chalcone; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Structure, Secondary; Quinazolines | 2017 |
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Heterogeneity; Humans; Liver Neoplasms; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2017 |
Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Humans; Lung Neoplasms; Male; Mutation; Pulmonary Surgical Procedures; Quinazolines; Remission Induction; Treatment Outcome | 2016 |
Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Octamer Transcription Factor-3; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering | 2016 |
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
One-step radiosynthesis of
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Mice; Molecular Structure; Positron Emission Tomography Computed Tomography; Quinazolines; Radioactive Tracers; Structure-Activity Relationship; Tissue Distribution | 2016 |
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epiderm
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Costs; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
Topics: A549 Cells; Angiogenesis Inhibitors; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Docetaxel; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Naphthoquinones; Neoplasm Recurrence, Local; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thioredoxin-Disulfide Reductase | 2017 |
Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies | 2016 |
Tolerability and efficacy of afatinib at a low starting dosage in 10 elderly or low performance status patients with advanced refractory non-small-cell lung cancer.
Topics: Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; ErbB Receptors; Female; Humans; Intra-Abdominal Fat; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Renal Dialysis | 2017 |
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Topics: Adult; Afatinib; Aged; Amino Acid Sequence; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Conformation; Protein Domains; Protein Multimerization; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Retrospective Studies; Sequence Alignment | 2017 |
The effect of low dosage of procaine on lung cancer cell proliferation.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mice; Procaine; Quinazolines | 2016 |
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome | 2016 |
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Snail Family Transcription Factors; STAT3 Transcription Factor | 2016 |
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases.
Topics: Aged; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Central Nervous System Neoplasms; Disease Models, Animal; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spinal Cord | 2016 |
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drugs, Chinese Herbal; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucin-1; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger | 2016 |
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Rate | 2017 |
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Computer Simulation; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Economic; Molecular Targeted Therapy; Mutation; Pemetrexed; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Time Factors; Treatment Outcome | 2017 |
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Long Noncoding | 2017 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan | 2017 |
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Circulating Tumor DNA; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Genome; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Neoplasm Metastasis; Oncogene Proteins, Fusion; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; Recurrence | 2017 |
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Saponins; Steroids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Aurora B expression modulates paclitaxel response in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Organophosphates; Paclitaxel; Quinazolines; Up-Regulation | 2017 |
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Novel EGFR Exon 18 (G721R) Mutation in a Patient with Non-Small Cell Lung Carcinoma with Lack of Response to Afatinib.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Heterogeneity; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines | 2017 |
Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Receptor, Endothelin B; Receptor, ErbB-2; Transcriptional Activation | 2017 |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Maytansine; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Quinazolines; Retrospective Studies; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2017 |
Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver X Receptors; Lung Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2017 |
Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Quinazolines | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
Topics: A549 Cells; Active Transport, Cell Nucleus; Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nuclear Export Signals; Nuclear Localization Signals; Protein Binding; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transfection | 2017 |
A fluorescent light-up aggregation-induced emission probe for screening gefitinib-sensitive non-small cell lung carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Optical Imaging; Peptides; Protein Kinase Inhibitors; Quinazolines; Stilbenes | 2017 |
Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topics: Afatinib; Agranulocytosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HMGA1a Protein; Humans; Lung Neoplasms; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2017 |
Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
From nihilism to individualism: the evolution of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK.
Topics: Amino Acid Substitution; Apoptosis; Arginine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leucine; Lung Neoplasms; Mitochondria; Mutation; Oxidative Phosphorylation; Protein Structure, Quaternary; Protein Transport; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering | 2008 |
EGFR polymorphism of the kinase domain in Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Polymorphism, Genetic; Prognosis; Quinazolines | 2008 |
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitomycin; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; RNA, Messenger; Transfection | 2008 |
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Peptides; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein C; Quinazolines | 2008 |
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines | 2008 |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2008 |
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor beta1 | 2009 |
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Survival Rate; Treatment Outcome | 2009 |
[Successful treatment of non-small cell lung cancer by gefitinib in an elderly patient with poor performance status].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines | 2008 |
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Topics: Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genes, erbB-1; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis | 2008 |
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Codon, Nonsense; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed | 2008 |
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
Topics: Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2008 |
Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Topics: Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoblotting; Lung Neoplasms; Mesoderm; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Electrospray Ionization; Thiophenes; Transforming Growth Factor beta; Tumor Cells, Cultured | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pulmonary Alveoli; Quinazolines; Tomography, X-Ray Computed | 2008 |
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2008 |
[Targeted therapies. New hopes, new challenges].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A | 2008 |
Gefitinib maintenance in stage III non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2008 |
SWOG S0023: what meets the eye may be only half the truth.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2008 |
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.
Topics: Aged; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2008 |
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cell Division; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Staging; Placebos; Platinum Compounds; Prognosis; Quinazolines; Survival Analysis | 2009 |
Non-small cell lung cancer-smokers or non-smokers, does it matter?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Newer opportunities in systemic therapy of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung; Lung Neoplasms; Middle Aged; Quinazolines; Radiation Pneumonitis; Radiotherapy; Treatment Outcome | 2008 |
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; Introns; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2008 |
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cohort Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Survival Analysis | 2009 |
Rosaceiform eruption induced by erlotinib.
Topics: Acneiform Eruptions; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2008 |
Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed | 2008 |
A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
A population-based study of gefitinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Demography; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking | 2009 |
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate | 2008 |
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Oncogene Protein v-akt; Quinazolines; Time Factors; Tumor Cells, Cultured | 2008 |
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; EGF Family of Proteins; Gefitinib; Genes, erbB-1; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Prolonged response to first-line erlotinib for advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Inteins; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Quinazolines; Treatment Outcome | 2009 |
Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Treatment Outcome | 2009 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proteasome Endopeptidase Complex; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2008 |
Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cicatrix; Disease Progression; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Risk Assessment | 2008 |
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2009 |
Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hematoma, Subdural; Humans; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2009 |
[Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Salvage Therapy; Treatment Failure | 2008 |
Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasms; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Reproducibility of Results; Tumor Cells, Cultured | 2009 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disseminated Intravascular Coagulation; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thrombocytopenia | 2009 |
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dideoxynucleosides; Down-Regulation; Early Detection of Cancer; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Lung Neoplasms; Mice; Positron-Emission Tomography; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2008 |
[Sequential administration of gefitinib and docetaxel as second-line therapy for advanced non-small cell lung cancer: analysis of 82 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Mice; Neoplasms; Oligopeptides; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tissue Distribution; Triazoles | 2009 |
Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclosporine; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2009 |
[Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Smoking; Survival Rate; Treatment Outcome | 2008 |
Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2009 |
[Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Utilization; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Erlotinib for the treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2009 |
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Caspase 12; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Transcription Factor CHOP; Tunicamycin | 2009 |
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Primers; Enzyme Inhibitors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Immunoprecipitation; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-3 | 2009 |
Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Multiple Primary; Quinazolines; Sequence Deletion; Treatment Outcome | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides | 2009 |
PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans.
Topics: Adult; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Ligands; Lung Neoplasms; Male; Metabolic Clearance Rate; Positron-Emission Tomography; Quinazolines; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Young Adult | 2009 |
[Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction | 2008 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Glutamates; Guanine; Humans; Integrin beta1; Lung Neoplasms; Morpholines; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Taxoids | 2008 |
[Erlotnib in the treatment of advanced non-small cell lung cancer failed to previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cisplatin; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Remission Induction; Treatment Failure; Young Adult | 2008 |
Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dual Specificity Phosphatase 1; ErbB Receptors; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tyrphostins | 2009 |
Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multivariate Analysis; Prognosis; Quinazolines; Reproducibility of Results; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Staging; Palliative Care; Quinazolines; Radiotherapy Dosage | 2009 |
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Depsipeptides; Drug Synergism; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Xenograft Model Antitumor Assays | 2009 |
Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Treatment Outcome | 2009 |
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Oxonic Acid; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Tegafur; Thymidylate Synthase | 2009 |
Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatomycoses; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Perineum; Quinazolines; Scalp Dermatoses; Treatment Outcome | 2009 |
Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2009 |
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Eukaryotic Initiation Factor-3; Female; Gefitinib; Gene Amplification; Genes, myc; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Avastin-Tarceva combination fails in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Neoplasms; Quinazolines | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Erlotinib-induced pustular eruption.
Topics: Acneiform Eruptions; Administration, Cutaneous; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythromycin; Gels; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2009 |
Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Diphosphonates; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Organophosphonates; Quinazolines; Transplantation, Heterologous; Zoledronic Acid | 2009 |
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Signal Transduction | 2009 |
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Wound Healing | 2009 |
[Description of erlotinib-related skin effects management in France. Results of the PRECEDE study].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; France; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Genes, ras; Genome; Humans; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Probability; Prognosis; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Survival Analysis | 2009 |
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2009 |
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cyclin D1; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines; Survival Rate | 2009 |
Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Smoking; Tissue Culture Techniques | 2009 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous | 2009 |
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Survival; Depsipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Aberrations; Cluster Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Gene Expression; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2009 |
[A case of non-small cell lung cancer with EGFR mutation responding to S-1 after a therapy with gefitinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oxonic Acid; Quinazolines; Tegafur; Tomography, X-Ray Computed | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Humans; Predictive Value of Tests; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Smoking | 2008 |
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
Topics: Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Metabolome; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines | 2009 |
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Immunosuppressive Agents; Lung Neoplasms; Phosphorylation; Quinazolines; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Meta-Analysis as Topic; Piperidines; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Docetaxel; Drug Costs; Erlotinib Hydrochloride; Germany; Glutamates; Guanine; Humans; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Topics: Antineoplastic Agents; Brazil; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost Control; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Sensitivity and Specificity; Taxoids | 2008 |
Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Culture Media, Serum-Free; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2009 |
[Potent and continuous relief of spinal bone pain due to metastasis of non-small cell lung cancer by treatment with gefitinib--a case report].
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Pain; Quinazolines; Spine; Tomography, X-Ray Computed | 2009 |
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Disease Progression; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Immunohistochemistry; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningitis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed | 2009 |
Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Aged; Artifacts; Biopsy; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radionuclide Imaging; Retrospective Studies | 2009 |
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; RNA, Small Interfering; src-Family Kinases | 2009 |
Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; K562 Cells; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tumor Cells, Cultured; Vincristine | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Disease Models, Animal; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Neoplasm Proteins; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Furans; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2009 |
Role of tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2009 |
A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inflammation; Lung Neoplasms; Middle Aged; Quinazolines | 2009 |
Molecular imaging of EGFR: it's time to go beyond receptor expression.
Topics: Adult; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Ligands; Lung Neoplasms; Male; Metabolic Clearance Rate; Molecular Probe Techniques; Positron-Emission Tomography; Quinazolines; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, X-Ray Computed; Young Adult | 2009 |
Assessment of erlotinib in chemoresponse assay.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2009 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2009 |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Analysis | 2010 |
[Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2009 |
Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Smoking; Treatment Outcome | 2009 |
Key questions for perioperative chemotherapy in resectable lung cancer: not pre vs post, but who and what?
Topics: Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Proteins; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Exons; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2009 |
Erlotinib for the treatment of relapsed non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Technology Assessment, Biomedical | 2009 |
Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Early Detection of Cancer; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2010 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines | 2010 |
Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Survival Analysis | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers.
Topics: Adult; Aged; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Quinazolines; RNA, Antisense; Signal Transduction; Smoking; Tyrphostins | 2009 |
Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy.
Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Injections, Intraocular; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vitreous Body | 2009 |
Wood-smoke exposure as a response and survival predictor in erlotinib-treated nonsmall cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoke; Survival Rate; Wood | 2009 |
[Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2009 |
The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells.
Topics: Animals; Anticarcinogenic Agents; Carcinoma, Non-Small-Cell Lung; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Mice; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2009 |
Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Europe; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2009 |
Gefitinib: phoenix from the flames.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2009 |
Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Y-Box-Binding Protein 1 | 2009 |
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking | 2009 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines | 2010 |
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2010 |
Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cysts; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors; Treatment Outcome | 2009 |
Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Stability; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2009 |
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Phosphorylation; Quinazolines; Tyrosine | 2009 |
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Online Systems; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Registries | 2009 |
Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Respiration; Enzyme Activation; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Membrane Glycoproteins; Mitochondria; NADPH Oxidase 2; NADPH Oxidases; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Estrogen replacement in female lung cancer during gefitinib therapy.
Topics: Animals; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Estrogen Replacement Therapy; Estrogens; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Personalized medicine and inhibition of EGFR signaling in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Screening for epidermal growth factor receptor mutations in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sex Distribution; Survival Analysis; Young Adult | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2009 |
Effect of gefitinib on warfarin antithrombotic activity.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; International Normalized Ratio; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Prothrombin Time; Quinazolines; Retrospective Studies; Time Factors; Warfarin | 2009 |
I am no one. No one is perfect...Therefore I am perfect.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2009 |
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids | 2009 |
Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Liver Cirrhosis; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction | 2010 |
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Insurance, Health, Reimbursement; Lung Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2010 |
Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.
Topics: Animals; Antineoplastic Agents; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glutathione; Hepatocytes; Humans; Lung; Lung Neoplasms; Mice; Microsomes; Microsomes, Liver; Quinazolines | 2009 |
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; src-Family Kinases; Thiazoles | 2010 |
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mitochondria; Quinazolines | 2010 |
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
Topics: Amphiregulin; Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Histone Acetyltransferases; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Ku Autoantigen; Lung Neoplasms; Mice; Quinazolines; Subcellular Fractions; Vorinostat | 2010 |
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Keratin-19; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Peptides; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2010 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Treatment Failure | 2009 |
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
EGFR-TKI treatment and surgical resection for oligometastatic NSCLC?
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Non-Small-Cell Lung; Community Health Services; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors | 2009 |
Clinical significance of the KRAS mutation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Guidelines as Topic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Hand-foot syndrome and seborrheic dermatitis-like eruption induced by erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dermatitis, Seborrheic; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Follow-Up Studies; Hand Dermatoses; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Syndrome | 2009 |
Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Topics: Animals; Apoptosis; Benzodioxoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Erlotinib-induced skin manifestations.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Estrogen Receptor beta; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Receptor Cross-Talk; Signal Transduction; Tamoxifen | 2010 |
[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Radiosurgery | 2009 |
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2009 |
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2010 |
Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer.
Topics: Budgets; Carcinoma, Non-Small-Cell Lung; Cost Control; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Economic; Protein Synthesis Inhibitors; Quinazolines | 2010 |
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Topics: Analgesics; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2010 |
[Lung cancer: an update in 2010].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA; Female; Gefitinib; Genotype; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Quinazolines | 2010 |
[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Remission Induction; Survival Rate | 2010 |
Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Taiwan; Young Adult | 2010 |
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
Randomized clinical trials with biomarkers: design issues.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; DNA-Binding Proteins; Endonucleases; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Staurosporine | 2010 |
Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2010 |
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
Topics: Afatinib; Amino Acid Substitution; Animals; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Furans; Humans; Lung Neoplasms; Molecular Structure; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2010 |
Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2010 |
First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Alopecia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Mutation; Quinazolines; Treatment Outcome | 2010 |
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2010 |
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?
Topics: Biomarkers, Tumor; Blood Chemical Analysis; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Predictive Value of Tests; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome | 2010 |
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion.
Topics: Aniline Compounds; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Models, Molecular; Quinazolines; Structure-Activity Relationship | 2010 |
[A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Quinazolines; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion; Predictive Value of Tests; Quinazolines; Survival Analysis | 2010 |
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Economics and the new generation of targeted therapies for non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; United States | 2010 |
Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Female; Hospitalization; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; Gefitinib; Hematuria; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Urinary Bladder Diseases | 2010 |
Discovery of N-methyl-4-(4-methoxyanilino)quinazolines as potent apoptosis inducers. Structure-activity relationship of the quinazoline ring.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Female; Humans; Quinazolines; Structure-Activity Relationship | 2010 |
Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disseminated Intravascular Coagulation; Female; Gefitinib; Humans; Quinazolines | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Multicenter Studies as Topic; Prognosis; Quinazolines; Retrospective Studies | 2011 |
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation | 2010 |
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Heterocyclic Compounds, 4 or More Rings; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Renal Dialysis; Tissue Distribution; Treatment Outcome | 2010 |
The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Deoxyadenosines; DNA Damage; DNA Glycosylases; DNA Repair; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Y-Box-Binding Protein 1 | 2010 |
BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Separation; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA Interference; RNA, Small Interfering | 2011 |
Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2009 |
[Maintenance treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Network meta-analysis: importance of appropriate trial selection.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Confidence Intervals; Docetaxel; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Meta-Analysis as Topic; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Taxoids | 2010 |
Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: a brief report.
Topics: Adenocarcinoma; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Osteoblasts; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.
Topics: Antibodies, Blocking; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Kidney; Lung Neoplasms; Octamer Transcription Factor-1; Organic Cation Transport Proteins; Organic Cation Transporter 2; Phosphorylation; Quinazolines; RNA, Messenger | 2010 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
Topics: Acetylcysteine; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neurokinin B; Phosphorylation; Phosphotyrosine; Quinazolines; Reactive Oxygen Species; Receptors, Bombesin; Transcriptional Activation; Tumor Cells, Cultured | 2010 |
Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Serious hematologic complications following erlotinib treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Topics: Animals; Antineoplastic Agents; Butadienes; Carcinoma, Non-Small-Cell Lung; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Mice; Mutation; Nitriles; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines | 2010 |
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Exanthema; Female; Humans; Japan; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quinazolines; Risk | 2010 |
Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seasons; Vaccination | 2010 |
Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Furans; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases | 2010 |
EGFR mutations in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2010 |
Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; DNA Primers; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2010 |
Folliculitis decalvans associated with erlotinib.
Topics: Alopecia; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Folliculitis; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Staphylococcus aureus | 2010 |
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Endothelial Cells; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stem Cells; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Quinazolines; Signal Transduction | 2011 |
A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Point Mutation; Prognosis; Quinazolines | 2010 |
Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mice; Mutation; Oxonic Acid; Pemetrexed; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2010 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Amplification; Gene Deletion; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Markov Chains; Neoplasm Staging; Pemetrexed; Placebos; Quinazolines; Remission Induction; Survival Rate; Treatment Outcome | 2010 |
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Topics: Acneiform Eruptions; Adolescent; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-1; Keratinocytes; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Interleukin-1; Receptors, Interleukin-1 Type II; RNA, Messenger; Signal Transduction | 2010 |
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Erlotinib-based perioperative adjuvant therapy for a case of unresectable stage IIIA (N2) nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
One more fallen star--ZODIAC and its implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Endpoint Determination; Humans; Lung Neoplasms; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2010 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Face; Female; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Quinazolines | 2010 |
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured | 2010 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Serum concentrations of Erlotinib at a dose of 25 mg daily.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cetuximab; Disease-Free Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Dosage; Gene Knockdown Techniques; Humans; Immunohistochemistry; Lung Neoplasms; Nuclear Receptor Coactivator 3; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction | 2010 |
[Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quinazolines; Retrospective Studies; Young Adult | 2010 |
Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Bilateral anterior uveitis secondary to erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Uveitis | 2010 |
First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Methylation; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Poly-ADP-Ribose Binding Proteins; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Ubiquitin-Protein Ligases | 2011 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Topics: Animals; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta | 2010 |
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Topics: Animals; Antibodies, Monoclonal; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Primers; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Elevated international normalized ratio associated with concomitant warfarin and erlotinib.
Topics: Adenocarcinoma; Anticoagulants; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; International Normalized Ratio; Lung Neoplasms; Male; Middle Aged; Quinazolines; Thromboembolism; Warfarin | 2010 |
Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equipment Design; Equipment Failure Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hydrogels; Lung Neoplasms; Peptides; Protein Array Analysis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Proteins | 2010 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
Gefitinib. Still no convincing results in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Sequence Deletion | 2010 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Feasibility Studies; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Radiotherapy; Withholding Treatment | 2011 |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2011 |
Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Toxicity manifesting as cosmetic hair alterations during erlotinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Hypertrichosis; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gemcitabine; Gene Expression; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Transfection; Ubiquitin | 2010 |
Compassionate use programs or phase IV trials of innovative molecular targeted drugs in lung cancer: deal or no deal?
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase IV as Topic; Compassionate Use Trials; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Topics: Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Dermatologic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Isotretinoin; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Fatal necrotizing pancreatitis during combined treatment with erlotinib and sunitinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Quinazolines; Sunitinib | 2010 |
Interstitial lung disease and gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Product Surveillance, Postmarketing; Quinazolines | 2010 |
Interstitial lung disease and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Genotype; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Polymerase Chain Reaction; Protein Tyrosine Phosphatases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tyrphostins | 2010 |
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines | 2010 |
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockout Techniques; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a.
Topics: Alternative Splicing; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Lung Neoplasms; Mutation; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Serine-Arginine Splicing Factors; Signal Transduction | 2010 |
Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrin beta1; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2010 |
[TARCEVA Clinical Registry].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Registries | 2010 |
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Array Analysis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2010 |
Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2010 |
Anti-tumor effects of B-2, a novel 2,3-disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazoline derivative, on the human lung adenocarcinoma A549 cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; ErbB Receptors; Flow Cytometry; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Molecular Dynamics Simulation; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21.
Topics: Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; Erlotinib Hydrochloride; Female; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Transforming Growth Factor alpha | 2010 |
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Topics: Amino Acid Sequence; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Immunoprecipitation; Lung Neoplasms; Mice; Mice, Nude; Molecular Sequence Data; Peptide Fragments; Peptide Mapping; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2011 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
[Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines | 2010 |
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Long-lasting drop in perfusion of a non-small cell lung cancer induced by monotherapy with the epithelial growth factor receptor inhibitor erlotinib persisting despite tumor progression at remote sites.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2010 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
[Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Codon; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking; Young Adult | 2010 |
Targeted therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation.
Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lower Extremity; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Invasiveness; Neoplasm Staging; Prednisolone; Quinazolines; Risk Assessment; Skin Diseases, Vascular; Treatment Outcome; Vasculitis | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Fibroblast Growth Factor 7; Fibroblasts; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Genes, erbB-1; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Survivin | 2010 |
Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Lung cancer: recent advances.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2010 |
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Mutation; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Translocation, Genetic | 2011 |
Erlotinib and pantoprazole: a relevant interaction or not?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Quinazolines | 2010 |
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids, Cyclic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Fusion Regulatory Protein-1; Gefitinib; Humans; Immunohistochemistry; Large Neutral Amino Acid-Transporter 1; Leucine; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases | 2010 |
Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment--case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation, Radiation; Dyspnea; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.
Topics: Amino Acid Substitution; Animals; Binding, Competitive; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Imaging; Mutant Proteins; Mutation; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2011 |
Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Survival Rate | 2010 |
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Repair; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Genes, BRCA1; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA, Messenger; Treatment Outcome | 2011 |
The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Karnofsky Performance Status; Lipoproteins, HDL; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Sex Factors; Survival Analysis; Time Factors; Weight Loss | 2011 |
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Signal Transduction; Transforming Growth Factor alpha | 2011 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2011 |
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines | 2011 |
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2011 |
C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Survival Rate | 2011 |
ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mutation; Nitriles; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; RNA, Small Interfering; Tyrphostins | 2011 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Humans; Mice; Mice, Nude; Mutation; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retroviridae; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Discovery; Drug Industry; Gefitinib; Humans; Lung Neoplasms; Politics; Quinazolines; United States; United States Food and Drug Administration | 2011 |
Screening for EGFR mutations in lung cancer, a report from India.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; India; Lung Neoplasms; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Sequence Deletion; Sex Factors | 2011 |
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Genome-Wide Association Study; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Precision Medicine; Quinazolines; Treatment Outcome | 2011 |
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Exons; Female; Humans; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; RNA, Messenger | 2011 |
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
[Survival-related clinical factors of patients with advanced non-small cell lung cancer after 2000].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Survival Rate | 2011 |
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Pyridines; Quinazolines; RNA Interference; STAT3 Transcription Factor; Tumor Suppressor Protein p53; Tyrphostins | 2011 |
Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines | 2010 |
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Topics: Adult; Aged; Antibodies, Monoclonal; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Polymerase Chain Reaction; Quinazolines; Recurrence; Sensitivity and Specificity; Sequence Deletion | 2011 |
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Membrane Proteins; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2011 |
Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Cicatrix; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2011 |
"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Taiwan; Treatment Outcome | 2011 |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pharmacogenetics; Quinazolines; Retrospective Studies; Taiwan; Treatment Outcome | 2011 |
Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Ultrasonography, Interventional | 2011 |
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2011 |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2011 |
Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.
Topics: Aged; Algorithms; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan; Treatment Outcome | 2011 |
[Clinical case of the month. A patient with advanced non-small-cell lung cancer presenting with an exceptional response to targeted therapies].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Combined treatment of curcumin and small molecule inhibitors suppresses proliferation of A549 and H1299 human non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Biological Availability; Caffeic Acids; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Curcuma; Curcumin; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Humans; Morpholines; NF-kappa B; Phenylethyl Alcohol; Phosphoinositide-3 Kinase Inhibitors; Phytotherapy; Plant Extracts; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Signal Transduction; Somatomedins; Tyrphostins | 2012 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids | 2011 |
Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Withholding Treatment | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; France; Germany; Glutamates; Guanine; Italy; Pemetrexed; Quinazolines; Spain | 2011 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].
Topics: Adenocarcinoma; Algorithms; Austria; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Oncogene Protein v-akt; Phosphorylation; Quinazolines; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2011 |
Salvage with erlotinib plus bevacizumab: not in NSCLC.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2011 |
SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells.
Topics: Alternative Splicing; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enhancer Elements, Genetic; Erlotinib Hydrochloride; HeLa Cells; Humans; Introns; Lung Diseases; Nuclear Proteins; Paclitaxel; Quinazolines; RNA Precursors; RNA Splice Sites; RNA-Binding Proteins; RNA, Antisense; RNA, Small Interfering; Serine-Arginine Splicing Factors | 2011 |
Palmar bullous blistering induced by erlotinib.
Topics: Adenocarcinoma; Blister; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Hand Dermatoses; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Intestinal Fistula; Intestinal Perforation; Protein Kinase Inhibitors; Quinazolines; Radiography; Sigmoid Diseases | 2011 |
Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outpatients; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2011 |
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Technology Assessment, Biomedical; Treatment Outcome | 2011 |
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines | 2011 |
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Confocal; Microscopy, Electron; Microtubule-Associated Proteins; Phagosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2011 |
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Markov Chains; Medical Oncology; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Sensitivity and Specificity | 2012 |
Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
[Erlotinib in non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292.
Topics: Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Neoplasm Invasiveness; Osteoblasts; Osteolysis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Ileal perforation induced by acute radiation injury under gefitinib treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enteritis; ErbB Receptors; Female; Gefitinib; Humans; Intestinal Mucosa; Intestine, Small; Lung Neoplasms; Peritonitis; Quinazolines; Radiation Injuries; Radiotherapy; Wound Healing | 2011 |
Gefitinib versus docetaxel for previously treated NSCLC--letter.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2011 |
Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2008 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
The use of erlotinib in daily practice: a study on adherence and patients' experiences.
Topics: Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Culture; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Monitoring; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Informed Consent; Lung Neoplasms; Medication Adherence; Multicenter Studies as Topic; Patient Selection; Patients; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design | 2011 |
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2012 |
Afatinib (BIBW 2992) development in non-small-cell lung cancer.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2011 |
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Evolution, Molecular; Female; Gefitinib; Genes, erbB-1; Humans; Mice; Mice, Nude; Models, Theoretical; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2011 |
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Spectrophotometry, Ultraviolet | 2011 |
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Marsdenia; Mutation; Phosphorylation; Plant Extracts; Proteasome Endopeptidase Complex; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[What choice of first-line treatment?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Translocation, Genetic | 2011 |
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[What is the best sequence of treatment for patients with EGFR mutations?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
[Management of patients with resistance to EGFR-TKI].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Medical Oncology; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2011 |
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Gefitinib; Genome-Wide Association Study; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies | 2011 |
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib-induced rash spares previously irradiated skin.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Fatal Outcome; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2011 |
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.
Topics: Asian People; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Databases, Protein; Discriminant Analysis; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Peptides; Phenotype; Proteomics; Quality Control; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lung Neoplasms; Membrane Potential, Mitochondrial; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sirolimus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
[A case of alveolar hemorrhage caused by gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Pulmonary Alveoli; Quinazolines | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mutation; Quinazolines; Radionuclide Imaging | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2011 |
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Cetuximab; DNA Breaks, Double-Stranded; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2011 |
Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Intestinal Mucosa; Intestines; Lung Neoplasms; Mice; Mice, SCID; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Ubiquitination; Xenograft Model Antitumor Assays | 2011 |
[Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2011 |
Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Quinazolines | 2011 |
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
EGFR mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Quinolines | 2012 |
Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
[Association of serum EGFR protein concentration with the efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2011 |
[Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Topics: Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Topics: Aged; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Regression Analysis; Retrospective Studies; Survival Analysis; Young Adult | 2011 |
NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Congresses as Topic; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; United Kingdom | 2011 |
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genetic Markers; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2012 |
Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2011 |
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cornea; Corneal Diseases; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lung Neoplasms; Microscopy, Acoustic; Piperidines; Quinazolines; Visual Acuity | 2011 |
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
Topics: Adult; Aged; Aged, 80 and over; Binding Sites; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorescent Antibody Technique; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis | 2011 |
Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Radiography | 2011 |
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Models, Biological; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2011 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Deliberating Tarceva: A case study of how British NHS managers decide whether to purchase a high-cost drug in the shadow of NICE guidance.
Topics: Carcinoma, Non-Small-Cell Lung; Decision Making; Decision Support Techniques; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Middle Aged; Pharmacopoeias as Topic; Protein Kinase Inhibitors; Quinazolines; State Medicine; Tape Recording; United Kingdom | 2011 |
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morphine; Quinazolines; Receptors, Opioid, mu | 2011 |
Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Topics: Adenocarcinoma; Adult; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
[Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Treatment Outcome | 2011 |
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Morpholines; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2011 |
Pharmacokinetics of gefitinib and erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; British Columbia; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Taxoids | 2011 |
Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Real-Time Polymerase Chain Reaction | 2011 |
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin | 2012 |
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2011 |
[New 'targeted therapy' for lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Treatment Outcome | 2011 |
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays | 2011 |
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines | 2011 |
Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Laboratory Techniques; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Services; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Office Visits; Pemetrexed; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Taxoids; United States | 2012 |
Does chemotherapy have a role after erlotinib treatment in NSCLC?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Diffuse interstitial lung disease linked to vandetanib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Hypersensitivity; Drug Substitution; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Quinazolines; Spirometry; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Erlotinib Hydrochloride; Female; France; Germany; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Spain | 2012 |
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2011 |
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2011 |
Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genistein; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Erlotinib treatment for persistent spontaneous pneumothorax in non-small cell lung cancer: a case report.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pneumothorax; Protein Kinase Inhibitors; Quinazolines | 2010 |
Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Eruptions; Drug Interactions; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Hematoma; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Neoplasm Staging; Quinazolines; Severity of Illness Index; Venous Thrombosis | 2012 |
Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2012 |
Drug approvals 2011: focus on companion diagnostics.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib | 2012 |
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.
Topics: Adenocarcinoma; Adult; Afatinib; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Neoplasm Invasiveness; Prognosis; Protein Kinase Inhibitors; Quinazolines; Transcription Factors; Transfection | 2012 |
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fluorescent Antibody Technique; Fulvestrant; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-3 | 2012 |
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Neovascularization, Pathologic; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2012 |
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Optimising therapy for EGFR-addicted NSCLC: just the start.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Vimentin; Young Adult | 2012 |
Impacts of treatment lines and initiation timing of erlotinib for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate | 2012 |
Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Dasatinib; Discoidin Domain Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; src-Family Kinases; Thiazoles | 2011 |
Subacute transient encephalopathy induced by erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Confusion; Erlotinib Hydrochloride; Female; Humans; Irritable Mood; Lethargy; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Seizures; Unconsciousness; Urinary Incontinence | 2011 |
3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Inbred BALB C; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Sulfonamides; Tomography, X-Ray Computed | 2012 |
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Body Height; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Drug Eruptions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Statistics as Topic; Survival Analysis | 2012 |
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Predictive Value of Tests; Proportional Hazards Models; Quinazolines; Smoking; Taxoids; Tubulin | 2012 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Leukoencephalopathies; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mutation, Missense; Naltrexone; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Opioid, kappa; Signal Transduction; STAT3 Transcription Factor | 2012 |
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Conformation; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Pain; Protein Kinase Inhibitors; Quinazolines | 2011 |
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
Topics: Apoptosis; Aurora Kinase B; Aurora Kinases; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cobalt Radioisotopes; Combined Modality Therapy; Dose Fractionation, Radiation; Enzyme Inhibitors; G2 Phase; Humans; Lung Neoplasms; Neoplasm Proteins; Polyploidy; Protein Serine-Threonine Kinases; Quinazolines; Tumor Stem Cell Assay | 2012 |
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors.
Topics: Antigens, CD; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines; Tumor Stem Cell Assay | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2012 |
FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors | 2012 |
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
Second-line erlotinib for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Peptides; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survivors | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
[Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
3rd line Erlotinib for lung cancer in Asia may be as cost-effective as in the Western world.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2012 |
Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Male; Quinazolines | 2012 |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Time Factors; Treatment Outcome | 2013 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Method to our madness or madness in our methods? Pitfalls in trial methodology.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Ipilimumab; Lung Neoplasms; Male; Melanoma; Paclitaxel; Quinazolines; Smoking; Solvents | 2012 |
Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Receptors, Estrogen; Signal Transduction; Up-Regulation | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2012 |
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Female; Gefitinib; Hospital Mortality; Humans; Hypoxia; Incidence; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Taiwan | 2013 |
Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Product Surveillance, Postmarketing; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Survival Rate; Young Adult | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comprehension; Female; Focus Groups; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Patient Preference; Perception; Qualitative Research; Quality of Life; Quinazolines; Texas; Treatment Outcome | 2012 |
Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gene Knockdown Techniques; Genes, ras; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptors, Tumor Necrosis Factor; Signal Transduction; Tumor Cells, Cultured; TWEAK Receptor | 2012 |
Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, MDR; Humans; Lung Neoplasms; Microtubules; Mutation; Paclitaxel; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin Modulators | 2012 |
Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Puncture | 2011 |
[Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lung Neoplasms; Quinazolines; Radiation Tolerance; Survival Analysis | 2012 |
[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Cross-Sectional Studies; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Public Health Practice; Quality of Life; Quinazolines; Retrospective Studies; Safety; Survivors; Time Factors; Treatment Outcome | 2012 |
Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Onycholysis; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2011 |
Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking; Survival Rate | 2012 |
Management of non-small cell lung cancer: focus on erlotinib. Foreword.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2012 |
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; Tankyrases; Wnt Proteins; Xenograft Model Antitumor Assays | 2012 |
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Topics: Adult; Aged; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.
Topics: Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Linear Models; Lung Neoplasms; Multivariate Analysis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Membrane; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines | 2013 |
A novel EGFR mutation in exon 19 showed stable disease after TKI treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Kringles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Proportional Hazards Models; Quinazolines; STAT5 Transcription Factor; Tumor Burden | 2012 |
A case report: successful treatment of meningeal metastasis with concurrent whole brain radiotherapy and erlotinib in a patient with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Triazoles | 2012 |
Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Treatment of leptomeningeal spread of NSCLC: a continuing challenge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cytarabine; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Meningeal Neoplasms; Methotrexate; Mutation; Pemetrexed; Quinazolines; Radiation Dosage | 2012 |
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Tumor Burden | 2012 |
Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endocytosis; Endosomes; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Phosphorylation; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorting Nexins | 2012 |
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor alpha; Up-Regulation | 2012 |
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Keratin-19; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Factors | 2012 |
KRAS wild-type lung cancer: a moving target in an era of genotype migration.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
Topics: 3' Untranslated Regions; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; In Situ Hybridization; Lung Neoplasms; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2012 |
[Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Female; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Russia; Survival Analysis; Treatment Outcome | 2012 |
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Topics: Afatinib; Animals; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Receptors, Interleukin-6; Signal Transduction; STAT3 Transcription Factor; Stromal Cells; Xenograft Model Antitumor Assays | 2012 |
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography; Treatment Outcome | 2012 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Salvage Therapy | 2013 |
Analysis of chemotherapy and molecular therapy efficiency in advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2012 |
[EGFR mutations in patients with advanced NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2012 |
[Gefitinib in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Poland; Quinazolines | 2012 |
Erlotinib-associated dermatological toxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Facial Dermatoses; Female; Humans; Lung Neoplasms; Quinazolines | 2013 |
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus | 2012 |
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Advanced non-small cell lung cancer (NSCLC): maintenance therapy for all?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Induction Chemotherapy; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Quinazolines | 2012 |
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry | 2013 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Models, Theoretical; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution; Tumor Cells, Cultured | 2012 |
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Topics: Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; MAP Kinase Signaling System; Nitriles; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Triazoles | 2012 |
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorine Radioisotopes; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, IGF Type 1; Thymidine; Triazines; Tumor Burden | 2013 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Young Adult | 2012 |
Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Gene Amplification; Gene Expression; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies | 2012 |
[Timing the change of chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2012 |
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2012 |
Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2012 |
Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver Neoplasms; Middle Aged; Quinazolines; Treatment Outcome | 2012 |
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multicenter Studies as Topic; Multivariate Analysis; Quinazolines; Treatment Outcome | 2012 |
Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2012 |
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Topics: Animals; Antipsychotic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Gefitinib; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Quinazolines; Random Allocation; Sensitivity and Specificity; Trifluoperazine; Tumor Cells, Cultured | 2012 |
NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Humans; Lung Neoplasms; Mutation; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Treatment Outcome; United Kingdom | 2012 |
Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Disease-Free Survival; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Integrins; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Multivariate Analysis; Neoplasm Transplantation; Phosphoproteins; Phosphorylation; Proportional Hazards Models; Protein Processing, Post-Translational; Quinazolines; Receptor Cross-Talk; Retrospective Studies; RNA, Small Interfering; Signal Transduction | 2012 |
[Personalised treatment of lung cancer].
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Positron-Emission Tomography; Precision Medicine; Quinazolines | 2012 |
Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2013 |
Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Topics: Adenocarcinoma; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Practice Patterns, Physicians'; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2013 |
A novel EGFR mutation in exon 18 with high sensitivity to EGFR TKI treatment with reduced dose.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
Who should receive EGFR tyrosine-kinase inhibitors?
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2012 |
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure; Tumor Burden | 2013 |
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cytochrome P-450 CYP2D6; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
[The TULUNG clinical registry].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Czech Republic; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Registries | 2012 |
Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Isothiocyanates; MAP Kinase Signaling System; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Transcription Factor AP-1; Transcriptional Activation | 2013 |
Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer.
Topics: Apoptosis; Autophagy; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epithelial Cells; Erlotinib Hydrochloride; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; RNA Interference; TOR Serine-Threonine Kinases; Ubiquitin-Conjugating Enzymes | 2012 |
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proteins; Proteomics; Quinazolines; Survival Analysis | 2013 |
Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Models, Statistical; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.
Topics: Adult; Base Sequence; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed | 2013 |
Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Quinazolines; Treatment Outcome | 2013 |
Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer.
Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Quinazolines; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome; Triazoles | 2012 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytoskeletal Proteins; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.
Topics: Acyclovir; Afatinib; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; ErbB Receptors; Esophagitis; Hematuria; Herpes Simplex; Humans; Intestinal Perforation; Lung Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Proteins; Peritonitis; Protein Kinase Inhibitors; Quinazolines; Valacyclovir; Valine; Viremia; Virus Activation | 2012 |
[Clinical observation of icotinib hydrochloride for patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
First-line erlotinib inferior to chemo in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2012 |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Quinazolines; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 3) Non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: a retrospective, observational, multicentric study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Kv1.1 Potassium Channel; Lung Neoplasms; Male; Mice; Mice, Nude; Peptides; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2012 |
Patients with advanced lung cancer: is there scope to discontinue inappropriate medication?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; England; Erlotinib Hydrochloride; Humans; Inappropriate Prescribing; Lung Neoplasms; Polypharmacy; Prevalence; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Topics: Analysis of Variance; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Cell Survival; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Stability; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2013 |
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromones; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Second line treatment in advanced non-small cell lung cancer (NSCLC): comparison of efficacy of erlotinib and chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gene Targeting; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2013 |
Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; MAP Kinase Kinase Kinases; Membrane Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured | 2013 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Genes, erbB-1; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Piperidines; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Keratin-7; Lung; Lung Neoplasms; Middle Aged; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Thyroid Nuclear Factor 1; Time Factors; Transcription Factors; Treatment Outcome | 2013 |
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
[The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Spheroid culture of primary lung cancer cells with neuregulin 1/HER3 pathway activation.
Topics: Adenocarcinoma; Animals; Blotting, Western; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spheroids, Cellular; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Exons; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2013 |
Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta2; Tumor Cells, Cultured | 2013 |
Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Inflammation; Quinazolines; Tumor Necrosis Factor-alpha | 2013 |
To target or not to target, that is the question.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2013 |
Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
Topics: Adult; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Family Health; Fatal Outcome; Female; Germ-Line Mutation; Humans; In Situ Hybridization; Lung; Lung Neoplasms; Middle Aged; Mutation, Missense; Neoplasms, Squamous Cell; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Adenocarcinoma; Amides; Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Markov Chains; Medical Assistance; Models, Economic; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Uncertainty | 2013 |
A mathematical model for microRNA in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer Simulation; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Genetic; Mutation; Oncogene Protein p21(ras); Proto-Oncogene Proteins c-myc; Quinazolines; Signal Transduction | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; LIM Domain Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; Signal Transduction | 2013 |
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
Topics: Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Thoracic Diseases; Treatment Outcome | 2013 |
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Membrane Proteins; Mice; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles.
Topics: Acetylation; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; E1A-Associated p300 Protein; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Histones; Humans; Nanoparticles; Quinazolines | 2013 |
Erlotinib plus parenteral nutrition: an opportunity to get through the hardest days of advanced non-small cell lung cancer with cancer anorexia-cachexia syndrome.
Topics: Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Parenteral Nutrition; Quinazolines; Syndrome | 2013 |
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 2013 |
Gefitinib (Iressa) for advanced non-small cell lung cancer.
Topics: Biological Availability; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Diarrhea; Drug Interactions; ErbB Receptors; Gefitinib; Half-Life; Lung Neoplasms; Multicenter Studies as Topic; Quinazolines | 2002 |
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Phosphorylation; Pleural Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2002 |
Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.
Topics: Amphiregulin; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Culture Media, Conditioned; Dose-Response Relationship, Drug; EGF Family of Proteins; Gefitinib; Glycoproteins; HeLa Cells; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Kinetics; Lung Neoplasms; Phosphorylation; Precipitin Tests; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Time Factors; Tumor Cells, Cultured; Tyrosine; Tyrphostins | 2002 |
Surprise phase III failure for ZD1839.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Relationship of EGFR signal-transduction modulation by tyrosine kinase inhibitors to chemosensitivity and programmed cell death in lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Precipitin Tests; Protein Tyrosine Phosphatases; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2003 |
Demand grows for early access to promising cancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Approval; Drug Costs; Drugs, Investigational; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Neoplasms; Patient Advocacy; Quinazolines; United States; United States Food and Drug Administration | 2002 |
What went wrong with Iressa?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Quinazolines; Treatment Outcome | 2002 |
Severe acute interstitial pneumonia and gefitinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Congresses as Topic; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Treatment Failure | 2003 |
Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Health Status Indicators; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Surveys and Questionnaires; Treatment Outcome | 2003 |
A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Treatment Outcome | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Commentary on ZD1839 (Iressa) in non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[14th EORTC-NCI-AAACR Symposium on New Molecular Targets and Cancer Therapeutics].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Germany; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines | 2003 |
More haste, less speed.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Approval; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure; United States; United States Food and Drug Administration | 2003 |
Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Complementary; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors; Up-Regulation | 2003 |
Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Health Status; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2003 |
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quality of Life; Quinazolines | 2003 |
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 1; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2003 |
Clinical efficacy and toxiciy of gefitinib in patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Ascites; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hepatitis C, Chronic; Humans; Hypoalbuminemia; Liver Cirrhosis; Lung Diseases, Interstitial; Lung Neoplasms; Male; Quinazolines | 2003 |
Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2003 |
Gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Pneumonectomy; Postoperative Care; Quinazolines; Risk Assessment; Sampling Studies; Wound Healing | 2003 |
Acute lung injury as a possible adverse drug reaction related to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Distress Syndrome | 2003 |
Selection bias, phase II trials, and the FDA accelerated approval process.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines; Selection Bias; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gefitinib; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2003 |
Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2003 |
Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases; Lung Neoplasms; Quinazolines | 2003 |
For investigational targeted drugs, combination trials pose challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Industry; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Evaluation Studies as Topic; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell; Multiple Myeloma; National Institutes of Health (U.S.); Quinazolines; Receptor, ErbB-2; Rituximab; Thalidomide; Trastuzumab; United States | 2003 |
The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Extensive experience of disease control with gefitinib and the role of prognostic markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Survival Analysis | 2003 |
Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2003 |
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2004 |
Pharmacy practice issues with targeted therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Insurance, Health, Reimbursement; Lung Neoplasms; Patient Compliance; Patient Education as Topic; Pharmaceutical Services; Quinazolines; United States | 2003 |
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; United States | 2003 |
[Transient liver injury caused by gefitinib].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Models, Chemical; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2004 |
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
[Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain, Intractable; Quality of Life; Quinazolines | 2004 |
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Smoking | 2004 |
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Topics: Acneiform Eruptions; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Retrospective Studies; Signal Transduction; Skin; Urticaria | 2004 |
Predictors of clinical response of non-small cell cancer to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Ubiquitin-Protein Ligases | 2004 |
Gefitinib for advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Australia; Canada; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Costs; Epidermal Growth Factor; Humans; Japan; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2004 |
Targeting targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2004 |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2004 |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Controlled Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Mutation, Missense; Phosphorylation; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Treatment Outcome; United States | 2004 |
Medicine. Why a new cancer drug works well, in some patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epidemiologic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
A deadly disease, a promising drug.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
The miracle of Iressa.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Cancer. A bull's eye for targeted lung cancer therapy.
Topics: Adenocarcinoma; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Japan; Ligands; Lung Neoplasms; Mutation; Phosphorylation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Smoking; Treatment Outcome; United States | 2004 |
From bench to bedside and back again?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Orphan Drug Production; Quinazolines; Research Design | 2004 |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Epidermal growth factor receptor mutations: a new insight.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Salvage Therapy; Sex Factors; Time Factors; Treatment Outcome | 2004 |
Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2004 |
Early-stage lung cancer findings end a debate, put focus on next steps.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Quinazolines; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2004 |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Milk Proteins; Mitogen-Activated Protein Kinases; Mutation; Mutation, Missense; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Sequence Deletion; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Transfection; Tyrosine | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Cell growth after withdrawal of gefitinib ("Iressa", ZD1839) in human lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Predictive Value of Tests; Prognosis; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2004 |
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
2004 highlights from: 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Congresses as Topic; ErbB Receptors; Erlotinib Hydrochloride; Ethnicity; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Societies, Medical; United States | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quinazolines | 2004 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Quinazolines | 2004 |
[Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome | 2004 |
Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2004 |
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2004 |
Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; France; Japan; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States | 2004 |
[Two cases of lung cancer in the third decade of life].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed | 2004 |
Approved use of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Labeling; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Immunity in medicine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Male; Prognosis; Quinazolines; Risk Assessment; Survival Rate; Treatment Outcome | 2004 |
[Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Survival Rate | 2004 |
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme Inhibitors; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2005 |
ERBB2 kinase mutations in lung-cancer tumours.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2004 |
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Hyperpigmentation; Lung Neoplasms; Middle Aged; Paronychia; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Acute gefitinib-induced pneumonitis.
Topics: Acute Disease; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Pneumonia; Quinazolines; Respiratory Insufficiency | 2004 |
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; ErbB Receptors; Exanthema; Eye; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Patient Education as Topic; Quinazolines; Radiography | 2005 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Keratin-19; Keratins; Lung Neoplasms; Male; Prognosis; Quinazolines | 2005 |
[French experience of gefitinib in non-small cell bronchial carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Male; Middle Aged; Palliative Care; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sex Factors; Smoking | 2004 |
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan | 2004 |
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Endothelial Cells; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxygen; Piperidines; Quinazolines; Radiotherapy; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
[New era in cancer therapy. Gefitinib: small molecule--strong action].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Time Factors | 2004 |
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Emerging role of erlotinib (OSI-774) in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2004 |
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2005 |
Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines | 2005 |
Erlotinib hydrochloride.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Expert Testimony; Humans; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Treatment Outcome | 2005 |
Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Homology, Amino Acid; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2005 |
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Survival Analysis; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA | 2005 |
Chasing mutations in the epidermal growth factor in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, abl; Humans; Lung Neoplasms; Mutation; Quinazolines | 2005 |
APL during gefitinib treatment for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines | 2005 |
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CHO Cells; Cricetinae; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3 | 2005 |
EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
[IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction | 2004 |
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2005 |
Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Transcriptional Activation | 2005 |
Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance | 2005 |
Iressa failure raises fears about accelerated approvals.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Gefitinib; Humans; Quinazolines; Treatment Outcome | 2005 |
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; GRB2 Adaptor Protein; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Son of Sevenless Protein, Drosophila | 2005 |
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
[Gefitinib therapy in non-small-cell lung cancer].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Finland; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines | 2005 |
Gefitinib does not increase survival in lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Gefitinib; Genotype; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR pharmacogenomics: the story continues to mutate and evolve.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Quinazolines; Rad51 Recombinase; Radiation-Sensitizing Agents; Signal Transduction; Xenograft Model Antitumor Assays | 2005 |
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Failure | 2005 |
Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2005 |
Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Treatment Outcome | 2005 |
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Primers; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Spain; Treatment Outcome | 2005 |
[Treatment of non-small cell lung cancer with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Sequence Data; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Quinazolines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Endothelial Growth Factors | 2005 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
EGFR mutation and response of lung cancer to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Point Mutation; Quinazolines | 2005 |
[Non-small-cell lung cancer third-line therapy with gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2005 |
EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2005 |
Gefitinib has the potential of activating cell immunity against malignant cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Immunity, Cellular; Lung Neoplasms; Quinazolines | 2005 |
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; North America; Predictive Value of Tests; Quinazolines; Retrospective Studies; White People | 2005 |
Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Survival Analysis | 2005 |
Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2005 |
Updated data from the Iressa survival in lung cancer trial.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Multicenter Studies as Topic; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2005 |
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Phosphorylation; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Erlotinib in gliomas: should selection be based on EGFR and Akt analyses?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Patient Selection; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Treatment Outcome | 2005 |
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure | 2005 |
Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Ligands; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Receptors, Bombesin; Signal Transduction; Transforming Growth Factor alpha | 2005 |
Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2005 |
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Quinazolines; Retrospective Studies | 2005 |
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genes, ras; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Sirolimus; Tumor Cells, Cultured | 2006 |
Drug interaction between gefitinib and warfarin.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Thrombosis; Warfarin | 2005 |
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mucin 5AC; Mucins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured | 2005 |
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Targeting EGFR in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2005 |
Gefitinib is also active for carcinomatous meningitis in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Meningitis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Cord Neoplasms; Treatment Outcome | 2005 |
Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Dosage; Gene Expression Profiling; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Models, Animal; Mutation; Neoplasm Proteins; Prostatic Neoplasms; Quinazolines; Receptors, Cell Surface; Xenograft Model Antitumor Assays | 2005 |
Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2005 |
Gefitinib versus cetuximab in lung cancer: round one.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2005 |
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib in colorectal cancer: if wishes were horses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genotype; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Asian People; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dinucleotide Repeats; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome; White People | 2005 |
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors | 2005 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Interstitial lung disease associated with gefitinib.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Chemokine CXCL10; Chemokines, CC; Chemokines, CXC; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Respiratory Function Tests; Retrospective Studies | 2006 |
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics | 2005 |
Hair growth after gefitinib treatment.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Gefitinib; Hair; Humans; Hypertrichosis; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2005 |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemokine CCL4; Cytokines; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Male; Middle Aged; Phenotype; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Skin | 2005 |
Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Oxidation-Reduction; Oxygen; Positron-Emission Tomography; Quinazolines; Tissue Distribution | 2005 |
Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2006 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Methylation; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Exons; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Proto-Oncogene Proteins p21(ras); Quinazolines; Smoking; Tumor Suppressor Proteins | 2005 |
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chlorocebus aethiops; COS Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Immunoprecipitation; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Tyrosine; Ubiquitin | 2006 |
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2005 |
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; EGF Family of Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transforming Growth Factor alpha | 2005 |
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2005 |
Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2005 |
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2005 |
Erlotinib in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Placebos; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2005 |
Biomarkers of response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Sequence Deletion; Treatment Outcome | 2005 |
Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; Gefitinib; Humans; Lung Neoplasms; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines | 2005 |
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, ErbB-3; Sex Factors; Survival Analysis | 2005 |
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2005 |
EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Phosphorylation; Prognosis; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Array Analysis | 2005 |
Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome | 2005 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |
Erlotinib in patient with non-small cell lung cancer: significant symptomatic improvement within a few days but without change in chest X-ray.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2006 |
Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's Pace?
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelium; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mesoderm; Mice; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Genes, Neoplasm; Humans; Immunohistochemistry; Lung Neoplasms; Mesoderm; Mutation; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vimentin | 2005 |
Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2005 |
The role of EGFR-TK inhibition in non-small cell lung cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome | 2005 |
PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Humans; Lung Neoplasms; PPAR gamma; PTEN Phosphohydrolase; Quinazolines; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Tumor Cells, Cultured | 2006 |
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2005 |
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
ZD6474 headed for phase III trials in the fall.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Humans; Lung Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |
Gefitinib-induced lung injury successfully treated with high-dose corticosteroids.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Photomicrography; Quinazolines; Tomography, X-Ray Computed | 2006 |
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Quinazolines; Transcription Factors; Transfection; Zinc Finger E-box-Binding Homeobox 1 | 2006 |
[Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Smoking; Survival Rate | 2006 |
An acneiform eruption due to erlotinib: prognostic implications and management.
Topics: Acneiform Eruptions; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2006 |
Assessing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Paraffin Embedding; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Survival Analysis | 2006 |
Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxyribonuclease I; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Formaldehyde; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paraffin Embedding; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity | 2006 |
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2006 |
Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gene Deletion; Humans; Lung Neoplasms; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Quinazolines | 2006 |
[A new medication for lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2005 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
What's the rush? The dissemination and adoption of preliminary research results.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Congresses as Topic; Diffusion of Innovation; Evidence-Based Medicine; Female; Gefitinib; Humans; Information Dissemination; Lung Neoplasms; Multicenter Studies as Topic; Neoplasms; Practice Patterns, Physicians'; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United States | 2006 |
Analgesic effect of gefitinib in the treatment of non-small cell lung cancer.
Topics: Aged; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Osteoarthritis; Quinazolines | 2006 |
Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Time Factors | 2006 |
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Patient Selection; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptor, IGF Type 1; Survival Analysis | 2006 |
[Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2006 |
Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Patient Selection; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; United States | 2006 |
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Sulfacetamide; Triamcinolone | 2006 |
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film | 2006 |
Erlotinib: optimizing therapy with predictors of response?
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Forecasting; Gene Amplification; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2006 |
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Dosage; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome | 2006 |
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured | 2006 |
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A | 2006 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Time Factors | 2006 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Dosage; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Quinazolines | 2006 |
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2006 |
Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quinazolines | 2006 |
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Meningitis; Middle Aged; Neoplasm Proteins; Paclitaxel; Palliative Care; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Vinblastine; Vinorelbine | 2006 |
Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2006 |
Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Glyburide; Humans; Lung Neoplasms; Pioglitazone; Quinazolines; Thiazolidinediones | 2006 |
Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Middle Aged; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin-3; Lung Neoplasms; Quinazolines; Quinolines; Receptor, ErbB-2 | 2006 |
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Quinazolines; Recurrence | 2006 |
Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Korea; Lung Neoplasms; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; CD4 Antigens; Chemokine CCL5; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Neoplasm Staging; P-Selectin; Prognosis; Quinazolines; Receptors, Interleukin-2 | 2006 |
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Paclitaxel; Piperidines; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spiro Compounds; Xenograft Model Antitumor Assays | 2006 |
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Inflammation; Lung Neoplasms; Quinazolines; Time Factors | 2006 |
Gefitinib: a cause of pyogenic granulomalike lesions of the nail.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Gefitinib; Granuloma, Pyogenic; Humans; Lung Neoplasms; Nail Diseases; Quinazolines | 2006 |
Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Meningitis; Quinazolines | 2006 |
Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2006 |
Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2006 |
K-ras mutations in lung cancer: the "mysterious mutation".
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2006 |
Pulmonary fibrosis in a patient treated with erlotinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lung Neoplasms; Multigene Family; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proteome; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome; Tumor Cells, Cultured | 2006 |
L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Genotype; Humans; Japan; Linear Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Survival Rate | 2006 |
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methionine; Mutation; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Threonine | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Influence of whole-brain radiotherapy on remission of brain metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Ribosomal Protein S6 Kinases; Signal Transduction; TOR Serine-Threonine Kinases | 2006 |
Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2006 |
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Characteristics; Smoking; Survival Analysis | 2006 |
Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors | 2006 |
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Smoking; Survival Analysis; Treatment Outcome | 2006 |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Squamous Cell; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Belgium; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Follicular rash during therapy with erlotinib (Tarceva).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Facial Dermatoses; Folliculitis; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Topics: Apoptosis; Beta Particles; Carcinoma, Non-Small-Cell Lung; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gamma Rays; Gefitinib; Genes, erbB-1; Genes, p53; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Protein Structure, Tertiary; Quinazolines; Radiation Tolerance; Recombinant Fusion Proteins; Sequence Deletion; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2006 |
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging | 2006 |
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid | 2006 |
[Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate | 2006 |
Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Receptors, Somatomedin; RNA, Messenger; Signal Transduction; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2006 |
Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Nucleic Acid Heteroduplexes; Quinazolines; Treatment Outcome | 2006 |
Molecular on/off switch.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome | 2006 |
Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2006 |
Effect of gefitinib on brain metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2006 |
Erlotinib-associated skin reactions - case report and proposal for classification.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2006 |
Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Topics: Adenoviridae; Adenoviridae Infections; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; eIF-2 Kinase; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2006 |
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
Topics: Adult; Aged; Aurora Kinase B; Aurora Kinases; Benzamides; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Inhibitors; Female; Genes, p16; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Neoplasm Proteins; Protein Serine-Threonine Kinases; Quinazolines; Survival Analysis; Survivin; Tumor Cells, Cultured; Up-Regulation | 2006 |
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Predictive Value of Tests; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transplantation, Heterologous | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Ligands; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2006 |
[Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Young Adult | 2006 |
Resistance to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines | 2006 |
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Polymorphism, Genetic; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
[New medications; erlotinib].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Treatment Outcome | 2006 |
Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2007 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quinazolines | 2006 |
[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-2; Genes, ras; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Respiratory Mucosa | 2007 |
[Clinical results observed with tyrosine kinase inhibitors].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Associations of tyrosine kinase inhibitors with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Use of tyrosine kinase inhibitors in particular situations].
Topics: Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
[Perspectives and future developments of epidermal growth factor receptors inhibitors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Dermatitis, Phototoxic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; fas Receptor; Gefitinib; Humans; Lung Neoplasms; Oligonucleotides, Antisense; Quinazolines; Transfection; Tumor Suppressor Protein p53 | 2007 |
Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cetuximab; DNA, Complementary; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Neuregulin-1; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2007 |
[Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2007 |
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Genes, ras; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2007 |
Clairvoyance or reliable prediction of the future?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2007 |
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured | 2007 |
[Lung cancer: targeted therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gastrin-Releasing Peptide; Gastrointestinal Agents; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Bombesin; Signal Transduction; src-Family Kinases; Transfection | 2007 |
The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cathepsin D; Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lysosomal Membrane Proteins; Lysosomes; Microscopy, Fluorescence; Protein Transport; Qa-SNARE Proteins; Quinazolines; Receptors, Scavenger; Signal Transduction; Transferrin | 2007 |
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Significant drug interaction: phenytoin toxicity due to erlotinib.
Topics: Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Seizures | 2007 |
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Smoking | 2007 |
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies | 2007 |
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Receptor, ErbB-2 | 2007 |
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Transfection; Tumor Cells, Cultured | 2007 |
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Probability; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Assessment; Survival Analysis; Taiwan; Treatment Outcome | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Palliative Care; Protein Kinase Inhibitors; Quinazolines | 2007 |
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Quinazolines | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2007 |
Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2007 |
[Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Deletion | 2007 |
Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.
Topics: Active Transport, Cell Nucleus; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; S Phase; Up-Regulation | 2007 |
Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors | 2007 |
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Amplification; Humans; Indoles; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; Sulfones | 2007 |
Erlotinib-associated acute pneumonitis: report of two cases.
Topics: Acute Disease; Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Glucocorticoids; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Shock, Septic | 2007 |
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Somatomedins; Survivin; Up-Regulation | 2007 |
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
Topics: Aged; Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2007 |
[Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Europe; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tegafur; United States; Uracil | 2007 |
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
EGFR expression and mutational analysis as a predictive test.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Predictive Value of Tests; Quinazolines | 2007 |
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Circadian Rhythm; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2007 |
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Head and Neck Neoplasms; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Quinazolines | 2007 |
Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer].
Topics: Adult; Age Distribution; Aged; Base Sequence; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Quinazolines; Racial Groups; Sex Distribution | 2007 |
Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2007 |
Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Drug Costs; Female; Gefitinib; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Quinazolines; Survival Analysis | 2007 |
Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Agents; Brachiocephalic Veins; Carcinoma, Non-Small-Cell Lung; Cyanosis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Superior Vena Cava Syndrome; Syncope; Tomography, X-Ray Computed; Venous Thrombosis | 2007 |
[Medical treatment for stage III non-small-cell lung cancer (NSCLC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mitomycin; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate | 2007 |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines | 2007 |
Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Endothelial growth factor receptor inhibition after radiotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Injuries; Receptors, Vascular Endothelial Growth Factor; Skin | 2007 |
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering | 2007 |
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2007 |
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Proteins; Quinazolines; Radiography, Thoracic; Smoking; Tomography, X-Ray Computed | 2007 |
Fulminant hepatic failure secondary to erlotinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Liver Failure, Acute; Liver Neoplasms; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Polymorphism, Single Nucleotide; Protein Structure, Tertiary; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2007 |
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Proteins; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
[Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Quinazolines; Sequence Deletion; Tyrosine | 2008 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Erlotinib in second/third line treatment for non-small cell lung cancer (NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3 | 2007 |
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; G(M3) Ganglioside; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Sialyltransferases; Tumor Cells, Cultured | 2007 |
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Survival Rate | 2008 |
Epidermal growth factor receptor inhibitor-related folliculitis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Face; Folliculitis; Humans; Lung Neoplasms; Male; Neck; Protein Kinase Inhibitors; Quinazolines | 2007 |
[EGFR gene mutation status among lung cancer patients in China].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Frequency; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Sex Factors; Smoking; Treatment Outcome | 2007 |
[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Prognosis; Quinazolines; Sequence Deletion | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2008 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Erlotinib effective against refractory bronchorrhea from advanced non-small cell lung cancer.
Topics: Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic | 2007 |
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2007 |
Pulmonary toxicity associated with erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.
Topics: Bacterial Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Luminescent Proteins; Lung Neoplasms; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Point Mutation; Polymorphism, Genetic; Quinazolines; Sequence Deletion | 2007 |
EGFR inhibitors in the treatment of lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines | 2007 |
Treating non-small-cell lung cancer first line with erlotinib monotherapy in elderly patients: discussion of a case series.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2007 |
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2008 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Financial aspects of targeted therapy of lung cancer as compared to conventional chemotherapy].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hungary; Immunohistochemistry; Lung Neoplasms; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; ras Proteins | 2007 |
Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects.
Topics: Adenocarcinoma; Back; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Drug Eruptions; Epidermal Growth Factor; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Skin | 2007 |
Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kinetics; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2007 |
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Smoking | 2008 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2007 |
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines | 2007 |
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Nitrophenols; Piperazines; Proto-Oncogene Proteins; Quinazolines; Sulfonamides | 2007 |
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; MAP Kinase Signaling System; Mouth Mucosa; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; Time Factors | 2007 |
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2007 |
KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Mucin-1; Quinazolines | 2008 |
Acneiform reaction to erlotinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2007 |
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colorimetry; Drug Synergism; Flow Cytometry; Humans; Indicators and Reagents; Lapatinib; Mutation; Oncogene Protein v-akt; Piperidines; Prenylation; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2008 |
Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cesarean Section; Disease Progression; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Humans; Infant, Newborn; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First; Quinazolines; Withholding Treatment | 2008 |
[Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2007 |
[In these days molecule target drug in advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Time Factors | 2008 |
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Topics: Antineoplastic Agents; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Non-Small-Cell Lung; Caspase 9; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Lung Neoplasms; Membrane Proteins; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Small Interfering; Signal Transduction | 2007 |
Erlotinib-associated alopecia in a lung cancer patient.
Topics: Aged; Alopecia; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment | 2007 |
[TRUST study: general practice relevant data on erlotinib in NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Topics: Acne Vulgaris; Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Skin | 2008 |
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Signaling networks assembled by oncogenic EGFR and c-Met.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Neoplasm Metastasis; Phosphotyrosine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2008 |
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Genes, ras; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2007 |
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Cell Cycle; Cell Death; Cell Extracts; Cell Line, Tumor; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Folic Acid Antagonists; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Morpholines; Pemetrexed; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Tetrahydrofolate Dehydrogenase; Thymidylate Synthase | 2008 |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutant Proteins; Phosphorylation; Polymorphism, Single Nucleotide; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
Topics: Cadherins; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2008 |
[Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Vomiting | 2007 |
Late fatal recurrence in gefitinib-treated NSCLC patients.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tomography, X-Ray Computed | 2007 |
Molecule of the month. Overcoming resistance.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Design; Drug Resistance; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2008 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Targeted combinatorial therapy of non-small cell lung carcinoma using a GST-fusion protein of full-length or truncated MDA-7/IL-24 with Tarceva.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Green Fluorescent Proteins; Humans; Interleukins; Lung Neoplasms; MAP Kinase Signaling System; Mutant Proteins; Organ Specificity; p38 Mitogen-Activated Protein Kinases; Quinazolines; Recombinant Fusion Proteins; Tumor Stem Cell Assay | 2008 |
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Oligonucleotides; Peptide Nucleic Acids; Point Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2008 |
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2008 |
Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Eruptions; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors | 2008 |
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydantoins; Lung Neoplasms; Models, Biological; Phosphorylation; Quinazolines; Tumor Suppressor Protein p53 | 2008 |
Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Comet Assay; DNA Repair; Electrophoresis, Gel, Pulsed-Field; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Quinazolines; Radiation Tolerance; Radiotherapy | 2008 |
Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.
Topics: Bacteremia; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin; Staphylococcal Infections | 2008 |
Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erythema; Female; Gefitinib; Humans; Leg; Lung Neoplasms; Male; Purpura; Quinazolines | 2008 |
Differential sensitivity of A549 non-small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors.
Topics: Antibodies, Blocking; Antineoplastic Agents; Biological Assay; Carcinoma, Non-Small-Cell Lung; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tyrphostins | 2008 |
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Farnesyltranstransferase; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Phosphatidylinositols; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Sirolimus | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Survival Analysis | 2008 |
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Squamous Cell; Ovarian Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2008 |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC).
Topics: Adult; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vascular Endothelial Growth Factor A | 2008 |
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2008 |
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2008 |
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome | 2008 |
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Gefitinib; Humans; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2008 |
Recurrent gefitinib-induced interstitial lung disease.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2008 |
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Probes; Down-Regulation; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2008 |
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Chlorocebus aethiops; COS Cells; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Mutation; Quinazolines | 2008 |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Signal Transduction; Transfection | 2008 |
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; NIH 3T3 Cells; Phosphorylation; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2008 |
[Efficacy of erlotinib on advanced non-small cell lung cancer].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2008 |
Acute and fatal diarrhoea after erlotinib plus abdominal palliative hypofractionated radiotherapy in a metastatic non-small cell lung cancer patient: a case report.
Topics: Acute Disease; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Pain Management; Palliative Care; Quinazolines; Radiotherapy; Shock; Spinal Cord Compression | 2008 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Biopsy, Needle; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Smoking; Survival Analysis | 2008 |
Bilateral eardrum perforation after long-term treatment with erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tympanic Membrane Perforation | 2008 |
Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Fluorescence; Phosphorylation; Quinazolines; Signal Transduction; Sorting Nexins; Vesicular Transport Proteins | 2008 |
Growth inhibition of human lung adenocarcinoma cells by antibodies against epidermal growth factor receptor and by ganglioside GM3: involvement of receptor-directed protein tyrosine phosphatase(s).
Topics: Adenocarcinoma; Benzylidene Compounds; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Membrane; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; G(M3) Ganglioside; Humans; Lung Neoplasms; Nitriles; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Radioligand Assay; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 1997 |
ZD-1839 (AstraZeneca).
Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2001 |
Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Cancer medicine hits a target.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Delivery Systems; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Trimetrexate | 1990 |
Quality of life assessment during chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Folic Acid Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Trimetrexate | 1990 |
Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Trimetrexate | 1989 |
Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Trimetrexate | 1988 |
Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Trimetrexate | 1988 |
Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Trimetrexate | 1988 |